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Summary: Phenotype – genotype associations in a large cohort of patients with 
pulmonary arterial hypertension. Charaka Mayura Bandara Hadinnapola 
Idiopathic and heritable pulmonary arterial hypertension (PAH) are rare diseases with a poor 
prognosis. There is significant heterogeneity in clinical features at diagnosis, and in a 
proportion of patients there is a genetic cause of the disease. This clinical and genetic 
heterogeneity has hindered accurate risk stratification and the development of personalised 
treatments. 
 
The National Institute of Health Research BioResource – Rare Diseases PAH Study and the 
Medical Research Council / British Heart Foundation National Cohort Study of Idiopathic and 
Heritable PAH were established to investigate disease pathogenesis through whole genome 
sequencing and deep phenotyping. One thousand and seventy patients were sequenced and 
391 clinical variables were captured for each patient.  
 
In patients with idiopathic PAH the age at diagnosis, gender, right atrial pressure and the 
transfer coefficient for carbon monoxide were identified as independent prognostic variables. 
However, the presence of rare and predicted deleterious variants in BMPR2 was not of 
prognostic significance. Variants in genes previously associated with disease pathogenesis 
were identified in 204 patients (19 %). Patients with variants in BMPR2 were younger at 
diagnosis and had more severe pulmonary haemodynamic impairment compared to patients 
with idiopathic PAH. Novel associations between BMPR2 variant status and both 
haemoglobin concentration and white blood cell count were observed. Four patients carried 
variants in both SMAD9 and either BMPR2 or EIF2AK4. The clinical significance of this requires 
further study. Unexpectedly, biallelic variants in EIF2AK4 were identified in patients with a 
clinical diagnosis of idiopathic PAH. These patients had a significantly worse prognosis 
compared to patients with idiopathic PAH. The spectrum of phenotypic, radiological and 
histological changes associated with biallelic EIF2AK4 variants was broader than previously 
recognised.  
 
As these datasets mature, further analyses assessing the response to specific treatments and 
the outcomes of specific subgroups will be possible. 
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Introduction 
Pulmonary hypertension 
Pulmonary hypertension (PH) is a disorder of the pulmonary circulation defined by a mean 
pulmonary artery pressure (mPAP) ≥ 25 mmHg measured when supine and at rest by right 
heart catheterization (1). The 1st World Symposium on Pulmonary Hypertension classified the 
disorder into 3 broad groups primary, secondary and associated PH (2). The disorder was 
reclassified in 1998, during the 2nd World Symposium on Pulmonary Hypertension, into 5 
groups that continue to form the basis of the latest clinical classification. These groups were 
thought to share pathophysiological processes, clinical characteristics and similar treatment 
options. The 3rd World Symposium on Pulmonary Hypertension, in 2003, further amended 
the classification. The term “primary pulmonary hypertension” was replaced by idiopathic 
pulmonary arterial hypertension (PAH) (3). This classification was reviewed in 2014 at the 5th 
World Symposium on Pulmonary Hypertension and further refinements were made based on 
recent advances in the understanding of the disease, including novel genetic and 
environmental causes of the disease (4). 
 
Clinical classification 
The current clinical classification of PH categorizes the disorder into five groups (1). Group 1 
of the current classification system is designated as PAH. The haemodynamic definition of 
PAH is a mPAP ≥ 25 mmHg and a pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg, 
indicating that the pathology is pre-capillary. Subtypes are defined on the presence or 
absence of associated conditions, exposures to drugs and toxins as well as the presence of 
pathogenic variants in disease associated genes. Associated conditions include congenital 
heart disease, connective tissues disease, human immunodeficiency virus (HIV), portal 
hypertension and schistosomiasis. Exposures to specific drugs and toxins, such as appetite 
suppressants (e.g. dexfenfluramine), dasatinib and methamphetamines have also been 
implicated in disease pathogenesis (5-7).  
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Table 1. Clinical classification of pulmonary hypertension 
Group Name 
1 PAH 
1.1 Idiopathic PAH (no identifiable cause and no family history) 
1.2 
Heritable PAH (confirmed family history of PAH and / or a pathogenic 
variant in a disease associated gene): 
1.2.1 BMPR2 
1.2.2 Variants in other genes 
1.3 Drug and toxin induced 
1.4 
Associated with: 
1.4.1 Connective tissue disease 
1.4.2 HIV 
1.4.3 Portal hypertension 
1.4.4 Congenital heart disease 
1.4.5 Schistosomiasis 
1’ PVOD / PCH 
1’.1 Idiopathic PVOD / PCH 
1’.2 
Heritable PVOD / PCH: 
1’.2.1 Biallelic EIF2AK4 variants 
1’.2.2 Other variants 
1’.3 Drug and toxin induced 
1’.4 
Associated with: 
1’.4.1 Connective tissue disease 
1’.4.2 HIV 
1’’ Persistent pulmonary hypertension of the newborn 
2 Pulmonary hypertension due to left heart disease 
3 Pulmonary hypertension due to lung disease or hypoxia 
4 CTEPH and other pulmonary vascular obstructions 
5 Multifactorial or unclear mechanism 
Adapted from Galie et al. 2016 (1). PAH – pulmonary arterial hypertension, BMPR2 – bone 
morphogenetic protein receptor type 2, HIV – human immunodeficiency virus, PVOD / PCH 
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– pulmonary veno-occlusive disease / pulmonary capillary haemangiomatosis, EIF2AK4 – 
eukaryotic translation initiation factor 2 alpha kinase 4, CTEPH – chronic thromboembolic 
pulmonary hypertension. 
 
Heritable PAH, as defined during the 5th World Symposium on PAH, groups together patients 
with a family history of the disease and / or a pathogenic variant in a disease associated gene. 
Whereas, idiopathic PAH is a diagnosis of exclusion and by definition the aetiology is 
uncertain. It requires careful exclusion of the associated conditions and the absence of a 
family history of the disease and / or a variant in a disease associated gene. However, studies 
have shown that approximately 20 % of patients with sporadic idiopathic PAH have variants 
in the gene encoding the bone morphogenetic protein receptor type 2 (BMPR2) (8-16). In 
comparison, up to 80 % of patients with a family history of the disease have variants in BMPR2 
(17-19). 
 
Group 1’ (1 prime) of the current classification is pulmonary veno-occlusive disease (PVOD) / 
pulmonary capillary haemangiomatosis (PCH) (1). This is an amendment from the previous 
classification, where it was part of Group 2. It was reclassified to recognise the histological 
and pathophysiological similarities between PAH and PVOD / PCH. Similar to PAH, PVOD / 
PCH is also subdivided into idiopathic disease, heritable disease (caused by autosomal 
recessive variants in the gene eukaryotic translation initiation factor 2 alpha kinase 4 
[EIF2AK4], that encodes the protein eukaryotic translation initiation factor 2 alpha kinase 
general control nonderepressible 2 [GCN2]), and cases associated with connective tissue 
diseases, HIV, and ingestion of drugs or toxins (20-22).  
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Idiopathic and heritable pulmonary arterial hypertension 
Epidemiology 
Regulation (EC) No. 141/2000 of the European Parliament from the Council on orphan 
medicinal products defines a rare disease as pathological condition with a prevalence of less 
than 5 in 10,000 (23). While the Orphan Drug Act in the United States defines a rare disease 
as affecting less than 200,000 patients in the United States (24). By either definition, even 
together, idiopathic and heritable PAH can be considered a rare disease. 
 
Ling et al., using data collected between 2007 and 2009 from all the UK National Pulmonary 
Hypertension Centres, estimated the incidence of idiopathic, heritable and anorexigen 
associated PAH at 1.1 per million per year (25). A more recent, but comparable study from 
the United States (REVEAL Study French Comparison Cohort [i.e. patients with a PCWP ≤ 15 
mmHg]) estimated an incidence of 0.9 per million per year (26). Whereas, in a French cohort 
from 2002 to 2003, the estimated incidence of Group 1 PAH was 2.4 per million of the 
population per year (27). The incidence of just idiopathic or heritable PAH was not reported. 
 
In the UK, Ling et al. estimated the prevalence of idiopathic, heritable and anorexigen induced 
PAH to be 6.6 per million of the population (25). With increasing awareness of the disease 
and longer survival, the UK estimates have increased. The UK National Pulmonary 
Hypertension Audit 2015, estimated the prevalence of PAH in the UK was now 16 per million 
of the population (28). While in the United States, prevalence was 10.6 per million of the 
population from the REVEAL Study (26). Differences between countries may in part be 
explained by the nature and access to healthcare systems, in particular, whether or not care 
is centralised to specialist hospitals as it is in the UK and France. 
 
Most contemporary disease registries have not systematically screened for variants in genes 
previously associated with PAH in their cohorts. The exception to this is in France, where all 
patients with idiopathic, heritable and anorexigen associated PAH are offered clinical genetic 
testing (29). Girerd et al. report that in their national cohort of adult PAH patients who 
underwent genetic screening 80 % had a diagnosis of idiopathic PAH with no known family 
history of the disease. In this group 17 % of patients had a pathogenic variant in either BMPR2, 
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ACVRL1, ENG, KCNK3, CAV1 or SMAD9. The majority carried variants in BMPR2 (15 % of those 
with idiopathic PAH). Whereas, in patients with a family history of the disease, 89 % carried a 
disease associated variant. Evans et al. collated the results of eight studies (1550 patients) 
systematically evaluating BMPR2 variants in patients with idiopathic, heritable and 
anorexigen associated PAH (30). They reported that 17 % of patients with idiopathic PAH 
carried a BMPR2 variant. In comparison, 82 % of those with a family history of the disease 
carried a BMPR2 variant. 
 
Pathophysiology  
Genetics basis 
A genetic susceptibility to develop PAH has been recognised since the first case reports of the 
disease occurring within families (31). In 1927 Clarke et al. described two sisters who died of 
right ventricular failure and proposed “familial” events as a cause of the disease. 
Subsequently in 1954, Dresdale et al. first described a family with confirmed elevation of their 
pulmonary artery pressures and suggested a “familial tendency” for “primary pulmonary 
hypertension” (32). While, Melmon and Braunwald described a three-generation family in 
which five members of the family were diagnosed with “primary pulmonary hypertension” 
(31). From this one family, the authors postulated an autosomal dominant mode of 
transmission with variable penetrance. They also suggested the possibility of genetic 
anticipation as a younger age of disease onset was reported in the third generation. Most 
studies of families with PAH concluded that an autosomal dominant mode of inheritance with 
reduced penetrance was characteristic (33). However, in one family an autosomal recessive 
mode of transmission was suggested as the affected cases were restricted to just one 
generation (34). In this family two of the three patients had digital clubbing and pleural 
effusions, possibly suggestive of PVOD / PCH. However, no histological assessment of the 
pulmonary veins or capillaries were provided. 
 
Bone morphogenetic protein receptor type 2 
In the late 1990s genetic analysis of families with PAH and an apparent autosomal dominant 
pattern of inheritance suggested that the gene responsible for the disease lay around 2q33, 
the locus was termed primary pulmonary hypertension 1 (PPH1) (35, 36). Two independent 
groups assessed the likelihood of linkage (logarithm of the odds score [LOD score]) between 
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the phenotype and genetic markers across the genome (37). In stark contrast to modern 
genome wide association studies (GWAS) just 260 and 370 such genetic markers were 
assessed in the two studies respectively. Follow up studies were then able to use 
microsatellite polymorphisms to narrow the area in which the responsible gene lay. 
Sequencing of candidate genes in this area led to the identification of heterozygous protein 
altering variants in BMPR2 in the majority (88 % and 47 %) of families studied (18, 19). 
Following the identification of heterozygous BMPR2 variants in heritable PAH, pathogenic 
variants were also reported in 26 % of PAH patients with apparent sporadic disease (i.e. with 
no confirmed family history) (8). 
 
Following these early studies many other studies have reported protein truncating variants 
(PTVs), missense variants and splice site variants in BMPR2 in cohorts of patients with PAH 
(17, 38). Additionally, multiplex ligation-dependent probe amplification (MLPA) (and prior to 
this Southern blotting), identified copy number variation (CNVs; deletions or duplications) in 
BMPR2 that could not be identified through traditional Sanger sequencing alone (39-41). A 
recent review by Machado et al. collated 384 distinct BMPR2 variants, as well as variants in 
the other 9 genes currently associated with PAH (42). 
 
More recently, a variant in the BMPR2 promoter region (c.-699G>A), altering transcription 
factor binding and reducing BMPR2 transcription has been reported (43, 44). Viales et al. 
suggested that the promoter variant co-occurred with a BMPR2 deletion in a patient with PAH 
possibly influencing penetrance. Other candidate promoter variants have also been 
identified, that in-vitro appear to reduce BMPR2 transcription, but further work is required to 
assess the impact and significance of these variants (45). A cryptic translation start site (c.-
944_5GC>AT) has also been described in a family with PAH but no protein coding sequence 
variants in BMPR2 (46). 
 
Nearly all protein coding sequence variants in BMPR2 have been found in a heterozygous 
state, suggesting haploinsufficiency as the mechanism of action (17). One patient, with early 
onset disease, has been reported to have two missense variants on separate alleles (47). 
However, it is generally accepted that loss of both BMPR2 alleles is fatal in utero. 
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Observing 53 families with heritable PAH and BMPR2 variants, Larkin et al., were able to show 
that genetic anticipation was not a feature of heritable PAH caused by BMPR2 variants (48). 
They reported that anticipation was an artefact of not following up unaffected family 
members for sufficient time for the disease to manifest. Furthermore, by assessing the 
frequency of heritable PAH amongst siblings with BMPR2 variants they calculated the 
penetrance of BMPR2 variants as 27 %. However, there were significant gender differences 
with penetrance amongst females reported at 42 % and penetrance amongst males as 14 %. 
This reduced penetrance suggests that a second genetic or environmental “hit” is required to 
develop disease.  
 
Several mechanisms have been proposed to explain the reduced penetrance. Hamid et al. 
demonstrated that patients with heritable PAH and BMPR2 PTVs have reduced levels of their 
wildtype BMPR2 transcript compared to unaffected relatives with the same PTV (49). 
However, this was only tested in patient derived lymphoblastoid cell lines. Transcription of 
BMPR2 has been shown to be regulated by several different processes, including 
inflammation, serotonin signalling and sex hormones; these are discussed in more detail 
below. 
 
Alternative splicing of BMPR2, resulting in the loss of exon 12, was shown to be more common 
in heritable PAH patients with BMPR2 variants compared to unaffected BMPR2 variant 
carriers (38). This study was also carried out in lymphoblastoid cell lines, which may not 
recapitulate endothelial cell biology fully (https://gtexportal.org/home/gene/BMPR2). These 
studies are all in keeping with the concept that additional hits to BMPR2 signalling are 
required to manifest disease. This is supported by reduced BMPR2 expression in endothelial 
cells from plexiform and concentric lesions from patients with idiopathic PAH, PAH associated 
with congenital heart disease and scleroderma, as well as patients with chronic 
thromboembolic pulmonary hypertension (CTEPH) who carry no identifiable BMPR2 variants 
(50, 51). 
 
Another mechanism proposed to explain the reduced penetrance of BMPR2 variants is the 
occurrence of somatic mutations to cause the loss of the wildtype BMPR2 allele. However, 
analysis of microsatellite instability in plexiform lesions dissected from 7 patients with 
 25 
heritable PAH did not provide any evidence for this (47). Although, Aldred et al. did 
demonstrate in pulmonary artery endothelial cells in a patient with a germline mutation of 
BMPR2, there was a somatic deletion of chromosome 13 resulting in the loss of mothers 
against decapentaplegic homolog (SMAD) 9, which is part of the BMPR2 signalling pathway 
(52).  
 
The BMPR2 gene consists of 191,442 base pairs (bp) and is divided into 13 exons that are all 
transcribed in the canonical transcript. It encodes the 1038 amino acid type 2 transforming 
growth factor b (TGFb) receptor, bone morphogenetic protein receptor type 2 (53). Five 
distinct regions / domains are recognised: a signal sequence (exon 1), the extracellular ligand 
binding domain (exons 2 and 3), a transmembrane domain (exons 4 and 5), a serine / 
threonine kinase (exons 6 to 11) and a large cytoplasmic tail that may interact with the 
cytoskeleton and cSrc (exons 12 and 13) (54-56). Disease associated variants have been 
reported in all exons (42). Variants in the cytoplasmic tail may not disrupt canonical BMPR2 
signalling but may affect interactions with the cytoskeleton and cSrc (55, 57-59). 
 
BMPR2 forms a heterodimeric complex with a TGFb type 1 receptor, and this determines 
ligand specificity. In endothelial cells, BMPR2 forms a complex with activin A receptor like 
type 1 (ACVRL1) and binds specifically to bone morphogenetic protein 9 (BMP9; encoded by 
the gene, growth differentiation factor 2 [GDF2]), and bone morphogenetic protein 10 
(BMP10) (60). Endoglin (ENG) acts as an accessory receptor promoting ACVRL1 signalling over 
competing ALK5 signalling (61). Ligand binding to BMPR2 results in phosphorylation and 
activation of ACVRL1 leading to downstream signalling through receptor-regulated SMAD 
proteins. In particular, ACVRL1 phosphorylates SMAD 1, 5 and 8 (encoded by SMAD1, SMAD5 
and SMAD9 respectively). These activated receptor-regulated SMAD proteins form 
heteromeric complexes with SMAD4 and are translocated to the nucleus where they can bind 
to SMAD binding elements to promote transcription. Variants in genes other than BMPR2 
involved in this signalling cascade have also been implicated in heritable PAH disease 
pathogenesis.  
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Activin A receptor like type 1 
ACVRL1 encodes a type 1 TGFb receptor that is expressed on endothelial cells (62). In complex 
with BMPR2, ACVRL1 activation leads to phosphorylation of the receptor-regulated SMADs 
(SMADs 1, 5, 8). Variants in ACVRL1 were initially reported in hereditary haemorrhagic 
telangiectasia type 2 (HHT2 and also known as Rendu-Osler-Weber syndrome), a highly 
penetrant autosomal dominant disease associated with the formation of mucocutaneous 
telangiectases and arteriovenous malformations (63). Vorselaars et al. recently estimated 
that approximately 18 % of patients with HHT have evidence of pulmonary hypertension 
when assessed by echocardiography (64). This may be related to an elevated PCWP, high 
pulmonary artery flow secondary to arteriovenous malformations or due to PAH (65). 
 
Variants in ACVRL1 are reported in heritable and idiopathic PAH usually in association with 
HHT (66, 67). There are also reports of paediatric onset PAH patients with variants in AVCRL1 
who do not have the clinical features of HHT (11, 13). These patients may manifest features 
of HHT later in life. 
  
Endoglin 
Endoglin, encoded by ENG, is an accessory receptor expressed on endothelial cells that 
enhances receptor-regulated SMAD signalling through the BMPR2-ACVRL1 complex. Similar 
to ACVRL1, variants in ENG are associated with HHT (HHT type 1) (68). HHT type 1 and HHT 
type 2 show phenotypic differences. The frequency and locations of arteriovenous 
malformations differ between the two forms of HHT. Furthermore, in a small study of patients 
with HHT and confirmed pulmonary hypertension (n = 28), ENG variants were less common 
than ACVRL1 variants (6 ACVRL1 variants, 1 ENG variant and 1 BMPR2 variant; the identities 
of these variants were not stated to allow further critique) (65). Variants in ENG have been 
reported in patients with PAH and HHT (11, 67, 69). Although in a number of these patients, 
other risk factors for pulmonary hypertension were also present including anorexigen use, 
congenital heart disease and high pulmonary artery flows. 
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Other TGFb pathway genes 
Variants in other genes in the TGFb signalling pathway have also been reported. In some 
cases, functional data and demonstration of familial co-segregation of the variants have not 
been provided to confirm a causal role in PAH pathogenesis. Further study is hindered by the 
fact variants in these genes are extremely rare. Nasim et al. looked for rare variants in SMAD 
proteins in patients with PAH and no variants in BMPR2 or ACVRL1. They reported 2 variants 
in SMAD4 (associated with HHT type 3), 1 variant in SMAD1 and 1 variant in SMAD9 from a 
mixed cohort of 324 patients with PAH (70). The four patients with variants all had a diagnosis 
of idiopathic PAH. The SMAD9 variant carrier had paediatric onset disease. Shintani et al. also 
described a paediatric onset PAH patient with a protein truncating variant in SMAD9 resulting 
in loss of the ACVRL1 phosphorylation site; the variant was not present in their unaffected 
father (71).  
 
Chida et al. described two paediatric patients with idiopathic PAH carrying variants in 
BMPR1B, an alternative TGFb type 1 receptor (72). Although one variant, p.F392L, appeared 
to promote SMAD8 phosphorylation in the presence of BMP4 and it was also found in the 
unaffected father of the proband, casting doubt on its role in disease pathogenesis. 
 
More recently, a case report of a homozygous missense variant in GDF2 causing childhood 
onset PAH with no features of HHT has been published (73). Both unaffected parents were 
heterozygous for the variant suggesting an autosomal recessive pattern of inheritance. GDF2 
variants, in a heterozygous state, have been reported in three patients with capillary 
malformations and a phenotype similar to HHT, although only two variants appeared to 
impact the signalling pathway (74). No information regarding the presence or absence of 
pulmonary hypertension in these two patients were provided. 
 
Potassium two pore domain channel subfamily K member 3  
Potassium two pore domain channel subfamily K member 3 (KCNK3) encodes a potassium 
channel. It was initially identified by Ma et al. through whole exome sequencing (WES) of a 
single family in which five members had heritable PAH and no identifiable variants in genes 
previously associated with the disease (75). An autosomal dominant pattern of inheritance 
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was described in the family. By identifying variants that were 1) rare, 2) found in affected 
family members, 3) found in a heterozygous state (given the autosomal dominant mode of 
transmission) and 4) predicted to be deleterious, they were able to narrow the search to 24 
variants. The variant in KCNK3 was considered further as the gene had previously been 
associated with maintaining pulmonary artery vascular tone (76). Screening of patients with 
no variants in genes previously associated with disease pathogenesis revealed KCNK3 variants 
in 1 % of patients with idiopathic PAH and 3 % of probands with heritable PAH (i.e. a family 
history of the disease). The patients were relatively young at disease onset (aged 8 to 44 years 
old) and did not respond to acute pulmonary vasodilator challenges. Incomplete penetrance 
was suggested by the presence of variant carriers who had not developed the disease by their 
40th decade. KCNK3 variants have subsequently been reported in other PAH cohorts (77, 78). 
Interestingly, Tejedor et al. include a Romani family in which the index case carried a KCNK3 
variant in a homozygous state and was diagnosed with PAH at just 2 months of age. Both 
parents were found to be heterozygotes and the mother developed PAH a year after giving 
birth to the index case (77). 
 
Caveolin 1 
Caveolin 1 (encoded by CAV1) is a transmembrane protein integral to the formation of 
caveolae. Caveolae are flask like invaginations in the plasma membrane that are thought to 
play a role in promoting receptor mediated signalling and mechanotransduction (79). By 
employing WES to study a family with heritable PAH, Austin et al. were able to identify a 
variant in CAV1 (80). Subsequently, screening for CAV1 variants in 260 patients with either 
heritable or idiopathic PAH revealed just one other patient with a de novo frameshift variant 
and a diagnosis of idiopathic PAH. Thus, variants in CAV1 as a cause of PAH are extremely 
rare. Several studies provide descriptions of the same young girl with both idiopathic PAH and 
congenital generalised lipodystrophy (81-83). Congenital generalised lipodystrophy is 
associated with absence of adipose tissue, abnormal lipid metabolism and insulin resistance, 
and has been associated with CAV1 variants in the absence of pulmonary hypertension (84, 
85). Gomez et al. reported another patient with a missense variant in CAV1, but this is actually 
a variant of unknown significance with discordant Sorting Intolerant From Tolerant (SIFT) and 
Polymorphism Phenotyping v2 (PolyPhen-2) deleteriousness scores (86).  
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T-Box 4 
Microdeletions involving 17q22q23.2 have been reported to cause early onset pulmonary 
hypertension as well as other congenital abnormalities (87, 88). These microdeletions were 
postulated to cause haploinsufficiency of TBX4, encoding the transcription factor, T-Box 4. 
Kerstjens-Frederikse et al. found evidence of microdeletions involving 17q22q23.2 in 3 out of 
6 paediatric onset cases of idiopathic PAH who also had unexplained mental retardation or 
dysmorphic features (89). These deletions were not present in the unaffected parents and 
the area of overlap between all 3 cases contained 6 genes including TBX4. Amongst a further 
14 paediatric onset cases of idiopathic PAH another 3 patients were found to have deleterious 
variants in TBX4. Reassessment of these patients revealed features consistent with small 
patella syndrome (hypoplastic or absent patella, a large gap between 1st and 2nd toes and long 
3rd and 4th toes), a syndrome previously associated with TBX4 variants (90). Amongst a cohort 
of 49 adult patients one patient with idiopathic PAH was found to carry a deleterious TBX4 
missense variant but did not have features of small patella syndrome. The authors found no 
evidence of PAH amongst 23 patients diagnosed with small patella syndrome. TBX4 variants 
have since been described in further cohorts of paediatric and adult onset PAH (91, 92). 
 
Other putative genes 
Rare and predicted deleterious variants in several other genes have also been implicated in 
PAH pathogenesis, however, additional numbers, further phenotypic information and/or 
functional studies are required to confirm their significance. Biallelic EIF2AK4 variants were 
first reported in patients with PVOD / PCH (20, 21). More recently two reports have described 
biallelic EIF2AK4 variants in a kindred of Iberian Romani and in two sisters with apparent 
heritable PAH (22, 93). In the former report, half the patients had a clinical suspicion of PVOD 
/ PCH although no histological confirmation of the diagnoses were presented. In the latter 
study, both sisters had a low transfer coefficient for carbon monoxide (KCO) but neither had 
assessment of the lung parenchyma by computer tomography (CT), that may have suggested 
a diagnosis of PVOD / PCH. 
 
A single case report describes a family with heritable PAH and a missense variant in Krüppel-
like factor 2 (KLF2) (94). KLF2 encodes a shear stress induced transcription factor, that can 
increase expression of aquaporin 1 (AQP1) and thereby increase nitric oxide (NO) mediated 
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vasorelaxation (95, 96). Variants in KLF2 have also been implicated in splenic marginal zone 
lymphoma (97). 
 
KCNA5, encodes the a subunit of the voltage gated potassium channel, Kv1.5. Decreased 
expression of Kv1.5 in pulmonary artery smooth muscle cells from patients with PAH has been 
observed and results in increased cellular proliferation (98). Remillard et al. identified both 
common and rare variants in both the protein coding sequence and putative promoter 
sequence of KCNA5, that were predicted to impact channel function or interfere with 
transcription factor binding (99). They reported that the frequency of two single nucleotide 
polymorphisms (SNPs) were significantly different between patients who had a vasoreactive 
response to an acute pulmonary vasodilator challenge and those that did not. While the 
frequency of another SNP was different between those with a history of exposure to 
fenfluramine / phentermine and those without. In a separate Spanish cohort, predicted 
deleterious and rare missense variants, as well as novel splice site variants in KCNA5 have 
been reported (100). Furthermore, a case report describes early onset heritable PAH in a 
patient with both a missense BMPR2 variant (previously reported in several patients with 
heritable PAH) and a frameshift variant in KCNA5 (101). The authors hypothesised that the 
early age of onset was due to the combination of the two variants. The patient’s unaffected 
mother also carried the KCNA5 variant. 
  
As well as rare and predicted deleterious variants that are likely causal for PAH, common SNPs 
have also been implicated in disease pathogenesis usually as disease modifiers. Candidate 
gene association studies and a single GWAS have assessed the role of common variation in 
PAH pathogenesis. SNPs, identified through candidate gene approaches, in genes linked to 
inflammation, metabolism and sex hormone signalling are discussed in more detail in the 
relevant sections below. 
 
GWAS require large well-defined cohorts, appropriate controls and careful selection of SNPs 
to take forward into the association study. In the only GWAS in PAH to date, Germain et al. 
assessed 340 patients with idiopathic or heritable PAH and no identifiable BMPR2 variants 
(102). They were unable to identify any SNPs that were significantly different between cases 
and controls at a genome wide significance level in their discovery cohort. However, they took 
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forward 319 SNPs that had uncorrected p values less than 6.87 x10-4 for further analysis. Two 
of these SNPs were then also seen in a smaller validation cohort of 285 patients. Both SNPs 
were downstream of the cerebellin 2 precursor gene (CBLN2). CBLN2 encodes cerebellin-2, 
which had previously been thought to be expressed by neuronal tissue. Germain et al. showed 
that cerebellin-2 was expressed at higher levels in pulmonary artery endothelial cells from 
PAH patients compared to those from controls, but their functional role in PAH pathogenesis 
remains to be elucidated. 
 
In a small WES study of just 12 patients with idiopathic PAH, common variation in 
topoisomerase (DNA) II binding protein 1 (TOPBP1) was suggested to be associated with 
disease pathogenesis (103). However, the methodology used in the study to identify the 
variants was biased and the study itself remains underpowered. 
 
Summary of the genetic basis of PAH 
The BMPR2 signalling pathway is now recognised as a playing a crucial role in disease 
pathogenesis. BMPR2 mutations are the commonest cause of heritable PAH. Although 
BMPR2 is expressed in several cell types, in endothelial cells BMPR2 forms a unique complex 
with ACVRL1, and the accessory receptor ENG. When bound to the ligands BMP9 and BMP10 
this receptor complex initiates a specific signalling cascade of importance to endothelial cell 
biology. Mutations in genes encoding all these proteins, with the exception of BMP10, have 
already been identified. This also demonstrates the critical role of the pulmonary endothelial 
cell in disease pathogenesis. 
 
Additionally, there is an increasing body of evidence to suggest that variation in genes not 
directly part of the canonical BMPR2 signalling pathway, and non-genetic factors (which are 
further discussed below) can modulate this key pathway. This growing understanding of 
disease pathogenesis has led to the development of interventions which promise to deliver 
new classes of therapeutics to combat and potentially cure this disease. Figure 1 summarises 
the BMPR2 signalling pathway and includes other genetic and non-genetic factors that may 
influence it. 
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Figure 1. Diagram of the BMPR2 signalling pathway and other genes previously associated with PAH and PVOD/PCH 
The BMPR2 signalling pathway plays a central role in the pathogenesis of PAH. BMPR2 is a type 2 TGFb receptor which forms a receptor complex with ACVRL1 on the 
endothelial cell surface membrane. This receptor complex, along with the co-receptor ENG, have an affinity to the ligands BMP9 and BMP10. Ligand binding leads to 
phosphorylation of SMADs 1, 5 and 8, which then bind to SMAD 4 before being translocated to the nucleus where they can bind to BMP responsive elements (BRE) to 
influence transcription. Mutations in many genes contributing to this signalling cascade have already been implicated in the development of PAH (shown in red). Other genes 
have also been implicated in disease pathogenesis (also labelled in red). CAV1 helps the formation of caveolae on the cell surface membrane where BMPR2 receptors 
colocalise. KCNK3 is a potassium channel implicated in controlling vascular tone. TBX4 is a transcription factor implicated in paediatric onset PAH. GCN2, encoded by EIF2AK4, 
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has been associated with both PAH and PVOD / PCH. It is part of the integrated stress response. When activated it phosphorylates eIF2a, which leads to an increase in ATF4 
transcription and a global reduction in protein translation. 
 
BMPR2 – bone morphogenetic protein type 2 receptor, ACVRL1 – activin A receptor like type 1, ENG – endoglin, BMP9 – bone morphogenetic protein 9, SMAD – mothers 
against decapentaplegic homolog, BRE – BMP responsive elements, CAV1 – caveolin 1, KCNK3 – potassium two pore domain channel subfamily K member 3, TBX4 - T-Box 4, 
GCN2 - eukaryotic translation initiation factor 2 a kinase general control nonderepressible 2, TNFa – tumour necrosis factor a, IL – interleukin, SERT – serotonin transporter 
protein, PPARγ – peroxisome proliferator-activated receptor γ, ApoE – apolipoprotein E, KCNA5 - Kv1.5 a subunit. 
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Histological descriptions 
Remodelling of the pulmonary vasculature was first recognised by Romberg in 1891, when he 
described sclerosis of the pulmonary arteries. Dresdale et al. associated these changes with 
“primary pulmonary hypertension”. In their first descriptions of “primary pulmonary 
hypertension” they described widespread but variable “sclerotic changes” throughout the 
pulmonary circulation (104). They also reported plaque formation in larger vessels, intimal 
and medial thickening, as well as subintimal proliferation narrowing the vessel lumen of 
microscopic vessels. Thrombotic lesions at different stages of organisation in both pre and 
post-capillary microscopic pulmonary vessels were also observed. 
 
Wagenvoort and Wagenvoort described the histological features of lung tissue from 156 
patients with “primary pulmonary hypertension” and considered it possible to categorise 
them into groups: chronic thromboembolism, chronic pulmonary venous hypertension, 
pulmonary veno-occlusive disease, sarcoidosis, chronic bronchiolitis and emphysema, 
pulmonary schistosomiasis and “vasoconstrictive primary pulmonary hypertension” (105). 
“Vasoconstrictive primary pulmonary hypertension” was characterised by intimal fibrosis, 
plexiform lesions, fibrinoid necrosis and pulmonary arteritis. 
 
Intimal thickening, medial hypertrophy, perivascular inflammation, and the presence of 
plexiform lesions are now considered key histological features of PAH. Medial hypertrophy is 
caused by proliferation and hypertrophy of the vascular smooth muscle cells and can 
correlate with pulmonary vascular resistance (PVR) (106). 
 
Plexiform lesions were once considered pathognomonic of idiopathic and heritable PAH but 
have also been reported in other forms of PH including CTEPH and PAH associated with 
congenital heart disease (107-110). Additionally, plexiform lesions are only variably reported 
in patients with idiopathic PAH, ranging from 20 % to 90 % (106, 109). Plexiform lesions are 
characterised by endothelial cell proliferation in pulmonary arteries < 100 µm in diameter and 
can result in near obliteration of the vessel lumen. They were thought to be associated with 
severe pulmonary hypertension (111). 
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A more recent histological study, by Ghinga et al., reported pulmonary venous remodelling, 
in particular smooth muscle hyperplasia in septal veins, in patients with BMPR2 variants (112). 
This study, compared 23 patients with BMPR2 variants to 21 patients with idiopathic PAH and 
no identifiable disease associated variants. The amount of arterial remodelling, the density of 
plexiform lesions and the degree of perivascular inflammation was similar between the two 
groups. However, BMPR2 variant carriers had increased bronchial artery hypertrophy and 
dilation compared to patients with idiopathic PAH. Changes to the bronchial circulation were 
associated with a history of haemoptysis. 
 
Inflammation 
Many studies have suggested that inflammation is an important aspect of PAH pathogenesis 
and an interaction between inflammation and genetic factors has been postulated. 
Pathological studies have described an abundance of inflammatory cells in the perivascular 
tissue, particularly around plexiform lesions (106, 113). T cells, B cells and macrophages have 
been observed. The degree of inflammation within the perivascular space has been 
associated with the severity of pulmonary hypertension (106). However, no difference in the 
degree of perivascular inflammation was seen between patients with BMPR2 variants and 
patients with idiopathic PAH (112). 
 
Immune dysregulation is thought to be an important process in some forms of PAH such as 
those associated with HIV infection, systemic sclerosis and systemic lupus erythematosus 
(SLE). Tamosiuniene et al. reported the development of severe pulmonary hypertension in 
athymic mice exposed to the vascular endothelial growth factor receptor 2 antagonist, 
SU5416 (Sugen), alone (unlike in regular mice where hypoxia is also required) (114). They 
found that immune reconstitution with regulatory T cells (cluster of differentiation [CD] 
4+CD25hi or CD4+CD25-) prior to exposure of Sugen prevented the development of pulmonary 
hypertension. This was associated with reduced perivascular inflammation (B cells and 
macrophages), reduced circulating levels of tumour necrosis factor a (TNFa) and interleukin 
(IL) 6, as well as increased BMPR2 expression in pulmonary vascular cells.  
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Serological studies have identified increases in circulating cytokines, such as IL1a, IL1b, IL2, 
IL4, IL6, IL8, IL10, IL12p70, IL13, TNFa, monocyte chemoattractant protein 1 (MCP1) and CC 
chemokine ligand 2 (CCL2), in patients with idiopathic or heritable PAH (115-119). No 
differences in these cytokines have been reported between patients with idiopathic PAH and 
those carrying BMPR2 variants (115). Although, preclinical studies have suggested increased 
IL6 in mice with dominant negative variants in BMPR2 in smooth muscle cells (120). Some of 
these cytokines are reported to be prognostic markers in univariate analyses, but not always 
in multivariate Cox proportional hazards models (115, 119, 121).  
 
Chaout et al. further investigated the link between BMPR2 and IL6. In a study of patients with 
chronic obstructive pulmonary disease (COPD), patients with the G / G genotype at position 
c.-174 in the gene encoding IL6 (G being the major allele) was associated with an increased 
susceptibility to developing pulmonary hypertension and increased levels of circulating IL6 
amongst current smokers (122). Brock et al. proposed that IL6 reduced BMPR2 function by 
increasing transcription of the micro ribonucleic acid (miRNA / miR) 17-92, which in turn 
reduces translation of BMPR2 (123). Preclinical models have also suggested that a “second 
hit”, such as exposure to TNFa, lipopolysaccharide or hypoxia, is required in mice with 
heterozygous BMPR2 variants, to develop significant pulmonary hypertension (124-127).  
Further indirect evidence for a role of inflammation in PAH arises from the co-occurrence of 
inflammatory disorders in patients with idiopathic PAH, such as autoimmune thyroiditis (128-
130). Patients with an initial clinical diagnosis of idiopathic PAH can develop autoantibodies 
and connective tissue diseases over time. 
 
Metabolic changes in PAH 
Proliferation and hypertrophy of pulmonary artery smooth muscle cells, endothelial cells and 
fibroblasts are features of the vascular remodelling observed in PAH (106, 131). This is 
associated with changes to cellular metabolism, similar to that seen in malignant processes. 
In fact, the proliferative changes associated with PAH, such as plexiform lesions, have been 
reported as being reminiscent of cancers (113). 
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The exact cause of this hyperproliferative, anti-apoptotic cellular phenotype remains to be 
fully elucidated, but mitochondrial dysfunction has been proposed as an important factor. 
Mitochondria from PAH tissue are hyperpolarised. This can contribute to a proliferative 
phenotype through activation of transcription factors such as hypoxia-inducible factor 1a 
(HIF1a) and altered intracellular calcium and potassium concentrations (132-134).  
 
Furthermore, suppression of mitochondrial respiration results in a shift from aerobic 
respiration / glucose oxidation to an increased reliance on glycolysis even in normoxic 
conditions (the Warburg Effect), similar to that seen in malignant cells (135). Pyruvate 
dehydrogenase (PDH) is a critical enzyme in this regard, linking glycolysis to glucose oxidation 
by playing a role in the conversion of pyruvate to acetyl-CoA, which can enter the citric acid 
cycle. Pyruvate dehydrogenase kinase (PDK) can reduce PDH activity, increasing glycolysis and 
reducing glucose oxidation. Dichloroacetate, an inhibitor of PDK, can both prevent and 
reverse the development of pulmonary hypertension in preclinical models (136-138). The 
inflammatory cytokine, TNFa, can also reduce PDH activity (139). A consequence of the 
reduction of PDH activity is increased utilisation of fatty acids in the citric acid cycle and 
diversion of critical amino acids for cellular proliferation (140). Zhao et al. took a global 
metabolomics approach to investigate changes in metabolism in the lungs of patients with 
end stage PAH. Compared to control lung tissue, lung tissue from PAH patients showed a 
significantly different profile based on unsupervised principal component analysis (PCA). They 
were able to demonstrate significant differences in metabolites associated with the glycolytic, 
citric acid cycle and fatty acid oxidation pathways. 
 
The development of insulin resistance is another feature of this metabolic impairment seen 
in patients with PAH (141-143). Several preclinical studies have suggested links between 
pulmonary hypertension and insulin resistance. Deficiency or knock out of the ligand 
activated transcription factor, peroxisome proliferator-activated receptor γ (PPARγ), or its 
downstream effector, apolipoprotein E (apoE) can cause both insulin resistance and 
pulmonary hypertension in mice (144, 145). Interestingly deficiency of adiponectin (another 
protein downstream of PPARγ), is associated with obesity and insulin resistance, and results 
in the development of pulmonary hypertension in an age dependent manner in mice (146). 
This may be driven through reduced NO production or increased expression of endothelial 
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adhesion molecules such as E-selectin. PPARγ is reported to be reduced in the lungs of 
patients with PAH (147). The importance of insulin resistance in PAH is further demonstrated 
by the prognostic significance of haemoglobin (Hb) A1C, a marker of insulin resistance and 
hyperglycaemia (148). 
 
BMPR2 signalling is thought to play a role in cellular metabolism and survival. Early in the 
disease endothelial cells are considered to have a pro-apoptotic phenotype that results in the 
selection and expansion of endothelial cells with the anti-apoptotic phenotype (149). BMPR2 
signalling is thought to promote endothelial cell survival, therefore pathogenic variants in 
BMPR2 can promote endothelial apoptosis. This potentially acts as the initiating event leading 
to the development of PAH (150-152). Furthermore, the anti-proliferative effects of BMPR2 
signalling is dependent on PPARγ and ApoE (145). BMPR2 endothelial cell knockout mice have 
also been shown to have hyperpolarised pulmonary endothelial mitochondrial membrane 
potentials and this has been attributed to increased p53 and PPARγ co-activator 1a 
expression (153).  
 
Comparison of human pulmonary microvascular endothelial cells with and without BMPR2 
variants showed changes across many metabolic pathways. This included increases in 
metabolites found in the glycolytic pathway and decreases in metabolites associated with 
fatty acid metabolism and the citric acid cycle (154). Similar changes have been shown in the 
right ventricle of patients with BMPR2 variants and this is thought to cause impaired right 
ventricular function through increased cardiac lipid deposition (155). 
 
Serotonin 
Several lines of evidence suggest serotonin (5HT) is involved in disease pathogenesis, 
particularly mediating proliferation of vascular smooth muscle and vasoconstriction (156, 
157). The relationship between 5HT and PAH was first suggested following an epidemic of 
PAH associated with anorexigen use in the late 1960s (5, 158). The latest guidelines now 
recognise aminorex, fenfluramine, dexfenfluramine, benfluorex and selective serotonin 
reuptake inhibitors (SSRIs) as “definite” causes of PAH (1, 5, 6, 159-162). All of these modulate 
the 5HT pathway. The histological appearances of the pulmonary vasculature in patients 
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exposed to aminorex are similar to that seen in other forms of PAH and include the presence 
of plexiform lesions. However, there are some notable phenotypic features of patients 
exposed to anorexigens. There is evidence of disease reversibility and good long-term 
outcomes in patients with anorexigen associated PAH, unlike patients with other forms of 
PAH (163). Administration of aminorex to rats failed to cause the disease and only 2 % of 
patients taking the drug developed PAH, suggesting a genetic predisposition, particularly in 
women, is required (163, 164). 
 
The serotonin transporter protein (SERT) is required for the proliferative effects of 5HT on 
pulmonary vascular smooth muscle (165-167). Anorexigens can inhibit SERT and promote the 
release of indolamine, both of which increase extracellular 5HT (161, 168). Furthermore, 
anorexigens can be a substrate for SERT, leading to intracellular 5HT like actions (169). In a 
meta-analysis, an insertion / deletion polymorphism (L / L genotype) in the promoter region 
of SERT was associated with increased SERT expression and PAH (170-172). In one of the 
original studies included in the meta-analysis, patients with BMPR2 variants and the L / L 
genotype had a younger age at diagnosis (171).  
 
Methamphetamines are also associated with the development of PAH and can interact with 
SERT at high doses (168). Although methamphetamines and amphetamines can also exert 
their effects through other mechanisms such as by increasing oxidative phosphorylation 
leading to increased reactive oxygen species and deoxyribonucleic acid (DNA) damage (173). 
 
Further evidence for the role of 5HT in PAH comes from elevated plasma 5HT in PAH patients, 
although this is not a consistent finding (174, 175). This was thought to arise due to abnormal 
platelet handling. Additionally, SSRIs have been associated with persistent pulmonary 
hypertension of the newborn (176). 
 
Oestrogen 
Interest in the role of the sex hormones in PAH pathogenesis arose from the female sex bias 
seen in many forms of PAH (5, 177). Oestrogen and its metabolites have been shown to 
influence pulmonary artery endothelial and smooth muscle cells, potentially explaining the 
increased risk of disease in females. Cytochrome P450 1B1 is involved in the oxidation of 
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oestrogen to 2- and 4- hydroxyestrogens. While hydroxylation of oestrogen results in the 
formation of 16α hydroxyestrone, which is more potent at causing cellular proliferation 
through activation of the oestrogen receptors compared to other oestrogen metabolites. 
Polymorphisms in cytochrome P450 1B1, resulting in reduced transcription, have been 
reported in female patients with heritable PAH (178). In keeping with this the ratio of urinary 
2-hydroxyestrogen to 16α hydroxyestrone was reduced in a small subgroup. 
 
The BMPR2 promoter sequence also contains an oestrogen receptor binding site that reduces 
BMPR2 transcription (179). In human pulmonary artery smooth muscle cells, BMPR2 
expression was greater in male derived cells compared to female derived cells (180). In this 
study, 17β oestradiol (the main oestrogen produced prior to menopause) increased cellular 
proliferation, providing a potential mechanism to explain the female bias in PAH registries 
and increased penetrance of BMPR2 variants in women. Furthermore, White et al. showed 
that in SERT overexpressing mice only females developed pulmonary hypertension and this 
was abolished by oophorectomy (181). They went on to show that administration of 17β 
oestradiol permitted the development of pulmonary hypertension in the oophorectomized, 
SERT overexpressing mice. This may explain, at least in part, the female bias seen in 
anorexigen associated PAH. 
 
Paradoxically, despite the female gender bias in PAH, female patients have a better prognosis 
compared to male patients (182, 183). This may be related to the effect of sex hormones on 
the right ventricle (184, 185). Several preclinical studies suggest that oestrogen metabolites 
improve right ventricular remodelling in pulmonary hypertension (181, 186). 
 
In mice models of pulmonary hypertension, treatment with antagonists of the oestrogen 
receptor α or anastrozole, an aromatase inhibitor, led to increased BMPR2 expression and 
prevented or reduced the development of pulmonary hypertension (187, 188). A recent study 
also showed that the combination of anastrozole and fulvestrant (a selective oestrogen 
receptor degrader), can prevent and even reverse pulmonary hypertension in a mouse model 
with an inducible BMPR2 variant (189). This was associated with increases in PPARγ and 
improvements in insulin resistance. Furthermore, a recently published small phase 2 study of 
18 PAH patients showed that anastrozole could increase six-minute walk test (6mwt) distance 
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after 3 months of therapy (190). Further work is required to assess the benefit of such an 
intervention, especially given the potentially protective effect that 17β oestradiol may have 
on the right ventricle. 
 
Demographics 
An increasing awareness of the disease amongst both primary and secondary care physicians 
in recent years has resulted in increasing referrals, particularly of older patients, to specialist 
centres (28). Compared to early PAH registries, such as the US National Institute of Health 
(NIH) Study, analysis of the REVEAL registry demonstrated that the average age at diagnosis 
was now significantly older (36.4 years vs. 44.9 years) (26, 177). Similar trends have been seen 
in the UK, where Ling et al. showed that, between 2001 and 2009, the mean age of diagnosis 
increased amongst patients diagnosed with idiopathic, heritable and anorexigen induced PAH 
(25). This was associated with an increased body mass index (BMI), more comorbidities and 
a reduction in the KCO. Recent registries from Brazil and China, show that the mean age of 
diagnosis for patients diagnosed with idiopathic PAH is still less than 40 years of age (191, 
192). Taken together, this may suggest that the pathogenesis of disease in patients diagnosed 
with apparent idiopathic PAH in modern cohorts from more economically developed 
countries may be more heterogeneous, with increasing numbers of patients with 
cardiovascular comorbidities (193). In the prospective European Compera registry the median 
age of diagnosis for patients with idiopathic PAH was 71 years (194). 
 
A bias in the proportion of female to male patients is seen in all forms of pulmonary arterial 
hypertension. In the US NIH Study, the ratio of female to male patients diagnosed with 
idiopathic or heritable PAH was 1.7 to 1. In modern registries, the bias is sometimes even 
more prominent but has been variable. The REVEAL Study had the highest ratio 3.6 to 1 (3.8 
to 1 in the comparable REVEALNIH cohort). While UK, French and European registries have 
ratios between 1.6 and 2.3 to 1 (25-27, 194). 
 
The only recent study to assess the ethnicities of patients with PAH was the REVEAL Study 
(26). Frost et al. report that the frequency of white Caucasians was as expected, whereas 
patients of Afro-Caribbean ancestry were over-represented and those of Asian or Hispanic 
ancestry under-represented. The authors comment that this may be due to ascertainment 
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biases and disparities in access to health care. Additionally, Kawut et al. identified Asian or 
African-American ethnicity to be a poor prognostic marker (195). 
 
Clinical features and assessments 
Symptoms associated with PAH are non-specific and usually insidious in onset. These factors 
combined with the rarity of the disease and lack of familiarity amongst health care providers, 
can delay clinical suspicion of the disease, referral to a specialist centre and definitive 
management. Analysis of the REVEAL Study population revealed that younger patients and 
those with less severe pulmonary haemodynamics were more likely to have a delay from 
symptom onset to diagnosis (defined as more than 2 years) (196). Smaller studies have 
quantified that the mean duration between symptom onset and diagnosis was between 2.3 
and 3.9 years even in modern healthcare systems (27, 197, 198). It has been presumed that 
older patients are more likely to be offered early echocardiography to assess left ventricular 
or valvular function and are consequently referred to specialist centres earlier. 
 
The most common symptom associated with PAH is unexplained exertional dyspnoea, with 
98 % of the UK cohort reported by Ling et al. presenting with dyspnoea (25, 177). Enlargement 
of the pulmonary artery may result in extrinsic compression of the other structures in the 
mediastinum leading to cough (compression of main bronchi), hoarse voice (compression of 
left recurrent laryngeal nerve) and chest pain (compression of left main coronary artery) 
(199). Haemoptysis is reported particularly in those with BMPR2 variants (112). Symptoms 
associated with worsening right ventricular function include palpitations, postural dizziness 
and syncope on exertion. Ling et al. reported that younger patients were more likely to 
present with syncope, perhaps consistent with their later presentation to health care 
providers (25). Syncope is associated with poor prognosis as it is a reflection of impaired 
cardiac function (200). Other non-specific symptoms include fatigue and abdominal 
discomfort from ascites. 
 
Clinical signs elucidated from patients with PAH are also non-specific and unreliable for 
confirming the diagnosis (201). The most frequent signs are related to right ventricular 
hypertrophy and failure: parasternal heave, pan systolic murmur loudest on inspiration, loud 
pulmonary component of the second heart sound, elevated jugular venous pulse with a large 
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v wave, ascites and peripheral oedema. Digital clubbing has rarely been reported in PAH but 
is more frequently associated with PVOD / PCH and PAH associated with connective tissue 
diseases or congenital heart disease. Similarly, Raynaud’s is usually associated with PAH 
associated with connective tissue disease but was also found to be a poor prognostic marker 
in “primary pulmonary hypertension” (202). 
 
Clinical investigations required for the assessment of patients presenting with suspected 
idiopathic or heritable PAH, have three aims: 1) confirm a definitive diagnosis of PAH, 2) 
exclude other forms of pulmonary hypertension, especially associated PAH, 3) assess the 
severity of disease, which may aid risk stratification. 
 
A definitive diagnosis of PAH requires right heart catheterisation to measure pulmonary 
artery pressures at rest and in a supine position. In addition, right heart catheterisation allows 
measurement of right atrial pressure (RAP), cardiac index (CI) and mixed venous oxygen 
saturations (SvO2) all of which are of prognostic value (1, 183, 202, 203). BMPR2 variant 
carriers have been shown to have a younger age at disease onset and more severe pulmonary 
haemodynamic impairment (higher PVR and lower CI) compared to those with idiopathic PAH 
(30, 204). 
 
A small subset of patients will have a positive response to an acute pulmonary vasodilator 
challenge. Identification of these patients is important as they will respond to long term 
calcium channel blockers (CCBs) and have a significantly better prognosis (205, 206). For 
vasoreactivity testing, patients inhale 40 parts per million (ppm) NO for 5 minutes prior to 
reassessment of their pulmonary haemodynamics (1, 207). An acute vasodilator response is 
defined as a drop in mPAP ³ 10 mmHg to an absolute level < 40 mmHg and with no change in 
cardiac output (CO). BMPR2 variant carriers are significantly less likely to have a vasoreactive 
response compared to those without a BMPR2 variant (2.6 % vs. 16.2 %) (30, 208). Similarly, 
those in functional class 3 (4.7 %) and 4 (3.0 %) are less likely to respond to a vasodilator 
challenge compared to those in functional class 1 or 2 (9.8 %) (27). 
 
Other investigations used to assess patients with pulmonary hypertension are summarised in 
Table 2.  
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Table 2. Clinical investigations used to assess patients with PAH 
Investigation Variable / Feature Utility 
Prognostic in 
univariate tests 
Electrocardiogram 
(ECG) 
Right axis deviation; right bundle branch block; 
right ventricular (RV) hypertrophy 
Evidence of RV strain  
Arrhythmias Evidence of RV strain (209) 
Echocardiogram Right atrial (RA) size;  
RV size, morphology and ejection fraction 
Evidence of RV strain  
Estimated systolic pulmonary artery pressure Non-invasive assessment of pulmonary 
artery pressures 
 
Pulmonary acceleration time   
Tricuspid annular plane systolic excursion (TAPSE) Evidence of RV strain (210, 211) 
Left ventricular (LV) eccentricity index Evidence of RV strain (211) 
Pericardial effusion Evidence of RV strain (182, 211) 
Left atrial (LA) size; 
LV size, morphology and function; 
aortic and mitral valve morphology and function 
Evidence of left heart disease contributing 
to pulmonary hypertension 
 
Shunts Exclude congenital heart disease  
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Blood tests N-terminal pro brain natriuretic peptide (NT-
ProBNP) 
RA stretch (182, 203, 212) 
Autoimmune screen Assess for features of connective tissue 
disease 
PAH associated with 
connective tissue 
disease has a worse 
prognosis (182, 213) 
Full blood count Polycythaemia may be associated with 
hypoxia or congenital heart disease 
Red cell distribution 
width (214) 
Platelets (215) 
Renal function Poor renal function may be associated 
with poor organ perfusion or use of 
diuretics 
Creatinine (182, 216) 
C reactive protein Marker of inflammation (217) 
Iron indices Low iron associated with PAH Soluble transferrin 
receptor (218) 
Uric acid Severity of disease (219) 
Thyroid function Associated with PAH (129) 
Lipid profile Assess cardiovascular risks High density 
lipoprotein (220) 
 46 
Lung function tests Forced expiratory volume in 1 second / forced vital 
capacity (FEV1 / FVC) 
Evidence of parenchymal lung disease FVC (221) 
KCO Low KCO despite normal spirometry 
associated with PVOD / PCH  
(182, 202) 
Chest radiograph 
(CXR) 
Enlarged hilar In keeping with dilated pulmonary arteries  
Globular heart RV dilation ± pericardial effusion  
Pleural effusion More in keeping with PVOD / PCH  
Ventilation 
perfusion 
scintigraphy / 
single-photon 
emission computed 
tomography / lung 
perfusion magnetic 
resonance imaging 
(MRI) 
Mismatched perfusion defects Exclude CTEPH  
CT thorax Pulmonary angiogram Assess for presence of chronic 
thromboembolic material and 
arteriovenous malformations 
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Lung parenchyma Centrilobular ground glass opacification, 
interlobular septal thickening and 
mediastinal lymphadenopathy associated 
with PVOD / PCH  
Septal thickening and 
opacifications in 
Group 1 PAH (222, 
223) 
RV size, pulmonary artery size Assess severity of disease  
Cardiac MRI RA size;  
RV size, function, ejection fraction and stroke 
volume 
Assess severity of disease (224, 225) 
Proximal pulmonary artery relative area change Vascular stiffness (225) 
Shunts Exclude congenital heart disease  
LV size, function and ejection fraction; valvular 
function 
Exclude left heart disease or valvular heart 
disease 
 
Walk test (6-minute 
walk test or shuttle 
walk test) 
Distance walked Assess functional capacity (182, 183, 203, 226-
229) 
Cardiopulmonary 
exercise test 
Peak work; peak oxygen consumption (VO2 max); 
anaerobic threshold; oxygen uptake efficiency 
slope 
Assess functional capacity  
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Oxygen pulse; ventilatory equivalents; maximal 
heart rate; maximal blood pressure 
Assess cardiac and ventilatory reserve Maximal heart rate 
(227) 
VE/VCO2 (227) 
Right heart 
catheterisation 
Systolic, diastolic and mean pulmonary artery 
pressure 
Gold standard for confirming pulmonary 
hypertension 
mPAP (202) 
PCWP Surrogate for LA pressure  – exclude 
significant left heart disease 
 
RAP Disease severity (182, 183, 203, 221) 
CO and CI Disease severity (183, 202, 203) 
PVR Disease severity (182) 
SvO2 Disease severity (203, 221) 
Vasoreactivity testing Identify those who may benefit from CCBs (221) 
Left heart 
catheterisation 
Left ventricular end-diastolic pressure (LVEDP) Exclude significant left heart disease, 
when PCWP unreliable 
 
Coronary angiogram Exclude significant coronary artery disease  
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Genetic counselling and clinical genetic testing 
Current guidelines recommend that genetic testing be offered to patients with idiopathic, 
heritable and anorexigen associated PAH, as well as patients with PVOD / PCH (1). Genetic 
testing can be used to identify families at risk (screening of symptomatic index cases), identify 
at risk relatives (presymptomatic screening of relatives), aid family planning, determine pre-
implantation genetic diagnosis and help risk stratify patients (230-232). It is thought that 
knowing your risk of carrying a disease associated variant and the risk to family members can 
be beneficial. Jones and Clayton showed that patients and relatives who undergo genetic 
testing reduced their distress levels more than those who declined further investigation (233). 
The most common reasons given for pursuing genetic testing was to determine the risk of 
passing a variant to children and the risk of carrying a variant for the individual (234, 235). Yet 
the uptake of genetic testing can be low. In the study by Jones et al. uptake was just 9 %. This 
may not be helped by the perception, amongst PAH healthcare professionals, that the utility 
of genetic testing and counselling is low (236). 
 
Even prior to the recognition of the role of BMPR2 in disease pathogenesis, microsatellite 
marker segregation was being used to identify at risk patients in families with heritable PAH. 
In the first such reported case, Morse and Barst identified an apparently unaffected sibling 
who carried a disease associated haplotype (segregating amongst affected family members) 
(237). Further assessment of the at-risk sibling uncovered that she did have heritable PAH and 
had been misdiagnosed with asthma. 
 
Current PAH guidelines recommend that prior to clinical genetic testing patients and relatives 
receive genetic counselling to understand the nature of the tests and their implications (1). 
However, the implementation of genetic counselling and testing is usually in accordance with 
national guidelines (235). Even prior to genetic testing, genetic counsellors (and other trained 
healthcare professionals) can inform patients about the risks of carrying a disease-causing 
variant and the risk of developing disease. This is usually based on what is known about 
BMPR2 variants, given that they account for the majority of heritable PAH cases. For example, 
an offspring of a parent who has a disease associated BMPR2 variant has a 50 % chance of 
inheriting the variant. Yet the low penetrance of the variant means that a female child will 
only have a 21 % risk of developing PAH and a male child has just a 7 % risk. While the risk of 
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disease in a child, whose parent has idiopathic PAH and has not undergone genetic testing, is 
4 % if the child is female and just 1 % if the child is male (assuming 17 % of those with 
idiopathic PAH have a variant in BMPR2). At risk individuals should be offered annual follow 
up with echocardiography to assess for the development of PAH (1). 
 
Current practice for clinical genetic testing is first to screen for variants (single nucleotide 
variants (SNVs), indels and larger structural variants) in BMPR2; in those with idiopathic, 
heritable or anorexigen associated PAH, unless there are clear features of HHT or PVOD / PCH 
(1, 235). If no disease associated variants are identified then screening for variants in ACVRL1, 
ENG and SMAD9 can be performed. If both these initial screens fail to identify a causal variant, 
then variants in the other genes associated with PAH can be assessed. Sanger sequencing and 
MLPA remain the gold standard for clinical genetic testing. Next generation sequencing (NGS) 
technologies allowing high throughput screening for variants in multiple genes may 
streamline this process (86, 238). NGS technologies are discussed further below. 
 
Treatment 
Treatment options for idiopathic and heritable pulmonary arterial hypertension remain 
limited. Current therapies licenced in the United Kingdom, Europe and the United States all 
act as pulmonary artery vasodilators. These licenced therapies do prolong survival, increasing 
exercise capacity and improve quality of life. However, there is currently no cure for the 
disease other than lung transplantation. 
 
Prostaglandin I2 (prostacyclin; normally synthesised in endothelial cells) and its analogues 
were first used to treat PAH (239, 240). They are agonists of the prostaglandin I2 receptor (a 
Gs protein coupled receptor), and cause vasodilation. They can also activate other prostanoids 
receptors (241). Endothelial surface receptor binding leads to activation of adenylyl cyclase, 
increasing cyclic adenosine monophosphate (cAMP), which in turn leads to the activation of 
protein kinase A (PKA) and ultimately phosphorylation of the myosin light chain kinase. 
Activation of other prostanoids receptors on pulmonary artery smooth muscle cells may 
cause anti-proliferative effects. Prostacyclin analogues currently used include, epoprostenol 
(intravenous), iloprost (intravenous and inhaled), treprostinil (intravenous, subcutaneous, 
and inhaled), beraprost (oral) and the prostaglandin I2 receptor agonist, selexipag (oral). 
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Randomised control trials have shown a prognostic benefit with intravenous epoprostenol 
therapy (226). 
 
Endothelial derived NO is another potent pulmonary artery vasodilator and acts by activating 
soluble guanylate cyclase, thereby increasing cytosolic cyclic guanosine monophosphate 
(cGMP) in pulmonary artery smooth muscle cells (242). cGMP causes a reduction in cellular 
calcium and hyperpolarisation of the cell membrane by activating potassium channels. 
Phosphodiesterase 5 inhibitors (PDE5i) such as sildenafil and tadalafil prevent the 
degradation of cGMP enhancing smooth muscle relaxation. Sildenafil monotherapy has been 
shown in randomised control trials to improve functional capacity and quality of life (243, 
244). 
 
Endothelin 1, produced by endothelial cells, is a potent vasoconstrictor which exerts its 
effects through endothelin receptors A and B (ET-A and ET-B). ET-A and ET-B are Gq coupled 
receptors. Activation of the receptors leads to an increase in inositol triphosphate (IP3) and 
diacylgycerol (DAG) by phospholipase C. IP3 binds to ligand gated calcium channels to release 
calcium into the cytoplasm and trigger smooth muscle contraction. Whereas DAG activates 
protein kinase C ultimately leading to increased phosphorylation of myosin light chain by 
inhibition of myosin light chain phosphatase. Endothelin receptor antagonists (ERAs), such as 
bosentan, ambrisentan and macitentan, block this signalling pathway leading to vasodilation. 
Bosentan and ambrisentan monotherapy has been shown to improve exercise capacity and 
symptoms, while also improving time to clinical worsening in extended studies (245-248). 
 
In more recent clinical trials, owing to the fact it would be unethical to run placebo-controlled 
trials on treatment naïve patients, randomised clinical trials have assessed the impact of 
introducing an additional drug class on top of existing therapies (249, 250). These studies 
showed that the addition of a new class of drug improves composite end-points, such as time 
to clinical worsening (that includes death, transplantation, initiation of intravenous therapy 
or worsening of pulmonary hypertension). A goal directed approach to the treatment of 
pulmonary hypertension has supported sequential combination therapy or increasing the 
dose of existing therapies (1, 251, 252). More recently, studies have shown that upfront 
combination therapy with two classes of drug (PDE5i and ERA) results in improved time to 
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clinical worsening (253, 254). A single French trial showed a benefit from upfront combination 
of all 3 classes of currently licenced pulmonary artery vasodilator therapies in those with 
severe disease (255). 
 
CCBs, such as diltiazem and nifedipine, are indicated only in those who show a vasoreactive 
response to an acute pulmonary vasodilator challenge. The dose of CCBs should be titrated 
up until the vasoreactivity is lost on follow up testing or patients do not tolerate further dose 
escalation. Failure to normalise pulmonary artery pressures and improve functional class 
should lead to commencement of pulmonary artery vasodilator therapies (1). 
 
Atrial septostomy creates a right atrial to left atrial shunt to improve pulmonary 
haemodynamics and improve left ventricular filling pressures (256, 257). It is now rarely 
performed and current guidelines limits its role to a palliative therapy or as a bridge to lung 
transplantation (1, 258). 
 
Lung transplantation remains the only potential cure for PAH and is considered in those with 
an inadequate haemodynamic and/or functional improvement following medical therapy (1). 
The mortality amongst patients with idiopathic PAH on lung transplantation waiting lists is 
greater than those with other chronic lung diseases. Therefore, prompt and appropriate 
referral for lung transplantation assessment is required (1, 259-261). On the other hand, with 
improvements in medical therapies, the rates of lung transplantation for PAH have fallen 
(262). Double lung transplants are the most common form of transplant offered to idiopathic 
PAH patients as the RV has been shown to reverse remodel and improve function following 
the reduction in RV afterload accompanying lung transplantation (263-265). 
 
Prognosis 
The median survival of patients with idiopathic and heritable PAH prior to the advent of 
pulmonary artery vasodilator therapies from the US NIH Study was just 2.8 years; while 1, 3 
and 5-year survival was 68 %, 48 %, and 34 % respectively (202). The changing demographics 
of the disease and differences in cohort composition can confound comparison to this early 
study, but in general survival in comparable and more recent cohorts have improved (Table 
3). In the UK National Registry 1, 3, and 5-year survival are reported as 93 %, 73 % and 61 % 
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respectively (25). Following lung transplantation the median survival in patients with 
idiopathic PAH is 10 years, although there is a significant early mortality risk for these patients 
(265). 
 
An important observation in many of these studies is the worse prognosis of incident patients 
when compared to patients with prevalent disease (202, 266, 267). Therefore, survival 
analyses from registry data that include both prevalent and incident cases should account for 
survivor bias. This bias arises from the fact that prevalent patients have already survived a 
certain period of time prior to enrolment in the study. Therefore, they can be considered to 
have either less severe disease or a better response to treatments compared to patients 
diagnosed at a similar time point but who die prior to enrolment in the study. In contrast, 
incident patients consist of both patients with a poor prognosis who die early and patients 
with a good prognosis. Consequently, incident patients will have a worse overall prognosis 
compared to prevalent patients. This may confound the results of survival analyses trying to 
identify other prognostic factors. 
 
A family history of PAH was an independent marker of poor prognosis in a cohort of patients 
with PAH in comparison to patients with idiopathic PAH (182, 268). In keeping with this finding 
Evans et al. report that patients with BMPR2 variants have a significantly worse prognosis 
than patients with idiopathic PAH (30). This was a consequence of poor RV function in the 
former group. Other variables consistently reported as independent prognostic indicators in 
multivariate models include age, gender, functional class, 6mwt distance, NT-ProBNP, 
pericardial effusion, DLCO, RAP, CO, CI and PVR (182, 183, 269-272). Although older patients 
have less severe pulmonary haemodynamics they have a worse all-cause mortality (273). 
Although, coronary artery disease is not an independent predictor of survival (274). With 
regard to gender, male patients aged over 60 years at diagnosis have the worst prognosis, 
whereas no difference in prognosis is seen between male and female patients under the age 
of 60 years (275). 
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Table 3. Summary of studies reporting survival in patients with idiopathic and heritable PAH 
Study Cohort 
1 / 2 / 3 / 5-year 
survival (%) 
Median survival 
(years) 
Significant prognostic variables 
on multivariate analysis 
National Institute of 
Health (US) (202) 
1981 – 1985 
Incident and prevalent 
“Primary pulmonary hypertension” 
PCWP < 12 mmHg 
68 / NA / 48 / 34 
Overall 2.8 
Incident 2.6 
Prevalent 3.2 
Functional class 3 or 4, mPAP, 
RAP, CI, diffusion coefficient for 
carbon monoxide (DLCO),   
Mexican cohort (221) 
1977 – 1991 
“Primary pulmonary hypertension” 
mPAP ≤ 22 mmHg 
 
Combined 4.0 
No vasodilator 
therapy 2.1 
Vasodilator 
therapy 5.0 
FVC, CI, RAP 
Pulmonary 
Hypertension 
Connection Registry 
(US) (269) 
1991 – 2007 
Incident 
Idiopathic, heritable, anorexigen 
associated PAH 
91 / NA / 75 /65  Age, functional class, RAP, CI 
Kawut et al. (US 
single centre) (195) 
1994 – 2002 
Incident 
Idiopathic, heritable or anorexigen 
associated PAH 
87 / NA / 75 / 61  
Ethnicity, albumin, CI, 
vasoreactivity, warfarin use 
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Hannover Cohort 
(Germany) (271) 
1995 – 2005 
Incident and prevalent 
Idiopathic PAH 
93 / 77 / 67 / 60  6mwt distance, RAP, PaCO2 
Spanish Registry of 
Pulmonary Arterial 
Hypertension (276) 
1998 – 2008 
Incident and prevalent 
Idiopathic PAH 
89 / NA / 77 / 68   
Ogawa et al. (Japan) 
(277) 
1998 – 2012  
Incident and prevalent 
Idiopathic and heritable PAH 
98 / 96 / 96 /96   
Jing et al. (China) 
(192) 
1999 – 2004 
Idiopathic and heritable PAH 
68 / 57 / 39 / 21   
Jansa et al. (Czech 
Republic) (278) 
2000 – 2007 
Incident and prevalent 
Idiopathic and heritable PAH 
85 / 70 / 62 / NA  
Incident group only: Creatinine 
clearance, 6mwt distance 
REVEAL (US) (279) 
2000 – 2009 
Incident and prevalent 
Idiopathic and heritable PAH 
91 / NA / 74 / 65   
Pulmonary 
Hypertension 
Registry of the 
2001 – 2009 
Incident 
93 / 84 / 73 / 61   
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United Kingdom and 
Ireland (25) 
Idiopathic, heritable and anorexigen 
associated PAH 
French Pulmonary 
Hypertension 
Network (183, 266) 
2002 – 2003 
Incident and prevalent 
Idiopathic, heritable and anorexigen 
associated PAH 
 
Incident:  
89 / 68 / 55 / NA 
Prevalent: 
89 / 77 / 69 / NA 
 
 
 Gender, 6mwt distance, CO 
Zeng et al. (China) 
(272)  
2006 – 2009 
Incident 
Idiopathic PAH 
84 / 74 / 71 / NA  
Age, BMI, pericardial effusion, 
absence of pulmonary artery 
vasodilator therapy 
Zhang et al. (China) 
(280) 
2007 – 2009 
Incident 
Idiopathic PAH 
mPAP > 30mmHg during exercise 
included 
92 / 80 / 75 / NA  
Including PAH associated with 
connective tissue disease: DLCO, 
functional class 
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Pulmonary veno-occlusive disease and pulmonary capillary haemangiomatosis 
Epidemiology 
PVOD / PCH are extremely rare forms of PAH. The French registry data contains arguably the 
most thorough assessment of PVOD / PCH in any national registry. However, their population 
includes at risk groups, such as North African families with high levels of consanguinity that 
predispose them to autosomal recessive genetic conditions such as PVOD / PCH. Therefore, 
the French registry data may not be generalisable to other populations. It is estimated that 
the prevalence of PVOD / PCH is 1 to 2 per million of the population (281). Whilst, the UK 
2015 National Pulmonary Hypertension Audit states that 1 % of all referrals in 2013 to 2014 
(approximately 20 patients) resulted in a diagnosis of PVOD / PCH (28). 
 
Pathophysiology of PVOD / PCH 
Genetic basis 
The first confirmed familial cases of PVOD / PCH were reported by Voordes et al. in 1978 
(282). In this family two brothers from non-consanguineous parents died at 8 weeks and 3 
months from PVOD. The authors concluded that the rarity of familial PVOD may suggest that 
environmental rather than genetic factors were the cause of the disease. A few years later a 
recessive pattern of inheritance was postulated for familial PCH in a report describing three 
siblings with PCH (283). 
 
In their seminal paper, Eyries et al. studied French families with PVOD (20). They noted that 
the disease was seen most commonly in children from consanguineous parents, suggesting 
an autosomal recessive pattern of inheritance. Through WES and Sanger sequencing they 
were able to identify biallelic EIF2AK4 variants as the cause of familial PVOD in all 13 families 
studied. They went on to show that approximately 25 % of patients with apparently sporadic 
PVOD also carried biallelic EIF2AK4 variants. 
 
Soon afterwards, Best et al. reported biallelic EIF2AK4 variants in patients with PCH, 
confirming that PVOD and PCH are part of the same disease spectrum (21). In this study one 
family with PCH was initially screened with WES to identify the causal variant. Subsequent 
assessment of patients with sporadic PCH revealed 20 % also carried biallelic EIF2AK4 
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variants. Interestingly, they also report a second family with an apparent autosomal dominant 
pattern of inheritance that did not carry EIF2AK4 variants. 
 
As discussed earlier, two recent reports have described a single family and a large kindred of 
Iberian gypsies with apparent heritable PAH, all of whom also carried biallelic EIF2AK4 
variants (22, 93). However, the phenotypic characterisation of patients in both studies was 
insufficient. 
  
Variants in BMPR2 have also been reported in 6 patients with apparent PVOD (41, 281, 284, 
285). However, some authors have argued that this is likely to be due to misclassification of 
these patients (281). 
 
GCN2 is part of the integrated stress response that stops global protein translation in 
response to environmental stressors such as amino acid starvation (286). Amino acid 
starvation results in an increase in uncharged transfer RNAs (tRNAs). Uncharged tRNAs, that 
would normally attach to essential amino acids that cannot be synthesised, bind and activate 
GCN2 (287). Therefore, GCN2 can act as a sensor for amino acid paucity and starts a series of 
reactions preventing the transfer of methionyl-initiator tRNA to the 40s ribosomal complex 
that is required to initiate translation. 
 
Activated GCN2 phosphorylates serine 51 of the eukaryotic translation initiation factor 2 
alpha subunit (eIF2a) (288, 289). eIF2a binds guanosine-5'-triphosphate (GTP) / guanosine-
5'-diphosphate (GDP) and is part of the heterotrimeric complex eIF2. Prior to protein 
translation, EIF2 binds with the guanine nucleotide exchange factor (eIF2B) to convert GDP to 
GTP. This conversion of GDP to GTP is inhibited if the serine 51 residue of eIF2a is 
phosphorylated (290). eIF2-GDP is unable to bind methionyl-initiator tRNA preventing the 
initiation of translation.  
 
Conversely, the sparsity of primed 40s ribosomal complexes facilitates the translation of 
activating transcription factor 4 (ATF4), which switches on pathways related to the integrated 
stress response. The translation of ATF4 is usually reduced in amino acid replete conditions 
by the presence of inhibitory upstream open reading frames (291). When there is a scarcity 
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of amino acids and few primed 40s ribosomal complexes, translation initiation is improved at 
the ATF4 start codon. 
 
The mechanism by which disease associated variants in EIF2AK4 (that are unable to 
phosphorylate eIF2a in response to cellular stresses) leads to PVOD / PCH is unknown. 
However, the importance of its role is suggested by the fact that environmental exposures 
associated with the development of PVOD / PCH also cause a reduction in GCN2 protein levels 
(292). 
 
Environmental exposures and toxins 
Alkylating agents 
Registry data from France has linked exposure to alkylating chemotherapy drugs such as 
cyclophosphamide and mitomycin-C, to the development of PVOD / PCH, giving weight to 
previous case reports suggesting an association (293). Furthermore, animals exposed to these 
agents developed pulmonary hypertension and demonstrated pulmonary venous 
remodelling (292, 293). Perros et al. linked exposure of mitomycin-C to GCN2 by 
demonstrating that administration to rats resulted in a reduction of GCN2 in lung tissue. 
 
Organic solvents 
A case-control study of consecutive patients presenting to the French National PH Centre 
showed an increased risk of exposure to organic solvents, particularly trichloroethylene, 
amongst patients with PVOD / PCH compared to PAH (294). In the study Montani et al. 
reported that PVOD patients with biallelic EIF2AK4 variants were younger at diagnosis 
compared to patients exposed to organic solvents. 
 
Histological descriptions 
In their 1970 paper of 156 patients with a clinical diagnosis of “primary pulmonary 
hypertension” Wagenvoort and Wagenvoort were able to identify 5 patients (3 %) who they 
classified histologically as PVOD (105). These patients had early onset disease (average age 
just 16 years) and were characterised by severe obstruction of the small pulmonary veins and 
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venules. Although pulmonary arterial changes were also observed this was not as severe 
compared to the “vasoconstrictive primary pulmonary hypertension” group. 
 
Pulmonary venous remodelling is the hallmark of PVOD / PCH (281, 295). Assessment of the 
lung parenchyma, often post-mortem or following lung transplantation, remains the gold 
standard for the diagnosis of PVOD / PCH. However, the histological features of PVOD / PCH 
can be heterogeneous in distribution, requiring careful assessment of all lobes of the 
explanted lungs for an accurate histological diagnosis (109). 
 
The main histological features of PVOD / PCH are intimal fibrosis of the paraseptal veins and 
capillary haemangiomatosis. Intimal fibrosis and thrombosis of the pulmonary venules and 
paraseptal veins can lead to occlusion of these vessels. The media of the paraseptal veins also 
show signs of “arterialisation” with medial hypertrophy and increased deposition of elastic 
fibres. In PVOD / PCH, unlike other forms of PAH (such as connective tissue disease associated 
PAH and PH associated with mitral stenosis), these pulmonary venous changes are usually 
florid and the predominant histological feature (296, 297). 
 
Haemangiomatosis of the pulmonary capillaries, whereby there is invasion of the pulmonary 
capillaries into surrounding tissue, is another hallmark of the disease. It is found in both PVOD 
and PCH, suggesting the two are part of the same disease spectrum (295). Pulmonary 
arteriopathy may also be present but is not the predominant feature. Other histological 
features associated with the disease include dilation of pulmonary lymphatics, presumably 
due to increased interstitial oedema, and enlarged mediastinal lymph nodes. Hemosiderin 
laden alveolar macrophages are also characteristic of PVOD / PCH and can be detected in 
bronchoalvelolar lavage fluid (298). Yet, these histological features do not always correlate 
with the clinical diagnosis. Stacher et al. reported two patients with a clinical diagnosis of 
PVOD who had histological features more in keeping with those with idiopathic PAH (106). 
Autopsy series have also confirmed that approximately 10 % of patients with a clinical 
diagnosis of PAH may have a histological diagnosis of PVOD (299). 
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Demographics 
The age of disease onset for PVOD / PCH is extremely wide from infancy to old age (20, 282, 
300). Interestingly, a bimodal distribution for age of diagnosis was suggested by Montani et 
al. with patients with biallelic EIF2AK4 variants presenting at an earlier age compared to those 
with exposure to organic solvents (294). 
 
The gender of patients also appears to vary depending on disease aetiology. Those with 
biallelic EIF2AK4 variants have an equal gender split, whereas there is a male predominance 
amongst those with exposure to organic solvents, likely reflecting gender differences in 
occupation (294). 
 
Clinical features and assessments 
The clinical features and results of clinical assessments for PVOD / PCH are not specific and 
similar to PAH. Autopsy series have suggested that up to 10 % of patients with histological 
evidence of PVOD / PCH may be misdiagnosed as PAH based on clinical assessments. 
Therefore, histological confirmation remains the gold standard for diagnosis. However, lung 
biopsy in patients with all forms of PH is associated with morbidity due to bleeding (1). 
Consequently, it is not routinely performed. 
 
Although not specific for PVOD / PCH, as it is also reported in PAH, digital clubbing has been 
described as a feature of the disease (301, 302). The most striking clinical characteristics of 
PVOD / PCH is a lower arterial oxygen saturation and more marked desaturation on exertion 
compared to patients with PAH (300). This is associated with a reduced KCO in patients with 
PVOD / PCH (303). Godinas et al. assessed the diffusion capacity of the lung for both carbon 
monoxide (DLCO) and nitric oxide (DLNO) to determine whether this reduction in gas exchange 
was due to reduced blood flow or impaired diffusion across the alveolar membrane. They 
report that patients with PVOD had a higher DLNO / DLCO ratio compared to patients with PAH, 
suggesting that the reduction in gas exchange was due to reduce blood flow through the 
capillary bed (304). Haemoptysis, which is also associated with BMPR2 variants, is not more 
common amongst patients with PVOD / PCH despite the presence of hemosiderin laden 
macrophages in bronchoalvelolar fluid (112, 298, 300). 
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Apart from confirming the presence of pulmonary hypertension, right heart catheterisation 
does not provide any additional information to suggest a diagnosis of PVOD / PCH. It is 
generally accepted that most patients with PVOD / PCH do not have an acute vasoreactive 
response, but some patients (even with biallelic EIF2AK4 variants) do show a positive 
response (305, 306). Some have argued that a response to inhaled nitric oxide can be used as 
a marker for response to pulmonary artery vasodilator therapies, although this has not been 
systematically investigated (307). The PCWP for patients with PVOD / PCH is usually less than 
15 mmHg unlike patients with PH associated with left heart disease. 
 
High resolution CT of the lung parenchyma is a useful tool for assessing for PVOD / PCH. 
Radiological features such as mediastinal lymphadenopathy, interlobular septal thickening, 
and centrilobular groundglass opacification may be suggestive of PVOD / PCH but all these 
features can also be found in other forms of PAH (222, 308). The presence of 2 of these 
radiographic features (along with a KCO < 60 % predicted, mPAP ³ 25 mmHg and PCWP £ 15 
mmHg) have been used in studies to identify patients highly likely to have PVOD / PCH (306). 
 
Treatment and prognosis 
No large randomised control trials have been performed in patients with PVOD / PCH. Case 
reports and series have suggested sildenafil and intravenous prostanoids therapies are of 
benefit in some patients with PVOD / PCH (309, 310). However, these pulmonary artery 
vasodilator therapies can result in fatal pulmonary oedema and therefore should be used with 
caution (300, 310-313). No trials have assessed which patients may be at highest risk of 
developing pulmonary oedema. Montani et al. report that pulmonary oedema can occur in 
both EIF2AK4 variant carriers (21 %) and those with idiopathic PVOD / PCH (23 %) (306). 
Consequently, lung transplantation remains the only form of treatment for some patients. 
Early referral for lung transplantation assessment is recommended as it is reported patients 
with PVOD / PCH have a higher risk of death while on lung transplantation waiting lists 
compared to patients with PAH (314). 
 
The prognosis for patients with PVOD / PCH is poor in comparison to PAH (276). Amongst 
patients with biallelic EIF2AK4 variants the 1, 2 and 3-year event free survival rates were 63 
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%, 52 % and 32 %. The rates for those without EIF2AK4 variants were similar: 75 %, 44 % and 
34 % (306). 
 
UK Pulmonary Hypertension Centres 
The clinical care of patients in the UK with PAH is centralised in 8 National Pulmonary 
Hypertension Centres and their satellite units (Appendix 1). The centralised system of care 
has resulted in specialist centres with a wealth of clinical experience and the infrastructure to 
conduct research into the disease. It facilitates the recruitment of patients in large numbers 
and standardises the work up and management of patients through the national pulmonary 
hypertension audits (28). 
 
National Institute of Health Research BioResource – Rare Diseases Study  
The National Institute of Health Research (NIHR) BioResource – Rare Diseases (BRIDGE) Study 
(https://bioresource.nihr.ac.uk/rare-diseases/rare-diseases/) was set up to investigate the 
genetic basis of rare inherited diseases whose pathogenesis remained uncertain. This was to 
be achieved through next generation whole genome sequencing (WGS), conducted by 
Illumina Inc (USA), and deep phenotyping. Idiopathic PAH was chosen as one of the rare 
diseases suitable for further evaluation. The other rare disease cohorts assessed as part of 
the study are listed in Appendix 2. 
 
Next generation sequencing 
Benefits and drawbacks of next generation sequencing 
NGS technologies differ from conventional Sanger sequencing and capillary electrophoresis 
by providing high-throughput, low cost, massively parallel (adapters used to create DNA 
libraries can be coded to identify different samples) and unbiased sequencing capabilities. 
NGS technologies can sequence the entire genome (WGS), protein coding sequences (WES) 
or just a panel of pre-defined genes (315). However, NGS technologies also have 
disadvantages compared to traditional Sanger sequencing. For example, the read lengths 
generated by NGS are comparatively short compared to that generated by capillary 
electrophoresis, this can make sequence alignment to a reference genome more difficult. 
There is also a higher error rate in base calling, which may lead to false positive variant calls. 
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In an assessment of a particular type of second generation sequencing technology called 
sequencing by synthesis (SBS; Illumina, USA), Bentley et al. compared SNVs called by SBS to 
genotyped calls and report > 99.5 % concordance between the two. Although, the false 
positive rate with SBS was 2.5 % (316). Sanger sequencing is recommended to confirm a NGS 
called variant (317). Furthermore, in their study of patients with heritable PVOD / PCH Eyries 
et al. demonstrated variants in EIF2AK4 that were initially not called by WES but were 
subsequently identified by Sanger sequencing (20). This lack of sensitivity is more significant 
in WES compared to WGS due to the biases introduced by the need for exon specific primers 
with WES. 
 
Another disadvantage of NGS, and in particular WGS, is the sheer volume of data generated. 
Consequently, false positive results and incidental findings need to be assessed and acted on. 
NGS based gene panels overcome this issue as only a small, targeted number of genes are 
assessed. This can be a useful first clinical screen for diseases where the genetic basis is well 
understood. Nonetheless, it is limited and biased as a research tool for identifying variants in 
novel disease associated genes or genetic modifiers. Even in complex polygenic diseases rare 
variation with relatively large affect sizes may explain the missing heritability seen in large 
studies assessing the role of common variation in disease (318). Therefore, WES and WGS are 
well suited to further investigate both rare and common genetic disorders (319). WES 
sequencing technology has already been used in families with heritable PAH and PVOD / PCH 
to identify variants in EIF2AK4, CAV1 and KCNK3 (20, 21, 75, 80). Importantly, all these studies 
confirmed identified variants through Sanger sequencing. 
 
While it is estimated 85 % of disease causing variants are in the protein coding sequence, WES 
has been shown to be less accurate and more biased compared to WGS (320). WES requires 
exon specific primers and polymerase chain reaction (PCR) amplification of these protein 
coding sequences. Whereas with the latest library preparation kits no PCR amplification is 
required for WGS, reducing the biases associated with primer selection. The use of primers 
can also result in a reduction in read depth (the number of sequencing strands covering a 
single position in the genome) in areas of the genome where there is an abundance of 
repetitive guanine and cytosine residues (GC rich areas) (321). WGS is also a better tool to 
assess structural variation across the entire genome by analysing drops in read depth and 
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differences in the distance between pair-end reads. Even in the protein coding sequence, 
WGS is more sensitive at identifying variants compared to WES (322). On the other hand, WES 
generally provides higher read depths, which may make it more suitable for identifying 
somatic variants and mosaicism compared to WGS. 
 
Sequencing by synthesis 
Illumina’s SBS technology is currently the most commonly used second generation 
sequencing technology (316, 317, 323). The first step in SBS is the creation of a library of DNA 
fragments. Initially, genomic DNA or complementary DNA (cDNA) molecules are randomly 
fragmented and ligated at both the 3’ and 5’ ends with adapter sequences. Fragments of a 
specific size are taken forward. These fragments are amplified by PCR to create a DNA library. 
Although the latest WGS technologies do not require PCR amplification. 
 
In preparation for sequencing, the library is exposed to a flow cell surface lined with 
complementary oligonucleotides to which the adapter sequences bind. The flow cell surface 
is where the sequencing reactions occur. However, the fluorescence signal generated by a 
single molecule is too weak to be picked up. Therefore, the bound DNA fragments undergo a 
process of bridge amplification, through solid state PCR, to create a cluster of approximately 
a million identical fragments in close proximity with each other. It is the fluorescent signals 
generated by these clusters that are detected by the sequencer. 
 
During each sequencing cycle, all four dideoxynucleotides (ddNTPs; adenine, guanine, 
cytosine and thymine) are flowed across the flow cell simultaneously. The ddNTPs 
competitively bind complementary nucleotides in the DNA fragments attached to the flow 
cell surface. Each added ddNTP is modified on the 3’ end to carry a specific fluorophore and 
blocking group. This allows identification of the ddNTP once it has been incorporated and 
prevents further binding to the 3’ end, ensuring only one ddNTP binds each DNA fragment 
during each cycle. An advantage of SBS over other NGS technologies is the presence of all four 
ddNTPs during each sequencing cycle (316). The competition for binding between the ddNTPs 
enhances the accuracy with which the ddNTPs bind the appropriate complementary 
nucleotides on the attached DNA fragments. 
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At the end of each reaction the fluorophores emit a flash of light after being excited by a laser. 
The sequencer determines the nucleotide incorporated within each cluster by identifying the 
wavelength of the light emission. This entire process is repeated after the fluorophores and 
blocking groups are removed, restoring the 3’ ends of the incorporated ddNTPs to allow 
further extension. In this manner, the sequence of the DNA fragments in each clonal cluster 
is determined one nucleotide at a time. The number of times the process is repeated 
determines the length of the sequence (the read length). 
 
For paired-end sequencing, double stranded DNA is created from the DNA fragments and the 
original strand removed from the flow cell before the process is repeated for the new 
complimentary strand. As the DNA fragments are of a known length and the read length is 
also known, the distance between the two paired-end sequences can be determined. This 
enhances alignment of reads to highly repetitive regions of the reference genome (mitigating 
one of the drawbacks of NGS technology) and facilitates the identification of structural 
variants (both small indels and larger deletions and insertions) (324). Paired-end sequencing 
also aids the identification and removal of PCR duplicates and has been shown to identify 
more SNVs compared to single-read sequencing.  
 
Bioinformatics pipeline 
Following sequencing several quality control (QC) and processing steps are required prior to 
the identification of both SNVs and structural variants. There is no gold standard but four 
steps are required: 1) QC of the reads, 2) alignment of reads against a reference genome, 3) 
variant and genotype calling and 4) variant annotation (325). Multiple open source and 
proprietary software options exist for each of these steps. 
 
As well as generating the reads, the sequencer can also estimate the quality of base calls at 
each position of a read (Phred quality score). This is based on numerous factors including 
signal intensity, signals from surrounding clusters and the location in a read (less accuracy at 
longer read lengths and at the very beginning of a read). This information along with the base 
calls, information regarding the sequencer and flow cell are contained in FASTQ text files 
generated by the sequencer. 
 
 67 
Further QC checks are performed on these FASTQ files. They can be analysed to assess Phred 
quality scores relative to read position, GC content, and the percentage of each nucleotide 
relative to the position in a read. These provide some estimates of the quality of the reads. 
After removal of the adapter sequences from the reads, the reads are further trimmed to 
remove inaccuracies at the beginning and end of each read. Furthermore, reads with extreme 
GC content can be removed to increase the overall quality of the remaining reads. 
 
The next step is to align and sort the reads against a reference genome. The Genome 
Reference Consortium (GRC) curates reference sequences for humans and other organisms. 
The current iteration for humans (GRCh38) was released in December 2013 and consists of 
sequencing data from many individuals. This superseded GRCh37, which was released in 
2009. GRCh38 increases the number protein coding sequences and improves sequence 
representation so that fewer reads from NGS remain unaligned (326). A particular issue with 
NGS generated reads is their comparatively short length, which means that it is harder to align 
to a reference genome, especially in areas of high variability (e.g. the major histocompatibility 
complex) or areas with many repetitive sequences areas (e.g. areas of high GC content) (327). 
Alignment software uses algorithms to maximise the consensus between a read and a section 
of the reference genome (328). However, variation in the reads, which can either be real SNVs 
or sequencing errors, complicate this process. Alignment software can take into account the 
quality scores of bases to identify potential errors in the reads. Ultimately unaligned reads or 
reads that align with more than one part of the genome are removed. The output of alignment 
software is usually in the Sequence Alignment/Map (SAM) format or its binary equivalent, 
BAM.  
 
Variant and genotype calling software takes aligned and sorted sequence information and 
determines differences compared to the reference genome. PCR duplicates must be removed 
at this stage to avoid potential variation in the duplicates biasing variant calling. The software 
uses Bayesian statistical models to determine if there is difference at a particular position 
compared to the reference genome (329). Several factors are taken into consideration 
depending on the software, such as the quality of the base call, the position within a read, the 
number of reads that call a variant, and variation around the position of interest. While 
databases of SNPs such as dbSNP can be used to determine prior probabilities for a variant at 
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a particular position. SNVs that fail checks such as deviation from the Hardy-Weinberg 
equilibrium, have insufficient coverage or poor-quality base calls are excluded to reduce the 
rate of false positive variants called. A variant call format (VCF) file contains information about 
variation in a genome and is the standard output of variant and genotype calling software. 
VCF files typically also contains information about where and what the variant is, a quality 
score for the variants and a summary of filters that a variant has passed. Additional 
information such as allele frequencies, deleteriousness scores, and associated phenotypes 
can be added. 
 
Once a variant has been identified further information is required to determine its 
significance and this is referred to as variant annotation. Variant annotation provides 
information of the consequence of a variant on transcription and translation (e.g. stop gained 
or missense variant), the frequency of the variant in previously studied populations, 
assessment of its conservation between different species and in-silico predictions of its 
deleteriousness. Databases, such as the Exome Aggregation Consortium (ExAC) database and 
the UK10K database, can be used to assess the allele frequency of variants in specific 
populations (330, 331). There are several different bioinformatic tools that predict the 
deleteriousness of a variant. Their methods vary but are generally based on in-silico 
predictions of biochemical affects, frequency in the general population and conservation 
between species. Examples include the combined annotation dependent depletion score 
(CADD score), PolyPhen-2 prediction and SIFT prediction (332-334). 
 
Medical Research Council / British Heart Foundation National Cohort Study of 
Idiopathic and Heritable Pulmonary Arterial Hypertension 
The Medical Research Council (MRC) / British Heart Foundation (BHF) National Cohort Study 
of Idiopathic and Heritable Pulmonary Arterial Hypertension (Cohort Study) was closely 
associated with the NIHR BRIDGE PAH Study. The aims of the study were to longitudinally 
follow up patients with PAH and PVOD / PCH in the UK, biobank samples from patients, recruit 
unaffected family members for longitudinal follow up and conduct epidemiological research. 
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Hypothesis 
My hypothesis was that idiopathic and heritable PAH are heterogeneous disorders, with 
diverse aetiologies, clinical features and outcomes, and that WGS and careful phenotyping of 
these patients could help identify clinically important subgroups. 
 
Aims 
My aims were to: 
1) To phenotype a contemporary cohort of patients with idiopathic and heritable PAH, 
as well as PVOD / PCH, from diagnostic data collected through the NIHR BRIDGE PAH 
Study. 
2) To identify prognostically important characteristics in patients with idiopathic PAH 
and use this to identify clinically important subgroups. 
3) To assess the phenotypes of patients with variants in the known disease-associated 
genes, in particular those with BMPR2 variants. 
4) To assess the phenotypic consequences of biallelic EIF2AK4 variants.  
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Methods 
My Thesis is the result of two highly collaborative studies (the NIHR BioResource – Rare 
Diseases Study [NIHR BRIDGE Study] and the MRC / BHF National Cohort Study of Idiopathic 
and Heritable Pulmonary Arterial Hypertension [Cohort Study]). My direct contributions to 
the Thesis are highlighted in bold in the Methods Section below. 
 
NIHR BioResource – Rare Diseases Study 
The NIHR BRIDGE Study, was set up to investigate the genetic basis of rare heritable diseases 
whose pathogenesis has not been fully elucidated. The study is comprised of several disease 
cohorts of which PAH was one (Appendix 2). The study involved WGS, performed by Illumina 
Inc (USA), and deep phenotyping of the disease cohorts. Patients recruited to other disease 
cohorts acted as controls for the PAH sub-study. Recruitment to the NIHR BRIDGE PAH Study 
started in January 2013 and was closed in May 2017 after recruiting the allocated number of 
patients (1250).  
 
MRC / BHF National Cohort Study of Idiopathic and Heritable Pulmonary Arterial 
Hypertension 
The Cohort Study is a longitudinal study recruiting UK patients with PAH and their relatives. 
Patients are followed up at approximately 6 monthly intervals as part of their routine clinical 
care. Clinical information from these visits are prospectively captured for the study. In 
addition, blood and urine samples from these patients are biobanked for future studies. 
Patients have the choice to take part in several sub-studies including an epidemiology study 
and a MRI study. Recruitment to the Cohort Study commenced in April 2013 and the study is 
still open to recruitment.  
 
My PhD started after the NIHR BRIDGE Study and the Cohort Study commenced patient 
recruitment. I was involved with later amendments to the studies and was responsible for 
the overhaul of the phenotype data captured for the studies as specified below. 
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Ethical approval and consent 
Ethical approval for the NIHR BRIDGE Study was organised by the NIHR BRIDGE study team 
for all disease cohorts. All patients recruited to the NIHR BRIDGE Study provided written 
informed consent by signing either NIHR BioResource – Rare Diseases consent forms 
(Research Ethics Committee ID: 13/EE/0325) or local tissue bank consent forms that specified 
the use of biobanked blood samples for genetic sequencing and capture of clinical data 
(including paper records, electronic records and imaging studies). Prospectively recruited 
patients from the UK signed NIHR BioResource – Rare Diseases consent forms. Deceased UK 
patients recruited through local tissue banks and non-UK patients had previously signed local 
tissue bank consent forms. 
 
Patients from the UK were recruited to the Cohort Study for longitudinal follow up. They 
provided written informed consent by signing MRC / BHF National Cohort Study of Idiopathic 
and Heritable Pulmonary Arterial Hypertension consent forms (13/EE/0203). Ethical approval 
for the Cohort Study was organised by the PAH coordinating team [Carmen Treacy, Katherine 
Yates, Jennifer Martin] and the principle investigator, Prof. Nicholas Morrell. I helped draft 
study amendments, including specifying the recruitment of patients with PVOD / PCH for 
both studies and control subjects for the Cohort Study. 
 
Explanted lung tissue from a single patient with PAH was obtained through the Papworth 
Hospital Research Tissue Bank (08/H0304/56). Patients recruited to the tissue bank provided 
written informed consent for use of explanted organs and tissue for research, including 
genetic studies. 
 
Patient recruitment 
For the NIHR BRIDGE Study, patients were recruited from all the UK pulmonary hypertension 
specialist centres as well as specialist centres in Europe (Appendix 1). Research nurses and 
coordinators at each centre were responsible for patient recruitment, initial blood sample 
processing and data entry. 
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Patients were recruited to the study from specialist pulmonary hypertension centres if they 
had a diagnosis of idiopathic, heritable or drug / toxin associated PAH based on the latest 
clinical guidelines (1). Patients with PVOD / PCH were also recruited. The diagnosis was based 
on right heart catheterisation demonstrating a mPAP ³ 25 mmHg and PCWP £ 15 mmHg 
measured at rest and in a supine position. For a diagnosis of idiopathic, heritable or drug / 
toxin associated PAH, other forms of PH needed to be excluded. For a diagnosis of PVOD / 
PCH a clinical suspicion of the disease was required based on computed tomographic imaging 
of the lung parenchyma in the absence of a histological diagnosis. 
 
Throughout this Thesis, patients are classified as idiopathic PAH or familial PAH based on the 
absence or presence of a family history of the disease. The term heritable PAH does not 
distinguish between PAH patients with variants in disease associated genes (with or without 
a family history of the disease), and patients with a family history of PAH with no identifiable 
variants in disease associated genes. In this Thesis the term heritable PAH is used intentionally 
to include those with an identifiable disease associated variant and / or a family history of the 
disease. It is also used when referring to previous publications and guidelines. 
 
Inclusion criteria 
1) Incident and prevalent patients with a diagnosis of: 
a) Idiopathic PAH 
b) Heritable PAH 
c) Drug and toxin associated PAH 
d) PVOD 
e) PCH 
2) Patients able to provide written informed consent 
 
Exclusion criteria 
1) Patients diagnosed with other forms of pulmonary hypertension 
2) Patients unable to provide written informed consent 
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Phenotype data 
OpenClinica 
Phenotype data was captured using an open-source secure online tool called OpenClinicaÓ 
(OpenClinica LLC, USA). Electronic case report forms (eCRFs) were adapted to capture 
demographic information and clinical assessments from both the time of diagnosis (Cohort 
and NIHR BRIDGE Studies) and from follow up visits (Cohort Study). The eCRFs were created 
on Microsoft Excel (Microsoft, USA) templates, which were uploaded into OpenClinica. An 
example spreadsheet is provided in Appendix 3 and a screenshot of an eCRF is shown in 
Appendix 4. I was responsible for overhauling how data was captured in OpenClinica after 
starting my PhD. This included creating open eCRFs (such as the drug and family history 
eCRFs which required continuous updating) and refining the templates for all the other 
eCRFs. In addition to correcting errors in the templates, the updates made data entry and 
analysis more efficient. 
 
The eCRFs were designed to minimise the use of free text. Drop boxes were provided where 
possible to allow selection of specific responses. Discrepancy notes could be created to record 
relevant information not captured in the standard eCRF fields or identify changes to data. I 
reviewed the first batch of discrepancy notes entered into OpenClinica and noted that 
entries into the discrepancy notes were haphazard and sometimes overly complicated. 
Consequently, I introduced a “controlled vocabulary” and standard operating procedure 
(SOP) to use when entering discrepancy notes to speed up entry and improve the analysis 
of the discrepancy notes (Appendix 5). 
 
A list of the eCRFs is shown below (Table 4) and a list of all the data items captured in 
OpenClinica is provided in Appendix 6. Most eCRFs captured information from a specific event 
(e.g. diagnosis, Cohort visit 1, visit 2 …), while others could be updated at any time (e.g. drug 
therapies, risk factors, family history). The choice of data to be captured in OpenClinica was 
made collaboratively with physicians from the UK pulmonary hypertension centres. 
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Table 4. Overview of data collected in OpenClinica for the NIHR BRIDGE PAH Study 
Type of eCRF Name of eCRF Information captured 
Diagnosis Arterial blood gases  
Body system Height and weight 
Clinical blood tests  
Clinical features at 
diagnosis 
 
Clinical features by 
examination 
E.g. clubbing, Raynaud’s 
Demographics Gender, date of birth and ethnicity 
Echocardiogram  
Electrocardiogram  
Exercise performance Walk test and cardiopulmonary exercise testing 
Functional class  
Haemodynamics 
Diagnostic right heart catheter ± vasodilator 
challenge 
ID capture Diagnosis, BRIDGE and Cohort Study IDs 
Imaging investigations  
Lung function 
Spirometry, lung volumes, KCO, overnight 
oxygen saturation 
Continuous 
Associated diseases 
e.g. presence of congenital heart disease, 
connective tissue disease 
Cohort relatives 
OpenClinica ID of relatives recruited to the 
Cohort Study 
Drug treatment (Other)  
Drug treatment (PAH)  
Family history  
Risk factors 
e.g. history of exposure to anorexigens, 
recreational drugs, pregnancy 
Suspension 
 
Death, transplantation or other reason for 
suspension including date  
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Data entry 
Research staff at each recruiting centre were responsible for data entry for patients recruited 
at their centre. Access to OpenClinica was on a named person basis and password protected. 
Accounts were only provided following a training session on the use of OpenClinica [study 
coordinators]. SOPs for using OpenClinica were created for reference and accessible to all 
sites. Individuals outside the core study team (i.e. the computational genomics group and 
study coordinators) were only given access to records of patients from their site. 
 
Diagnostic data for most patients recruited to the NIHR BRIDGE PAH Study was entered 
retrospectively from source data. Longitudinal follow up data for the Cohort Study was 
entered prospectively. Local hospital databases, including those storing radiographic images, 
as well as paper and electronic medical records served as the source data. Diagnostic data 
was defined as clinical information obtained prior to the commencement of pulmonary artery 
vasodilator therapies. Longitudinal follow up data for the Cohort Study was defined as clinical 
information obtained six weeks either side of a study visit date. 
 
Survival data for UK patients were obtained from recruiting centres through the NHS National 
Spine and local databases. A census of all patients was performed in November 2016. In 
addition to verifying whether a patient was alive or dead at the time, centres were also asked 
to provide the date of last contact with patients. To ensure the accuracy of the survival data, 
if a patient had not been seen for over one year, centres were asked to verify if they had been 
lost to follow up or had died. 
 
The European recruiting centres, with the exception of the VU University Medical Center, 
Amsterdam, did not have a named research team for the study. These European centres 
provided Microsoft Excel spreadsheets containing a limited range of phenotype data. 
Information in the spreadsheets were processed to ensure it was compatible with the 
OpenClinica database. This included conversion of values in different units and 
standardisation of categorical variables. This information was uploaded directly into the 
OpenClinica database [Matthias Haimel]. 
 
 76 
I assessed the completeness of the data entered into OpenClinica. This involved analysing 
the amount of data entered for each data item and assessing any patterns in missing data 
(e.g. lack of data being entered by a particular site). I looked specifically for missing data in 
demographic, haemodynamic or functional variables and asked each site to double check if 
these were available to maximise the amount of data available for analysis. 
 
Data storage 
Data entered into OpenClinica was stored on secure servers maintained by Cambridge 
University School of Clinical Medicine Computing Service and the computational genomics 
group. Access to the servers was on a named person basis with password protection and only 
through the Cambridge University Clinical School network. Data was stored in a SQL database 
and extracted using MySQL (Oracle, USA) [computational genomics group]. 
 
R (www.r-project.org) was used to process the extracted data prior to analysis [computational 
genomics group and myself]. I wrote scripts that combined data from OpenClinica with 
additional data provided in Microsoft Excel spreadsheets (e.g. phenotype data from the 
European centres), created secondary clinical variables (e.g. calculating age of disease onset 
and identifying pulmonary artery vasodilator responders based on haemodynamic criteria), 
and merged subject identifiers (IDs; OpenClinica IDs, BRIDGE IDs and Cohort IDs). The R script 
I wrote for these functions is provided in Appendix 7. The output was a single R data object 
that was used for further analysis, including data cleaning. 
 
Data cleaning and verification 
Several processes were put in place to ensure the accuracy of the phenotype data: 
1) Training and supervision: 
a. Training was provided to all research staff regarding data entry [study 
coordinators: Carmen Treacy, Katherine Yates, Jennifer Martin] 
b. SOPs were created and circulated to all sites 
c. Monthly teleconferences between sites were held to facilitate sharing of best 
practice and highlight any problems [study coordinators] 
2) Monitoring visits: 
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a. Each UK centre was visited by the study coordinators to review 10 % of 
recruited patients. A report was generated to highlight problems and further 
training given on site if required. 
3) I devised and carried out data error checks: 
a. The extracted data was assessed for: 
i. Implausible results (Appendix 8; e.g. mPAP > systolic pulmonary artery 
pressure [sPAP]) 
ii. Outliers: defined as 1.5 times the interquartile range (IQR) below the 
1st quartile and 1.5 times the IQR above the 3rd quartile 
iii. Anomalous results flagged up by visual inspection of plotted 
distributions of continuous variables 
iv. Anomalous results flagged by assessing the relationship between pairs 
of variables (Appendix 8; e.g. visual assessment of plots of FEV1 and 
FEV1 % predicted, or mPAP and sPAP). 
v. Gender differences between self-declared and WGS inferred gender 
b. Errors or queries identified by downstream analyses 
 
Results that were identified as either being incorrect or an outlier were collated into a master 
spreadsheet. I assigned a unique ID to each query (consisting of a patient’s OpenClinica ID, 
the visit number [e.g. diagnosis, visit 1, visit 2… etc.], the variable name and the initial value 
entered). This was used to exclude previously verified outliers from future rounds of checks. 
 
The queries were circulated to the appropriate centre to verify each result. Until a result was 
verified by the centre its was omitted from further downstream analysis. Results highlighted 
as an outlier may be incorrect or reflect an important clinical characteristic. Outliers may also 
overly influence the results of regression models. Therefore, if they were identified as 
influencing the result of such models they were excluded, and the models rerun (further 
details below). 
 
Despite these efforts the possibility of finding errors in the data during further analysis 
remained. Ad hoc queries, arising from downstream analyses, were handled in the same way 
as the outliers and errors described above. 
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Computed tomography imaging of the lungs 
CT images of the chest taken at the time of diagnosis (in a subset of patients that are defined 
below) were obtained from each centre where available. The images were sent to Papworth 
Hospital and the Royal Hallamshire Hospital after being anonymised and burnt to compact 
disc. The images were reported centrally by two expert radiologists in pulmonary 
hypertension [Dr Nicholas Screaton and Dr Andrew Swift], who were blinded to the diagnosis 
and genotype. The CT images were assessed based on a customised prospectively designed 
proforma (Appendix 9). The images were read independently and a consensus diagnosis (PAH 
or any suspicion of PVOD / PCH) reached for each patient. 
 
CT images for patients with biallelic EIF2AK4 variants from all centres were assessed and 
compared to CT images from patients with BMPR2 variants or with no variants in previously 
identified disease associated genes from Papworth Hospital and the Royal Hallamshire 
Hospital. Only patients with normal spirometry (FEV1 and FVC > 80 %, FEV1 / FVC > 0.7) were 
selected for the latter two groups. 
 
Histology 
The explanted lung tissue of one patient with a clinical diagnosis of idiopathic PAH and biallelic 
EIF2AK4 variants was available for further analysis. Four micrometre (µm) tissue sections 
were cut from formalin-fixed paraffin wax embedded blocks from the explanted lung tissue 
[Dr Mark Southwood]. Representative sections from each lobe of both lungs were stained 
with Haemotoxylin and Eosin and Elastic-Van Gieson stains. Two expert histopathologists 
examined the sections independently by light microscopy [Dr Peter Dorfmüller and Dr Stephen 
Preston]. 
 
Whole genome sequencing 
Sample preparation 
Whole blood samples, from patients recruited to the NIHR BRIDGE Study cohorts, were sent 
to the Cambridge Translational Genomics (CATGO) laboratory for central processing. Two six 
millilitre whole blood samples collected in ethylenediaminetetraacetic acid (EDTA) tubes 
were required for each patient. Genomic DNA was extracted from the samples then their 
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concentration and quality assessed by Qubit and gel electrophoresis respectively. The 
samples were sent to Illumina for preparation of DNA libraries (PCR free). The libraries 
underwent next generation sequencing using 100 to 150 bp paired-end sequencing on 
Illumina HiSeq 2500 and HiSeq X platforms (Illumina Inc, San Diego, USA). 
 
Bioinformatics pipeline 
The processing and annotation of the WGS data was performed by the NIHR BRIDGE Study 
bioinformaticians. Their contributions are specified in brackets below. Batches of FASTQ files 
were returned by Illumina to the BRIDGE Study core bioinformatics team for further 
processing into merged VCF files. Reads were aligned against GRCh37 and variants were called 
using the Issac Aligner and Variant Caller respectively (version 2, Illumina Inc.). Genebuilds for 
genes previously associated with PAH (BMPR2, ACVRL1, ENG, SMAD1, SMAD4, SMAD9, TBX4, 
KCNK3, CAV1, and EIF2AK4) were based on Ensembl v75. Variants in these genes were 
extracted and annotated using Ensembl’s Variant Effect Predictor (VEP) v84 [Dr Stefan Gräf] 
(335). VEP was also used to annotate data from the Exome Aggregation Consortium’s (ExAC) 
database (330). 
 
Deletions (resulting in the loss of more than 50 bp) were identified by applying Isaac copy 
number variant caller (Canvas, Illumina) and Isaac Structural Variant Caller (Manta, Illumina) 
[Matthias Haimel]. To be called by both Canvas and Manta deletions required a reciprocal 
overlap of ≥ 20 %. Overlapping deletions represented in the Zarrei dataset with a reciprocal 
overlap of ≥ 50 % and deletions with a non-PAH BRIDGE control frequency of more than 1 in 
1,000 were excluded (336). 
 
WGS inferred ethnicity assessment 
The Genesis package in R was used by Marta Bleda to estimate the ethnicities of patients 
recruited to the study. Initially, 2100 patients recruited to the 1000 Genomes Project with 
known ethnicity (European, African, East-Asian, South-Asian) were assessed based on a 
selection of 35,114 autosomal SNPs that were present in both the 1000 Genomes Project 
dataset and the NIHR BRIDGE Study, were fully sequenced in the BRIDGE dataset, and had a 
minor allele frequency of more than 0.3. PCA was performed on these SNPs and the loadings 
for the five leading principal components taken forward. The genotypes of the NIHR BRIDGE 
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PAH patients were compared to this and the likelihood of the individuals recruited to the 
study belonging to each of the 4 ethnicities calculated. The ethnicity with the highest 
likelihood was used as the WGS inferred ethnicity for that individual. 
 
Identification of unrelated individuals 
The PRIMUS software package was used to identify non-related individuals (i.e. no closer than 
3rd degree relationships) amongst both non-PAH BRIDGE control subjects and PAH patients 
[computational genomics group] (337). The number of unrelated non-PAH control subjects 
from other BRIDGE Study cohorts was maximised by including either patients with other rare 
diseases or their unaffected relatives. 
 
Variant filtering 
Likely causal variants were identified based on minor allele frequency (MAF) and predicted 
deleteriousness. Variants were considered further if they had a MAF of less than 1 in 10,000 
in unrelated non-PAH BRIDGE controls, the ExAC database and the UK 10K Study (330, 331). 
Rare variants that passed the MAF filtering step were then assessed for deleteriousness. 
Variants were considered pathogenic based on a CADD score ³ 15 and PolyPhen-2 or SIFT 
predictions not classified as “benign” or “tolerated” respectively (332-334). 
 
Statistical analysis 
I performed all the statistical analyses in R. R was also used to create the graphs presented in 
the Thesis. Annotated examples of the R code I used in the statistical analyses are provided 
in Appendix 10. 
 
Summary statistics 
Summary data is presented as median and IQR unless otherwise stated. Percentages were 
calculated using the number of subjects with recorded observations as the denominator. 
 
Group comparisons 
Differences between groups for categorical variables were assessed using Fisher’s exact test. 
Fisher’s exact test was selected (over the Chi square test) given that some features may be 
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rarely represented in the dataset (e.g. hyperlipidaemia in young patients). The Cochran-
Armitage test was applied, using the chisq_test function from the “coin” package, to assess 
between group differences for ordinal (ordered categorical) variables (338). Continuous 
variables were assessed for normality by performing the Shapiro-Wilk test and visually 
assessing histograms of their distributions. Non-parametric variables were assessed using the 
Mann-Whitney U / Wilcoxon rank-sum test (2 comparator groups) and the Kruskal-Wallis test 
(3 or more comparator groups). While parametric variables were assessed using the Student 
t test or ANOVA. Post-hoc pairwise comparisons were performed using Dunn’s test with 
Bonferroni corrections applied. 
 
Regression models 
Simple linear models were created to assess associations between variables. Dependent 
variables were transformed to normalise their distribution where required (square and 
square root transformations). Independent variables that were associated with the 
dependent variable with a p < 0.1 in simple models were used to create multiple linear 
models. Multiple collinearity between independent variables was assessed by calculating the 
variance inflation factors and assessing correlation matrices. Residuals plots for the models 
were visually inspected to confirm the suitability of the models and identify outliers with an 
extreme effect on the model.  
 
If the dependent variable could not be transformed to fit a normal distribution rank 
regression models were used to test for associations between variables. Rank regression uses 
the ranking of the data point in the dataset rather than its actual value for analysis. Therefore, 
they can be used to analyses variables that are not normally distributed. They are also less 
affected than linear models by extreme outliers. Multivariate rank regression models were 
created to assess differences between groups using the Rfit package (339). The Bent3 score 
was used to optimise the models for the skewed distributions. Models were checked by 
visually assessing q-q plots of the studentised residuals. 
 
Where missing data resulted in the loss of large numbers of subjects in multiple regression 
models these variables were excluded from the models. 
 
 82 
Survival analyses 
Semi-parametric Cox-proportional hazards models were used to assess survival using the 
“survival” package in R (340). Survival was assessed from both diagnosis to death (in which 
patients were right censored at transplantation) and diagnosis to death or transplantation. 
Covariates such as age at diagnosis, gender and genotype were used in the models. 
 
The proportional hazards assumptions were tested by assessing Schoenfeld residuals over log 
time (341). The goodness of fit of the model was assessed by plotting the log of cumulative 
hazard of the Cox-Snell residuals against the log of time and confirming the simple regression 
has a 0 intercept and a slope of 1 (342). 
 
The inclusion of retrospectively recruited and prevalent patients in a survival analysis 
assessing time from diagnosis to death / transplantation can cause immortal time bias. The 
immortal time is the period between diagnosis and enrolment in the study. Prospectively 
recruited patients must have survived up until recruitment. However, patients with a worse 
prognosis diagnosed at a similar time point may not have survived long enough to enrol in 
the study. The inclusion of retrospectively recruited patients introduces a further selection 
bias. To understand the effect of these biases, left truncated survival analyses were 
performed on UK patients recruited prospectively to the study. In these analyses, the survival 
period was defined as the time from diagnosis to death and patients only entered the risk set 
after enrolment into the study (consent date). This applied to all patients included in the left 
truncated analyses, so no selection bias was introduced and nor was the immortal period 
differentially misclassified. 
 
Over representation analyses 
Differences in the frequency of EIF2AK4 variants in a heterozygous state between PAH 
patients and non-PAH control subjects was assessed using the Fisher’s exact test. For this 
analysis only variants in unrelated subjects were included. The frequency of rare and 
predicted deleterious EIF2AK4 variants in a heterozygous state in PAH index cases was also 
compared to publicly available information in the ExAC database 
(http://exac.broadinstitute.org) (330). This analysis provides the maximum estimate of the 
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frequency of EIF2AK4 variants in a heterozygous state in the ExAC database as variants in 
ExAC were assumed not to be in a compound heterozygous state. 
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Results 1: Description of the NIHR BRIDGE PAH Study 
Introduction 
PAH is a heterogeneous group of related conditions defined haemodynamically by a mPAP ≥ 
25 mmHg and a PCWP ≤ 15 mmHg (1). PAH forms group 1 of the current clinical PH 
classification (Table 1) and is sub-classified based on disease pathogenesis (i.e. idiopathic, 
heritable, drug / toxin induced and associated forms). The classification is of clinical relevance, 
despite treatment options being similar for each subgroup, as the different subgroups have 
significantly different prognoses. For example, patients with heritable PAH and variants in 
BMPR2 and PAH associated with connective tissue diseases have a significantly worse 
prognosis compared to patients with idiopathic PAH (30, 343). In contrast, patients with 
exposure to anorexigens have a similar prognosis compared to those with idiopathic PAH 
(162, 344). 
 
Large national and international collaborations have set up registries of patients with PH to 
assess their clinical characteristics and long-term outcomes (25, 183, 192, 202, 266, 269, 279). 
The European Union Guidelines on Pharmacovigilance for Medicinal Products for Human Use 
define a registry as “a list of patients presenting with the same characteristic(s)” (345). This 
definition is of importance as these registries have differing inclusion and exclusion criteria. 
Differences are found in the diagnoses included, the haemodynamic criteria for inclusion 
and/or the inclusion of prevalent as well as incident cases. For example, the REVEAL study 
includes all patients with PAH, whereas the French registry limits its inclusion criteria to 
idiopathic, heritable and anorexigen associated PAH (183, 266, 279). Although this may lead 
to difficulties in direct comparisons it also provides the ability to contrast different 
populations of patients. The characteristics of some of the major registries are summarised 
in Table 3. 
 
Registries provide “real world” information regarding the assessment and follow up of 
patients with PAH. There is heterogeneity in assessments even within individual registries. 
Such heterogeneity may arise from subjectivity on the part of clinicians or from differences in 
guidelines and assays used in hospitals. As an example, significant variation in functional class 
determined by clinicians has been reported (346). Variability is also present in more objective 
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assessments, such as the measurement of PCWP, despite the availability of consensus 
guidelines (347). In part, this variation in practice increases the generalisability of registry 
derived data in comparison to data from randomised control trials. However, such variation 
also needs to be assessed as a potential confounder. A further drawback of registry data is 
that due to their observational nature datasets for individual patients may be incomplete. 
 
The inclusion of prevalent patients is a contentious issue in registries especially when 
assessing survival. The inclusion of such patients can lead to survival bias (whereby prevalent 
patients are likely to have less severe disease and therefore a better prognosis) and immortal 
time bias (whereby there is a period of time prior to the start of the study that is unobserved 
and patients with a poor prognosis would not have survived to be recruited in to the study). 
Yet, in a rare disease such as PAH, the recruitment of incident patients alone necessitates a 
prolonged recruitment period and a longer follow up period in order to observe enough 
events to sufficiently power any survival analysis. Alternatively, statistical methods, such as 
left truncation that delays the entry of prevalent patients into the risk set, can minimize these 
biases (348). 
 
PAH registries have sought to assess characteristics of prognostic significance (Table 3). 
However, most variables identified to be of prognostic significance have not been validated 
across all studies. The heterogeneity in study design and insufficient study power may in part 
explain this lack of concordance. Variables shown to be of prognostic significance across 
several studies include age, gender, functional class, 6mwt distance, NT-ProBNP, pericardial 
effusions, DLCO, RAP, CO, CI and PVR (182, 183, 269-272). Risk stratification calculators have 
been formulated to identify patients with poor outcomes using these prognostic variables (1, 
266, 349, 350). Early identification of patients with poor outcomes can lead to more 
aggressive upfront treatment and/or early referral for lung transplantation assessment. 
Although, many registries have sought to identify variables of prognostic significance, only a 
few studies have sought to describe idiopathic PAH patients by dichotomising them based on 
these variables (351). 
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The BRIDGE PAH Study is a prospective study enrolling patients with PAH to elucidate the 
genetic basis of the disease through WGS and phenotyping. The study shares many of the 
features of a registry described above. In this chapter I will aim to: 
1) Describe the quality of the phenotype data captured as part of the study. 
2) Describe the demographics and disease aetiology of patients recruited to the study. 
3) Identify characteristics of prognostic importance in idiopathic PAH. 
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Phenotype data verification 
Before detailed analysis of the diagnostic phenotype data collected as part of the BRIDGE PAH 
Study, I assessed the data for accuracy and completeness. A data freeze was performed on 
14/10/2017. Only patients with WGS data available at this time were taken forward for 
further assessment and phenotype data captured in OpenClinica by this date was used. 
 
One-thousand one-hundred and thirty-one patients recruited to BRIDGE PAH Study had been 
sequenced by the time of the data lock. On review, 61 patients were determined not to meet 
the inclusion criteria for the study and were excluded. For the remaining 1,070 patients, 
108,218 data points had been captured in OpenClinica. On average this equated to 101 data 
points per patient recruited to the study. Given the retrospective nature of data collection, 
manual data entry and variation in practices between centres I systematically assessed data 
entry to maximise data capture and ensure its accuracy for downstream analyses. 
 
Data completion 
The amount of diagnostic data entered into OpenClinica varied between the recruiting 
centres (Table 5). In particular, the European centres that did not have dedicated research 
staff for the study provided limited phenotypic data. The exception to this was the VU Medical 
Center in Amsterdam that had named research nurses responsible for data entry directly into 
OpenClinica. 
 
Great Ormond Street Hospital, a paediatric specialist centre, entered less data compared to 
the UK adult pulmonary hypertension centres. This reflects differences in the assessment of 
paediatric patients, for example exercise testing and lung function testing are not routinely 
performed (Figure 2). The data completion rates for all diagnostic data from all recruiting 
centres are provided in Appendix 11 and summarised in Figure 3. 
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Table 5. Amount of diagnostic data collected in OpenClinica  
 Number 
of 
patients 
recruited 
Number of data 
points captured 
in OpenClinica 
Average number 
of data points 
captured per 
patient 
Royal United Hospital, Bath 23 3363 146.2 
Royal Free Hospital, London 29 4117 142.0 
Hammersmith Hospital, London 249 34224 137.4 
Royal Jubilee Hospital, Glasgow 80 10534 131.7 
Royal Brompton Hospital, London 59 7452 126.3 
VU University Medical Center, 
Amsterdam 
45 5602 124.5 
Freeman Hospital, Newcastle 59 7331 124.3 
Royal Hallamshire Hospital, Sheffield 118 13898 117.8 
Papworth Hospital, Cambridge 120 13910 115.9 
Great Ormond Street Hospital, 
London 
10 1009 100.9 
Slovenia* 3 253 84.3 
University of South Paris 144 4541 31.5 
San Matteo Hospital, Pavia 49 989 20.2 
University Hospital Giessen 77 995 12.9 
*3 paediatric onset patients 
 
 89 
 
 
 
Figure 2. Differences in data collection by recruiting centre 
The amount of data collected in OpenClinica was assessed. The mean number of data items captured and 
entered into OpenClinica for each eCRF for each centre was calculated. This value is presented in the figure. 
Each column is coloured according to rank with the centre collecting the least data for a particular eCRF coloured 
red and the centre collecting the most data coloured blue. The European recruiting centres provided much less 
phenotypic data than the UK centres. 
 
 
Centre Arterial	blood	gas Body	system Blood	tests Examination History Echo ECG Exercise	test
Right	heart	
catheterisation
Vasodilator	
study Imaging Lung	function
Golden	Jubillee	
Hospital 4.1 4.4 36.1 10.6 6.0 7.2 9.0 10.7 17.8 5.9 8.4 9.5
Great	Ormond	
Street	Hospital 0.5 4.4 30.3 10.3 6.1 8.7 7.4 2.2 16.3 6.6 3.4 1.3
Hammersmith	
Hospital 3.2 3.4 45.2 11.3 6.3 7.7 8.9 12.1 14.9 3.4 8.9 11.2
Freeman	Hospital 3.7 4.8 35.3 9.9 6.9 6.5 7.3 10.8 17.4 4.2 3.4 9.0
Papworth	Hospital 1.7 4.9 34.9 10.3 6.6 6.9 5.4 7.7 16.2 2.1 5.7 8.6
Royal	Brompton	
Hospital 2.9 4.6 38.6 10.3 6.5 7.2 7.1 8.7 14.0 7.2 8.8 7.4
Royal	Free	Hospital 1.7 5.0 44.7 10.3 6.9 7.0 7.5 8.1 19.2 9.4 8.1 10.0
Royal	Hallamshire	
Hospital 0.9 4.7 32.2 10.4 6.8 5.1 7.6 6.6 17.0 7.0 9.7 5.7
Royal	United	
Hospital	Bath 0.8 5.0 47.9 11.6 7.0 10.0 10.3 9.6 20.6 4.3 10.2 10.4
San	Matteo	
Hospital 0.0 0.0 0.0 0.0 1.0 0.0 0.0 1.6 6.7 0.9 0.0 0.0
Slovenia 0.0 5.0 8.3 11.0 6.7 6.7 7.0 4.3 15.0 8.7 4.3 0.7
University	Hospital	
Giessen 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 2.9 0.0 0.0 0.0
University	of	South	
Paris 0.0 0.0 0.0 0.0 5.8 1.0 0.0 3.5 8.3 0.0 0.0 0.0
VU	University	
Medical	Center	
Amsterdam
2.2 4.8 30.2 8.5 6.6 5.8 7.7 16.1 16.1 8.1 9.7 5.6
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Figure 3. Summary of the completeness of data collection in OpenClinica 
The amount of data captured in OpenClinica was assessed for each data item (or variable; n = 257). The 
figure is generated from the data presented in Appendix 11, which provides the name and amount of data 
collected for each item. Approximately one-third of the data items requested in OpenClinica have a data 
completion rate of more than 75 %. A similar proportion of data items have a data collection rate of less 
than 25 %. Future studies may choose to exclude poorly reported data that are less informative and focus 
on better reported data items. 
 
Given the discrepancy between UK and European centres, only data completion for the UK 
pulmonary hypertension centres was assessed further. The data completion rates for selected 
data items (variables) are shown in Table 6. Data items related to cardiopulmonary exercise 
testing, acute pulmonary artery vasodilator challenge testing and z-scores of pulmonary 
function tests were the least well reported. Only 33 % of data items had completion rates 
more than 75 %. A similar proportion (34 %) had completion rates of less than 25 %. 
 
Even amongst UK centres there were differences in the amount of data entered. This may 
represent variation in clinical practice and record keeping between centres. As an example, 
echocardiography is no longer routinely used to assess patients referred to the Royal 
Hallamshire Hospital, Sheffield as this has been replaced with cardiac MRI. Missing data in 
what were considered core variables (gender, date of birth, date of diagnosis, mPAP, PCWP, 
CO, functional class and 6mwt distance) were queried with the centres. Despite this, PCWP, 
a haemodynamic criterion required for the diagnosis of PAH, was only available for 81 % of 
patients. This may reflect difficulties in obtaining an accurate PCWP (352). In order to 
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maximise the number of patients included in the study a missing PCWP was accepted if the 
expert centre felt that the clinical diagnosis was consistent with the inclusion / exclusion 
criteria. 
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Table 6. Data completion rates for selected variables from UK centres 
Item name Number complete % complete 
Date of birth 747 100.0 
Centre 747 100.0 
Gender 747 100.0 
Diagnosis 746 99.9 
Ethnic category 746 99.9 
Weight (kg) 709 94.9 
Date of right heart catheterisation 709 94.9 
Functional class 704 94.2 
mPAP (mmHg) 698 93.4 
WBC (x109/l) 695 93.0 
Hb (g/l) 691 92.5 
Platelets (x109/l) 690 92.4 
Height (cm) 689 92.2 
sPAP (mmHg) 688 92.1 
dPAP (mmHg) 686 91.8 
Creatinine (µmol/l) 681 91.2 
Systemic diastolic BP (mmHg) 677 90.6 
Systemic systolic BP (mmHg) 677 90.6 
CO (L/min) 675 90.4 
RAP (mmHg) 667 89.3 
Resting SaO2 (%) 652 87.3 
6mwt distance (m) 636 85.1 
PVR (WU) 625 83.7 
FEV1 (L) 625 83.7 
FVC (L) 621 83.1 
SvO2 (%) 617 82.6 
FEV1 (% predicted) 615 82.3 
PCWP (mmHg) 606 81.1 
FVC (% predicted) 600 80.3 
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KCO (mmol/min/kPa/l) 561 75.1 
KCO (% predicted) 532 71.2 
NT-ProBNP (ng/l) 194 26.0 
6mwt – six minute walk test, BP – blood pressure, CO – cardiac output, dPAP – diastolic 
pulmonary artery pressure, FEV1 – forced expiratory volume in 1 second, FVC – forced 
vital capacity, Hb – haemoglobin, KCO – transfer coefficient for carbon monoxide, mPAP 
– mean pulmonary artery pressure, NT-ProBNP – N terminal Pro brain natriuretic 
peptide, PCWP – pulmonary capillary wedge pressure, PVR – pulmonary vascular 
resistance, RAP – right atrial pressure, SaO2 – peripheral arterial oxygen saturation, sPAP 
– systolic pulmonary artery pressure, SvO2 – mixed venous oxygen saturation, WBC – 
white blood cells 
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Monitoring visits 
The BRIDGE PAH / Cohort Study coordinators have monitored each UK centre twice since the 
study began. I analysed the monitoring report forms generated to assess the errors picked up 
during the monitoring visits. The monitoring reports documented errors identified in 
OpenClinica but did not always specify which data fields were verified as correct. The stated 
aim was to check all diagnostic data fields for patients selected for monitoring. Therefore, it 
was not possible to quantify accurately which variables in OpenClinica were checked. To 
improve this and allow better quantification of errors, the discrepancy note function in 
OpenClinica will be used to document which variables are checked in future monitoring visits. 
 
During the monitoring visits, 85 patient records (8 % of all patients recruited and 11 % of UK 
patients) entered in OpenClinica were compared to source documentation. In total 74 errors 
were identified, all of which were amended. Thirty errors related to right heart 
catheterisation data. The Royal Brompton Hospital had 4 queries related to the clinical 
diagnosis and 2 of these patients were subsequently excluded from the study. The 
identification of these errors at the Royal Brompton Hospital resulted in changes to the 
oversight of the research nurses and review of all patients recruited to the study by both the 
research nurses and the principle investigator. 
 
Missing data for the core variables (defined above) were identified in 15 patients and 
amended. Three-hundred and seven eCRFs, from 75 patients, were identified as having 
accurate records. 
 
Data verification  
To further improve the accuracy of the phenotype data entered into OpenClinica I checked 
the data for errors and outliers (Appendix 8). Items flagged up by these checks were sent to 
the centres for verification and correction in OpenClinica if required. In total 2,017 queries 
were raised. This consisted of 85 errors, 90 unit discrepancies, 5 gender discrepancies (WGS 
inferred gender different from the gender entered into OpenClinica), 24 date queries and 
1,813 outliers. A total of 1,486 queries (74 %) were checked by the centres, 437 queries (22 
%) were still pending verification and 94 queries (5 %) were not checked as the source 
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documentation was no longer available. From the queries that were checked by the centres 
262 (18 %) resulted in a change to the data entered in OpenClinica. Data related to queries 
that could not be confirmed or were still pending confirmation were removed from further 
analysis. 
 
After I had verified these queries with the recruiting centres a number of critical discrepancies 
remained. There was a mismatch between WGS inferred gender and the gender entered into 
OpenClinica for 3 patients. There was no history of gender reassignment in these patients. It 
is likely that these DNA samples were incorrectly assigned. Consequently, these patients were 
excluded from further analysis. 
 
Nine patients who had a mPAP < 25 mmHg were also excluded from further analysis. Forty-
two patients had a PCWP and/or a left ventricular end diastolic pressure (LVEDP) > 15 mmHg, 
these patients were excluded from subsequent analyses. Another 213 patients did not have 
a recorded PCWP or LVEDP but were included in the study as they were confirmed to have a 
clinical diagnosis consistent with the inclusion / exclusion criteria. A further 66 patients did 
not have a mPAP recorded but were also included in the analysis as they were confirmed to 
have a clinical diagnosis consistent with the inclusion / exclusion criteria. 
 
Differences between recruiting centres 
An important confounder to take into account was variation in practices, protocols and assays 
between the different recruiting hospitals. Given the limited data that was provided by most 
European centres, I assessed for differences amongst the recruiting UK centres and the VU 
Medical Center, Amsterdam. After correction for multiple testing 55 variables remained 
significantly different between centres. These are summarised in Appendix 12 and Figure 4. 
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Figure 4. Significant difference between patients under the care of different recruiting 
centres 
Differences in the characteristics of patients from different recruiting centres were assessed. Fisher’s exact test 
was used to assess differences in categorical variables and the Kruskal Wallis test was used to assess differences 
in continuous variables. Correction for multiple testing was made with the false discovery rate adjustment. 
Variables that remained significantly different are summarised in the figure. Each column is independently 
coloured according to the rank of each centre to aid visualisation of which centres may be responsible for the 
significant differences. As expected paediatric patients from Great Ormond Street Hospital were responsible for 
some of the extreme values compared to other centres. 
 
Values indicate the median value (continuous variables) or the percentage of the total (categorical variables) for 
each recruiting centre. 
 
6mwt – six-minute walk test, BMI – body mass index, BSA – body surface area, CI – cardiac index, CO – cardiac 
output, DBP – diastolic blood pressure, dPAP – diastolic pulmonary artery pressure, FEV1 – forced expiratory 
volume in 1 second, FVC – forced vital capacity, RAP – right atrial pressure, mPAP – mean pulmonary artery 
pressure, PCWP – pulmonary capillary wedge pressure, RBBB – right bundle branch block, RV – right ventricle, 
Age RAP sPAP dPAP mPAP PCWP CO CI SvO2 RV	diastolic	volume RVEF
Abnormal	
RV	on	echo TAPSE
Glasgow 52.3 8 87 32 52 8 3.8 2.1 62.9 191 39 70 1.4
Great	Ormond	
Street 7.8 5 46.5 16.5 29.5 7.5 3.1 3 69.3 98.5 58 8 1.9
Hammersmith 47.5 10 85 33 54 10 3.7 2 64 203.5 35 218 1.5
Newcastle 59.1 8 81 28 48 8 4 2.1 65 223 34.5 47 1.6
Papworth 47.8 8 88 35 53 10 3.5 2 66.5 201 36 96 1.6
Royal	Brompton 42.9 6 79 35 53 7.5 3.9 2 64.7 190 45 46 1.6
Royal	Free 46.7 9 91 35 54 11 4.2 2.4 66 197 33 21 2
Bath 62 11 91 38 57 14 3.9 2 61.9 119.5 46 21 1.6
Sheffield 51.3 10 87 36 55 10 4 2.2 62.4 146.7 37 74 1.4
Amsterdam 45.3 7.5 78 33 50 8 4.6 2.4 67.5 142 40 18 1.5
Syncope RBBB Dominant	R	wave Vasoresponder
6mwt	
distance
FVC	(%	
predicted)
FEV1	(%	
predicted)
Resting	
SaO2
Pre	walk	
SaO2
Post	walk	
SaO2 Height Weight BMI BSA
Systemic	
SBP
Systemic	
DBP
Glasgow 28 15 30 7 320 97 87 94.5 94.5 87 163 78.4 28.7 1.9 121 74
Great	Ormond	
Street 7 0 1 0 240 56 52 98 95 97 121.2 21.6 16.2 0.8 93.5 57.5
Hammersmith 65 53 86 2 280 89 82.1 95 96 93 165 73 27.6 1.9 126 78.5
Newcastle 6 7 15 2 313 92 80.5 94 94 89 162.5 75 28.3 1.8 118 72
Papworth 27 10 11 7 343 100 88 96 96 91 163 74.1 27.1 1.8 120 76
Royal	Brompton 15 9 7 0 315 93.2 81.2 95 97 92 164 77.5 26.8 1.8 117 74
Royal	Free 7 4 10 1 352 98.3 80.3 95 96.5 94.5 165 73 27.1 1.8 118 78
Bath 5 2 13 0 209 101 90 95 96 92 163 87 31.6 1.9 125 82
Sheffield 24 11 15 11 320 98.3 87.5 96 95 86 165 78.5 27.9 1.9 124.5 78.5
Amsterdam 5 2 20 2 475 102 96 97 97 93 169 72 24.3 1.8 114 80
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RVEF – right ventricular ejection fraction, SBP – systolic blood pressure, sPAP – systolic pulmonary artery 
pressure, TAPSE – tricuspid annular plane systolic excursion.  
 
Figure 4 demonstrates qualitatively that many of the differences identified are due to patients 
recruited from Great Ormond Street Hospital and Royal United Hospitals Bath (Bath). To 
quantify which pairwise comparisons were significantly different Dunn tests were performed 
with Bonferroni corrections. As expected age at diagnosis was significantly different between 
centres, in particular patients had a significantly younger age at diagnosis at Great Ormond 
Street Hospital (median [IQR]: 8 years [5 - 10]) compared to all the other centres. Additionally, 
the age at diagnosis of patients recruited in Amsterdam (45 years [29 - 51]) was younger 
compared to Glasgow (52 years [41 - 66]), Newcastle (59 years [41 - 69]) and Bath (62 years 
[48 - 72]; all p < 0.05). Brompton (43 years [33 - 54]) also had a younger age at diagnosis 
compared to Newcastle and Bath (p < 0.05). The centres based in London (Great Ormond 
Street, Royal Brompton, Royal Free and Hammersmith Hospital) and Amsterdam had a higher 
proportion of non-European patients compared to the other centres. The proportion of 
female patients was not significantly different between centres. 
 
With regard to pulmonary haemodynamic variables, mPAP was significantly lower amongst 
patients from Great Ormond Street (30 mmHg [28 - 33]) compared to patients from all other 
centres except for Newcastle (48 mmHg [39 - 56]). Whereas the PCWP was significantly lower 
in patients from Glasgow (8 mmHg [5 - 10]) compared to Hammersmith (10 mmHg [8 - 13]), 
Royal Free (11 mmHg [9 - 12]), Bath (14 mmHg [11 - 15]) and Sheffield (10 mmHg [8 - 13]; all 
p < 0.05). While Bath (14 mmHg [11 - 15]) had higher PCWPs compared to Papworth (10 
mmHg [8 - 11]), Hammersmith, Newcastle (8 mmHg [6 - 10]), Brompton (8 mmHg [6 - 11]) 
and Amsterdam (8 mmHg [7 - 10]; all p < 0.05). CI was similar between most centres. 
Although, patients from Amsterdam (2.4 L/min/m2 [2.0 - 3.2]) had a higher CI compared to 
patients from Hammersmith (2.0 L/min/m2 [1.6 - 2.6]) and Papworth (2.0 L/min/m2 [1.6 - 2.4]; 
all p < 0.05). 
 
Differences in the demographics of each centre’s catchment area and variation in local assays 
and tests are likely to explain the disparities between the centres demonstrated above. 
Therefore, in regression models presented in this Thesis, recruiting centre was always 
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assessed as an independent variable in univariate models. If significant in univariate models 
recruiting centre was also included as a covariate in multivariate models. 
 
Patient recruitment 
A total of 1,327 patients were recruited to the BRIDGE PAH Study; the recruitment target was 
1,250. WGS data was available for 1,131 patients (85 %) at the time of the data lock. 
Sequencing data for the remainder was pending delivery by Illumina. One-hundred and 
twelve patients were excluded following the data verification and cleaning processes 
described above. The remaining 1,019 patients were retained for analysis. Of these 1,019 
patients, 1,009 were classified as index cases and 10 as affected relatives. A breakdown of the 
study population is provided in Figure 5. 
 
 
Figure 5. Composition of patients recruited to the NIHR BRIDGE PAH Study and used for 
analysis 
 
In the results chapters of this Thesis patients are classified as having either familial PAH or 
idiopathic PAH, based on the presence or absence of a family history of the disease. The term 
heritable PAH is used when referring to patients with a causal variant in a disease associated 
1327 patients 
recruited to the 
BRIDGE PAH 
Study  
1131 WGS data 
available
1019 retained for 
analysis
Exclusions:
58 – not meeting inclusion / exclusion 
criteria
3 – gender discrepancies
9 – mPAP < 25 mmHg
42 – PCWP / LVEDP > 15 mmHg
998 PAH 21 PVOD / PCH
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gene or those with a family history of the disease. Additionally, the term PAH is used to refer 
to patients with either heritable, idiopathic PAH or drug/toxin associated PAH. It does not 
include the other forms of PAH listed in group 1 of the current classification (1). 
 
Demographics 
Gender 
Sixty-eight percent of the study population were female, resulting in a 2.2 : 1 female gender 
bias. This bias was not significantly different between patients diagnosed with PAH (2.2 : 1) 
and PVOD / PCH (1.6 : 1; Fisher’s exact test p = 0.489). 
 
Age at diagnosis 
The median age of the study population was 49 years [36 - 63] (median [IQR]). This was not 
significantly different between patients diagnosed with PAH (49 years [35 - 63]) and PVOD / 
PCH (54 years [42 - 68); Wilcoxon rank-sum test p = 0.172). The age at diagnosis was 
significantly different between male and female patients. Male patients were diagnosed later 
in life (53 years [38 - 67]) compared to female patients (48 years [34 - 61]; Wilcoxon rank-sum 
test p = 0.003). This appears not to be due to a delay in diagnosis in male patients as the time 
from symptom onset to diagnosis was similar between male (1.2 years [0.6 - 2.5]) and female 
patients (1.1 years [0.6 - 2.1]; Wilcoxon rank-sum test p = 0.928). 
 
The density plots of age at diagnosis show bimodal distributions for both male and female 
patients, but this was most obvious for male patients (Figure 6). For female patients, the 
modes were at 33 years and 49 years. Whereas for male patients, the modes were at 43 years 
and 68 years. The nadir for male patients, 53 years, was selected to dichotomise the study 
population into “younger” and “older” groups. Based on this dichotomisation 57 % of patients 
were classified in the younger group and 43 % in the older group. In the older group, there 
was still a female gender bias (1.7 : 1) but this was significantly less than in the younger group 
(2.6 : 1; Fisher’s exact test p = 0.003). 
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Figure 6. Density plot showing the distribution of age at diagnosis by gender  
Age at diagnosis was calculated for all patients (n = 1019).The density plot is chosen to represent the data over 
a histogram because of the large overlap between the two groups. As age at diagnosis is a continuous variable 
and there are a large number of observations a density plot is a valid visualisation of the data. A bimodal 
distribution for age at diagnosis can be seen for both genders. Additionally a higher proportion of male patients 
(35 %) are diagnosed at an older age (defined as over 53 years) compared to female patients (22 %). 
 
A bimodal distribution for age at diagnosis was seen amongst patients with a diagnosis of 
PVOD / PCH (Figure 7). These patients have modes at 46 years and 67 years. In contrast, 
patients with a diagnosis of PAH have a unimodal distribution for age at diagnosis (mode: 45 
years) when not dichotomised by gender. 
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Figure 7. Density plot of age at diagnosis by clinical diagnosis  
A bimodal distribution can be seen for the age at diagnosis for patients with PVOD / PCH (modes at 46 and 67 
years), perhaps indicative of the distinction between younger patients with a genetic cause and older patients 
with cardiovascular comorbidities (Results Chapter 3). 
 
Ethnicity 
WGS data was used to determine the ethnicity of patients recruited to the BRIDGE Study 
[BRIDGE core bioinformatics team]. The majority of patients recruited to the BRIDGE PAH 
Study were of European ancestry (89 %; Figure 8). The female gender bias was more 
pronounced amongst non-European patients (3.5 : 1) compared to European patients (2.1 : 
1); Fisher’s exact test p = 0.022). Non-European patients were more likely to be diagnosed 
earlier in life with 85 % of non-Europeans classified in the younger group compared to 73 % 
of Europeans (Fisher’s exact test p = 0.004). The ancestry of patients with PAH and PVOD / 
PCH were similar with 89 % of patients with PAH and 91 % of patients with PVOD / PCH being 
of European ancestry (Fisher’s exact test p = 1). 
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Figure 8. WGS inferred ethnicity of the NIHR BRIDGE PAH Study population  
Ethnicity was inferred by comparing 35,114 autosomal SNPs from patients in the study to the same SNPs in 2100 
patients of known ethnicity recruited to the 1000 Genomes Project. This was done by Marta Bleda using PC Air. 
The majority of patients recruited to the study (89 %) were of European ethnicity. 
 
The WGS inferred ethnicity was compared to self-reported ethnicity as collected in the 
National Health Service and UK National Census (Appendix 13). There were several patients 
whose self-declared ethnicity was different to their WGS inferred ethnicity. Four of these 
individuals identified themselves as “British” but were of non-European ethnicity according 
to the WGS data. Two individuals of European inferred ethnicity identified themselves as 
“other black” and “Caribbean”. These discrepancies may show differences in people’s 
perception of their ethnicity and also the lack of granularity in both the self-reported and 
WGS inferred categories. 
 
Pulmonary haemodynamics 
Pulmonary haemodynamic variables are used to diagnose (mPAP, PCWP and PVR) and risk 
stratify (RAP, CI and SvO2) patients with pulmonary hypertension. Correlation matrices were 
used to further check the validity of the haemodynamic data. As expected there were 
significant correlations between haemodynamic variables (Figure 9), with increased right 
ventricular afterload associated with worse right ventricular function. This has implications 
European
89.3%
South Asian
6.0%
African
2.9%
East Asian
1.8%
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for the selection of covariates in multivariate regression analyses that require independence 
between the covariates. 
 
 
 
Figure 9. Matrix showing Pearson correlations between haemodynamic variables 
Pearson correlation coefficients between the haemodynamic variables collected for all patients recruited to the 
study (n = 1019) were calculated. A significant correlation is seen between most haemodynamic variables, other 
than PCWP. Increases in right ventricular afterload (increases in mPAP and PVR) were associated with worse 
cardiac function (increase in RAP and reductions in CI and SvO2). 
x – p < 0.001, ^ – p < 0.05 
 
The distributions and summary statistics (median [IQR]) of the pulmonary haemodynamic 
variables recorded in the study are summarised in Figure 10. None of these variables had a 
Gaussian distribution (Shapiro-Wilk test p ≤ 0.001). The skewed distributions suggest that a 
small subset of patients have more severe disease with increased right ventricular afterload 
and worse right ventricular function.  
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Figure 10. Density plots of the pulmonary haemodynamic variables recorded in OpenClinica 
Data was not available for all patients (RAP: n = 876 , mPAP: n = 1003, PCWP: n = 816, PVR: n = 898, CI: n = 436, 
SvO2: n = 657). The skewed distributions of the all the haemodynamic variables are demonstrated. Consequently, 
rank regression models were used to further analyse the data. The significant difference in PVR between male 
and female patients demonstrated in the rank regression models can be visualised in the plot. 
Median [IQR] of all patients presented. 
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The distributions of these haemodynamic variables could not be transformed into Gaussian 
distributions. Therefore, linear regression models could not be used to further assess the data 
as they make the assumption that the dependent variable is normally distributed. Instead, as 
discussed in the methods, rank regression models were used to assess associations between 
haemodynamic variables and both age at diagnosis and gender. Rank regression models use 
the rank of the observations rather than their actual value. 
 
In a univariate rank regression model, male gender was associated with a significantly lower 
PVR (regression coefficient [b] = -1.8, standard error [SE] = 0.4, p < 0.001). Whereas, older age 
was also associated with: 
lower mPAP (b = -0.2, SE = 0.02, p < 0.001),  
lower PVR (b = -0.04, SE = 0.01, p < 0.001),  
lower CI (b = -0.005, SE = 0.002, p < 0.001), and  
lower SvO2 (b = -0.10, SE = 0.02, p < 0.001),  
as well as a higher PCWP (b = 0.03, SE = 0.01, p < 0.001).  
 
In multivariate rank regression models (including age at diagnosis, gender and recruiting 
centre as covariates), age at diagnosis was significantly associated with all haemodynamic 
variables except RAP (Table 7). Older age was associated with a lower mPAP and PVR but also 
reduced cardiac function. In this multivariate model, male gender was still significantly 
associated with a lower PVR (b = -1.72, SE = 0.39, p < 0.001). This can be appreciated from the 
density plots for PVR that show a clear difference between male and female patients (Figure 
10). 
 
The significant association between reduced cardiac function and older age may partly 
explain the poor prognosis seen in older patients as reported previously and explored later in 
this chapter. 
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Table 7. Rank regression models assessing associations between age at diagnosis and 
haemodynamic variables 
 
Regression 
coefficient (b) 
Standard error p 
mPAP -0.220 0.025 <0.001 
PCWP  0.025 0.007 0.001 
PVR -0.041 0.011 <0.001 
CI -0.004 0.002 0.013 
SvO2 -0.092 0.022 <0.001 
Results of multivariate rank regression models using age at diagnosis, gender and recruiting 
centre as covariates.  
CI – cardiac index, mPAP – mean pulmonary artery pressure, PCWP – pulmonary capillary 
wedge pressure, PVR – pulmonary vascular resistance, SvO2 – mixed venous oxygen 
saturation 
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Aetiology 
In the remainder of this chapter the characteristics of patients with PAH were assessed. The 
21 patients with a clinical diagnosis of PVOD / PCH were excluded from this analysis. Initially 
I used the phenotype data to determine the possible aetiology of PAH in these patients. A 
history of exposure to drugs and toxins associated with PAH pathogenesis or a family history 
of the disease were used to categorise patients as drug associated PAH and familial PAH 
respectively. Where no information was available or there was no history of exposure to drugs 
or toxins and no family history of PAH, patients were assumed to have idiopathic PAH. I 
assessed whether there were phenotypic differences between these 3 aetiological groups 
(familial PAH, drug associated PAH and idiopathic PAH). 
 
Sixty-five patients (7 %) had a family history of PAH (familial PAH), suggesting an underlying 
genetic cause. Fifty-seven patients (6 %) had a history of exposure to a drug or toxin previously 
associated with disease pathogenesis (anorexigens, methamphetamines, amphetamines or 
dasatinib). One patient who had a family history of PAH (an affected sister who was also 
recruited to the study) and had taken amphetamines was categorised as familial PAH. 
 
The gender bias between these aetiological groups was significantly different (Fisher’s exact 
test p < 0.001). Patients with drug associated PAH had the greatest female gender bias (7.0 : 
1). Whereas in those with idiopathic PAH the female gender bias was 2.2 : 1 and 1.2 : 1 in 
familial PAH. The striking gender difference amongst patients with drug associated PAH may 
be due to an ascertainment bias given that only 110 patients had information of drug and 
toxin exposure recorded in OpenClinica. Furthermore, the intensity of drug / toxin exposure 
and its temporal relationship to disease onset was not always accurately recorded. Therefore, 
misclassification of these patients was a possibility. Although, it can be hypothesised that 
female patients were more likely to have taken appetite suppressants and therefore were 
more likely to develop PAH. 
 
Age at diagnosis was significantly different between aetiological groups (Figure 11). Those 
with familial PAH were diagnosed at an earlier age (37 years [29 - 50]) compared to those with 
idiopathic PAH (50 years [36 - 64], Dunn’s test p < 0.001) and those with drug associated PAH 
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(52 years [41 - 59], Dunn’s test p < 0.001). This is in keeping with early onset disease in those 
with a genetic basis for the disease. Yet, even amongst those with familial PAH, 14 patients 
(21.5 %) were classified in the older group (i.e. over 52 years of age at diagnosis).  
 
 
Figure 11. Differences in age at diagnosis between aetiological groups 
From the data captured in OpenClinica, patients were classified into aetiological groups based on the presence 
or absence of a family history of the disease or relevant drug exposure. No genetic data was used to guide this 
initial classification. The age at diagnosis was not significantly different between the three aetiological groups 
(idiopathic PAH [n = 877], familial PAH [n = 65] or drug associated PAH [n = 56]). 
 
No significant differences were found between the aetiological groups for the other 
phenotypic variables following correction for multiple testing. However, this approach is 
limited by the fact that approximately 17 % of patients with idiopathic PAH are thought to 
harbour disease-associated variants and are thus misclassified as idiopathic PAH using just 
clinical data (30). 
 
Genetic basis 
To refine this classification further, WGS data was used to identify rare and predicted 
deleterious variants in genes previously associated with PAH pathogenesis (BMPR2, ACVRL1, 
ENG, SMAD1, SMAD9, KCNK3, CAV1, TBX4 and biallelic EIF2AK4) [computational genomics 
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group including myself]. Amongst patients with a diagnosis of PAH 218 such variants were 
identified in 204 patients (Table 8). Further assessment of these variants was made, where 
possible, to identify variants that did not segregate with phenotype within families. The 
variants identified in the 10 index cases with an affected relative also recruited to the study 
were also identified in the affected family member. The exception to this was the SMAD1 
variant that did not segregate with phenotype. It was present in the index case but not in 
their affected son. Consequently, it was considered not to be causal. The 9 patients with 
biallelic EIF2AK4 variants (5 variant homozygotes and 4 compound heterozygotes) and a 
clinical diagnosis of PAH are assessed further in Results Chapter 3 and are excluded from 
further analysis in this chapter along with the other patients with a clinical diagnosis of PVOD 
/ PCH. 
 
Table 8. Rare and predicted deleterious variants identified in PAH patients 
Gene n 
BMPR2 159 
TBX4 16 
ACVRL1 10 
Biallelic EIF2AK4 (number of variants) 9 (14) 
ENG 8 
SMAD9 6 
KCNK3 4 
SMAD1* 1 
* not segregating with phenotype and therefore not considered associated with PAH 
 
Ten patients had at least 2 variants in one or more disease associated gene, these patients 
are summarised in Table 9: 
2 patients with 2 BMPR2 variants, 
2 patients with BMPR2 + ENG variants,  
2 patients with BMPR2 + SMAD9 variants,  
1 patient with BMPR2 + SMAD1 variants,  
1 patient with TBX4 + ENG variants,  
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2 patients with biallelic EIF2AK4 + SMAD9 variants.  
 
Without familial segregation information and functional assessments, it is not possible to be 
certain whether both variants were causal for the disease, if one variant acted as a disease 
modifier or even if one or both variants were not associated with disease pathogenesis at all. 
For classification purposes, genetic and phenotypic considerations were used to identify the 
most likely “causal” variant for these 10 individuals. The variants identified as most likely to 
be causal are denoted by an * in Table 9.  
1) PTVs were assumed to be the causal variant when it co-occurred with a missense 
variant. 
2) Variants that segregated with phenotype within families were considered causal. 
3) There were no features of HHT in the patients with missense ENG variants so these 
ENG variants were considered less likely to be causal. 
4) Patients with biallelic EIF2AK4 variants had a characteristic reduced KCO (Results 
Chapter 3) so these were considered causal. 
 
The identification of the causal variant(s) was more difficult for 3 patients (Table 9). Patient 4 
carried variants in both BMPR2 and SMAD9 that had previously been associated with the 
disease (353). The BMPR2 variant was predicted to result in the loss of a critical cysteine 
residue in the ligand binding domain of the protein. The SMAD9 variant resulted in a 
premature truncation of the protein and is also reported to reduce non-canonical miR 
signalling similar to known pathogenic BMPR2 variants (353). However, the SMAD9 variant is 
also found in the ExAC database with an allele frequency of 8.24x10-6. This may suggest that 
the SMAD9 variant is not always causal for the disease and additional hits are required to 
manifest disease. However, the phenotypes of individuals in the ExAC database are not 
known and therefore further study is required. No relatives were available for a segregation 
analysis. For categorisation purposes this patient was deemed to have a BMPR2 variant. 
Unfortunately, detailed phenotypic information from this patient was not available as they 
were recruited retrospectively. However, they did have an early age at diagnosis (37 years) 
and a marked increase in PVR (28 WU) perhaps suggesting more severe disease as a result of 
multiple hits to the BMPR2 signalling pathway. 
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Patients 7 and 8 were confirmed to be half-sisters. Therefore, both BMPR2 variants were 
likely to be on the same allele. Furthermore, biallelic BMPR2 variants are considered fatal in 
utero. 
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Table 9. Rare and predicted deleterious variants found in combination 
Patient Gene Consequence HGVS 
BRIDGE 
control allele 
frequency 
ExAC allele 
frequency 
CADD 
score 
PolyPhen-2 SIFT 
1 
BMPR2* 
frameshift 
variant 
c.156_157delTC Not reported Not reported 34   
SMAD1 
splice donor 
variant 
c.400+1G>A Not reported Not reported 26.2   
2 
BMPR2* 
frameshift 
variant 
c.2027_2030dupACCT Not reported Not reported 34   
SMAD9 
missense 
variant 
c.1099G>A Not reported 1.65E-05 27.9 
possibly 
damaging (0.804) 
deleterious 
(0.05) 
3 
BMPR2* 
deletion 
(exons 11 – 13) 
g.203411230_203418627del Not reported NA    
ENG 
missense 
variant 
c.1955G>A Not reported Not reported 27.7 
probably 
damaging (1) 
deleterious 
(0) 
4 
BMPR2* 
missense 
variant 
c.367T>C Not reported Not reported 26.6 
probably 
damaging (1) 
deleterious 
(0) 
SMAD9 stop gained c.880C>T Not reported 8.24E-06 40   
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5 
TBX4* 
frameshift 
variant 
c.972delT Not reported Not reported 34   
ENG 
missense 
variant 
c.1934G>C Not reported 3.45E-05 27.9 
probably 
damaging (1) 
deleterious 
(0) 
6 
BMPR2* 
Deletion 
(exons 6/7 – 
13) 
g.203383741_203388057del 
 Not reported NA    
ENG 
missense 
variant & splice 
region variant 
c.1850C>T Not reported 4.96E-05 32 
probably 
damaging (1) 
deleterious 
(0) 
7 
BMPR2 
missense 
variant 
c.1471C>T Not reported  35 
probably 
damaging (1) 
deleterious 
(0) 
BMPR2 
missense 
variant 
c.1772G>A Not reported  26.5 
probably 
damaging (1) 
deleterious 
(0.02) 
8 
BMPR2 
missense 
variant 
c.1471C>T Not reported  35 
probably 
damaging (1) 
deleterious 
(0) 
BMPR2 
missense 
variant 
c.1772G>A Not reported  26.5 
probably 
damaging (1) 
deleterious 
(0.02) 
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9 
EIF2AK4* 
splice region 
variant & 
intron variant 
c.257+4A>C Not reported 8.28E-06 15.5   
EIF2AK4* 
frameshift 
variant 
c.1392delT Not reported 2.48E-05 35   
SMAD9 
missense 
variant 
c.419C>T Not reported Not reported 24.3 
benign 
(0.216) 
deleterious 
(0.01) 
10 
EIF2AK4* 
missense & 
splice region 
c.1820T>G Not reported 8.28E-06 15.5   
EIF2AK4* 
missense 
variant 
c.2727C>G Not reported 2.48E-05 35   
SMAD9 
missense 
variant 
c.1099G>A Not reported 1.65E-05 27.9 
possibly 
damaging 
(0.804) 
deleterious 
(0.05) 
* likely disease “causing” variant (see text). CADD – combined annotation dependent depletion score, ExAC – Exome Aggregation Consortium, 
HGVS – human genome variation society nomenclature. Biallelic EIF2AK4 variants described further in Results Chapter 3. 
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Using WGS-derived information patients were classified as heritable PAH (i.e. carrying a 
disease-associated variant and/or with a family history of the disease; n = 210), drug 
associated PAH (n = 49) or idiopathic PAH (n = 730). Eight patients with heritable PAH also 
had a history of exposure to drugs or toxins associated with PAH. Four of these patients 
carried variants in BMPR2 that had previously been associated with PAH, 2 had large deletions 
in BMPR2 and 1 had a variant in TBX4 previously associated with Small Patella Syndrome. One 
patient with a history of exposure to fenfluramine (time and duration of exposure not known) 
had a predicted deleterious missense variant in ENG (c.1795G>A, p.Ala599Thr). This variant 
had not previously been associated with HHT (HHT mutation database; 
http://www.arup.utah.edu/database/ENG/ENG_welcome.php) and the patient did not have 
any features of HHT either. Therefore, the pathogenicity of this ENG variant requires further 
assessment. 
 
Of interest, in 15 patients with a family history of PAH no rare and predicted deleterious 
variants (SNV or CNV) were identified in the genes previously associated with disease 
pathogenesis. This group of patients may prove valuable in the identification of novel genes 
associated with disease pathogenesis. 
 
I reassessed the phenotypes of patients based on this refined classification (the basis of the 
current guidelines). The main phenotypic traits of these patients are summarised in Table 10. 
Patients with heritable PAH were significantly younger at diagnosis, had more severe 
pulmonary haemodynamic impairment and were less likely to respond to an acute pulmonary 
artery vasodilator challenge. Furthermore, patients with heritable PAH were more likely to 
have normal spirometry and a preserved KCO compared to both patients with idiopathic and 
drug associated PAH. Despite these differences in the severity of disease there were no 
significant differences in functional class or 6mwt distance between the groups. There were 
no significant differences between patients with drug associated PAH and idiopathic PAH, 
other than the increased female preponderance seen in drug associated PAH. More detailed 
phenotypic assessments of patients with variants in specific genes are provided in Results 
Chapter 2. 
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Table 10. Phenotypes of patients based on the current PAH classification 
 Heritable PAH Drug associated PAH Idiopathic PAH Corrected p 
n [%] 210 [21.2%] 49 [5.0%] 730 [73.8%]  
Ethnicity: Afr / E Asian / 
Eur / S Asian (n [%]) 
5 [2.4%] / 4 [1.9%] /  
195 [92.9%] / 6 [2.9%] 
2 [4.1%] / 2 [4.1%] /  
43 [87.8%] / 2 [4.1%] 
22 [3.0%] / 12 [1.6%] /  
650 [89.0%] / 46 [6.3%] 
0.510 
Gender: female (n [%]) 135 [64.3%] 44 [89.8%] 500 [68.6%] 0.006 
Age at diagnosis (years) 40.3 [31.8 – 52.3] 53.6 [40.9 – 59.9] 51.1 [38.1 – 65.6] <0.001 
Drug exposure: Yes (n [%]) 8 [3.8%] 49 [100.0%] 0 [0.0%] <0.001 
mPAP (mmHg) 57.0 [49.8 – 66.0] 51.0 [44.2 – 59.0] 51.0 [42.2 – 60.0] <0.001 
PCWP (mmHg) 10.0 [7.0 – 12.0] 8.0 [6.0 – 10.0] 9.0 [7.0 – 11.0] 0.396 
CO (L/min) 3.5 [2.8 – 4.3] 4.3 [3.8 – 5.2] 4.0 [3.3 – 5.2] <0.001 
CI (L/min/m2) 1.9 [1.6 – 2.3] 2.3 [1.9 – 2.7] 2.2 [1.8 – 2.7] 0.002 
PVR (WU) 13.7 [9.8 – 18.8] 10.4 [7.4 – 12.3] 10.2 [7.0 – 14.0] <0.001 
SvO2 (%) 61.0 [57.0 – 66.6] 64.0 [59.5 – 73.2] 65.5 [59.6 – 71.3] <0.001 
Vasoresponder (n [%]) 1 [1.6%] 1 [11.1%] 30 [18.5%] 0.006 
FC: 1 / 2 / 3 / 4 (n [%]) 
3 [1.5%] / 45 [23.2%] /  
118 [60.8%] / 28 [14.4%] 
0 [0.0%] / 6 [13.0%] /  
37 [80.4%] / 3 [6.5%] 
15 [2.4%] / 137 [22.0%] /  
402 [64.6%] / 68 [10.9%] 
0.446 
6mwt distance (m) 345.5 [285.8 – 431.0] 260.0 [165.0 – 369.0] 312.0 [159.0 – 411.0] 0.251 
KCO (% predicted) 82.0 [72.0 – 94.0] 79.0 [64.0 – 93.2] 70.0 [48.0 – 84.0] <0.001 
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Spirometry pattern: 
Normal / Obstructive / 
Restrictive (n [%]) 
90 [74.4%] / 19 [15.7%] /  
12 [9.9%] 
18 [62.1%] / 9 [31.0%] /  
2 [6.9%] 
226 [53.2%] / 126 [29.6%] /  
73 [17.2%] 
0.006 
6mwt – six-minute walk test, Afr – African, CI – cardiac index, CO – cardiac output, E Asian – East Asian, Eur – European, FC – functional class, 
KCO – transfer coefficient for carbon monoxide, mPAP – mean pulmonary artery pressure, PCWP – pulmonary capillary wedge pressure, PVR 
– pulmonary vascular resistance, S Asian – South Asian, SvO2 – mixed venous oxygen saturation. Kruskal-Wallis test used to assess continuous 
variables, Fisher’s exact test used to assess categorical variables, Cochran–Armitage test used to assess ordinal variables. 
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In a left truncated multivariate Cox proportional-hazards model including age at diagnosis and 
gender as covariates, disease aetiology was not a significant predictor of survival despite the 
more severe pulmonary hypertension and worse right ventricular function observed in 
patients with heritable PAH (Table 11). Age (hazard ratio [95% confidence interval]: 1.037 
[1.022 – 1.052]) and gender (1.858 [1.244 – 2.777]) were significant predictors of survival. 
 
Table 11. Prognostic significance of disease aetiology 
 
Hazard ratio [95% 
confidence interval] 
p 
Heritable PAH* 0.852 [0.464 – 1.563] 0.604 
Drug associated PAH* 1.336 [0.575 – 3.103] 0.501 
Age at diagnosis 1.037 [1.022 – 1.052] < 0.001 
Gender (male) ^ 1.858 [1.244 – 2.777] 0.002 
Results of a multivariate Cox proportional hazards model using disease aetiology, age at 
diagnosis and gender as covariates. 
* compared to patients with idiopathic PAH, ^ compared to female patients 
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Prognostic variables 
Given the apparent lack of a prognostic difference between those with idiopathic and 
heritable PAH I investigated other variables that may be of prognostic significance. This 
analysis was restricted to patients with idiopathic PAH (n = 730). Patients with no survival 
data (date of last contact [for right censoring] or date of death or transplantation; n = 75) 
were excluded from the analysis. All but four of these excluded patients were recruited from 
University Hospital Giessen. 
 
The idiopathic PAH subgroup consisted of a mixture of prevalent (n = 449) and incident (n = 
206) cases. This included patients who had died prior to the study start date and were 
recruited retrospectively. In total 155 deaths and 12 transplants were observed. The inclusion 
of retrospectively recruited and prevalent patients introduces immortal time and survivor 
biases. Such biases can be minimized in left truncated survival analyses. In left truncated 
survival analyses 56 events were excluded as they occurred in the unobserved period prior to 
the study start date. Left truncated survival analyses were performed as secondary analyses 
due to the small number of events observed. 
 
Initially, phenotypic variables were assessed in univariate Cox proportional hazards models 
with no left truncation. In this analysis, an event was defined as death, survival defined as 
time from diagnosis to death and patients were censored if they were transplanted. Variables 
that were of prognostic significance with a false discovery rate adjusted p < 0.1 were taken 
forward into multivariate Cox proportional hazards models (n = 24; details provided in 
Appendix 14).  
 
Due to the limitations in data completeness and a relative lack of events, only age at diagnosis, 
gender and whether patients were incident or prevalent cases were used as covariates in the 
initial multivariate models. Phenotypic variables that were of prognostic significance 
following correction for multiple testing are presented in Table 12. In most of these models 
age at diagnosis, gender and incident / prevalent group were also significant markers of 
prognosis. The exceptions to this were in the models with either KCO or KCO % predicted, 
where age at diagnosis was no longer a significant independent prognostic factor. 
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Table 12. Variables of prognostic significance in multivariate Cox proportional hazards 
models 
 
Categorical 
group 
Number 
of 
patients 
Number 
of 
events 
Hazard 
ratio 
Confidence 
interval 
Corrected 
p 
Ascites Present 368 73 5.619 2.497 – 12.646 <0.001 
RBBB Present 256 55 2.470 1.433 – 4.256 0.017 
KCO  377 81 0.149 0.065 – 0.339 <0.001 
Functional 
class 
 621 149 1.514 1.146 – 1.999 0.045 
SaO2 during 
RHC 
 439 93 0.913 0.878 – 0.948 <0.001 
Albumin  465 117 0.933 0.898 – 0.968 0.004 
SaO2 at rest  449 110 0.934 0.904 – 0.965 0.001 
SvO2  432 95 0.936 0.914 – 0.959 <0.001 
RAP  577 135 1.063 1.032 – 1.096 0.001 
SaO2 pre-
walk 
 437 100 0.939 0.902 – 0.977 0.030 
KCO % 
predicted 
 366 84 0.967 0.956 – 0.978 <0.001 
6mwt 
distance 
 549 129 0.996 0.995 – 0.997 <0.001 
Results of multivariate Cox proportional hazards models including age at diagnosis, gender 
and incident / prevalent status as covariates along with the variable being assessed. 
6mwt – six-minute walk test, KCO – transfer coefficient for carbon monoxide, RAP – right 
atrial pressure, RBBB – right bundle branch block, RHC – right heart catheterisation, SaO2 – 
peripheral arterial oxygen saturation, SvO2 – mixed venous oxygen saturation. 
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Phenotypic variables of prognostic significance could be categorised into 4 groups: 
1. Those associated with poor RV function (presence of ascites, RBBB, reduced SvO2 
and increased RAP). 
2. Impaired functional assessments (reduced 6mwt distance and higher functional 
class). 
3. Associated with reduced peripheral oxygen saturations (reduced SaO2 and reduced 
KCO). 
4. A reduced blood albumin level was also a poor prognostic marker. This may be 
related to hepatic congestion associated with RV failure but is treated as an 
additional group. 
 
To identify independent markers of prognosis a larger multivariate Cox proportional hazards 
model was created using one variable from the four groups described above. Variables were 
manually selected to maximise the number of patients and events captured in the model, 
limit confounders and minimize multiple testing by assessing all permutations of variables 
from the 4 groups. RAP and functional class were selected as these two variables had the 
most observations recorded in their respective groups. KCO % predicted was selected as SaO2 
measurements may be confounded by supplemental O2 use and KCO does not take into 
account variation due to gender, age and height. In this model 309 patients were included 
and 73 events were observed. Age at diagnosis, gender, incident/prevalent group, RAP and 
KCO % predicted were identified as independent prognostic variables (Table 13). 
 
A secondary left truncated survival analysis was performed using a similar protocol to that 
used in the primary survival analysis to validate the results. A left truncated analysis takes into 
account the presence of both incident and prevalent patients, minimizing the immortal time 
bias (where prevalent patients must have already survived a certain period to be recruited 
into the study). In the left truncated analysis prevalent patients only enter the risk set from 
the study start date and retrospectively recruited patients (who have died prior to the start 
of the study) are excluded completely.  
 
Initially, in left truncated univariate survival analyses 11 variables were identified to be of 
prognostic significance after correcting for multiple testing (Appendix 14
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distribution width, peripheral oxygen saturations at rest and post 6mwt, as well as KCO % 
predicted remained of prognostic significance in small multivariate survival models that 
included age at diagnosis, gender and incident / prevalent group as covariates. The models 
maintained the proportional hazards assumption and the Cox-Snell residuals were 
exponentially distributed indicating good fit of the models. 
 
A more complex multivariate Cox proportional hazards model was then created to identify 
independent prognostic factors using the variables that were most frequently reported: age, 
gender, incident / prevalent group, SaO2 at rest and red cell distribution width. Despite using 
the most frequently reported variables only 163 patients were included in this left truncated 
survival analysis and only 34 events were observed. The Cox-Snell residuals in this model were 
not exponentially distributed suggesting inadequacy of model fit, possibly due to the lack of 
events observed. 
 
Regardless, the smaller multivariate left truncated survival analyses support the validity of 
some of the prognostic variables identified in the primary analysis. More data and events are 
required to assess the significance of the other variables and identify variables of independent 
prognostic significance. 
 
The significance of KCO as a prognostic factor was assessed further by assessing it in a cohort 
of patients with normal spirometry (n = 197). The KCO % predicted remained an independent 
prognostic variable in both the primary analysis (hazard ratio [95% confidence interval]: 0.959 
[0.940 - 0.978], p < 0.001) and a left truncated analysis (0.970 [0.947 - 0.993], p = 0.009). 
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Table 13. Identification of independent prognostic markers  
 
Categorical 
group 
Hazard ratio 
Confidence 
interval 
Corrected p 
Age at diagnosis  1.023 1.003 - 1.043 0.021 
Gender Male 2.936 1.799 - 4.792 <0.001 
Incident / Prevalent Prevalent 0.346 0.180 - 0.665 0.001 
RAP  1.059 1.012 - 1.108 0.012 
Functional class  1.040 0.666 - 1.625 0.861 
KCO % predicted  0.972 0.960 - 0.983 <0.001 
Albumin  0.956 0.912 - 1.002 0.060 
Results of a multivariate Cox proportional hazards model using the above variables as 
covariates. 
RAP – right atrial pressure, KCO – transfer coefficient for carbon monoxide 
 
Phenotypes of patients categorised by variables of prognostic significance 
Patients were categorised based on each of the variables identified to be of prognostic 
significance in the primary multivariate Cox proportional hazards model. For the continuous 
variables patients were dichotomised using the median value. All the differences identified 
between these groups are shown in Appendix 15 and the results are summarised below. 
 
Gender 
Forty phenotypic variables were observed to be significantly different between male and 
female patients after correction for multiple testing. Similar to the entire study cohort 
described earlier, male patients with idiopathic PAH were significantly older than female 
patients (median [IQR]: 60 years [42 - 69] vs. 49 years [35 - 62]; Wilcoxon rank-sum test p < 
0.001). As would be expected in the general population male patients were taller (174 cm 
[168 - 179] vs. 162 cm [157 - 166]; Wilcoxon rank-sum test p < 0.001) and heavier (84 kg [73 - 
96] vs. 71 kg [61 - 85]; Wilcoxon rank-sum test p < 0.001) than their female counterparts. Male 
patients had larger lung volumes (FEV1, FVC, TLC, VA) but a lower KCO compared to women. 
Although, the % predicted values for these variables showed no difference except for TLC % 
predicted, which was lower in men (91 % predicted [83 - 99] vs. 97 % predicted [86 - 104]; 
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Wilcoxon rank-sum test p = 0.032). Supporting this observation, a greater proportion of men 
were reported to have pulmonary fibrosis on CT (11 % vs. 4 %; Fisher’s exact test p = 0.049). 
Furthermore, men had a lower resting SaO2 (94 % [91 - 97] vs. 96 % [92 - 98]; Wilcoxon rank-
sum test p = 0.008) and desaturated more during the 6mwt (88 % [82 - 94] vs. 93 % [86 - 96]; 
Wilcoxon rank-sum test p = 0.004). 
 
Male patients had less severe pulmonary haemodynamic impairment compared to females 
(Wilcoxon rank-sum test p values report): 
mPAP:    49 mmHg [41 - 56] vs. 53 mmHg [44 - 62]; p = 0.010,  
CO:    4.4 L/min [3.5 - 5.7] vs. 3.9 L/min [3.2 - 4.9]; p < 0.001,  
PVR:    8.5 WU [6.3 - 12.5] vs. 11.1 WU [7.4 - 14.8]; p < 0.001.  
Despite this there were no significant differences in either their 6mwt distance or functional 
class. 
 
Significant differences were observed in haematological indices. As may be expected female 
patients had a lower Hb concentration (148 g/L [134 - 159] vs. 159 g/L [146 - 169]; Wilcoxon 
rank-sum test p < 0.001), lower haematocrit (0.4 [0.4 - 0.5] vs. 0.5 [0.4 - 0.5]; Wilcoxon rank-
sum test p < 0.001) and lower ferritin concentration (64 µg/L [28 - 109] vs. 121 µg/L [60 - 244]; 
Wilcoxon rank-sum test p < 0.001) compared to male patients. While platelet counts were 
higher in female patients (242 x109/l [199 – 294] vs. 197x109/l [169 – 242]; Wilcoxon rank-
sum test p < 0.001). 
 
In addition to the increased prevalence of pulmonary fibrosis, male patients were also more 
likely to have coronary artery disease (32 [19.4%] vs. 16 [4.4%]; Fisher’s exact test p < 0.001) 
and obesity (15 [9.1%] vs. 10 [2.8%]; Fisher’s exact test p < 0.001) compared to females. This 
may suggest that male patients, who were generally older, may have undiagnosed or mild left 
ventricular dysfunction contributing to disease pathogenesis. In support of this hypothesis, 
the left atrial size on echocardiogram (3.9 cm [3.4 - 4.1] vs. 3.5 cm [2.9 - 3.8]; Wilcoxon rank-
sum test p = 0.016) and the MRI derived left ventricular end diastolic volume (101 ml [91 - 
143] vs. 80 ml [667 - 105]; Wilcoxon rank-sum test p < 0.001) were significantly greater 
amongst male patients compared to female patients. As this may be influenced by gender 
differences, indexed values were assessed to investigate this further. Left atrial size index (n 
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= 106) and left ventricular end diastolic volume index (LVEDVI, n = 111) were calculated by 
dividing by body surface area where available. LVEDVI was significantly greater in male 
patients compared to female patients (1.8 ml/m2 [1.6 - 2.4] vs. 1.7 ml/m2 [1.3 - 2.1]; Wilcoxon 
rank-sum test punadjusted = 0.009). Although there was no significant difference in the left atrial 
size index based on echocardiographic measurements (0.067 cm/m2 [0.063 - 0.075] vs. 0.068 
cm/m2 [0.059 - 0.077]; Wilcoxon rank-sum test punadjusted = 0.835). 
 
Age 
When dichotomising idiopathic PAH patients by the median age (51.1 years) significant 
differences were observed between younger and older patients with respect to pulmonary 
haemodynamic variables, functional assessments and the presence of comorbidities. Despite 
younger patients having a higher right ventricular afterload compared to older patients they 
had better cardiac function and functional assessments (Wilcoxon rank-sum test p value 
provided unless stated): 
mPAP:    54 mmHg [46 - 63] vs. 49 mmHg [41 - 58]; p < 0.001,  
PVR:    10.7 WU [7.0 - 15.3] vs. 10.1 WU [7.0 - 13.4]; p < 0.001, 
CI:    2.3 L/min/m2 [1.9 - 2.9] vs. 2.1 L/min/m2 [1.7 - 2.6]; p = 0.006,  
SvO2:    68 % [62 - 73] vs. 64 % [58 - 70]; p < 0.001,  
NT-ProBNP:   568 ng/L [141 - 1463] vs. 1565 ng/L [360 - 3182]; p = 0.006,  
Ankle swelling:  58 [25.2%] vs. 93 [40.4%]; p = 0.004, 
Functional class 1/2/3/4:  12 [3.8%] / 95 [30.2%] / 173 [54.9%] / 35 [11.1%] vs.  
3 [1.0%] / 42 [13.7%] / 229 [74.8%] / 32 [10.5%];  
Cochran–Armitage test p < 0.001,  
6mwt distance: 380 m [300 - 438] vs. 218 m [96 - 330]; p < 0.001. 
 
Younger patients were less likely to have cardiovascular diseases, respiratory disorders or 
abnormal spirometry (Fisher’s exact test p provided unless stated): 
Diabetes mellitus:   9 [3.5%] vs. 41 [15.5%]; p < 0.001, 
Coronary artery disease:  1 [0.4%] vs. 47 [17.8%]; p < 0.001, 
Systemic hypertension:  5 [1.9%] vs. 31 [11.7%]; p < 0.001, 
Hyperlipidaemia:   2 [0.8%] vs. 28 [10.6%]; p < 0.001, 
Valvular heart disease:  0 [0.0%] vs. 7 [2.7%]; p = 0.044, 
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COPD / interstitial lung disease (ILD):     
5 [1.9%] vs. 41 [15.5%]; p < 0.001, 
Emphysema on CT (none / minimal / mild / moderate / severe):  
157 [96.9%] / 3 [1.9%] / 0 [0.0%] / 2 [1.2%] / 0 [0.0%] vs.  
166 [85.6%] / 6 [3.1%] / 12 [6.2%] / 9 [4.6%] / 1 [0.5%];  
Cochran–Armitage test p < 0.001, 
Fibrosis on CT (none / minimal / mild / moderate / severe):  
160 [98.2%] / 2 [1.2%] / 0 [0.0%] / 1 [0.6%] / 0 [0.0%] vs.  
176 [90.3%] / 10 [5.1%] / 8 [4.1%] / 0 [0.0%] / 1 [0.5%];  
Cochran–Armitage test p = 0.007, 
Lung function pattern (normal / obstructive / restrictive): 
126 [66.0%] / 24 [12.6%] / 41 [21.5%] vs.  
100 [42.7%] / 102 [43.6%] / 32 [13.7%]; p < 0.001.  
 
Given these age differences and the higher proportion of female patients in the younger 
group (276 [76.0 %] vs. 221 [60.9 %]; Fisher’s exact test p < 0.001) I investigated whether 
phenotypic differences existed between young (age at diagnosis < 51.1 years) male and 
female patients with idiopathic PAH (n = 363). Young female patients still had a higher PVR 
(11.6 WU [7.5 - 15.7] vs. 8.4 WU [6.2 - 12.7]; Wilcoxon rank-sum test p = 0.022) compared to 
male patients but there were no differences in CI or functional class. Despite the lack of 
difference in cardiac output, the 6mwt distance was lower in female patients (359 m [280 - 
426] vs. 437 m [403 - 476]; Wilcoxon rank-sum test p = 0.049). 
 
Figure 12 demonstrates that survival between young male and female patients with 
idiopathic PAH is similar. Older patients, particularly the older male patients, have a 
significantly worse survival compared to the younger patients (log rank p < 0.001). However, 
the presence of cardiovascular risk factors (systemic hypertension, coronary artery disease, 
diabetes mellitus and hyperlipidaemia), individually or grouped together, was not a significant 
independent prognostic factor in multivariate Cox proportional hazards models with age at 
diagnosis and gender included as covariates. 
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Figure 12. Kaplan-Meier plot demonstrating age and gender differences in survival 
The time from diagnosis to death was calculated for patients with idiopathic PAH where survival data was 
available (n = 655). Patients were censored at the time of last contact or if transplanted. Patients were 
categorised as young (aged < 51.1 years at diagnosis) or old (age ³ 51.1 years at diagnosis) and by gender. 
Younger patients (both male and female) have a better survival compared to older patients (log-rank test p < 
0.001). Younger male and female patients have a similar prognosis. 
 
Transfer coefficient for carbon monoxide 
When dichotomising idiopathic PAH patients by the median KCO % predicted (70 % predicted), 
patients with a low KCO % predicted were found to be significantly older compared to patients 
with a high KCO % predicted (65 years [52 - 72] vs. 45 years [35 - 57]; Wilcoxon rank-sum test 
p < 0.001). The proportion of female patients in the low and high KCO % predicted groups 
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were similar (118 [63.4%] vs. 130 [72.2%] respectively; Fisher exact test p = 0.254). The mPAP 
was lower in those with a low KCO % predicted (49 mmHg [42 - 56] vs. 55 mmHg [46 - 65]; 
Wilcoxon rank-sum test p < 0.001) but all other haemodynamic variables were similar 
between the two groups. 
 
Those with a low KCO % predicted were more likely to have abnormal spirometry, evidence of 
emphysema on CT and coexisting COPD or interstitial lung disease (ILD). 
Lung function pattern (Normal / Obstructive / Restrictive): 
90 [48.9%] / 77 [41.8%] / 17 [9.2%] vs.  
107 [60.8%] / 32 [18.2%] / 37 [21.0%]; Cochran-Armitage test p < 0.001, 
 CT emphysema (none / minimal / mild / moderate / severe):  
110 [82.7%] / 6 [4.5%] / 10 [7.5%] / 6 [4.5%] / 1 [0.8%] vs.  
126 [98.4%] / 1 [0.8%] / 1 [0.8%] / 0 [0.0%] / 0 [0.0%]; Cochran-
Armitage test p < 0.001, 
 COPD / ILD: 34 [18.5%] vs. 5 [2.8%]; Fisher’s exact test p < 0.001. 
 
Patients with a low KCO % predicted had lower peripheral oxygen saturations at rest (94 % [90 
- 97]) compared to patients with a high KCO % predicted (96 % [94 - 98]; Wilcoxon rank-sum 
test p < 0.001). Additionally, patients with a low KCO % predicted desaturated more during 
the 6mwt (87 % [81 - 93]) compared to those with a high KCO % predicted (94 % [89 - 96]; 
Wilcoxon rank-sum test p < 0.001). The SvO2 was also significantly reduced in patients with a 
low KCO % predicted (64 % [58 - 69]) compared to those with a high KCO % predicted (68 % 
[61 - 73]; Wilcoxon rank-sum test p = 0.011), although other measures of cardiac function 
were similar between the two groups. 
 
When restricting the analysis to patients with idiopathic PAH and normal spirometry only 226 
patients remained. Patients with a low KCO % predicted had a lower mPAP (48 mmHg [42 - 
55] vs. 54 mmHg [46 - 64]; Wilcoxon rank-sum test p = 0.030), lower resting SaO2 (95 % [93 - 
97] vs. 97 % [95 - 98]; Wilcoxon rank-sum test p = 0.004) and desaturated more during the 
6mwt (89 % [81 - 95] vs. 95 % [90 - 97]; Wilcoxon rank-sum test p = 0.008) compared to 
patients with a high KCO. 
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Interestingly, a larger proportion of patients in the high KCO % predicted group had a history 
of congenital heart disease (14 [13.2%]) though these were not thought to be clinically 
significant, compared to patients with a low KCO % predicted (3 [3.3%]; Fisher’s exact test p = 
0.020). These included atrial septal defects (n = 10, 1 of which was closed), patent foramen 
ovale (n = 4) and partial anomalous pulmonary venous drainage (n = 1, this coexisted with an 
atrial septal defect). In the high KCO % predicted group, patients with congenital heart disease 
had a higher KCO % predicted (96 % [83 - 101]) compared to those without any evidence of 
congenital heart disease (84 % [76 - 93]; Wilcoxon rank-sum test p = 0.033). This may suggest 
there is persistent left to right shunting in patients with congenital heart disease. Therefore, 
these shunts may be important to disease pathogenesis even though they were deemed 
clinically insignificant. 
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Discussion 
To the best of my knowledge this is the most comprehensive phenotypic description of 
patients with idiopathic and heritable PAH. The breadth of information collected as part of 
the study allowed clinically important observations regarding the heterogeneity of patients 
with idiopathic PAH to be made. The findings are in keeping with previous reports of the 
prognostic importance of age at diagnosis, gender, and KCO in this group of patients. 
Importantly, specific subgroups of patients with mild left ventricular diastolic dysfunction and 
congenital heart disease with small left to right shunts have been identified. Although these 
associated conditions may play a role in disease pathogenesis and have implications for 
treatment and prognosis, these patients were given a clinical diagnosis of idiopathic PAH. 
Further study of these subgroups is required to definitively ascertain their clinical relevance. 
 
Data quality 
As part of the BRIDGE PAH Study, phenotype data from the time of diagnosis was collected 
from patients diagnosed with idiopathic, heritable and drug- and toxin-associated PAH. The 
collection of this phenotype data from expert centres in the UK and Europe was the 
responsibility of research and clinical staff at each site. In order to maximise data capture and 
quality several steps were put into place at the outset of the study and adapted as the study 
progressed. 
 
Training and monitoring visits were crucial aspects of the study. Many of the research staff 
tasked with data entry did not have a clinical background or experience in PH. Therefore, 
considerable time and effort was put into training research staff at each centre. This is an 
ongoing process given the turnover of staff. In some centres, this training was inadequate and 
led to significant errors, such as patients not meeting the inclusion criteria being recruited. 
Although some errors were identified through the checks put in place it is possible that other 
errors have gone undetected. 
 
Errors may be systematic in nature or simply relate to mistakes in the transcription of data 
from clinical records into OpenClinica. Methods to overcome these problems include double 
data entry by site staff and review of all entries for all patients during monitoring visits (354). 
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Both of these options would be time consuming and resource intensive given the amount of 
data captured in study. As a compromise, all data for predefined core variables could be 
reviewed, in addition to full datasets for randomly selected individuals, during monitoring 
visits. This would undoubtedly improve the quality of the data entered and reduce missing 
data. 
 
Missing data could arise due to 1) omission from research staff entering data, 2) incomplete 
or missing medical records (particularly for older records), or 3) a test not being performed. 
The lack of complete records for patients reduces the power of the study and introduces 
selection biases when creating multivariate models that exclude patients with missing data. 
This is especially true of data that is not missing at random. The amount of missing data could 
be improved by obtaining further clinical information from the European centres. Imputation 
of missing data is possible and has been used successfully in similar studies (355). 
 
A significant problem encountered during the monitoring visits was the lack of access to 
source documentation from legacy patients whose medical records had either been 
transferred off site, transferred to microfilm or destroyed outright. In the near future, direct 
transfer of information held in electronic medical records may address some of the issues 
raised above. Although security and database compatibility issues would need to be 
addressed. 
 
Whole genome sequencing 
A unique aspect of this study was the availability of WGS data for all recruited patients. This 
allowed the standardised assessment of SNVs and CNVs that may be responsible for disease 
pathogenesis. Consequently, as shown in the results, it facilitated the accurate categorisation 
of patients as either idiopathic or heritable PAH. However, the study relied on bioinformatic 
tools such as CADD, PolyPhen-2 and SIFT, as well as allele frequencies to identify potentially 
pathogenic variants because of a lack of segregation data and/or experimental evidence of 
pathogenicity (332-334). A predicted deleterious variant is not necessarily disease causing. 
Consequently, the reliance on bioinformatic tools may have resulted in the misclassification 
of patients with predicted deleterious but non-disease-causing variants as heritable PAH. 
Examples of where this may have occurred are the rare and predicted deleterious missense 
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variants identified in ENG. Most patients with these variants did not have features of HHT, 
despite the disease being highly penetrant. Furthermore, these variants had not previously 
been reported in association with HHT or PAH. Despite this concern for over calling 
pathogenic variants, the proportion of patients that were identified as carrying disease-
causing variants was similar to that reported in other studies (42). However, many of these 
large genetic studies are also limited by the lack of experimental data or familial segregation 
data. 
 
Prognostic factors 
The identification of variables of prognostic significance is subject to survivor bias and 
immortal time bias. This is a consequence of the inclusion of prevalent patients who were 
diagnosed prior to the start of the study. In the future, a survival analysis including just 
incident cases should be possible. However, with approximately 100 new diagnoses of 
idiopathic PAH in the UK each year it will take a long time to recruit enough patients and 
observe sufficient numbers of events (deaths) (356). 
 
Left truncated survival analyses, that exclude patients that have died prior to the start of the 
study and delays entry of prevalent patients into the risk set until after the study start date, 
can be used to minimize these biases. However, as can be seen in the complex multivariate 
Cox proportional hazards model, insufficient patient numbers and events were present to 
properly utilise such statistical techniques. 
 
The identification of the KCO % predicted as a significant prognostic variable in both 
untruncated and left truncated analyses is of interest. It has previously been identified as a 
significant prognostic variable in untruncated analyses from single centre cohorts (351, 357). 
The significance of KCO % predicted remained even in an analysis restricted to patients with 
normal spirometry. This study supports the phenotypic description of patients with a low DLCO 
reported by Trip et al. They also report patients with a low DLCO were older and more likely 
to have co-existing cardiovascular diseases (351). 
 
The reason for the poor prognosis associated with a low KCO remains unclear. It is possible 
that patients with a low KCO have undiagnosed PVOD / PCH or PAH associated with connective 
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tissue disease. These two forms of PH are also associated with a low KCO and have a worse 
prognosis compared to idiopathic PAH (300, 358). van der Bruggen et al. showed that patients 
with a low DLCO had a similar response to pulmonary artery vasodilator therapies compared 
to patients with a high DLCO (359). The large range observed in KCO may suggest a variety of 
histopathological changes in the pulmonary circulation of patients with idiopathic PAH. These 
histopathological changes may be similar to the distinctive changes found in patients with 
PVOD / PCH and patients with BMPR2 variants (112, 295). 
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Summary 
As part of BRIDGE PAH Study, I sought to assess the depth and quality of the phenotype data 
captured in OpenClinica. Along with the bioinformatics team and study co-ordinators, I have 
set up a system to obtain and verify clinical data, which will form the basis of all subsequent 
analyses and efforts at new gene discovery. Difficulties were identified in obtaining complete 
datasets for patients, particularly for those diagnosed at European centres and for those 
whose clinical records were no longer available. Efforts were made to improve the quality of 
the data by identifying and checking possible errors with the recruiting centres. Although, 
without monitoring all data fields for all patients it is impossible to guarantee accurate data. 
 
Survival analyses were performed to identify clinically important phenotypes in patients with 
idiopathic PAH. Age at diagnosis, gender and KCO were identified as prognostic factors. 
However, biases in the survival analyses have been identified due to the inclusion of prevalent 
patients. As more patients are recruited to the study and more survival events are observed 
these analyses can be repeated to validate these initial findings. 
 
The strengths of this study were the availability of WGS data for all patients and the depth of 
the phenotype data captured. Patients carrying variants in genes previously associated with 
PAH were younger at diagnosis and had more severe pulmonary haemodynamic impairment 
compared to those with idiopathic PAH. These analyses are refined in subsequent results 
chapters where the phenotypes of patients with variants in specific genes are assessed 
further. 
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Results Chapter 2: Phenotype-genotype associations in heritable PAH 
Introduction 
Heritable PAH is diagnosed in a patient with PAH if they have either a family history of the 
disease or a pathogenic variant in a gene known to be associated with the disease (1). Ten 
genes are generally accepted at the present time to be associated with PAH . These are 
BMPR2, ACVRL1, ENG, SMAD9, SMAD4, SMAD1, KCNK3, CAV1, TBX4 and EIF2AK4. Other 
putative genes have been suggested but as yet there is insufficient clinical or experimental 
evidence to confirm their association with the disease. 
 
Disease associated variants in BMPR2 account for the majority of cases of heritable PAH. 
Studies have identified BMPR2 variants in approximately 17 % of patients with idiopathic PAH 
and 82 % of patients with heritable PAH (8-16, 30). Patients with BMPR2 variants are 
diagnosed at a younger age and have more severe pulmonary haemodynamic impairment. In 
a large international meta-analysis Evans et al. were able to confirm that BMPR2 variant 
carriers had a significantly worse prognosis compared to patients with idiopathic PAH in 
multivariate models including age and gender as covariates (30). It was suggested that this 
effect was partly due to more impaired RV function in patients with BMPR2 variants. 
 
Recently, Trip et al. showed patients with BMPR2 variants had a higher KCO compared to 
patients with idiopathic PAH (360). Patients with abnormal spirometry, abnormal lung 
parenchyma on high resolution computed tomography of the chest, or a significant smoking 
history were excluded from this study. However, few other studies have sought to 
characterise BMPR2 variant carriers despite the fact that BMPR2 is a widely expressed protein 
throughout the body and not just expressed in the pulmonary and systemic circulation (361). 
 
Disease associated variants in non-BMPR2 genes account for approximately 2 % of patients 
with sporadic PAH (i.e. no family history of the disease) and 7 % of patients with a family 
history of PAH (235). Variants in ACVRL1 and ENG, which are also associated with HHT, 
account for the majority of these patients. Most patients with variants in ACVRL1 or ENG  have 
features of HHT. This includes mucocutaneous telangiectasia, recurrent epistaxis and 
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arteriovenous malformations. The only exception to this being a few cases of childhood onset 
PAH where these features of HHT may not yet have manifested (11). 
 
Variants in KCNK3, CAV1, SMAD1, SMAD4, and SMAD9 are even more rare and only few 
patients with these variants have been described (70, 71, 75, 80, 353). As such, it remains 
unclear if these patients have characteristic phenotypes that differentiate them from patients 
with idiopathic PAH or patients with variants in other genes. It has been suggested that 
patients with KCNK3 variants have worse RV function and do not respond to acute pulmonary 
artery vasodilator challenges (75, 362). TBX4 variants were initially associated with Small 
Patella Syndrome (90). Since then patients with both paediatric and adult onset PAH have 
also been shown to carry TBX4 variants (89). All paediatric cases had evidence of Small Patella 
Syndrome on review. A few patients with adult onset PAH carrying TBX4 variants have also 
been described, but they did not show features of Small Patella Syndrome (89, 92). 
Conversely, screening of a cohort of 23 adult patients with Small Patella Syndrome failed to 
detect pulmonary hypertension in any of the patients (89). Furthermore, post-mortem 
histological assessment of one patient with a TBX4 variant showed changes consistent with 
PVOD rather than PAH. Thus, the phenotypic consequences of TBX4 variants appear variable. 
 
As discussed in the previous chapter the strengths of the NIHR BRIDGE PAH Study include its 
large size, breadth of phenotype data collected and availability of WGS data on all recruited 
patients. This provides an opportunity to phenotype patients carrying specific disease 
associated variants. In this chapter I aim to: 
1) Assess the burden and consequence of rare and predicted deleterious variants in 
disease associated genes in PAH patients recruited to the NIHR BRIDGE PAH Study. 
2) Describe the characteristics and clinical outcomes of patients with variants in BMPR2 
and other genes previously associated with PAH. 
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Rare and predicted deleterious variants in genes previously associated with PAH 
One-thousand and nineteen patients with PAH had WGS data available and were retained for 
analysis in the NIHR BRIDGE PAH Study as discussed in Results Chapter 1 and summarised in 
Figure 5. These patients could be classified as familial PAH (n = 64), drug associated PAH (n = 
49), idiopathic PAH (prior to genetic testing; n = 869) or PVOD / PCH (including patients with 
biallelic EIF2AK4 variants [Results Chapter 3]; n = 30). The number of patients with rare and 
predicted deleterious variants in genes associated with PAH are shown in Table 14. Although 
a higher proportion of patients with a family history of the disease had a variant in a disease 
associated gene, the greatest number of patients carrying such variants occurred in those 
with no apparent family history. This may reflect failure to obtain a complete family history, 
delayed presentation/diagnosis of other family members, reduced penetrance of these 
variants, or a high frequency of de novo variants.  
 
In Results Chapter 1 no significant differences were identified between patients with 
idiopathic PAH and drug associated PAH, other than the increased female bias in the latter 
group. Furthermore, the proportion of patients carrying a variant in a disease associated gene 
was similar between the two groups. Therefore, in the remainder of this chapter, patients 
with idiopathic and drug associated PAH (after excluding patients with disease associated 
variants identified by WGS; n = 779) were treated as a single “PAH” group. These PAH patients 
were compared to patients with variants in individual PAH associated genes. Patients with 
PVOD / PCH were again excluded from further analysis.  
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Table 14. Number of causal variants in genes previously associated with disease 
pathogenesis identified in each PAH subgroup 
Gene Idiopathic PAH Familial PAH 
Drug 
associated PAH 
PVOD / PCH^ 
ACVRL1 9 (1%) 1 (2%) 0 0 
BMPR2 107 (12%) 45 (70%) 5 (10%) 0 
CAV1 0 0 0 0 
Biallelic EIF2AK4 0 0 0 14 (47%) 
ENG 3 (0.3%) 1 (2%) 1 (2%)* 0 
KCNK3 4 (0.5%) 0 0 0 
SMAD1 0 0 0 0 
SMAD4 0 0 0 0 
SMAD9 3 (0.3%) 0 0 0 
TBX4 13 (1.5%) 2 (3%) 1 (2%) 0 
Ten patients also had variants in a second disease associated gene these were discounted 
for classification purposes as described in Results Chapter 1. *This includes the ENG variant 
of uncertain significance described previously. ^Includes biallelic EIF2AK4 variant carriers 
with a clinical diagnosis of idiopathic PAH (Results Chapter 3). Number and percentage of 
patients in each disease group shown. 
 
BMPR2  
Rare and predicted deleterious BMPR2 variants 
In control subjects from other NIHR BRIDGE studies, 24 rare and predicted deleterious 
variants were identified. Most of these variants (n = 16) occurred in the cytoplasmic tail 
domain of BMPR2 (encoded by exons 12 and 13). This included the frameshift variant 
p.Asn1006Ter, located well after the last PAH associated PTV in BMPR2 (p.Gln918Ter). All the 
other variants found in control subjects were missense variants, except for two inframe 
deletions. 
 
In the NIHR BRIDGE PAH Study 159 rare and predicted deleterious BMPR2 variants (138 SNVs 
and 21 CNVs) were identified in 157 patients (two half-sisters both carried 2 rare and 
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predicted deleterious BMPR2 missense variants; Results Chapter 1). These variants are listed 
in Appendix 16. There were 126 unique variants; 37 % of which have previously been 
reported. The consequence types and locations of these variants are shown in Table 15 and 
Figure 13. The extracellular domain and serine-threonine kinase domain had a higher 
proportion of missense variants (p = 0.004), highlighting the importance of key amino acid 
residues in ligand binding and catalytic activity. Whereas, the smaller proportion of missense 
variants in the transmembrane domain and cytoplasmic tail suggests that these areas do not 
carry critical amino acid residues but are of structural importance or required for protein 
trafficking 
 
Table 15. Consequence types and locations of BMPR2 variants identified in PAH patients 
Consequence 
type 
ECD TM PK CT NC Total 
Frameshift 
variant 
12 (40% 1 (20%) 15 (28%) 10 (38%) 0 (0%) 38 
Stop gained 
variant 
5 (17%) 4 (80%) 17 (31%) 12 (46%) 0 (0%) 38 
Splice region 
variant 
0 (0%) 0 (0%) 0 (0%) 0 (0%) 
23 
(100%) 
23 
Inframe insertion 
/ deletion 
0 (0%) 0 (0%) 2 (4%) 0 (0%) 0 (0%) 2 
Missense  
variant 
13 (43%) 0 (0%) 20 (37%) 4 (15%) 0 (0%) 37 
Total 30 5 54 26 23 138 
ECD – extracellular domain, TM – transmembrane domain, PK – serine / threonine kinase 
domain, CT – cytoplasmic tail, NC – non-coding. Percentages calculated with column totals. 
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Figure 13. Gene locus plot of BMPR2 variants identified in PAH patients 
Rare (minor allele frequency < 0.0001) and predicted deleterious (CADD score ³ 15, and PolyPhen-2 or SIFT 
predictions not classified as “benign” or “tolerated”) variants in BMPR2 were identified in patients recruited to 
the study. To create the figure the genomic coordinates for each variant, the reference and variant allele at that 
position, the consequence type of the variant and the amino acid change resulting from the variant were entered 
into MutationMapper. Splice site variants and deletions are not shown in the figure. The majority of missense 
variants are located in the extracellular and protein kinase domains where they alter critical amino acid residues 
resulting in the loss of protein function. 
Green – missense variant, Black – protein truncating variant, Purple – inframe variant. 
ECD – extracellular domain. 
Modified from http://www.cbioportal.org/mutation_mapper.jsp (363) 
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BMPR2 phenotype - genotype associations 
Comparisons were made between patients with BMPR2 variants (BMPR2+/-; n = 157) and PAH 
patients with no variants in disease associated genes (n = 779). All significant phenotypic 
differences between the two groups are shown in Appendix 17. In summary BMPR2 variant 
carriers were significantly younger (39 years [32 - 51] vs. 51 years [38 - 66]; Wilcoxon rank-
sum test p < 0.001), and had more severe pulmonary haemodynamic impairment compared 
to PAH patients (Wilcoxon rank-sum test p values provided): 
mPAP:  58 mmHg [51 - 68] vs. 51 mmHg [43 - 60]; p < 0.001, 
PVR:  14.2 WU [10.8 - 20.3] vs. 10.2 WU [7.0 - 14.0]; p < 0.001, 
CI:  1.8 L/min/m2 [1.5 - 2.2] vs. 2.2 L/min/m2 [1.8 - 2.7]; p < 0.001, 
SvO2:  60 % [56 - 66] vs. 65 % [60 - 71]; p < 0.001. 
 
BMPR2 variant carriers were less likely to have a positive vasoreactive response to an acute 
pulmonary artery vasodilator challenge (0 [0.0%] vs. 31 [18.1%]; Fisher’s exact test p = 0.007). 
However, functional assessments between the two groups were similar: 
6mwt distance: 331 m [287 - 427] vs. 310 m [160 - 410]; Wilcoxon rank-
sum test p = 0.210, 
 Functional class 1/2/3/4: 2 [1.4%] / 32 [21.6%] / 89 [60.1%] / 25 [16.9%] vs.  
15 [2.2%] / 143 [21.4%] / 439 [65.7%] / 71 [10.6%];  
Cochran-Armitage test p = 0.388. 
 
BMPR2 variant carriers were more likely to have normal spirometry and a preserved KCO 
compared to PAH patients. They were also less likely to desaturate during a 6mwt. 
 Lung function pattern (Normal / Obstructive / Restrictive):  
81 [81.0%] / 12 [12.0%] / 7 [7.0%] vs. 
244 [53.7%] / 135 [29.7%] / 75 [16.5%]; Fisher’s exact test p < 
0.001, 
KCO (% predicted): 82 % [74 - 94] vs. 70 % [49 - 85]; Wilcoxon rank-sum test p < 
0.001, 
Post walk SaO2 (%): 94 % [90 - 97] vs. 91 % [85 - 96]; Wilcoxon rank-sum test p = 
0.014. 
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Significant differences in full blood count indices were observed for the first time between 
BMPR2 variant carriers and PAH patients (Wilcoxon rank-sum test p values provided): 
Haemoglobin:  162 g/l [152 – 173] vs. 151 g/l [136 – 163]; p < 0.001, 
Haematocrit:  0.5 [0.5 – 0.5] vs. 0.4 [0.4 – 0.5]; p < 0.001, 
White blood cell count:  8.8 x109/l [7.3 – 10.8] vs. 8.1 x109/l [6.8 – 9.7]; p < 
0.014. 
 
Other blood test results suggested impaired liver function and possible differences in thyroid 
function in BMPR2 variant carriers (Wilcoxon rank-sum test p values provided): 
Alanine transferase:  30 iu/l [22 – 42] vs. 23 iu/l [17 – 33]; p < 0.001, 
Bilirubin:   19 µmol/l [13 – 29] vs. 14 µmol/l [10 – 22]; p < 0.003, 
Thyroid stimulating hormone: 2.5 mu/l [1.7 – 3.7] vs. 2.0 mu/l [1.2 – 3.1];  
p = 0.013. 
 
As demonstrated in Results Chapter 1, the age difference between the two groups may in 
part be responsible for some of the other differences described above. Figure 14 shows a 
clear difference in the distribution of age at diagnosis between the two groups, with a higher 
proportion of PAH patients being older than 50 years of age and under 18 years of age. 
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Figure 14. Age distribution of patients with and without BMPR2 variants 
Rare (minor allele frequency < 0.0001) and predicted deleterious (CADD score ³ 15, and PolyPhen-2 or SIFT 
predictions not classified as “benign” or “tolerated”) variants in BMPR2 were identified in patients recruited to 
the study. Comparison was made between patients with PAH and BMPR2 variants (BMPR2 +/-; n = 157) and 
patients with idiopathic PAH (BMPR2 +/+; i.e. no rare or predicted deleterious variants identified in any of the 
previously reported PAH associated genes; n = 779). A higher proportion of patients with BMPR2 variants were 
in the younger group (age < 51.1 years; 91 %) compared to patients with idiopathic PAH (69 %; Fisher’s exact p 
< 0.001). 
 
To account for this difference the analysis was rerun restricted to patients between the ages 
of 18 and 50 years. One-hundred and twelve patients with a BMPR2 variant and 343 PAH 
patients were included in this analysis. Similar phenotypic differences were identified 
between the two groups in this restricted analysis. No significant difference was seen in the 
gender bias between the two groups. Although there was a trend for the female bias to be 
less pronounced amongst patients with BMPR2 variants (number of females: 73 [65 %] vs. 
267 [78 %] Fisher’s exact test p = 0.059). BMPR2 variant carriers once again demonstrated 
more severe pulmonary haemodynamic impairment but functional assessments were again 
similar between the two groups. Similar to the initial analysis, significant differences were 
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demonstrated in full blood count indices, thyroid stimulating hormone levels and alanine 
transferase levels. Interestingly, there was no longer a significant difference in KCO between 
the two groups. 
 
As an alternative analysis, multivariate rank regression models (using BMPR2 variant status, 
age at diagnosis, gender and recruiting centre as covariates) were created to assess 
associations between the presence of rare and deleterious BMPR2 variants and phenotypic 
variables (Table 16). These rank regression models support the earlier findings that patients 
with BMPR2 variants have more severe pulmonary haemodynamic impairment. It also 
reinforces the novel associations described between BMPR2 and blood cell counts. Unlike the 
previous analysis that excluded patients under 18 years and over 50 years of age, the rank 
regression model suggests that BMPR2 does have an independent association with KCO; even 
when accounting for the age at diagnosis. The lack of a significant association in the previous 
analysis may be due to a lack of power and/or failure to account for other confounders, such 
as gender and differences in measurements between recruiting centres. Of note, a significant 
association was observed between alanine transferase and BMPR2. However, assessment of 
residuals plots revealed that this was being influenced by outliers. 
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Table 16. Rank regression models assessing the phenotypic differences between patients 
with idiopathic PAH and those with BMPR2 variants 
Variable 
Regression 
coefficient (b) 
Standard error 
Corrected p from 
model 
sPAP (mmHg) 8.004 2.108 <0.001 
dPAP (mmHg) 5.230 0.986 <0.001 
mPAP (mmHg) 5.220 1.164 <0.001 
PVR (WU) 4.170 0.499 <0.001 
CO (L/min) -0.841 0.117 <0.001 
CI (L/min/m2) -0.396 0.069 <0.001 
SvO2 (%) -6.132 0.949 <0.001 
Hb (g/l) 9.862 2.031 <0.001 
WBC (x109/l) 0.908 0.252 <0.001 
HCT 0.032 0.006 <0.001 
KCO 0.148 0.039 <0.001 
KCO (% predicted) 10.221 2.644 <0.001 
Results of multivariate rank regression models using BMPR2 status, age at diagnosis, 
gender and recruiting centre as covariates. Each variable presented in the table was used 
in turn as the dependent variable. The results of the multivariate rank regression models 
are presented. Values represent the effect of carrying a BMPR2 variant.  
CI – cardiac index, CO – cardiac output, dPAP – diastolic pulmonary artery pressure, Hb – 
haemoglobin, WBC – white blood cells, HCT – haematocrit, KCO – transfer coefficient for 
carbon monoxide, mPAP – mean pulmonary artery pressure, PVR – pulmonary vascular 
resistance, sPAP – systolic pulmonary artery pressure, SvO2 – mixed venous oxygen 
saturation. 
 
Effect of BMPR2 variant status on survival 
In a univariate Cox proportional hazards model, patients with BMPR2 variants had a 
significantly better survival compared to PAH patients (Figure 15; HR [95% confidence 
interval: 0.561 [0.356 - 0.885]; p = 0.013). This was similar in a left truncated analysis (HR: 
0.546 [0.283 - 1.051]; p = 0.070). However, this is not supported by previous studies that 
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suggest BMPR2 variant carriers have a worse prognosis (30). In a multivariate model using the 
variables of prognostic significance identified in Results Chapter 1 as covariates (age at 
diagnosis, gender, incident/prevalent, KCO % predicted, RAP), the presence of BMPR2 variants 
was not a significant prognostic marker (HR: 1.254 [0.660 - 2.384]; p = 0.490). 
 
 
Figure 15. Kaplan-Meier plot demonstrating the effect of BMPR2 variants on survival 
The time from diagnosis to death was calculated where survival data was available. Patients were censored at 
the time of last contact or if transplanted. Patients were categorised as idiopathic PAH (BMPR2 +/+ [i.e. not 
carrying any variants in any of the known disease associated genes]; n = 703) and BMPR2 variant carriers 
(BMPR2+/- [i.e. carrying a rare and predicted deleterious variant in BMPR2]; n = 151). In univariate analysis 
BMPR2 variant carriers had a significantly better prognosis compared to patients with idiopathic PAH (log-rank 
test p = 0.01). However, this does not take into account that patients with BMPR2 variants were significantly 
younger and this may have confounded the univariate analysis. 
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Phenotypic consequences of different BMPR2 variants  
The phenotypic consequences of distinct types of BMPR2 variant (variant consequence types 
and location of the variants) were assessed. Initially variants were categorised as deletions (n 
= 21), PTVs (frameshift and stop gained variants; n = 76), splice site variants (n = 23), and SNVs 
/ indels (missense variants and inframe insertions / deletions < 1 kb; n = 37). After correcting 
for multiple testing, no differences were observed amongst the different variant consequence 
types. Although this is in keeping with previous reports, it does not account for confounding 
by the location of the variant.  
 
To investigate whether there were any BMPR2 domain specific phenotypes, patients with 
missense variants and indels were assessed. Patients with PTVs and splice site variants were 
excluded as the consequence of the variant could not be reliably predicted (for example, did 
it result in a short protein or undergo nonsense mediated decay). The number of patients 
retained for this analysis was small, 37. Two variants were identified in the cytoplasmic tail 
domain, 13 in the extracellular ligand binding domain and 22 in the serine-threonine kinase 
domain. Again, no significant differences were identified between the different domains. 
Larger numbers of patients with BMPR2 variants are required to verify these results.  
 
ACVRL1 and ENG  
Rare and predicted deleterious ACVRL1 and ENG variants 
Sixteen rare and predicted deleterious ACVRL1 variants and 25 ENG variants were identified 
in control subjects recruited to other NIHR BRIDGE studies. This included an ACVRL1 stop 
gained variant (p.Glu159Ter), an ACVRL1 missense variant (p.Asp254Asn) and 3 ENG missense 
variants (p.Gly214Ser and p.Pro225Leu x2) that had previously been associated with HHT or 
PAH. Further phenotypic information was unavailable for these 5 subjects.  
 
Amongst patients recruited to the NIHR BRIDGE PAH Study, 10 rare and predicted deleterious 
ACVRL1 variants and 8 ENG variants were identified (Table 17). Six of these ACVRL1 variants 
and just a single ENG variant (p.Arg93Ter) had previously been associated with PAH or HHT. 
Of the 4 remaining ACVRL1 variants none had been confirmed as being pathogenic in the 
ARUP Laboratories database (listing HHT associated variants). Moreover, none of the 
remaining 7 ENG variants had previously been listed in the ARUP Laboratory’s database either 
 148 
(364). Of note, other than the stop gained ENG variant that had previously been associated 
with HHT (and was identified in a patient with a history of HHT), all the other ENG variants 
were missense variants. Two of the patients carrying ENG missense variants also had large 
BMPR2 deletions. While another patient also carried a TBX4 variant that had previously been 
associated with Small Patella Syndrome (Table 9). 
 
Phenotypes of patients with rare and predicted deleterious ACVRL1 and ENG variants  
Amongst the 794 PAH patients (with no variants in disease associated genes), one patient was 
reported to have evidence of multiple arteriovenous malformations on CTPA and another had 
a history of epistaxis, but none had a diagnosis of HHT. Six patients (60 %) with ACVRL1 
variants had a diagnosis of HHT. Only a single patient with an ENG variant (p.Arg93Ter) had a 
diagnosis of HHT. Of the remaining 11 patients with variants in either ACVRL1 or ENG and no 
diagnosis of HHT, 5 had no mention of arteriovenous malformations, telangiectasia or 
epistaxis recorded in OpenClinica. The remaining patients were from European centres and 
did not have further clinical information available.  
 
Phenotypic differences between patients with ACVRL1 or ENG variants and those with PAH 
were assessed. This study lacks power to identify further phenotypic differences. Additionally, 
the lack of a clinical diagnosis of HHT in some of the variant carriers and the lack of previously 
reported associations to PAH or HHT for some variants may suggest some of these variants 
are not pathogenic. Repeating the analysis with patients carrying a variant validated in the 
ARUP Laboratories database or with a clinical diagnosis of HHT, restricted the number of 
ACVRL1 and ENG variant carriers to just 9. No significant differences were observed between 
these 9 variant carriers and patients with PAH after correcting for multiple testing. 
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Table 17. Variants in ACVRL1 and ENG identified in PAH patients 
Gene HGVSc HGVSp Exon Consequence type CADD score ExAC AF ARUP database HHT diagnosis 
ACVRL1 c.334C>T p.Gln112Ter 4 of 10 Stop gained 35  Pathogenic Yes 
ACVRL1 c.647T>G p.Val216Gly 6 of 10 Missense variant 28.3  
Variant of uncertain 
significance 
Yes 
ACVRL1 c.1030T>C p.Cys344Arg 7 of 10 Missense variant 27  Pathogenic Yes 
ACVRL1 c.1450C>G p.Arg484Gly 10 of 10 Missense variant 27.6  Pending classification Yes 
ACVRL1 c.1451G>T p.Arg484Leu 10 of 10 Missense variant 32  Pending classification Yes 
ACVRL1 c.1450C>T p.Arg484Trp 10 of 10 Missense variant 33  Pathogenic Yes 
ACVRL1 c.1451G>A p.Arg484Gln 10 of 10 Missense variant 33  Pathogenic No 
ACVRL1 c.433C>T p.Arg145Trp 4 of 10 Missense variant 23.7  Not listed No 
ACVRL1 c.982C>G p.His328Asp 7 of 10 Missense variant 32  Not listed No 
ACVRL1 c.604G>C p.Val202Leu 5 of 10 Missense variant 24  Not listed No 
ENG c.277C>T p.Arg93Ter 3 of 15 Stop gained 37  Pathogenic Yes 
ENG c.1934G>C p.Gly645Ala 15 of 15 Missense variant 27.9 3.45x10-5 Not listed No 
ENG c.1419C>G p.Ser473Arg 11 of 15 Missense variant 21.6  Not listed No 
ENG c.1545C>A p.Asn515Lys 12 of 15 Missense variant 23.4  Not listed No 
ENG c.10G>A p.Gly4Ser 1 of 15 Missense variant 22  Not listed No 
ENG c.1795G>A p.Ala599Thr 14 of 15 Missense variant 33  Not listed No 
ENG c.1850C>T p.Thr617Met 14 of 15 Missense variant 32 4.96x10-5 Not listed No 
ENG c.1955G>A p.Cys652Tyr 15 of 15 Missense variant 27.7  Not listed No 
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TBX4  
Rare and predicted deleterious TBX4 variants 
Amongst control subjects recruited to the NIHR BRIDGE Study, 20 variants in TBX4 were 
identified. All but 1 of the variants were missense variants. The single frameshift variant 
(p.Pro412HisfsTer4) occurred in the final exon of the gene and was further downstream than 
previously reported disease associated PTVs. Furthermore, 9 missense variants also occurred 
in the final exon. None of these variants have previously been associated with Small Patella 
Syndrome or PAH (89, 90, 92). 
 
Amongst patients recruited to the NIHR BRIDGE PAH Study 16 TBX4 variants were identified 
(2 stop gained, 7 frameshift and 7 missense variants; Appendix 18). All protein truncating 
variants and all but of the 2 missense variants occurred upstream of the frameshift variant 
identified in control subjects. One variant had previously been associated with PAH 
(p.Tyr382Ser) and two with Small Patella Syndrome (p.Pro372SerfsTer14 identified in 2 
unrelated patients) (89, 90). Two patients had a family history of PAH. One of these patients 
with a family history of PAH did not have any other variants in disease associated genes. The 
second patient had a TBX4 variant (p.Thr326ProfsTer12) that has previously been associated 
with Small Patella Syndrome and also a missense variant in the final exon of ENG 
(p.Gly645Ala). This ENG variant had not previously been reported in the ARUP Laboratories 
database and the patient did not have a clinical diagnosis of HHT. This may question the 
pathogenicity of this ENG variant. 
 
Phenotypes of patients with rare and predicted deleterious TBX4 variants 
No significant differences were seen between the TBX4 variant carriers and patients with PAH. 
None of the patients were reported to have Small Patella Syndrome. Two patients had 
paediatric onset disease. None of the patients with TBX4 variants had a clinical diagnosis of 
PVOD / PCH or had a reduced KCO recorded (although this was only available for 3 patients). 
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KCNK3 
Rare and predicted deleterious KCNK3 variants 
Fourteen rare and predicted deleterious variants (13 missense variants and 1 inframe 
insertion) were identified in control subjects recruited to the NIHR BRIDGE Study. None of 
these variants were previously associated with PAH (78, 92). In the NIHR BRIDGE PAH Study 
4 further missense variants were identified in patients with a diagnosis of PAH (Appendix 19). 
These patients did not carry any other variants in disease associated genes. 
 
Phenotypes of patients with rare and predicted deleterious KCNK3 variants 
None of the patients carrying a KCNK3 variant had a family history of PAH. Three of the 
patients were aged under 30 years at the time of diagnosis (carrying the variants p.Ala114Thr, 
p.Glu182Gln, p.Gly236Ala) and the fourth was 72 years old (p.Arg51Leu). None of the patients 
had an acute pulmonary artery vasodilator challenge. No significant phenotypic differences 
were identified between the KCNK3 variant carriers and patients with PAH.  
 
SMAD9 
Rare and predicted deleterious SMAD9 variants 
In NIHR BRIDGE control subjects 21 rare and predicted deleterious SMAD9 variants (20 
missense variants and 1 stop gained variant) were identified. None of these variants have 
previously been associated with PAH (70, 71, 353). Amongst patients with a diagnosis of PAH 
4 missense variants and 1 stop gained variant (p.Arg294Ter – previously associated with PAH) 
were identified (Appendix 19) (353). Two additional patients carried both biallelic EIF2AK4 
variants and a SMAD9 missense variant (p.Pro140Leu and p.Gly367Ser) but are not included 
here as they are classified as PVOD / PCH.  
 
Interestingly, the SMAD9 stop gained variant was identified in a patient who also carried a 
previously described missense variant in BMPR2 (p.Cys123Arg), resulting in the loss of a 
critical cysteine residue in the extracellular domain (ligand binding domain) of the protein. A 
second patient also carried a novel missense variant in SMAD9 (p.Gly367Ser) and a previously 
described frameshift variant in BMPR2 (p.Lys678ProfsTer6). For the purposes of the 
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phenotype-genotype association analyses these 2 patients with variants in both SMAD9 and 
BMPR2 were excluded.  
 
Phenotypes of patients with rare and predicted deleterious SMAD9 variants 
None of the patients carrying a SMAD9 variant had a family history of PAH. Unsurprisingly, 
with only 3 patients carrying just a SMAD9 variant no significant phenotypic differences were 
seen between the SMAD9 variant carriers and patients with PAH. These patients did not have 
any striking phenotypic abnormality. Unlike the 2 patients carrying biallelic EIF2AK4 variants 
and a SMAD9 variant, the other SMAD9 variant carriers did not have a low KCO. This may 
suggest that the low KCO was not a phenotypic consequence of the loss of function of SMAD9. 
 
As discussed previously in Results Chapter 1, the male patient carrying the SMAD9 stop gained 
variant and the BMPR2 missense variant resulting in the loss of a critical cysteine residue was 
recruited retrospectively. Therefore, only limited clinical information was available. They had 
no apparent family history of the disease and were diagnosed at the age of 37 years. At the 
time of presentation, they had severe pulmonary hypertension (mPAP 76 mmHg, PVR 28.4 
WU) and impaired right ventricular function (CI 1.3 L/min/m2). They were in functional class 
3 at diagnosis and only managed 110 m on a 6mwt. The severity of their disease may be 
associated with two genetic hits to the BMPR2 signalling pathway. 
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Discussion 
Heritable PAH 
A strength of the study was the availability of WGS data for all patients recruited. This allowed 
an accurate assessment of the burden of rare and predicted deleterious SNVs and CNVs in 
this cohort of PAH patients. Although next generation sequencing technologies have been 
used to discover new disease associated genes, such as CAV1 and KCNK3, in families with a 
history of PAH, no previous studies have used high throughput sequencing in large numbers 
of patients with both idiopathic and heritable PAH (75, 80). Selection biases are minimized by 
employing WGS across the entire cohort. It also allowed the identification of several patients 
carrying variants in more than one disease associated gene. The proportion of patients 
carrying variants in disease associated genes was similar to what has previously been 
reported. This supports the validity of the study design and its findings, despite the lack of 
experimental and familial segregation information. 
 
The ENG and SMAD1 variants occurring in combination are unlikely to pathogenic as 
suggested by the complementary genetic and phenotypic information available. However, 
further experimental and clinical work is required to assess the significance of the SMAD9 
variants occurring in combination. In total 4 patients carried rare and predicted deleterious 
SMAD9 variants as well as likely causal variants in BMPR2 or biallelic variants in EIF2AK4. In 
the case of the patient carrying both a protein truncating variant in SMAD9 and a highly 
deleterious BMPR2 ligand binding domain variant, both variants are potentially pathogenic.  
 
BMPR2 
One-hundred and fifty-seven patients were found to carry a SNV or CNV in BMPR2. This 
provided sufficient numbers to assess novel phenotype-genotype associations through simple 
statistical methods and through more complex multivariate modelling that account for 
potential confounders. The validity of these analyses is supported by the confirmation of a 
younger age at diagnosis and more severe pulmonary haemodynamic impairment in patients 
with BMPR2 variants.  
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Several novel observations were also identified even when accounting for age, gender and 
recruiting centre in the multivariate models. Patients with BMPR2 variants had a significantly 
higher haemoglobin concentration (162 g/l [152 - 173]) and haematocrit (0.5 [0.5 - 0.5]) 
compared to patients with PAH (151 g/l [136 - 163] and 0.4 [0.4 - 0.5] respectively). There 
were no significant differences in markers of iron homeostasis such as the red cell distribution 
width, ferritin concentration, iron binding capacity or transferrin saturations. However, the 
study may have lacked power to identify differences in these biomarkers because of missing 
data. The data completion rates for these biomarkers were 28 %, 28 %, 17 % and 15 % 
respectively (Appendix 11). Assessment of iron homeostasis is not part of the routine clinical 
work up of patients with PAH. The mechanism for these observations is unclear. It has been 
shown, at least in-vitro, that BMPR2 downregulation increases hepcidin, which acts to reduce 
absorption of iron from the gastrointestinal tract (218). If this were the case, then patients 
with BMPR2 variants may be expected to have a lower haemoglobin concentration and 
haematocrit compared to patients with idiopathic PAH. Conversely, preclinical studies have 
suggested that BMPR2 has a redundant role in regulating hepcidin expression but loss of both 
BMPR2 and ActR2a (another type 2 bone morphogenetic protein receptor) results in a 
reduced basal expression of hepcidin (365).  
 
White blood cells were noted to be significantly higher in BMPR2 variant carriers (8.8 x109/l 
[7.3 - 10.8]) compared to PAH patients (8.1 x109/l [6.8 - 9.7]). Previous, clinical studies have 
not shown any effect of BMPR2 loss on immune function (112, 115). Although there is in-vitro 
and preclinical evidence for increased inflammatory responses in human pulmonary artery 
smooth muscle cells and mice with heterozygous BMPR2 variants (127). Further investigation 
of the white blood cell differential will be important in assessing the significance of this 
finding. 
 
One study by Girerd et al. suggested that patients with variants in the cytoplasmic tail domain 
of BMPR2 were significantly older and had a reduced right ventricular afterload compared to 
patients with other BMPR2 variants (366). It was postulated that activation of the SMAD 
pathway by these cytoplasmic tail domain variants, which was not demonstrated by protein 
kinase domain variants, might be the cause of this difference. The study also included familial 
segregation data for many of these variants, supporting their pathogenicity. Another study 
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reported that the cellular localisation of the BMPR2 receptor varied between variants in 
different functional domains but no phenotypic comparisons were made (367). In the NIHR 
BRIDGE PAH Study no phenotypic differences were identified between patients with different 
variant consequence types or locations. This may be due to a lack of numbers. However, Evans 
et al., reporting on the largest number of BMPR2 variant carriers to date, also found no 
phenotypic differences between variant consequence types. 
 
In a univariate survival analysis BMPR2 variant carriers had a significantly better prognosis 
compared to patients with PAH. However, in multivariate analyses including age and gender 
as covariates, no significant differences were seen. Insufficient observed events (n = 189) at 
this stage of the study prevented a more conclusive analysis. In comparison, the meta-analysis 
by Evans et al. that demonstrated a poorer prognosis for BMPR2 variant carriers, included 
448 BMPR2 variant carriers out of total study population of 1,550, and 354 deaths were 
observed (30). 
 
Other genes 
Despite the size of the study variants in other genes only accounted for 4 % of patients with 
either idiopathic, drug associated or heritable PAH. Therefore, insufficient numbers were 
available to identify novel phenotypes amongst patients with variants in these genes. As such 
the study could only assess previously reported phenotypes. HHT was diagnosed in most 
patients with ACVRL1 variants. The lack of such a diagnosis in the majority of patients with 
ENG variants questions the pathogenicity of these variants.  
 
Surprisingly, given the fact it has only relatively recently been described, variants in TBX4 were 
the second most commonly identified in patients with PAH. None of the patients in the study 
were identified as having Small Patella Syndrome, but further specific assessment for this is 
required, especially in the 2 childhood onset cases. 
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Summary 
The availability of WGS data for all patients recruited to NIHR BRIDGE PAH Study allowed for 
the unbiased identification of rare and predicted deleterious variants in disease associated 
genes. As has been reported previously, variants in BMPR2 were the most common in patients 
with PAH. Such variants were identified in 12 % of patients with idiopathic PAH and 70 % of 
those with a family history of PAH. Variants in other genes were much less common. Together 
they accounted for 4 % of patients with idiopathic PAH and 6 % of patients with a family 
history of the disease. 
 
Sufficient numbers of patients with BMPR2 variants were available to perform multivariate 
rank regression analyses to identify phenotypic differences between these patients and those 
without any variants in genes previously associated with PAH. As well as validating previous 
findings of a younger age at disease onset and more severe pulmonary haemodynamic 
impairment in patients with BMPR2 variants, several novel phenotype-genotype associations 
were identified. Patients with BMPR2 variants had a higher haemoglobin concentration, 
haematocrit and white blood cell count compared to those with PAH. Further work is required 
to understand the reasons for these observations and their potential clinical significance. 
 
The small numbers of patients with variants in other genes resulted in a lack of power to 
identify specific phenotypes associated with these variants. Sixty percent of patients with 
variants in ACVRL1 were noted to have HHT. However, only 1 out of 8 patients with ENG 
variants were reported to have HHT. This demonstrated how phenotype data along with 
additional genetic information can be used to assess the potential pathogenicity of rare and 
predicted deleterious variants. 
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Results Chapter 3: Phenotypic consequences of biallelic EIF2AK4 
variants 
Introduction 
PVOD / PCH is an ultra-rare form of PH that is associated with a poor prognosis. The clinical 
features described in patients with PVOD / PCH include a low KCO and oxygen desaturation 
on exertion, as well as the presence of centrilobular ground glass opacification, interlobular 
septal thickening and mediastinal lymphadenopathy on high resolution computed 
tomography (HRCT) of the lung parenchyma (300, 308). However, these clinical and 
radiological features have also been reported in idiopathic PAH (222, 351, 360). Consequently, 
the clinical distinction between PVOD / PCH and idiopathic PAH can be challenging. It has 
been estimated that 10 % of patients with PVOD / PCH are misdiagnosed as idiopathic PAH 
(368, 369). The diagnosis of PVOD / PCH is often only confirmed post mortem or from 
explanted lungs by histological assessment.  
 
The histological features of PVOD / PCH typically include pulmonary venous obstructions and 
pulmonary capillary proliferation, although the distribution of these changes within the lung 
can be heterogeneous (281, 295). Pulmonary artery smooth muscle hypertrophy and intimal 
hyperplasia, similar to the changes observed in other forms of PAH, may also be present. 
Furthermore, pulmonary venous changes have been reported in cases of idiopathic PAH, 
scleroderma-associated PAH and patients with BMPR2 variants, to varying extents (112, 296). 
 
A major advance in the molecular diagnosis of PVOD / PCH was the finding of biallelic variants 
in the gene encoding the eukaryotic translation initiation factor 2 alpha kinase 4 (EIF2AK4) in 
both familial (100 %) and sporadic (20 – 25 %) cases of PVOD / PCH (20, 21). EIF2AK4 is an 
activator of the integrated stress response pathway, and responds to environmental stresses, 
including amino acid deprivation, by phosphorylating the alpha subunit of eukaryotic 
translation initiation factor 2 (281, 288, 370). These discoveries suggest that EIF2AK4 variants 
are specific to PVOD / PCH and that finding biallelic EIF2AK4 variants in a patient with 
pulmonary hypertension would be diagnostic of PVOD / PCH. Patients with PVOD / PCH have 
a poor prognosis and risk fatal pulmonary oedema with the use of pulmonary artery 
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vasodilator therapies (300, 306, 311, 314). Consequently, early and accurate diagnosis is vital 
to guide clinical management.  
 
Heterozygous variants in the gene encoding the bone morphogenetic protein type 2 receptor 
(BMPR2) are the most common genetic cause of PAH. They are found in approximately 17 % 
of individuals with idiopathic PAH and 82 % with a family history of the disease (30). Variants 
in BMPR2 have also been reported in patients with histologically proven PVOD (41, 284, 285, 
300). Thus, there remains considerable uncertainty to what extent the finding of EIF2AK4 or 
BMPR2 variants reliably predicts the clinical phenotype and response to therapy in a 
population of patients with PAH. 
 
In this chapter I aim to: 
1) Assess the burden of EIF2AK4 variants in the NIHR BRIDGE Study 
2) Describe and assess the significance of EIF2AK4 variants in a heterozygous state 
3) Describe the phenotypic, radiological and histological features associated with 
biallelic EIF2AK4 variants 
4) Assess the clinical outcomes of patients with biallelic EIF2AK4 variants 
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Characteristics of patients with a clinical diagnosis of PVOD / PCH 
Twenty-one patients (2 %) recruited to the NIHR BRIDGE PAH Study had a clinical diagnosis of 
PVOD / PCH (20 PVOD and 1 PCH). Just one of these patients had a family history of the 
disease. One female patient with a clinical diagnosis of PVOD diagnosed at the age of 42 years 
gave a history of amphetamine use. No other patients gave a history exposure to drugs or 
toxins associated with PAH. No patients were recorded as having exposure to inorganic 
solvents. However, exposure to inorganic solvents, whose association with PVOD / PCH was 
only reported in 2015, was not specifically requested in OpenClinica (294). Furthermore, such 
exposures are unlikely to have been captured in clinical records prior to this time. The 
characteristics of these patients are summarised in Table 18. 
 
Patients with a clinical diagnosis of PVOD / PCH had a similar age at diagnosis (54 years [42 - 
68]) compared to patients with a diagnosis of PAH (heritable PAH, idiopathic PAH or drug 
associated PAH; 49 years [35 - 63]; Wilcoxon rank-sum test p = 0.639). The age distribution of 
patients with a clinical diagnosis of PVOD / PCH shows a bimodal distribution (Figure 7 [Results 
Chapter 1]) with modes at 46 and 67 years. These modes reflect those with a genetic cause 
for the disease (biallelic EIF2AK4 variants) and those without an identifiable genetic cause 
(idiopathic PVOD / PCH; Figure 16). 
 
A female gender bias (1.9 : 1) was observed in patients with a clinical diagnosis of PVOD / PCH 
similar to that observed in patients with PAH (2.2 : 1; Fisher’s exact test p = 0.892). 
Haemodynamic measurements were similar between the two groups. However, patients with 
a clinical diagnosis with PVOD / PCH had a lower KCO and lower O2 saturations both at rest 
and on exertion compared to patients with PAH (Wilcoxon rank-sum test p < 0.05). 
Furthermore, their SvO2 (57 % [53 - 61]) was lower than in patients with PAH (65 % [58 - 70]; 
Wilcoxon rank-sum test p = 0.024), despite a similar cardiac output. 
 
The distribution of KCO % predicted is shown in Figure 17. It demonstrates that a substantial 
proportion of patients (23 %) with a clinical diagnosis of PAH also have a reduced KCO % 
predicted (< 50 % predicted). This may be due to coexisting parenchymal lung diseases. To 
exclude this as a potential cause of the reduced KCO % predicted and other differences seen 
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between patients with PVOD / PCH and PAH, patients with abnormal spirometry were 
removed from the analysis. Subsequently, just 6 patients with PVOD / PCH and 340 with PAH 
were retained. No phenotypic characteristics were significantly different between these two 
groups with normal spirometry. The KCO % predicted of patients with a clinical diagnosis of 
PVOD / PCH and normal spirometry was 35 % predicted [30 - 40] compared to 76 % predicted 
[60 - 90] in patients with PAH and normal spirometry. This difference was not of statistical 
significance after correcting for multiple testing (Wilcoxon rank-sum test p = 0.070).  
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Table 18. Phenotypic differences between patients with a clinical diagnosis of PVOD / PCH 
and PAH 
 PAH PVOD / PCH 
p 
corrected 
n [%] 998 [97.9%] 21 [2.1%]  
WGS ethnicity: African / 
East-Asian / European / 
South-Asian (n [%]) 
29 [2.9%] / 18 [1.8%] / 
891 [89.3%] / 60 [6.0%] 
1 [4.8%] / 0 [0.0%] / 
19 [90.5%] / 1 [4.8%] 
1.000 
Gender: female (n [%]) 683 [68.5%] 13 [61.9%] 0.892 
Age at diagnosis (years) 48.8 [35.4 - 62.7] 54.0 [42.1 - 68.1] 0.639 
Family history: Yes (n [%]) 65 [6.5%] 1 [4.8%] 1.000 
Drug exposure: Yes (n [%]) 57 [5.7%] 1 [4.8%] 1.000 
mPAP (mmHg) 53.0 [44.0 - 61.0] 49.5 [41.8 - 57.2] 0.741 
PCWP (mmHg) 9.0 [7.0 - 12.0] 11.0 [8.0 - 12.0] 0.521 
CO (L/min) 4.0 [3.2 - 5.0] 3.4 [2.6 - 4.1] 0.323 
CI (L/min/m2) 2.1 [1.7 - 2.6] 1.8 [1.5 - 2.2] 0.320 
PVR (WU) 11.0 [7.4 - 15.1] 10.4 [9.2 - 15.3] 0.892 
Vasoresponder (n [%]) 32 [13.4%] 0 [0.0%] 1.000 
Functional class:  
1 / 2 / 3 / 4 (n [%]) 
18 [2.1%] / 189 
[21.7%] / 565 [64.9%] 
/ 99 [11.4%] 
0 [0.0%] / 2 [10.0%] / 
14 [70.0%] / 4 [20.0%] 
0.521 
KCO (% predicted) 73.0 [54.0 - 88.0] 38.0 [29.6 - 47.0] <0.001 
Resting SaO2 (%) 95.0 [92.0 - 97.0] 91.0 [87.0 - 93.5] 0.005 
Post walk SaO2 (%) 92.0 [85.0 - 96.0] 85.0 [80.0 - 88.0] 0.024 
SvO2 (%) 64.5 [58.4 - 70.3] 57.1 [52.7 - 61.4] 0.024 
6mwt distance (m) 340.0 [220.0 - 420.0] 219.0 [96.0 - 295.0] 0.032 
6mwt – six-minute walk test, CI – cardiac index, CO – cardiac output, KCO – transfer coefficient for 
carbon monoxide, mPAP – mean pulmonary artery pressure, PCWP – pulmonary capillary wedge 
pressure, PVR – pulmonary vascular resistance, SaO2 – peripheral oxygen saturation, SvO2 – mixed 
venous oxygen saturation, WGS – whole genome sequencing. Data presented as median [IQR] 
unless stated. Wilcoxon rank-sum test used to assess continuous variables, Fisher’s exact test used 
to assess categorical variables, Cochran–Armitage test used to assess ordinal variables. 
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Figure 16. Density plot demonstrating differences in the age at diagnosis in patients with 
PVOD / PCH  
Patients with a clinical diagnosis of PVOD / PCH not carrying biallelic EIF2AK4 variants (n = 16) were compared 
to patients carrying rare and predicted deleterious variants in EIF2AK4 (n = 5). The two groups have visibly 
different distributions for age at diagnosis. Patients carrying biallelic EIF2AK4 variants were younger at diagnosis 
(median [IQR]: 33 years [27 – 39]) compared to those without a mutation (65 years [49 – 69]; Wilcoxon rank-
sum test p = 0.002). 
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Figure 17. Distribution of KCO % predicted 
The KCO % predicted was collected in OpenClinica along with other lung function test results. The figure shows 
the distribution of KCO % predicted in all patients with a diagnosis of PAH (heritable PAH, idiopathic PAH or drug 
associated PAH; n = 998) and those with a clinical diagnosis of PVOD / PCH (n = 21). Patients with PVOD / PCH 
had a low KCO % predicted (all < 75 %). The KCO % predicted was much more variable in patients with PAH but a 
large proportion (23 %) had a KCO % predicted < 50 %. 
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EIF2AK4 variants 
In the NIHR BRIDGE Study, 74 rare and predicted deleterious EIF2AK4 variants were identified. 
Forty-three of these variants (36 in index cases and 7 in relatives) were identified in control 
subjects recruited to other NIHR BRIDGE studies. Two variants (p.Val385GlyfsTer30 and 
p.Pro1115Leu) found in control subjects have previously been associated with PVOD / PCH 
but only when found in a biallelic state (20-22). Importantly, these 43 control subjects were 
all EIF2AK4 heterozygotes. The locations of these variants are shown in Figure 18C. 
 
The remaining 31 rare and predicted deleterious EIF2AK4 variants were identified in patients 
recruited to the NIHR BRIDGE PAH Study. Fourteen patients carried biallelic EIF2AK4 variants 
(Figure 18A and Appendix 20). Seven variants were identified in a homozygous state in 7 
patients and 15 variants were identified in a potential compound heterozygous state in 7 
patients. Phasing information was not available for these 7 patients with potential compound 
heterozygous variants. However, as will be discussed later, the phenotypes of these patients 
were consistent with the variants being in a compound heterozygous state. One patient had 
two previously reported variants in a compound heterozygous state (p.Arg465ValfsTer38 and 
c.257+4A>C [splice region variant]) (21, 93). All the other variants identified have not 
previously been associated with PVOD / PCH. 
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Figure 18. Gene locus plots of rare and predicted deleterious EIF2AK4 variants identified in 
the NIHR BRIDGE Study 
Rare (minor allele frequency < 0.0001) and predicted deleterious (CADD score ³ 15, and PolyPhen-2 or SIFT 
predictions not classified as “benign” or “tolerated”) variants were identified in EIF2AK4 in patients recruited to 
the NIHR BRIDGE Study. To create the figure the genomic coordinates for each variant, the reference and variant 
allele at that position, the consequence type of the variant and the amino acid change resulting from the variant 
were entered into MutationMapper. Splice site variants and deletions are not shown in the figure.  
 
Comparison is made between: 
A – variants found in a biallelic state in the NIHR BRIDGE PAH Study, 
B – variants found in a heterozygous state in the NIHR BRIDGE PAH Study and 
C – variants found in control subjects recruited to other NIHR BRIDGE studies. 
Blue arrows – homozygous variants, Red arrow – variant found in a patient with a rare and predicted deleterious 
BMPR2 variant. 
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Significance of EIF2AK4 variants in a heterozygous state 
In addition, 9 EIF2AK4 variants in a heterozygous state were identified in 8 patients recruited 
to the NIHR BRIDGE PAH Study (Figure 18B and Appendix 20). One patient had 2 EIF2AK4 
variants (p.Gln816Ter and p.Arg1073Leu), both of which were also identified in her healthy 
mother, indicating that the 2 variants were carried on the same allele. 
 
The significance of these EIF2AK4 variants in a heterozygous state is uncertain. Previously, the 
disease phenotype has only been associated with biallelic EIF2AK4 variants. Eyries et al. and 
Best et al. reported that family members of patients with PVOD / PCH and biallelic EIF2AK4 
variants, who themselves carried EIF2AK4 variants in a heterozygous state, did not show 
features of PVOD / PCH (20, 21). Similarly, 2 control subjects recruited to other NIHR BRIDGE 
studies also carried EIF2AK4 variants in a heterozygous state (p.Val385GlyfsTer30 and 
p.Pro1115Leu) that have previously been associated with PVOD / PCH when found in a 
biallelic state. 
 
One patient with an EIF2AK4 variant in a heterozygous state (p.His1202Tyr) also carried a rare 
and predicted deleterious variant in BMPR2 (p.Arg899Ter) that has previously been 
associated with heritable PAH (Figure 18B and Appendix 20). This patient had no family 
history of the disease. Family members of this patient had not been recruited to assess 
whether or not the presence of an EIF2AK4 variant in a heterozygous state altered the 
penetrance of the BMPR2 variant as suggested by Eichstaedt et al. (371). 
 
To further investigate the significance of these EIF2AK4 variants in a heterozygous state the 
proportion of patients with such variants and a diagnosis of PAH was compared to the 
proportion of control subjects in other NIHR BRIDGE studies with EIF2AK4 variants in a 
heterozygous state. For this analysis only index cases were included and patients with biallelic 
EIF2AK4 variants were excluded. Amongst patients with a diagnosis of PAH 0.8 % carried a 
rare and predicted deleterious EIF2AK4 variant in a heterozygous state compared to 0.6 % of 
control subjects (Fisher’s exact test p = 0.263).  
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However, as stated above, disease associated variants when present in a heterozygous state 
were also found in control subjects. Therefore, the filtering strategy used to identify 
potentially disease-causing variants may not be as robust in identifying disease-associated (or 
modifying) variants or those causing a recessive trait. By excluding variants based on their 
allele frequency in control datasets, variants relevant to disease pathogenesis may be filtered 
out. To investigate this, an alternative variant filtering strategy was used. In this analysis 
deleterious variants, regardless of their allele frequency in control datasets, were selected. 
However, more stringent cut-offs were used to define deleterious variants (CADD score > 20 
and both SIFT and PolyPhen-2 scores predicted to be deleterious or damaging respectively). 
 
Using this modified filtering strategy, 107 predicted deleterious variants in EIF2AK4 were 
identified in the NIHR BRIDGE Study. In control subjects recruited to other NIHR BRIDGE 
studies, 66 EIF2AK4 variants in a heterozygous state were identified (51 in index cases). 
Additionally, 2 control subjects carried 2 predicted deleterious variants; potentially in a 
compound heterozygous state (phasing information was not known; p.Arg166Trp / 
p.Tyr444Cys and p.Thr943Met / p.Ser1251Cys).  
 
Amongst patients recruited to the NIHR BRIDGE PAH Study, 37 EIF2AK4 variants were 
identified. The modified variant filtering strategy identified all 7 EIF2AK4 homozygotes 
identified using the original variant filtering strategy. However, the modified variant filtering 
strategy also identified a new patient with a clinical diagnosis of PVOD who had 2 predicted 
deleterious PTVs in a potential compound heterozygous state (p.Tyr907Ter and 
p.Glu184GlyfsTer13). These 2 variants were not retained by the original variant filtering 
strategy as they had allele frequencies of 0.000106 and 0.00014 in the UK10K study. 
Conversely, the modified variant filtering strategy did not retain a splice site variant 
c.257+4A>C (as it had a CADD score of just 15.5) that was found in a patient with a clinical 
diagnosis of PAH, a low KCO % predicted (33 %) and who also had a second PTV in EIF2AK4. 
Furthermore, this splice site variant when found in a homozygous state has previously been 
associated with PAH (93).  
 
With the modified variant filtering strategy 15 EIF2AK4 variants were identified in a 
heterozygous state in 14 patients with a clinical diagnosis of PAH. Two of these variants had 
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previously been associated with PVOD / PCH (p.Arg465ValfsTer38 and p.Arg1256Ter) (20, 21). 
In an overrepresentation analysis limited to index cases, 1.5 % of patients with a clinical 
diagnosis of PAH carried an EIF2AK4 variant in a heterozygous state compared to 0.8 % of 
controls (Fisher’s exact test p = 0.059). Therefore, there remains insufficient evidence based 
on the above analyses alone to suggest a role for EIF2AK4 variants in a heterozygous state in 
PAH pathogenesis. 
 
The differences between the two strategies highlights the difficulties relying on 
computational predictions alone in identifying disease associated variants. Neither variant 
filtering strategy could be considered superior. Additional phenotypic, experimental or 
familial segregation data, could provide additional evidence when identifying disease 
associated / modifying variants.  
 
Both patients with EIF2AK4 variants identified in a potential compound heterozygous state 
with just one variant filtering strategy, have features to suggest these variants are disease 
associated (a clinical diagnosis of PVOD and / or a low KCO). Therefore, in the phenotype-
genotype association analyses in the next section both patients were considered to have 
biallelic EIF2AK4 variants. However, only EIF2AK4 variants in a heterozygous state identified 
using the original filtering strategy were taken forward. 
 
EIF2AK4 phenotype-genotype associations 
PVOD 
Amongst patients with a clinical diagnosis of PVOD / PCH (n = 21), 6 patients (29 %) carried 
biallelic EIF2AK4 variants. None of the patients with a clinical diagnosis of PVOD / PCH carried 
rare and predicted deleterious BMPR2 variants or EIF2AK4 variants in a heterozygous state.  
 
No significant differences were observed between patients with idiopathic PVOD / PCH and 
patients with PVOD / PCH carrying biallelic EIF2AK4 variants after correcting for multiple 
testing. A trend towards a younger age at diagnosis amongst those with biallelic EIF2AK4 
variants was observed (36 years [28 - 42] vs. 67 years [52 - 69]; Wilcoxon rank-sum test p = 
0.073). KCO % predicted was recorded in 16 patients with a diagnosis of PVOD / PCH, all of 
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whom had a reduced KCO % predicted but there was no difference between the two groups 
(biallelic EIF2AK4: 32 % predicted [23 – 36] vs. idiopathic: 40 % predicted [34 – 50]; Wilcoxon 
rank-sum p = 1.000). Haemodynamic parameters and functional assessments were similar 
between the two groups (biallelic EIF2AK4 vs. idiopathic; Wilcoxon rank-sum p value provided 
unless stated): 
 
 mPAP (mmHg):  46 [38 – 54] vs. 50 [46 – 58];  p = 1.000, 
 PVR (WU):   9.8 [9.3 – 10.2] vs. 12.6 [9.2 – 15.4]; p = 1.000, 
 CI (L/min/m2):   2.2 [2.0 – 2.3] vs. 1.8 [1.4 – 2.0];  p = 1.000, 
 6mwt distance (m):  183 [96 – 274] vs. 219 [96 – 295];  p = 1.000, 
 Functional class (1/2/3/4):  0 [0%] / 2 [33%] / 1 [17%] / 3 [50%] vs. 
0 [0%] / 0 [0%] / 13 [93%] / 1 [7%]; Cochran-Armitage 
p = 1.000. 
 
PAH 
Unexpectedly, 9 patients with a clinical diagnosis of PAH (8 with idiopathic PAH and 1 with a 
family history of PAH) carried biallelic EIF2AK4 variants. In these patients there was no clinical 
suspicion of PVOD / PCH.  
 
For the subsequent phenotype-genotype association assessment patients with a clinical 
diagnosis of PAH were divided into 4 groups based on their genotype (BMPR2 variant carriers 
[n = 157], biallelic EIF2AK4 variant carriers [n = 9], heterozygous EIF2AK4 variant carriers [n = 
7] and those with idiopathic PAH [no family history of PAH and no variants in genes previously 
associated with the disease; n = 772]). The patient with both a BMPR2 variant and an EIF2AK4 
variant in a heterozygous state was classified in the BMPR2 group. Fifty-three patients with 
variants in other PAH associated genes or a family history of the disease were excluded as 
were the patients with a clinical diagnosis of PVOD / PCH irrespective of their genotype. 
Phenotypic comparisons were made between the 4 groups (Table 19). Significant differences 
attributable to patients with EIF2AK4 variants in a biallelic or heterozygous state are 
summarised below.  
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Patients with biallelic EIF2AK4 variants and a clinical diagnosis of PAH were significantly 
younger (29 years [23 - 38]) compared to patients with idiopathic PAH (52 years [38 - 66]; 
Dunn’s test p = 0.010). No differences in haemodynamic or functional assessments were seen 
between patients with biallelic EIF2AK4 variants and patients with BMPR2 variants or patients 
with idiopathic PAH. There was a trend towards a higher SvO2 in patients with biallelic EIF2AK4 
variants (79 % [60 - 73]) compared to patients with BMPR2 variants (60 % [56 - 66]; Dunn’s 
test p = 0.075). Despite the preserved cardiac function in patients with biallelic EIF2AK4 
variants, a higher proportion (56 %) presented with syncope at diagnosis compared to 
patients with BMPR2 variants (40 %) or idiopathic PAH (27 % ; Fisher’s exact test p = 0.046). 
 
Patients with clinical diagnosis of PAH and biallelic EIF2AK4 variants had a significantly lower 
KCO (33 % predicted [30 - 35]) compared to patients with BMPR2 variants (82 % predicted [74 
- 94]; Dunn’s test p < 0.001) and idiopathic PAH (70 % predicted [49 - 85] ; Dunn’s test p = 
0.001). In support of this finding patients with biallelic EIF2AK4 variants also desaturated 
more during a 6mwt (76 % [74 - 82]) compared to patients with BMPR2 variants (94 % [90 - 
97]; Dunn’s test p < 0.001) and idiopathic PAH (91 % [85 - 96]; Dunn’s test p = 0.003). 
Furthermore, the haemoglobin concentration in patients with biallelic EIF2AK4 variants (178 
g/l [165- 183]) was higher than those with idiopathic PAH (151 g/l [136 - 163]; Dunn’s test p 
< 0.001).  
 
Although, no significant differences were seen in FEV1, FVC or TLC a higher proportion of 
patients with biallelic EIF2AK4 variants had a normal spirometry pattern (75%) compared to 
those with idiopathic PAH (54%, Fisher’s exact test p < 0.001). Patients with biallelic EIF2AK4 
variants were also more likely to have digital clubbing (43 %) compared to patients with 
BMPR2 variants (11 %) or idiopathic PAH (4 %; Fisher’s exact test p = 0.005).  
 
Similar results were observed after limiting the analysis to patients with normal spirometry. 
Patients with biallelic EIF2AK4 variants had a significantly lower KCO (32 % predicted [29 - 38]) 
compared to both BMPR2 variant carriers (82 % predicted [72 - 94]; Dunn’s test p < 0.001) 
and those with idiopathic PAH (72 % predicted [55 - 89]; Dunn’s test p = 0.001). 
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No significant differences were observed between patients with EIF2AK4 variants in a 
heterozygous state and idiopathic PAH patients. 
 
Amongst patients with a clinical diagnosis of PAH who had a KCO recorded, 114 (23 %) had a 
KCO less than 50 % predicted. Most of these patients (84 %) were over the age of 50 years at 
diagnosis. Only 13 patients aged under 50 years at diagnosis and who had normal spirometry 
had a KCO less than 50 % predicted. Six of these 13 patients carried biallelic rare and predicted 
deleterious EIF2AK4 variants. Therefore, the sensitivity and specificity of a low KCO (< 50 % 
predicted) and early age at diagnosis (< 50 years) for identifying biallelic EIF2AK4 variant 
carriers was 0.86 and 0.98 respectively. However, the positive predictive value was just 0.50. 
Nevertheless, in terms of the diagnostic yield, while genetic testing for biallelic EIF2AK4 
variants in the entire cohort of patients diagnosed clinically with PAH yielded a 1 % detection 
rate, the presence of biallelic EIF2AK4 variants in PAH patients with a KCO < 50 %, normal 
spirometry and aged under 50 at diagnosis was 50 %. 
 
Patients with a clinical diagnosis of PAH and biallelic EIF2AK4 variants had a similar phenotype 
(low KCO and early age at diagnosis) when compared to patients with a clinical diagnosis of 
PVOD / PCH and biallelic EIF2AK4 variants (Figure 19). However, while 43 % of patients with 
a clinical diagnosis of PAH and biallelic EIF2AK4 variants had digital clubbing none of the 
patients with a clinical diagnosis of PVOD / PCH and biallelic EIF2AK4 variants were clubbed. 
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Table 19. Phenotypic differences by genotype in patients with a clinical diagnosis of PAH 
 Idiopathic PAH BMPR2 Heterozygous EIF2AK4 Biallelic EIF2AK4 p corrected 
n [%] 772 [81.7%] 157 [16.6%] 7 [0.7%] 9 [1.0%]  
WGS population:  
African / East-Asian / 
European / South-Asian 
(n [%]) 
24 [3.1%] / 13 [1.7%] / 
687 [89.0%] /  
48 [6.2%] 
3 [1.9%] / 2 [1.3%] / 
147 [93.6%] / 5 [3.2%] 
0 [0.0%] / 1 [14.3%] /  
6 [85.7%] / 0 [0.0%] 
0 [0.0%] / 0 [0.0%] /  
3 [33.3%] / 6 [66.7%] 
<0.001 
Gender: female (n [%]) 538 [69.8%] 105 [66.9%] 6 [85.7%] 4 [44.4%] 0.507 
Age at diagnosis (years) 51.5 [38.2 - 65.5] 39.3 [32.0 - 51.1] 39.8 [32.0 - 64.3] 29.3 [23.0 - 37.6] <0.001 
Family history:  
Yes (n [%]) 
0 [0.0%] 45 [28.7%] 0 [0.0%] 1 [11.1%] <0.001 
mPAP (mmHg) 51.0 [43.0 - 60.0] 58.0 [51.0 - 68.2] 43.0 [42.0 - 54.0] 52.0 [46.0 - 65.0] <0.001 
PCWP (mmHg) 9.0 [7.0 - 11.0] 10.0 [7.0 - 12.0] 10.0 [8.0 - 11.0] 11.0 [7.5 - 12.5] 0.802 
CI (L/min/m2) 2.2 [1.8 - 2.7] 1.8 [1.5 - 2.2] 2.2 [1.8 - 2.8] 2.9 [1.7 - 3.1] <0.001 
SvO2 (%) 65.4 [59.5 - 71.3] 60.1 [56.0 - 65.9] 63.5 [60.0 - 72.0] 69.5 [60.4 - 73.2] <0.001 
PVR (WU) 10.3 [7.0 - 14.0] 14.2 [10.8 - 20.3] 7.7 [6.0 - 9.3] 8.6 [7.5 - 13.1] <0.001 
Vasoresponder: (n [%]) 31 [18.3%] 0 [0.0%] 0 [0.0%] 0 [0.0%] 0.01 
Functional class:  
1 / 2 / 3 / 4 (n [%]) 
15 [2.3%] /  
140 [21.2%] /  
435 [65.8%] / 71 [10.7%] 
2 [1.4%] / 32 [21.6%] / 
89 [60.1%] /  
25 [16.9%] 
0 [0.0%] / 3 [42.9%] /  
4 [57.1%] / 0 [0.0%] 
0 [0.0%] / 1 [11.1%] /  
8 [88.9%] / 0 [0.0%] 
0.447 
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6mwt distance (m)  309.5 [157.0 - 409.5] 331.0 [286.5 - 426.5] 370.0 [323.0 - 453.0] 502.0 [350.0 - 527.0] 0.226 
Post walk SaO2 (%) 91.0 [85.0 - 96.0] 94.0 [89.8 - 97.0] 94.0 [80.0 - 96.0] 76.0 [74.0 - 82.0] 0.001 
HCT 0.4 [0.4 - 0.5] 0.5 [0.5 - 0.5] 0.5 [0.5 - 0.5] 0.5 [0.5 - 0.5] <0.001 
Hb (g/l) 150.5 [136.0 - 163.0] 162.0 [152.0 - 173.2] 170.5 [157.7 - 171.8] 178.0 [165.0 - 182.8] <0.001 
FEV1 (L) 2.2 [1.8 - 2.8] 2.6 [2.2 - 3.3] 2.4 [1.9 - 3.0] 3.5 [2.3 - 4.1] <0.001 
FVC (L) 3.0 [2.4 - 3.8] 3.5 [2.9 - 4.2] 3.2 [2.2 - 3.5] 4.1 [3.1 - 5.2] <0.001 
KCO (% predicted) 70.0 [49.0 - 85.3] 82.0 [74.0 - 94.0] 81.0 [72.0 - 95.0] 33.0 [30.2 - 34.7] <0.001 
Spirometry pattern: 
Normal / Obstructive / 
Restrictive (n [%]) 
241 [53.7%] / 135 
[30.1%] / 73 [16.3%] 
81 [81.0%] / 12 
[12.0%] / 7 [7.0%] 
3 [60.0%] / 0 [0.0%] / 2 
[40.0%] 
6 [75.0%] / 2 [25.0%] / 
0 [0.0%] 
<0.001 
Clubbing: Yes (n [%]) 11 [3.7%] 7 [10.6%] 0 [0.0%] 3 [42.9%] 0.005 
Syncope at onset:  
Yes (n [%]) 
131 [27.0%] 41 [39.8%] 0 [0.0%] 5 [55.6%] 0.046 
6mwt – six-minute walk test, CI – cardiac index, FEV1 – forced expiratory volume in 1 second, FVC – forced vital capacity, Hb – haemoglobin, HCT 
– haematocrit, KCO – transfer coefficient for carbon monoxide, mPAP – mean pulmonary artery pressure, PCWP – pulmonary capillary wedge 
pressure, PVR – pulmonary vascular resistance, SaO2 – peripheral arterial oxygen saturation, SvO2 – mixed venous oxygen saturation, WGS – 
whole genome sequencing. Data presented as median [IQR] unless stated. Kruskal-Wallis test used to assess continuous variables, Fisher’s exact 
test used to assess categorical variables, Cochran–Armitage test used to assess ordinal variables. 
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Figure 19. Distributions of age at diagnosis and KCO % predicted in the NIHR BRIDGE PAH 
Study 
Patients recruited to the NIHR BRIDGE PAH Study were categorised by genotype and clinical diagnosis (idiopathic 
PAH [i.e. no rare or predicted deleterious variants identified in the previously identified disease associated 
genes]; n = 772), PAH BMPR2 (n = 157), PAH heterozygous EIF2AK4 (n = 7), PAH biallelic EIF2AK4 (n = 9), PVOD 
biallelic EIF2AK4 (n = 6), idiopathic PVOD (i.e. no rare or predicted deleterious EIF2AK4 variants identified; n = 
15). KCO % predicted not available for all patients. Patients with either a clinical diagnosis of PAH or PVOD / PCH 
and carrying biallelic EIF2AK4 variants had a similar phenotype with a young age at diagnosis (29 years [23 – 38] 
vs. 36 years [28 -42]) and low KCO % predicted (33 % [30 -35] vs. 32 % [30 – 36]). Although, patients with 
idiopathic PVOD / PCH also had a low KCO % predicted (40 % [34 – 50]) they were diagnosed later in life (67 years 
[52 – 69]). 
 
CT features of patients with PAH and biallelic EIF2AK4 variants 
The presence of centrilobular ground glass opacification, mediastinal lymphadenopathy and 
interlobular septal thickening on CT scans of the chest are suggestive of PVOD / PCH. To 
investigate whether or not patients with a clinical diagnosis of PAH and biallelic EIF2AK4 
variants were misdiagnosed as PAH, CT scans of a subgroup of patients with a clinical 
diagnosis of idiopathic PAH (n = 21), PAH and BMPR2 variants (n = 21), PAH and biallelic 
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EIF2AK4 variants (n = 7) and patients with a clinical diagnosis of PVOD / PCH (n = 14) were 
assessed (Table 20, Dr Nicholas Screaton and Dr Andy Swift).  
 
Subtle or gross centrilobular ground glass opacification was found in 38 % of patients with 
idiopathic PAH and 67 % of PAH patients with BMPR2 variants. This was not significantly 
different compared to patients with a clinical diagnosis of PAH and biallelic EIF2AK4 variants 
(86 %) and patients with a clinical diagnosis of PVOD / PCH (50 %). Gross interlobular septal 
thickening and mediastinal lymphadenopathy was significantly more frequent amongst 
patients with PAH and biallelic EIF2AK4 variants (29 % and 57 % respectively) and those with 
PVOD / PCH (64 % and 79 %) compared to patients with idiopathic PAH (5 % and 0 %) or PAH 
and BMPR2 variants (5 % and 10 %).  
 
Despite the presence of these radiological features in patients with PAH and biallelic EIF2AK4 
variants a radiological suspicion of PVOD / PCH was only raised in 57 %. This compared to a 
radiological suspicion of PVOD / PCH in 71 % of patients with a clinical diagnosis of PVOD / 
PCH, 14 % of patients with a clinical diagnosis of idiopathic PAH and 5 % of those with PAH 
and BMPR2 variants. Consequently, radiological appearances alone cannot accurately be 
used to distinguish between patients with a clinical diagnosis of PAH and biallelic EIF2AK4 
variants and patients with idiopathic PAH. 
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Table 20. CT features of patients with PAH by genotype 
  PAH BMPR2  Idiopathic PAH  
PAH biallelic 
EIF2AK4  
PVOD / PCH p 
n  21 21 7 14  
Centrilobular ground 
glass opacification 
density 
None 7 [33.3%] 13 [61.9%] 1 [14.3%] 7 [50.0%] 
0.122 Subtle 12 [57.1%] 5 [23.8%] 2 [28.6%] 3 [21.4%] 
Present 2 [9.5%] 3 [14.3%] 4 [57.1%] 4 [28.6%] 
Centrilobular ground 
glass opacification 
extent 
None 8 [38.1%] 13 [61.9%] 1 [4.3%] 8 [57.1%] 
0.077 
<5% 0 [0.0%] 3 [14.3%] 1 [14.3%] 1 [7.1%] 
5-25% 2 [9.5%] 0 [0.0%] 2 [28.6%] 1 [7.1%] 
25-50% 2 [9.5%] 4 [19.0%] 0 [0.0%] 2 [14.3%] 
50-75% 5 [23.8%] 1 [4.8%] 2 [28.6%] 0 [0.0%] 
75-100% 4 [19.0%] 0 [0.0%] 1 [14.3%] 2 [14.3%] 
Interlobular septal 
thickening 
None 17 [81.0%] 18 [85.7%] 5 [71.4%] 4 [28.6%] 
0.001 Subtle 3 [14.3%] 2 [9.5%] 0 [0.0%] 1 [7.1%] 
Present 1 [4.8%] 1 [4.8%] 2 [28.6%] 9 [64.3%] 
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Mediastinal 
lymphadenopathy 
None 19 [90.5%] 21 [100.0%] 3 [42.9%] 3 [21.4%] 
<0.001 
Present 2 [9.5%] 0 [0.0%] 4 [57.1%] 11 [78.6%] 
Pleural effusion 
None 17 [81.0%] 21 [100.0%] 7 [100.0%] 10 [71.4%] 
0.048 
Small 4 [19.0%] 0 [0.0%] 9 [0.0%] 4 [28.6%] 
Neovascularity 
None 12 [57.1%] 18 [85.7%] 6 [85.7%] 13 [92.9%] 
0.077 
Present 9 [42.9%] 3 [14.3%] 1 [14.3%] 1 [7.1%] 
CT diagnosis 
PAH 20 [95.2%] 18 [85.7%] 3 [42.9%] 4 [28.6%] 
 
PVOD / PCH 1 [4.8%] 3 [4.3%] 4 [57.1%] 10 [71.4%] 
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Histological features of a patient with PAH and a homozygous EIF2AK4 variant 
The gold standard for the diagnosis of PVOD / PCH remains histological assessment of the 
lung parenchyma. However, lung biopsy can be associated with significant morbidity in 
patients with elevated pulmonary artery pressures. Therefore, lung tissue is often only 
assessed after lung transplantation or post mortem.  
 
From the NIHR BRIDGE PAH Study, just one patient with a clinical diagnosis of idiopathic PAH 
and carrying a biallelic EIF2AK4 variant underwent lung transplantation and had lung tissue 
available for assessment. The patient was diagnosed at 22 years of age with idiopathic PAH. 
He had no family history of the disease. At presentation he had severe pulmonary 
hypertension with significant right ventricular impairment (mPAP 65 mmHg, PVR 18 WU, CI 
1.4 L/min/m2) and was in functional class 3. His KCO was 31 % predicted despite normal 
spirometry. Review of his HRCT chest revealed only subtle centrilobular groundglass 
opacification, no mediastinal lymphadenopathy and no interlobular septal thickening. There 
was no suspicion of PVOD / PCH on review of his HRCT chest. 
 
This patient had a homozygous EIF2AK4 missense variant (c.1795G>C, p.Gly599Arg). The 
missense variant was not reported in the ExAC database, occurred in a conserved area of the 
genome (GERP score 5.5) and was predicted to be deleterious (CADD score 32, PolyPhen-2 
prediction “probably damaging [1]”, SIFT prediction “deleterious [0]”). Interestingly, the same 
homozygous variant was also identified in a second unrelated patient with a clinical diagnosis 
of idiopathic PAH. 
 
The patient underwent lung transplantation and the explanted lung tissue examined. The 
predominant histological feature was pulmonary arterial vasculopathy (Dr Peter Dorfmüller; 
Figure 20). The pulmonary arteries predominantly showed concentric and eccentric intimal 
fibrosis . No plexiform lesions were observed. Although infrequent, there was some fibrosis 
of the septal veins and venules, some of which were nearly completely occluded. Although 
there was evidence of capillary congestion, no capillary hemangiomatosis was observed. The 
histological features, predominantly pulmonary arteriopathy, supported the clinical and 
radiological diagnosis of idiopathic PAH. 
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Figure 20. Representative histopathological images from a patient with a clinical diagnosis of 
idiopathic PAH and a rare and predicted deleterious homozygous EIF2AK4 variant 
The pulmonary arteries showed eccentric and concentric intimal fibrosis and medial hypertrophy (A, B) as well 
as some lesions with features of recanalised thrombus (C). Several concentrically muscularised arterioles were 
also observed (D). No complex plexiform lesions were present. There was patchy thickening of the alveolar septa 
with capillary congestion and pigmented intra-alveolar macrophages similar to PCH (E, F). Venous remodelling 
was difficult to trace and infrequent, but present. Fibrous thickening of the intima in septal veins (G, I) and a 
micro-vessel (H). [Photomicrographs by Dr Dorfmüller]. 
 
Response to treatment in patients with PAH and biallelic EIF2AK4 variants 
As patients with PVOD / PCH have a worse prognosis compared to patients with idiopathic 
PAH, the clinical outcomes of patients with biallelic EIF2AK4 variants and a clinical diagnosis 
of PAH were assessed. The response to pulmonary artery vasodilator therapies analysis was 
restricted to idiopathic PAH patients and PAH patients with BMPR2 variants included in the 
radiological analysis described above as well as all PAH patients with biallelic EIF2AK4 
variants. 
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The response to pulmonary artery vasodilator therapies after 1 and 3 years was assessed 
(Table 21). The change in functional class at both 1 and 3 years was significantly worse in 
patients with a clinical diagnosis of PAH and biallelic EIF2AK4 variants compared to patients 
with idiopathic PAH and PAH patients with BMPR2 variants. PAH patients with biallelic 
EIF2AK4 variants showed no change in functional class whereas patients with idiopathic PAH 
or PAH patients with BMPR2 variants improved their functional class by 1 class. The 
proportion of patients receiving prostanoids therapies was similar between the three groups. 
None of the PAH patients with biallelic EIF2AK4 variants developed pulmonary oedema. 
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Table 21. Response to pulmonary artery vasodilator therapies 
Group 
Time to 
assessment 1 
(days) 
n 
Change in 
6mwt 
distance 
(m) 
Change in 
FC 
Time to 
assessment 2 
(days) 
n 
Change in 
6mwt 
distance 
(m) 
Change in 
FC 
Number on 
prostanoid 
therapy 
before the 2nd 
assessment 
[%] 
PAH 
BMPR2 
357  
[314 - 386] 
21 
+69  
[20 - 100] 
-1  
[-1 - -1] 
1120  
[1055 - 1174] 
18 
+45  
[31 - 115] 
-1  
[-1 - -0.5] 
5 [23%] 
PAH 
biallelic 
EIF2AK4 
358  
[335 -388] 
9 
+28 
[-13 - 77] 
0  
[-1 - 0] 
1102 
[1090 - 1112] 
5 
+62  
[-8 - 132] 
0  
[0 - 0] 
1 [10%] 
Idiopathic 
PAH  
387  
[340 - 414] 
16 
+81  
[61 - 151] 
-1 
 [-1 - 0] 
1118  
[1105 - 1159] 
9 
+104  
[20 - 144] 
-1  
[-1 - 0] 
4 [17%] 
p 0.295  0.343 0.039 0.730  0.748 0.044 0.816 
6mwt – six-minute walk test, FC – functional class. Drop in number of patients between assessment 1 and 2 due to death, transplantation or lack of 
sufficient follow up time. Data presented as median [IQR] unless stated. Kruskal-Wallis test used to assess differences between groups. 
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Prognosis of patients with PAH and biallelic EIF2AK4 variants 
A Cox proportional hazards analysis was performed to assess whether or not patients with a 
clinical diagnosis of PAH and biallelic EIF2AK4 variants had a worse prognosis compared to 
other patients with PAH. Eight-hundred and seventy-four patients with survival data recorded 
were included in the analysis. Patients with variants in genes other than BMPR2 or biallelic 
EIF2AK4 variants were excluded. Age at diagnosis, gender and whether patients were incident 
/ prevalent cases were included as covariates. 
 
In an untruncated survival analysis PAH patients with biallelic EIF2AK4 variants had a 
significantly higher hazard ratio compared to patients with idiopathic PAH (5.00 [2.02 - 12.36]; 
p < 0.001). Older age (1.04 [1.03 - 1.05]; p < 0.001), male gender (1.57 [1.18 - 2.09]; p = 0.002) 
and incident cases (2.11 [1.40 - 3.17]; p < 0.001) were associated with significantly worse 
survival in this model. The model met the proportional hazards assumption and assessment 
of the Cox-Snell residuals suggested a good model fit. A left truncated survival analysis 
including age, gender and incident / prevalent status as covariates did not have a good model 
fit, likely due to small numbers. Figure 21 shows a Kaplan-Meier plot demonstrating the effect 
of genotype on survival. 
 
In a multivariate Cox proportional hazards model including KCO % predicted as a covariate, 
patients with a clinical diagnosis of PAH and biallelic EIF2AK4 variants did not have a 
significantly worse prognosis compared to patients with idiopathic PAH (2.34 [0.87 - 6.33]; p 
= 0.094). 
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Figure 21. Kaplan-Meier plot showing differences in survival by genotype 
The time from diagnosis to death was calculated where survival data was available. Patients were censored at 
the time of last contact or transplantation. Patients were categorised based on clinical diagnosis and genotype: 
idiopathic PAH (n = 696), PAH BMPR2 variant carriers (n = 151), PAH biallelic EIF2AK4 variant carriers (n = 9) and 
idiopathic PVOD (n = 21). In an untruncated multivariate Cox proportional hazards model (including age, gender, 
incident/prevalent status, and EIF2AK4 genotype) PAH patients with biallelic EIF2AK4 variants had a higher 
hazards ratio (5.00 [2.02 - 12.36]; p < 0.001) compared to patients with idiopathic PAH. 
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Biallelic EIF2AK4 variant carrier phenotype 
The above analyses demonstrate that patients with biallelic EIF2AK4 variants share many 
clinical and radiological characteristics regardless of their clinical diagnosis (either PVOD / PCH 
or PAH). However, the spectrum of clinical, radiological and histological features associated 
with PVOD / PCH is broader than has been previously recognised. Consequently, the presence 
of only subtle or not readily apparent features in patients with biallelic EIF2AK4 variants may 
result in a clinical diagnosis of PAH. 
 
Assuming a molecular diagnosis of PVOD / PCH in all patients with biallelic EIF2AK4 variants, 
differences between patients with idiopathic PVOD / PCH and patients with biallelic EIF2AK4 
variants were reassessed. Patients with biallelic EIF2AK4 variants were younger at diagnosis 
(33 years [IQR: 24 - 41]) compared to those with idiopathic PVOD / PCH (67 years [52 - 69], p 
= 0.001). No significant difference was seen in KCO between the two groups (33 % predicted 
[30 - 35] and 40 % predicted [34 - 50]; p = 0.557). However, in the CT subgroup analysis 
centrilobular ground glass opacification appeared more extensive in those with biallelic 
EIF2AK4 variants (82 %) compared to those with idiopathic PVOD / PCH (10 %; p = 0.012). 
Furthermore, pleural effusions were more common amongst those with idiopathic PVOD / 
PCH (40 %) compared to patients with biallelic EIF2AK4 variants (0 %, p = 0.035). This may 
suggest that patients with biallelic EIF2AK4 variants have a distinct radiological phenotype 
compared to patients with idiopathic PVOD / PCH. 
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Discussion 
This is the largest and most comprehensive description of patients with a clinical diagnosis of 
PAH carrying biallelic EIF2AK4 variants. Previously the presence of biallelic EIF2AK4 variants 
were reported in patients with a clear clinical diagnosis of PVOD / PCH as well as a large 
kindred and a single family with a possible diagnosis of PAH (20-22, 93, 306). Assuming that 
all patients with biallelic EIF2AK4 variants have a unified molecular diagnosis of PVOD / PCH, 
novel radiographic differences were identified between patients with idiopathic PVOD / PCH 
and those carrying biallelic EIF2AK4 variants. 
 
The discovery of biallelic EIF2AK4 variants in PVOD / PCH raised the possibility of a rapid 
molecular diagnosis in the majority of patients with familial, and up to 25 % of patients with 
sporadic PVOD / PCH (20, 21). In this study, the presence of biallelic EIF2AK4 variants was 
associated with a poor prognosis, even in patients who had a clinical diagnosis of PAH, and 
who did not develop pulmonary oedema in response to pulmonary artery vasodilator 
therapies. Therefore, early identification of these patients through clinical genetic testing may 
prompt early referral for lung transplantation similar to patients with clinically diagnosed 
PVOD / PCH (314).  
 
The presence of biallelic EIF2AK4 variants in patients with a clinical diagnosis of PAH raises 
the question whether EIF2AK4 variants can cause classical idiopathic PAH, or whether there 
are cases of PVOD / PCH caused by biallelic EIF2AK4 variants that are wrongly classified even 
by expert PH centres. This study shows that current clinical, radiological and histological 
assessments can be difficult to interpret. The presence of subtle or infrequent features may 
lead to an incorrect diagnosis of PAH in patients with biallelic EIF2AK4 variants. Consequently, 
it is important to recognise that patients with pathogenic biallelic EIF2AK4 variants may 
present with a spectrum of phenotypic, radiological and histological features that can overlap 
with PAH. 
 
PAH patients with biallelic EIF2AK4 variants demonstrated a reduced KCO despite normal 
spirometry, which is characteristic of patients with PVOD / PCH. The reduced KCO likely 
reflects widespread reduction in alveolar gas exchange due to endothelial proliferation and 
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patchy thickening of the blood gas barrier by the process of capillary haemangiomatosis. 
Ultrastructural thickening of the capillary basement membrane may also play a role (372). In 
keeping with previous reports in PVOD / PCH, PAH patients with biallelic variants in EIF2AK4 
were younger at diagnosis than patients with either BMPR2 variants or patients with 
idiopathic PAH (20, 306). However, the presence of these characteristic features has a low 
positive predictive value for the identification of patients with biallelic EIF2AK4 variants. 
 
In contrast to previous descriptions of patients with PVOD / PCH, none of the patients with 
clinically diagnosed PAH and biallelic EIF2AK4 variants developed pulmonary oedema in 
response to pulmonary artery vasodilator therapies. In classical PVOD / PCH patients, 
pulmonary oedema with intravenous prostanoids has been reported in up to 44% of patients 
after a median treatment duration of just 9 days (300). Presumably the extent and severity of 
the pulmonary venous involvement in these patients might underlie the differing responses 
to pulmonary artery vasodilators. 
 
It is generally considered that HRCT imaging is a useful non-invasive test to assist in the 
diagnosis of suspected PVOD / PCH (281). Although there was an increased prevalence of 
mediastinal lymphadenopathy and interlobular septal thickening in PAH patients with biallelic 
EIF2AK4 variants, the radiological features at the time of diagnosis could not accurately 
determine the underlying molecular diagnosis (222). The differing radiological features of all 
patients with biallelic EIF2AK4 variants compared to patients with idiopathic PVOD / PCH is of 
interest and a novel finding. This may reflect differences between the younger onset genetic 
cases of PVOD / PCH, compared with the predominantly older group of patients without 
EIF2AK4 variants in whom other non-genetic factors, such as exposure to inorganic solvents, 
may play an important role (294). Similar findings have been reported by Montani et al. They 
describe a younger age at disease onset for patients carrying biallelic EIF2AK4 variants, but 
no other clinical or prognostic differences were identified (306). Their study did not assess 
radiological features. 
 
Histological examination (usually post mortem or from explanted lungs) is often considered 
essential for diagnostic confirmation of PVOD / PCH but may be confounded by the 
heterogeneous nature of vascular pathology (109). Surgical biopsy of the lung in patients with 
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severe PAH is contraindicated. A limitation of this study is that lung tissue from only one 
patient with biallelic EIF2AK4 variants was available for analysis. This patient had a rare and 
predicted deleterious homozygous missense variant in EIF2AK4. The predominant feature on 
assessment of the explanted lung tissue was of pulmonary arteriopathy, as usually seen in 
PAH. Although only infrequent, fibrosis of the septal venules and the possible presence of 
siderophages in the alveolar space were observed. These features are found in patients with 
PVOD / PCH. This case supports the hypothesis that patients with biallelic EIF2AK4 variants 
may present with a spectrum of pulmonary venous and arterial involvement. 
 
There are increasing reports of phenotypic, radiological and histological similarities between 
PAH and PVOD / PCH (112, 222, 296). Tenorio et al. reported a homozygous missense variant 
in EIF2AK4 in a large kindred of Iberian Romani with apparent heritable PAH (22). This kindred 
is likely to have PVOD / PCH as these diagnoses were not confirmed histologically and PVOD 
was suspected in half the patients. More recently, Best et al. also report two sisters with 
apparent heritable PAH carrying biallelic EIF2AK4 variants (93). These patients also had a 
reduced KCO but had not had HRCT assessment of their lung parenchyma which may have 
altered their clinical diagnosis. Taken together, these previous reports are compatible with 
the findings in this larger cohort, that patients with a clinical presentation of idiopathic or 
heritable PAH may in fact have underlying PVOD / PCH as determined by genetic analysis. 
 
A strength of this study is the centralised reporting of radiographic features. However, the 
data collection was retrospective and incomplete in some cases. Assessing rare diseases, such 
as PAH and PVOD / PCH, with a prospective study recruiting incident cases would take a 
prohibitively long time. This is especially true when assessing survival and response to 
therapy. In this study, that included prevalent and retrospectively recruited patients, a worse 
prognosis in patients with a clinical diagnosis of PAH and biallelic EIF2AK4 variants was 
demonstrated. However, the inclusion of prevalent and retrospectively recruited patients can 
introduce biases such as immortal time bias, when there are extended periods between 
diagnosis and enrolment in the study, and survivor bias. The effect of these biases and 
confounders can be difficult to predict. In all groups there are likely to be patients who died 
prior to study enrolment, and thus would not feature in any analysis. A sensitivity (left 
truncated) analysis, attempting to eliminate these sources of bias, by including only 
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prospectively recruited patients from the UK, did not have sufficient power to show a 
difference in survival between genotypes. Larger studies of survival and response to therapy 
will be needed to definitively show whether “misclassified” PAH patients with biallelic 
EIF2AK4 variants have a similarly poor prognosis as classical PVOD / PCH patients. 
 
In previous studies variants in both EIF2AK4 alleles are required to cause PVOD / PCH (20, 21). 
In autosomal recessive disorders, it is unusual for the heterozygous state to manifest the 
disease phenotype and thus heterozygous EIF2AK4 variants would not be expected to be 
pathogenic. The finding of heterozygous EIF2AK4 variants is of interest in light of a recent 
report suggesting that they may alter disease penetrance in patients with BMPR2 variants 
(371). Further studies are required to determine whether heterozygous EIF2AK4 variants 
contribute to disease pathogenesis in PAH. 
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Summary 
The study identified a high proportion of biallelic EIF2AK4 variants in patients with a clinical 
diagnosis of PVOD / PCH. In addition, 9 patients with a clinical diagnosis of PAH were also 
shown to carry biallelic EIF2AK4 variants. These patients had a characteristic early age at 
diagnosis and low KCO, similar to that previously described in heritable PVOD / PCH. In 
addition, these patients had a poor prognosis compared to patients with idiopathic PAH 
despite the fact none developed pulmonary oedema in response to pulmonary artery 
vasodilator therapies.  
 
The range of clinical, radiological and histological findings associated with biallelic EIF2AK4 
variants is broader than previously recognised. Therefore, the presence of subtle or 
infrequent changes previously associated with PVOD / PCH may result in a misclassification 
of these patients as PAH, although the true molecular diagnosis is PVOD / PCH. Ascertaining 
the EIF2AK4 variant status of patients through clinical genetic testing provides additional 
information to aid risk stratification and guide management. In a young patient presenting 
with apparent PAH, the presence of a low KCO with normal spirometry strongly suggests the 
presence of underlying biallelic EIF2AK4 variants. 
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Discussion 
The clinical classification for pulmonary hypertension has evolved in parallel with our 
understanding of the disease. The current clinical classification, as agreed by consensus at the 
5th World Symposium on Pulmonary Hypertension in 2013, groups the disease based on 
similarities in disease pathogenesis, haemodynamics, associated conditions, treatment 
options and more recently the underlying molecular diagnosis (1). Our knowledge of the 
genetic basis of PAH has advanced rapidly over recent years. Previously, rare variants in 10 
genes have been associated with PAH or PVOD / PCH. More recently, 4 further novel genes 
(SOX17, AQP1, ATP13A3 and GDF2) have been implicated in disease pathogenesis through 
the NIHR BRIDGE PAH Study (373). However, only 24 % of patients recruited to the study were 
identified as carrying rare or predicted deleterious variants in genes associated with the 
disease. The majority of patients in the study had no causal agent (environmental or genetic) 
identified and were thus classified as idiopathic PAH – a diagnosis of exclusion. Consequently, 
the presenting clinical features, response to treatment and prognoses of patients with 
idiopathic PAH is very varied. Such heterogeneity hinders accurate risk stratification and a 
more personalised treatment approach, as well as complicating the interpretation of 
randomised clinical trials. Furthermore, much work is required to ascertain the clinical 
consequences of carrying rare and predicted deleterious variants in disease associated genes. 
 
In this Thesis, I have sought to identify clinically important subgroups of patients with 
idiopathic PAH as well as identify novel phenotype-genotype associations in patients carrying 
variants in disease associated genes. The availability of WGS data for all patients was pivotal 
to this as it allowed the accurate and unbiased categorisation of patients based on their 
genetic profile. While the breadth of phenotype data collected from the time of diagnosis 
allowed detailed characterisation of these patients.  
 
Comorbidities and utility of KCO measurement 
Amongst patients with idiopathic PAH, an important finding was the identification of mild left 
ventricular diastolic dysfunction and small left to right cardiac shunts leading to physiological 
changes that may have played a role in disease pathogenesis. The changing demographics of 
patients with idiopathic PAH has been noted previously. Compared to the first NIH registry, 
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published in 1987, patients recruited to this study and other contemporaneous registries are 
much older (26, 177). It may be hypothesised that this reflects the increasing prevalence of 
obesity and other cardiovascular risk factors in developed countries. These risk factors can 
result in subtle left ventricular diastolic dysfunction despite preserved systolic function. 
Unfortunately, the classification of these patients can be difficult if they develop pulmonary 
hypertension but their PCWP remains < 15 mmHg at rest when measured by right heart 
catheterisation (374). By current haemodynamic definitions these patients would have PAH 
and more specifically idiopathic PAH. The current clinical guidelines state that a combination 
of clinical risk factors and clinical assessments should be used to identify patients with Group 
2 pulmonary hypertension. However, as demonstrated, many patients with these risk factors 
and left atrial dilation are classified by expert centres as idiopathic PAH.  
 
I have shown that older male patients have the worst prognosis amongst patients with 
idiopathic PAH. This group of patients are more likely to have cardiovascular risk factors and 
left ventricular diastolic dysfunction (indicated by left atrial dilation). However, the presence 
of cardiovascular risk factors or left atrial dilation were not of prognostic significance. This 
may be due to incomplete assessment of cardiovascular risk factors leading to 
misclassification of patients and a lack of study power. Additional clinical assessments are 
required to fully assess the significance of left ventricular diastolic dysfunction in patients with 
PAH. For example, assessment of pulmonary artery compliance or detailed cardiac MRI 
studies may yield further insights in to disease pathogenesis and aid further classification of 
patients (375, 376).  
 
An important observation was the fact that KCO was also reduced in older patients with 
cardiovascular comorbidities and normal spirometry. This reduction in KCO may simply reflect 
increased pulmonary venous pressure or may suggest that there is pulmonary venous 
remodelling similar to that seen in PVOD / PCH. A recent study demonstrated that the 
pulmonary circulation remodelling seen in patients with heart failure with preserved ejection 
fraction (HFpEF) was similar to that seen in PVOD. These patients also had a reduced DLCO 
(377). Consequently, it could be hypothesised that the low KCO observed in these older 
patients with idiopathic PAH reflects pulmonary venous remodelling. If validated a low KCO 
could be used as an accurate and simple non-invasive marker to identify patients with 
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clinically important diastolic left ventricular dysfunction analogous to its use in identifying 
patients with PVOD / PCH or biallelic EIF2AK4 variants. The association between venous 
remodelling and a low KCO may also explain the prognostic significance of a low KCO observed 
in patients with idiopathic PAH.  
 
Differential remodelling of the pulmonary arterial and venous circulation has been used to 
differentiate between PAH and PVOD / PCH. However, in this Thesis it has been demonstrated 
that the spectrum of histological changes associated with PVOD / PCH is greater than 
previously thought and has significant overlap with PAH. Although the explanted lungs of just 
a single patient with biallelic EIF2AK4 variants and a clinical diagnosis of idiopathic PAH was 
available for assessment, CT scans were assessed in larger numbers of patients. It was shown 
that the radiographic features associated with PVOD / PCH (and pulmonary venous 
remodelling) were not always present (or only subtle) in patients with biallelic EIF2AK4 
variants and a clinical diagnosis of idiopathic PAH. However, all patients with biallelic EIF2AK4 
variants had a characteristic reduction in KCO. These observations also highlight the 
importance of assessing KCO in patients with pulmonary hypertension. 
 
The range of clinical, radiological and histological features associated with biallelic EIF2AK4 
variants results in difficulties in identifying patients carrying these variants based solely on 
current clinical assessments. Clinical genetic testing may help identify these patients earlier, 
allowing accurate risk stratification, earlier referral for transplant assessment and enable 
genetic counselling for at risk family members. 
 
Another important group of patients identified in this Thesis were the young patients (< 50 
years at diagnosis) with normal spirometry and a low KCO (< 50 % predicted). Unlike the older 
patients with a low KCO, these patients did not have evidence of left heart disease and were 
found not to have any obvious genetic cause for the disease (including common variation in 
EIF2AK4 or variants in other genes in the integrated stress response pathway [data not 
shown]). Their low KCO suggests that they too may have pulmonary venopathy. Further 
investigation of the cause of their disease and their prognosis would be important. In 
particular whether or not they have a poor outcome similar to patients with biallelic EIF2AK4 
variants should be explored. 
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Variation in BMPR2 and other disease associated genes 
Variants in BMPR2 account for most patients with heritable PAH. In this Thesis I have been 
able to confirm that patients with variants in BMPR2 are younger at diagnosis and have more 
severe pulmonary haemodynamic impairment. However, the prognosis of these patients did 
not appear to be worse than patients with idiopathic PAH, unlike previously reported by Evans 
et al. in a much larger study (30). Despite its size, this study may still lack statistical power to 
demonstrate any difference in survival.  
 
Novel associations with blood count indices were also observed. Characterisation of the 
effects of loss of BMPR2 signalling is an important step towards developing treatments aimed 
at restoring this signalling pathway. For example, exogenous BMP9 (the ligand of BMPR2) has 
been shown to reverse and prevent pulmonary hypertension in preclinical models (152). 
Understanding the full clinical consequences of pathogenic BMPR2 variation may be of value 
in monitoring the response to these novel treatments.  
 
The majority of patients with PAH do not appear to have a rare and deleterious variant 
causing their disease. However, common genetic variation in combination with 
environmental and other genetic risk factors may account for additional cases. Previous 
studies have used a candidate gene approach to investigate common genetic variation in PAH 
(99, 122, 170, 178). The only published GWAS in PAH to date has identified common variation 
in CBLN2 as a potential risk factor for the development of PAH (102). The NIHR BRIDGE PAH 
Study and other international studies now provide an opportunity to reassess common 
variation in PAH. A publication looking at the role of common variation arising in this study is 
currently in submission. Further study of the phenotypes of patients carrying these common 
variants would be of value to understand their clinical impact.  
 
Future perspectives 
There are many opportunities arising from the NIHR BRIDGE PAH Study and the MRC / BHF 
Cohort Study. In addition to the specific questions raised earlier in the discussion, a simple 
but important analysis will be to revisit the baseline diagnostic data after a period of time. 
Re-running the analyses described in this Thesis on a more mature dataset, with more 
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individuals and more events in the survival analyses, may yield further insights. However, this 
is unlikely to significantly increase the number of patients with rare variants in genes other 
than BMPR2. Efforts are already underway to combine the NIHR BRIDGE PAH Study WGS data 
with a whole exome sequencing study (National Biological Sample and Data Repository for 
Pulmonary Arterial Hypertension, also known as PAH Biobank) from the USA. Such large 
international collaborations will be required to identify further novel genetic variation 
involved in disease pathogenesis and to elucidate specific genotype-phenotype associations 
for most genes. 
 
In this Thesis I have used simple comparative statistics and rank regression models to identify 
genotype-phenotype associations. Alternative statistical methodologies may be employed in 
the future to identify specific subgroups of patients. Cluster analyses have been used in other 
diseases to identify clinically important subgroups (378, 379). However, meaningful 
application of these methods requires the selection of variables that may reflect disease 
pathogenesis, severity or outcomes. As individuals with incomplete datasets are excluded, 
this has hindered application of these methods to the current study. However, the results 
presented in this Thesis may be used to guide selection of variables for capture in future 
studies that will utilise these statistical methods. 
 
In addition to baseline diagnostic data, the MRC / BHF Cohort Study is collecting longitudinal 
clinical data from patients. This will provide a valuable dataset with which to explore response 
to pulmonary artery vasodilator therapies in specific groups of patients. Currently, there is no 
information available to suggest that one class of pulmonary artery vasodilator therapy is 
superior to another in specific groups or individuals. 
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Appendices 
Appendix 1 
 
Recruiting centres for the NIHR BRIDGE PAH Study 
Country Centre Principle investigator 
United Kingdom Freeman Hospital, 
Newcastle 
Paul A Corris 
Golden Jubilee National 
Hospital, Glasgow 
Andrew Peacock 
Great Ormond Street 
Hospital, London 
Shahin Moledina 
Hammersmith Hospital and 
Imperial College, London 
Martin R Wilkins 
Papworth Hospital, 
Cambridge 
Joanna Pepke-Zaba 
Royal Brompton Hospital, 
London 
Stephen J Wort 
Royal Free Hospital, London Gerry Coghlan 
Royal Hallamshire Hospital, 
Sheffield 
David G Kiely 
Royal United Hospitals Bath 
NHS Foundation Trust, Bath 
Jay Suntharalingam  
France University of South Paris, 
Paris 
Marc Humbert 
Germany University Hospital Giessen, 
Giessen 
Henning Gall 
Italy San Matteo Hospital, Pavia Stefano Ghio 
Netherlands VU University Medical 
Center, Amsterdam 
Anton Vonk Noordegraaf 
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Appendix 2 
 
Rare disease cohorts recruiting to the NIHR BioResource - Rare Diseases Study 
Genomics England 
Specialist Pathology: Evaluating Exomes in Diagnostics 
Primary Immune Disorders 
Bleeding and Platelet Disorders 
Pulmonary Arterial Hypertension 
Multiple Primary Malignant Tumours 
Hypertrophic Cardiomyopathy 
Cerebral Small Vessel Diseases 
Steroid Resistant Nephrotic Syndrome 
Intrahepatic Cholestasis of Pregnancy 
Stem Cell & Myeloid Disorders 
Primary Membranoproliferative Glomerulonephritis 
Neuropathic Pain Disorder 
Leber Hereditary Optic Neuropathy 
Control 
Ehlers-Danlos Syndromes 
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Appendix 3   
Example of a template used to create OpenClinica eCRFs 
 
 
ITEM NAME DESCRIPTION LABEL LEFT ITEM TEXT UNITS RIGHT ITEM TEXT
SECTION 
LABEL
GROUP 
LABEL HEADER SUBHEADER
PARENT 
ITEM
COLUMN 
NUMBER
PAGE 
NUMBER
QUESTION 
NUMBER
RESPONSE 
TYPE
RESPONSE 
LABEL RESPONSE OPTIONS TEXT RESPONSE VALUES OR CALCULATIONS
RESPONSE 
LAYOUT DEFAULT VALUE
DATA 
TYPE
WIDTH 
DECIMA
L
VALIDATION VALIDATION ERROR MESSAGE PHI REQUIRED
ITEM 
DISPLAY 
STATUS
SIMPLE CONDITIONAL 
DISPLAY
HB_Study Baseline	study RHC	done?
Right	heart	
catheter
Right	Heart	
Catheter
1 single-select D_N (select	one),done,not	done ,done,not	done (select	one) ST 0 1 SHOW
HB_Date Date Date
DD-MMM-
YYYY
Right	heart	
catheter
1 text date DATE 0 1 HIDE HB_Study,done,ERROR
HB_SUPPLEMENTAL_OXYGEN
Supplemental	
Oxygen
Supplemental	Oxygen
Right	heart	
catheter
1 single-select N_PC_Lmin
(select	one),No,Unknown,%	
(through	Venturi	mask),	L/min	(for	
other	forms	of	O2	delivery)
,no,UNK,%,Lmin ST 0 1 HIDE HB_Study,done,ERROR
HB_SUPPLEMENTAL_OXYGEN_LEVEL %	Oxygen	(FiO2) %	Oxygen	(FiO<sub>2</sub>) %
Right	heart	
catheter
2 text real REAL 0 1 HIDE
HB_SUPPLEMENTAL_OXYGE
N,%,ERROR
HB_SUPPLEMENTAL_OXYGEN_LEVEL
2
L/min	Oxygen	
Oxygen	in	L/min	through	
nasal	cannulae	
L/min
Right	heart	
catheter
2 text real REAL 0 1 HIDE
HB_SUPPLEMENTAL_OXYGE
N,Lmin,ERROR
HB_HR_DONE HR	done Heart	rate	measured?
Right	heart	
catheter
1 single-select D_N (select	one),done,not	done ,done,not	done (select	one) ST 0 1 HIDE HB_Study,done,ERROR
HB_HEART_RATE Heart	Rate Heart	Rate bpm
Right	heart	
catheter
2 text real REAL 0 1 HIDE HB_HR_DONE,done,ERROR
HB_BP_DONE Systemic	BP	done Systemic	BP	measured?
Right	heart	
catheter
Systemic	
pressure
1 single-select D_N (select	one),done,not	done ,done,not	done (select	one) ST 0 1 HIDE HB_Study,done,ERROR
HB_SP_SYST
Systemic	pressure:	
Systolic
Systemic	pressure	(systolic) mm	Hg
Right	heart	
catheter
text real REAL 0 1 HIDE HB_BP_DONE,done,ERROR
HB_SP_DIAS
Systemic	pressure:	
Diastolic
Systemic	pressure	(diastolic) mm	Hg
Right	heart	
catheter
text real REAL 0 1 HIDE HB_BP_DONE,done,ERROR
HB_SP_MEAN
Systemic	pressure:	
Mean
Systemic	pressure	(mean) mm	Hg
Right	heart	
catheter
calculation
CALC_PRESSU
RE_HB
calculation
func:	
((HB_SP_SYST+HB_SP_DIAS+HB_SP_DIA
S)/3)
REAL 0 0 HIDE
HB_LVEDP_DONE LVEDP	select LVEDP
Right	heart	
catheter
Other 1 single-select ND_mmHg (select	one),not	done,mm	Hg ,not	done,mm	Hg (select	one) ST 0 1 HIDE HB_Study,done,ERROR
HB_LVEDP LVEDP mm	Hg
Right	heart	
catheter
2 text real REAL 0 1 HIDE
HB_LVEDP_DONE,mm	
Hg,ERROR
HB_PAWP_M_DONE
PAWP:	mean	
select
PAWP	(mean)
Right	heart	
catheter
1 single-select ND_mmHg (select	one) ST 0 1 HIDE HB_Study,done,ERROR
HB_PAWP_M PAWP:	mean mm	Hg
Right	heart	
catheter
2 text real REAL 0 1 HIDE
HB_PAWP_M_DONE,mm	
Hg,ERROR
HB_PAP_S PAP:	Systolic PAP	(systolic) mm	Hg
Right	heart	
catheter
Pulmonary	
artery	pressure	
text real REAL 0 1 HIDE HB_Study,done,ERROR
HB_PAP_D PAP:	Diastolic PAP	(diastolic) mm	Hg
Right	heart	
catheter
text real REAL 0 1 HIDE HB_Study,done,ERROR
HB_PAP_M PAP:	mean PAP	(mean) mm	Hg
Right	heart	
catheter
text real REAL 0 1 HIDE HB_Study,done,ERROR
HB_RAP_DONE RAP	done
Right	atrial	pressure	
measured?
Right	heart	
catheter
1 single-select D_N (select	one),done,not	done ,done,not	done (select	one) ST 0 1 HIDE HB_Study,done,ERROR
HB_RAP_M RAP:	mean RAP	(mean) mm	Hg
Right	heart	
catheter
Right	atrial	
pressure
2 text real REAL 0 1 HIDE
HB_RAP_DONE,done,ERRO
R
HB_CARDIAC_OUTPUT_METHOD_1
Cardiac	output	
Method
Cardiac	output	Method
Right	heart	
catheter
Cardiac	output 1 single-select A_M_T_Ox
(select	one),assumed	Fick,	
measured	Fick,	thermodilution,	
other
,assumed,measured,thermodilution,oth
er
(select	one) ST 0 1 HIDE HB_Study,done,ERROR
HB_CARDIAC_OUTPUT_VALUE_1 Cardiac	output Cardiac	output l/min
Right	heart	
catheter
2 text real REAL 0 1 HIDE HB_Study,done,ERROR
HB_CARDIAC_INDEX_VALUE_1 Cardiac	index Cardiac	index
l/min/m<su
p>2</sup>
Right	heart	
catheter
1 text real REAL 0 0 HIDE HB_Study,done,ERROR
HB_CARDIAC_OUTPUT_2
Second	Cardiac	
output	
Measurement
Second	Cardiac	output	
Measurement
Right	heart	
catheter
1 single-select Y_N-ss (select	one),Yes,No,Unkown ,yes,no,UNK (select	one) ST 0 1 HIDE HB_Study,done,ERROR
HB_CARDIAC_OUTPUT_METHOD_2
Second	Cardiac	
output	Method
Second	Cardiac	output	
Method
Right	heart	
catheter
Second	Cardiac	
output	
Measurement
1 single-select A_M_T_Ox (select	one) ST 0 1 HIDE
HB_CARDIAC_OUTPUT_2,ye
s,ERROR
HB_CARDIAC_OUTPUT_VALUE_2
Second	Cardiac	
output
Second	Cardiac	output l/min
Right	heart	
catheter
2 text real REAL 0 1 HIDE
HB_CARDIAC_OUTPUT_2,ye
s,ERROR
HB_CARDIAC_INDEX_VALUE_2
Second	Cardiac	
index
Cardiac	index
l/min/m<su
p>2</sup>
Right	heart	
catheter
1 text real REAL 0 0 HIDE HB_Study,done,ERROR
HB_SA_O2 SaO2 SaO<sub>2</sub> %
Right	heart	
catheter
Other text real REAL 0 1 HIDE HB_Study,done,ERROR
HB_SV_O2 SvO2 SvO<sub>2</sub> %
from	PA	(if	only	
measurement	
from	SVC/IVC	
please	add	as	
annotation)
Right	heart	
catheter
text real REAL 0 1 HIDE HB_Study,done,ERROR
HB_PVR_Calc PVR PVR
Right	heart	
catheter
calculation PVR_Calc calculation
func:	(80*(	(HB_PAP_M	-	
HB_PAWP_M)/HB_CARDIAC_OUTPUT_V
ALUE_1))
REAL 0 0 HIDE
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Appendix 4 
Screenshot of the eCRF used to capture haemodynamic data in OpenClinica.  
 
20/09/2017, 18*58Op nClinica View Data Entry
Page 1 of 1https://bridge-openclinica.medschl.cam.ac.uk/OpenClinica/ViewSec…?module=manage&crfId=88&crfVersionId=131&tabId=1&crfListPage=yes
RHC done?
Date
Supplemental Oxygen % Oxygen (FiO2) Oxygen in L/min
through nasal
cannulae
Heart rate measured? Heart Rate
Systemic BP
measured?
Systemic pressure
(systolic)
Systemic pressure
(diastolic)
Systemic pressure
(mean)
LVEDP
PAWP (mean)
PAP (systolic)
PAP (diastolic)
PAP (mean)
Right atrial pressure
measured?
RAP (mean)
Cardiac output
Method
Cardiac output
Cardiac index
Second Cardiac output
Measurement
Second Cardiac output
Method
Second Cardiac output
Cardiac index
SaO2
SvO2
PVR
PAH: Haemodynamics V4.2.0     
CRF Header Info
Click the flag icon next to an input to enter/view discrepancy notes. Please note that you can only save the notes if CRF data entry has already started.
Exit  
Right h...(0/30) Vasodil...(0/33)
 
-- Select to Jump --
Title: Right heart catheter
Right Heart Catheter
(select one) *
 * (DD-MMM-YYYY)
(select one) * * (%) * (L/min)
(select one) * * (bpm)
Systemic pressure
(select one) *
* (mm Hg)
* (mm Hg)
(mm Hg)
Other
(select one) * * (mm Hg)
(select one) * * (mm Hg)
Pulmonary artery pressure
* (mm Hg)
* (mm Hg)
* (mm Hg)
(select one) * * (mm Hg)
Cardiac output
(select one) * * (l/min)
(l/min/m2)
(select one) *
Second Cardiac output Measurement
(select one) * * (l/min)
(l/min/m2)
Other
* (%)
* (%) from PA (if only measurement from SVC/IVC please add as annotation)
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Appendix 5 
 
Discrepancy notes 
 
When adding a Discrepancy note (or Flag) to the data you are entering, the Type of Note 
should be determined by the reason you are adding the note. Please use “Reason for 
Change”, “Annotation”, “Query” or “Failed Validation Check” appropriately. 
 
1) Please select the correct “Type” of discrepancy note.   
2) If additional information is available / data updated or amended in OC / an error is 
corrected etc. then select “Reason for Change”. 
3) Only select “Annotation” type discrepancy notes if you feel that information is available 
that should be recorded in OC but you cannot input the data appropriately.  (See below 
for further information).  
 
‘Reason for Change’ Discrepancy Notes 
1) To speed up discrepancy note entry and analysis please use the following controlled 
vocabulary in the “Description” section of the discrepancy note: 
a) If new information is available please state “UPDATE” in the discrepancy note 
description.  Further information can be provided in the details section if needed. 
b) If new information is added following a request during a monitoring visit please state 
“MONITORING” in the discrepancy note description.  Further information can be 
provided in the details section if needed. 
c) If new information is added following a data/discrepancy note query please state 
“RESPONSE” in the discrepancy note description. Further information can be provided 
in the details section if needed. 
2) If you think further clinical information / justification is important and needs to be added 
to the discrepancy note please add this into the “detailed notes” section. 
 
 
‘Annotation’ Discrepancy Notes  
Annotations are used to make comments or provide information about the data that cannot 
be adequately represented in the CRF. For example if data is definitely missing or is in a 
different format that cannot be converted accurately.  
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These types of notes are not intended to begin a conversation thread but are to be used to 
record data which otherwise cannot be entered into a field. Where data is missing from a 
non-compulsory field (* indicates compulsory), a note to explain that data is missing is not 
required. 
 
 
Again use the controlled vocabulary in the “description” box and any additional information 
in the “detailed notes” section.  Please use one of these 3 words in the “description” field: 
i) If an annotation is flagging up a clinical finding (e.g. MDT outcome) please state 
“CLINICAL”.  Please expand in the “detailed notes” section. 
ii) If an annotation is flagging up uncertainty in the data (e.g. a date) entered into OC 
please state “UNCERTAINTY”.  Please expand in the detailed notes section. 
iii) If an annotation is there to justify an unexpected result please state “JUSTIFY”.  
For example a lab result for which there is no reference range.  Please expand in 
the “detailed notes” section.  Note this is different to the “Failed Validation Check” 
type discrepancy note (see below). 
“Failed Validation Check” 
A Failed Validation Check Note Type is for data that does not comply with expected values. 
For example where a range has been set on a data field but in this particular case the patient’s 
reading is recorded as out of range and you are sure this is correct.  
 237 
These types of notes are not intended to begin a conversation thread but are to be used to 
record data which otherwise cannot be entered into a field. This note can be created 
manually, useful if you wish to add a detailed note. Otherwise if out of range data is entered 
and the page saved, OpenClinica first displays a warning message, then if the value is not 
changed to within range it creates a Failed Validation Check Discrepancy Note automatically.  
Please check the data that you have entered and if the source data is correct please state 
“REJECTION” in the description box and expand the error if needed in the “detailed notes” 
section. 
 
‘Query’ Discrepancy Notes  
A Query Note Type is used to ask a question about data provided in a CRF. For example, you 
might create a Query Discrepancy Note to check data that seems incomplete or incorrect, or 
a more general query about what information to input.  
Please use the following controlled words in the “description” box to describe your query and 
use the “detailed notes” section to expand on your query: 
i) “OC” if there is a query/error relating to OpenClinica. 
ii) “Data” if the queries relate to how to enter source data into OC. 
iii) “Other” for all other queries. 
It is important to email the COHORT coordinators when entering a “Query” type discrepancy 
note.  These types of Notes begin a conversation thread by you (the originator) assigning the 
discrepancy note to another user who can answer the question. By selecting ‘Email assigned 
User’ the question will be forwarded directly to the users’ email account (use 
cohortcoordination@medschl.cam.ac.uk).    
If this is not selected the user can still see that there is a Note that requires their attention by 
clicking ‘Notes and Discrepancies’ on the menu bar at the top of the Home page. The page 
will then display a link that shows specifically which Notes you are assigned. We recommend 
using the Email check box to ensure your query is answered promptly. 
 
This is a typical workflow: 
1. The originator creates the Query Note. The Status is New . The originator assigns the 
query to the user who can answer the question. 
2. The user it is assigned to updates the Query by adding a new ‘child’ Discrepancy Note to 
the parent thread. The user might or might not modify the data value in conjunction with the 
update. If the user believes the issue is resolved, the user sets the Status to Resolution 
Proposed  and assigns it to the originator, or, if the user believes further consideration is 
required, the user sets the Status to Updated . 
3. The originator reviews the response and if satisfied, marks it as Closed , or adds further 
comments, assigns it back to the user, and sets the Status to Updated. 
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Please select appropriate users to answer questions. Bioinformatics staff (Stefan or 
Matthias) should be assigned where the question is technical or related to the function of the 
CRF. The research coordinator (Katherine or Carmen) should be assigned where the question 
is more general. For patient or site specific queries, please assign them to your local PI or your 
colleague. 
 
Discrepancy Note Status 
The status of a note is indicated by the colour of the flag next to the CRF data and in the list 
under the ‘Notes and Discrepancies’ section. It provides an indication of who is responsible 
for the next step.  
For Annotations the status will always be Not Applicable  as no further action is required.  
 
For Query’s and Failed Validation Checks the initial status should be set to New , when 
responding it should be set to either Updated  or Resolution Proposed   (the thread can 
flick between these two statuses as resolution is discussed in a Query), and then finally once 
dealt with a further note should have the status Closed  so that no further notes can be 
added to the thread. 
 
More information 
For more detailed information on the use of Discrepancy note please visit the Help Section 
on OpenClinica: 
https://docs.openclinica.com/3.1/openclinica-user-guide/monitor-and-manage-data/notes-
and-discrepancies 
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Appendix 6 
 
Variables recorded in OpenClinica as part of the NIHR BRIDGE PAH Study 
Group eCRF Item 
Diagnosis ID Subject group (Case / Relative) 
Diagnosis (idiopathic PAH / heritable PAH / 
PVOD / PCH) 
BRIDGE ID 
Cohort ID 
Demographics Date of birth 
Gender 
Self-declared ethnicity 
Clinical features at 
diagnosis 
Date of diagnosis 
Date of symptom onset 
Infection at time of onset? (yes / no) 
Syncope? (yes / no) 
Haemoptysis? (yes / no) 
Raynaud’s? (yes / no) 
Clinical features by 
examination 
Date of physical examination 
Height 
Weight 
Body mass index 
Body surface area 
Resting oxygen saturations 
Supplemental oxygen? (yes / no) 
Amount of supplemental oxygen 
Systolic blood pressure (BP) 
Diastolic BP 
Mean BP 
Heart rate 
Jugular venous pressure 
Digital clubbing? (yes / no) 
Spider naevi? (yes / no) 
Peripheral oedema? (yes / no) 
Ascites? (yes / no) 
Functional class Functional class 
Haemodynamics Right heart catheterisation done? (yes / no) 
Date 
Supplemental oxygen? (yes / no) 
Amount of oxygen 
Heart rate 
Systolic BP 
Diastolic BP 
Mean BP 
Left ventricular end diastolic pressure 
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Pulmonary capillary wedge pressure 
Systolic pulmonary artery pressure 
Diastolic pulmonary artery pressure 
Mean pulmonary artery pressure 
Right atrial pressure 
Cardiac output 1 
Cardiac output 1 method (thermodilution / 
direct Fick / indirect Fick) 
Cardiac output 2  
Cardiac output 2 method (thermodilution / 
direct Fick / indirect Fick) 
Peripheral arterial oxygen saturation 
Mixed venous oxygen saturation 
Vasodilator challenge performed? (yes / no) 
Date 
Supplemental oxygen? (yes / no) 
Amount of oxygen 
Heart rate 
Vasodilator used 
Vasodilator responder? (yes / no) 
Systolic BP 
Diastolic BP 
Mean BP 
Left ventricular end diastolic pressure 
Pulmonary capillary wedge pressure 
Systolic pulmonary artery pressure 
Diastolic pulmonary artery pressure 
Mean pulmonary artery pressure 
Right atrial pressure 
Cardiac output 1 
Cardiac output 1 method (thermodilution / 
direct Fick / indirect Fick) 
Cardiac output 2  
Cardiac output 2 method (thermodilution / 
direct Fick / indirect Fick) 
Peripheral arterial oxygen saturation 
Mixed venous oxygen saturation 
Lung function tests Lung function testing done? (yes / no) 
Forced expiratory volume 1 second (FEV1) 
FEV1 (% predicted) 
Forced vital capacity (FVC) 
FVC (% predicted) 
Total lung capacity (TLC) 
TLC (% predicted) 
Transfer coefficient (KCO) 
KCO (% predicted) 
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Alveolar volume (VA) 
VA (% predicted) 
Sleep study done? (yes / no) 
Diagnosis (normal / obstructive sleep 
apnoea / central sleep apnoea) 
Supplemental oxygen (yes / no) 
Amount of oxygen 
Average nocturnal oxygen saturation 
Desaturation index 
Arterial blood gas 
(ABG) 
ABG done? (yes / no) 
ABG date 
Supplemental oxygen (yes / no) 
Amount of oxygen 
pH 
H+ 
PaO2 
PaCO2 
Exercise tests Exercise test done? (yes / no) 
Type of walk test (corridor / shuttle) 
Corridor length 
Date of test 
Time of test 
Supplemental oxygen (yes / no) 
Amount of oxygen 
Distance walked 
Peripheral oxygen saturation pre-walk 
Peripheral oxygen saturation post-walk 
Cardiopulmonary exercise test done? (yes / 
no) 
Date 
Time 
Height 
Weight 
Supplemental oxygen (yes / no) 
Amount of oxygen 
FEV1 
FVC 
Systolic BP rest 
Diastolic BP rest 
Mean BP rest 
O2 saturation rest 
O2 pulse rest 
VCO2 at anaerobic threshold 
VCO2 nadir 
PETCO2 at anaerobic threshold 
VO2 at anaerobic threshold 
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PETCO2 max 
Systolic BP peak 
Diastolic BP peak 
Mean BP peak 
Heart rate peak 
Oxygen saturation peak 
VO2 peak 
Peak work rate 
Peak ventilation 
Peak RER 
PETCO2 peak 
O2 pulse peak 
VO2-WR slope 
VE-VCO2 slope 
Oxygen utilisation efficiency slope 
Clinical blood tests Autoimmune screen done? 
Date 
ANA result (positive / negative) 
Anti-cardiolipin result (positive / negative) 
Anti dsDNA result (positive / negative) 
Anti SCL70 result (positive / negative) 
Anti-centromere result (positive / negative) 
Anti Ro result (positive / negative) 
Anti ENA result (positive / negative) 
ANCA result (positive / negative) 
Cardiac blood tests done? (yes / no) 
Date 
Bone natriuretic peptide (BNP) unit 
BNP level 
NT-ProBNP unit 
NT-ProBNP level 
Troponin unit 
Troponin level 
Urate unit 
Urate level 
Haematology sample done? (yes / no) 
Date 
Haematocrit unit 
Haematocrit 
Hb unit 
Hb 
Platelet unit 
Platelet count 
Red cell distribution width 
White blood cell count 
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Monoclonal band on serum electrophoresis? 
(paraprotein band yes / no) 
Inflammatory tests done? (yes / no) 
Date 
C reactive protein (CRP) unit 
CRP level 
High sensitivity CRP unit 
High sensitivity CRP level 
Iron studies done? (yes / no) 
Date 
Ferritin unit 
Ferritin level 
Iron unit 
Iron level 
Iron binding capacity 
Transferrin unit 
Transferrin level 
Lipids tested? (yes / no) 
Date 
Cholesterol unit 
Cholesterol level 
High density lipoprotein level 
Low density lipoprotein level 
Triglycerides level 
Liver function tests done? (yes / no) 
Date 
Alkaline phosphatase 
Albumin 
Alanine transferase 
Aspartate transferase 
Bilirubin 
Lactate dehydrogenase 
Total protein 
Renal function checked? (yes / no) 
Date 
Sodium 
Potassium 
Urea 
Creatinine unit 
Creatinine level 
Estimated glomerular filtration rate (eGFR) 
unit 
eGFR level 
Serological tests done? (yes / no) 
Date 
Hepatitis B 
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Human immunodeficiency virus 
Thyroid function done? (yes / no) 
Date 
Free thyroxine (T4) 
Thyroid stimulating hormone 
Echocardiogram Echocardiogram done? (yes / no) 
Date 
Pericardial effusion present? (yes / no) 
Tricuspid annular plane systolic excursion  
Right atrial area 
Left atrial size 
Right ventricle morphology (normal / 
abnormal) 
Electrocardiogram ECG done? (yes / no) 
Date 
Rhythm (sinus / atrial fibrillation / atrial 
flutter / other)  
QRS duration 
Right bundle branch block present? (yes / 
no) 
Dominant R wave present? (yes / no) 
Imaging studies Imaging studies performed? (yes / no) 
Ventilation – perfusion scan (V/Q) (yes / no) 
Date 
Report 
Pulmonary embolus on VQ? (yes / no) 
CT (yes / no) 
CTPA (yes / no) 
Date 
Report 
HRCT (yes / no) 
Date 
Report 
Emphysema (no / minimal / mild / moderate 
/ severe) 
Fibrosis (no / minimal / mild / moderate / 
severe) 
CTEPH (yes / no) 
Cardiac MRI (yes / no) 
Date 
Report 
Heart rate 
Right ventricular ejection fraction 
Right ventricular diastolic volume 
Right ventricular systolic volume 
Left ventricular ejection fraction 
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Left ventricular diastolic volume 
Left ventricular systolic volume 
Abdominal ultrasound (yes / no) 
Date 
Report 
Portal venous flow (normal / abnormal) 
Continuous Risk factors High altitude exposure? (yes / no) 
Date of high altitude exposure 
Duration of high altitude exposure 
Current smoker? (yes / no) 
Smoking history (pack years) 
Previous pregnancies? (yes / no) 
Any complications? (yes / no) 
Anorexigen use? (yes / no) 
Start date 
End date  
Duration 
Recreational drug use? (yes / no) 
Name 
Start date 
End date  
Duration 
Chemotherapy? (yes / no) 
Name 
Start date 
End date  
Duration 
Other drugs and toxins? (yes / no) 
Name 
Start date 
End date  
Duration 
Associated conditions Associated disease present? (yes / no) 
Congenital heart disease present? (yes / no) 
Eisenmenger syndrome present? (yes / no) 
Post-tricuspid valve defect? (yes / no) 
Pre-tricuspid valve defect? (yes / no) 
Congenital heart disease corrected? (yes / 
no) 
Year of surgery 
Other congenital heart disease (yes / no) 
International Classification of Diseases (ICD) 
10 code 
Connective tissue disease present? (yes / no) 
Date of diagnosis 
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Portal hypertension present? (yes / no) 
Date of diagnosis 
HIV? (yes / no) 
Date of diagnosis 
Chronic haemolytic anaemia present? (yes / 
no) 
Date of diagnosis 
Schistosomiasis present? (yes / no) 
Date of diagnosis 
Other associated disease present? 
ICD 10 
Family history Family history of PAH (yes / no) 
Relationship 
Year of birth 
Alive (yes / no) 
Cause of death known? 
Clinical features by 
history 
Comorbidities? (yes / no) 
Date of diagnosis 
ICD 10 code 
Drug therapies (not 
PAH specific) 
Other drug therapy? (yes / no) 
Name 
Start date 
End date 
Unit 
Dose 
Regular or as required 
Drug therapies (PAH 
specific) 
Soluble guanylate cyclase antagonists? (yes / 
no) 
Name 
Start date 
End date 
Unit 
Dose 
Trial drug? 
Placebo controlled? 
Duration of placebo-controlled phase 
Prostacyclin analogue (yes / no) 
Name 
Start date 
End date 
Unit 
Dose 
Trial drug? 
Placebo controlled? 
Duration of placebo-controlled phase 
Phosphodiesterase 5 inhibitor (yes / no) 
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Name 
Start date 
End date 
Unit 
Dose 
Trial drug? 
Placebo controlled? 
Duration of placebo-controlled phase 
Endothelin receptor antagonist (yes / no) 
Name 
Start date 
End date 
Unit 
Dose 
Trial drug? 
Placebo controlled? 
Duration of placebo-controlled phase 
Prostanoids receptor analogue (yes / no) 
Name 
Start date 
End date 
Unit 
Dose 
Trial drug? 
Placebo controlled? 
Duration of placebo-controlled phase 
Oral anticoagulant (yes / no) 
INR dependent? 
Start date 
End date 
Unit 
Dose 
Adjunctive therapies? 
Name 
Start date 
End date 
Unit 
Dose 
Suspension Suspension Date of suspension 
Reason for suspension (death / 
transplantation / lost to follow up / left 
county / administrative) 
Cause of death known? (yes / no) 
Death certificate available? (yes / no) 
Part 1a 
Part 1b 
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Part 1c 
Part 2 
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Appendix 7 
 
The R script that I wrote for merging different datasets and creating / calculating new 
clinical variables (text proceeded by # are annotations explaining the function of the code): 
 
#Specify programs and files to use then run checks of the data: 
require(xlsx) 
options(stringsAsFactors = FALSE) 
args <- commandArgs(trailingOnly = TRUE) 
bridge_mapping <- "" 
cohort_mapping <- "" 
normalised_data <- "" 
verification_data <- "" 
legacy_data <- "" 
output_dir <- "" 
 
i <- 1 
while(i <= length(args)){ 
  if (args[i] == "--bridge-mapping"){ 
    bridge_mapping <- args[i+1] 
    i <- i + 2 
  } else if (args[i] == "--cohort-mapping"){ 
    cohort_mapping <- args[i+1] 
    i <- i + 2 
  } else if (args[i] == "--clean-data"){ 
    normalised_data <- args[i+1] 
    i <- i + 2 
  } else if (args[i] == "--verification-data") { 
    verification_data <- args[i+1] 
    i <- i + 2 
  } else if (args[i] == "--paris1") { 
    paris1_file <- args[i+1] 
    i <- i + 2 
  } else if (args[i] == "--paris2") { 
    paris2_file <- args[i+1] 
    i <- i + 2 
  } else if (args[i] == "--diagnosis_original") { 
      diagnosis_orginial_file <- args[i+1] 
      i <- i + 2 
  } else if (args[i] == "--drugs") { 
    drug_exp_file <- args[i+1] 
    i <- i + 2 
  } else if (args[i] == "--legacy-data") { 
    legacy_data <- args[i+1] 
    i <- i + 2 
  } else if (args[i] == "--output-dir") { 
    output_dir <- args[i+1] 
    i <- i + 2 
  #  print(args[i]) 
  } 
} 
 
if (cohort_mapping == "") { 
  stop("Please provide cohort mapping") 
} else if (!file.exists(cohort_mapping)) { 
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  stop("Please check cohort id file exists") 
} else if (file.exists(cohort_mapping)){ 
  cohort_id <- read.table(file=cohort_mapping, na.strings = c("", "NA", "NULL"), stringsAsFactors = F, 
encoding = "UTF-8", sep = ("\t"), header = T) 
   if (dim(cohort_id)[2] != 3){ 
     stop("Check structure of cohort id file") 
   } else if (dim(cohort_id[duplicated(cohort_id[,2]),])[1] !=0) { 
     print(cohort_id[duplicated(cohort_id[,2]) | duplicated(cohort_id[,2], fromLast=T),]) 
     stop("duplicated OC ID in cohort id file found") 
   } else if (dim(cohort_id[duplicated(cohort_id[,3]),])[1] !=0) { 
     stop("duplicated COHORT ID in cohort id file found") 
   } 
}  
 
if (bridge_mapping == "") { 
  stop("Please provide BRIDGE mapping") 
} else if (!file.exists(bridge_mapping)) { 
  stop("Please check BRIDGE ID file exists") 
} else if (file.exists(bridge_mapping)){ 
  bridge_id <- read.table(file=bridge_mapping, na.strings = c("", "NA", "NULL"), stringsAsFactors = F, 
encoding = "UTF-8", sep = ("\t"), header = T) 
  if (dim(bridge_id)[2] != 3){ 
   stop("Check structure of BRIDGE ID file") 
 } else if (dim(bridge_id[duplicated(bridge_id[,2]),])[1] !=0) { 
   print(bridge_id[duplicated(bridge_id[,2]) | duplicated(bridge_id[,2], fromLast=T),]) 
   stop("duplicated OC ID in BRIDGE ID file found") 
 } else if (dim(bridge_id[duplicated(bridge_id[,3]),])[1] !=0) { 
   print(bridge_id[duplicated(bridge_id[,3]) | duplicated(bridge_id[,3], fromLast=T),]) 
   stop("duplicated BRIDGE ID in BRIDGE ID file found") 
 } 
}  
 
if (normalised_data == "") { 
  stop("Please provide normalised data") 
} else if (!file.exists(normalised_data)) { 
  stop("Please check clean Rdata file exists") 
} else if (file.exists(normalised_data)){ 
  load(file = normalised_data) 
}  
 
if (verification_data == "") { 
  stop("Please provide verification data") 
} else if (!file.exists(verification_data)) { 
  stop("Please check verification spreadsheet exists") 
} else if (file.exists(verification_data)){ 
  verification <- read.xlsx(file=verification_data, 1, header = T, stringsAsFactors = F) 
}  
 
if (paris1_file == "") { 
  stop("Please provide Paris1 data") 
} else if (!file.exists(paris1_file)) { 
  stop("Please check paris1 spreadsheet exists") 
} else if (file.exists(paris1_file)){ 
  Paris_Fhx1 <- read.xlsx(file=paris1_file, sheetIndex = 1, startRow = 2, header = T, as.data.frame = T) 
}  
 
if (paris2_file == "") { 
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  stop("Please provide Paris2 data") 
} else if (!file.exists(paris2_file)) { 
  stop("Please check paris2 spreadsheet exists") 
} else if (file.exists(paris2_file)){ 
  Paris_Fhx2 <- read.xlsx(file=paris2_file, sheetIndex = 1, startRow = 1, header = T, as.data.frame = T) 
} 
 
if (diagnosis_orginial_file == "") { 
    stop("Please provide Diagnosis original file") 
} else if (!file.exists(diagnosis_orginial_file)) { 
    stop("Please check diagnosis_original spreadsheet exists") 
} else if (file.exists(diagnosis_orginial_file)){ 
    Diagnosis_original <- read.xlsx(file=diagnosis_orginial_file, sheetIndex = 1, startRow = 1, header = T, 
as.data.frame = T) 
} 
 
if (drug_exp_file == "") { 
  stop("Please provide drug exposure data") 
} else if (!file.exists(drug_exp_file)) { 
  stop("Please check drug exposure spreadsheet exists") 
} else if (file.exists(drug_exp_file)){ 
  drug_induced_confirmed <- read.csv(file = drug_exp_file, header = T, stringsAsFactors = F, na.strings 
= "") 
}  
 
if (legacy_data == "") { 
  stop("Please provide legacy spreadsheet") 
} else if (!file.exists(legacy_data)) { 
  stop("Please check legacy spreadsheet exists") 
} else if (file.exists(legacy_data)){ 
  legacy <- read.csv(file=legacy_data, header = T, stringsAsFactors = F, na.strings = c("", "NA")) 
}  
 
if (output_dir == "") { 
  stop("Please provide Output directory") 
} else if (!dir.exists(output_dir)) { 
  stop("Please check Output directory exists") 
}  
 
###Prepare BRIDGE IDs: 
colnames(bridge_id) <- c("Centre","id", "pah_subject_id_bridge_validated") 
 
###Prepare COHORT IDs: 
colnames(cohort_id) <- c("Centre","id", "pah_subject_id_cohort_validated") 
 
#### 
#Merge all ids together: 
data.checked <- merge(data.clean, bridge_id, by.x = "id", by.y = "id", all.x=T) 
data.checked <- merge(data.checked, cohort_id, by.x = "id", by.y = "id", all.x=T) 
 
#Define functions to correct errors in the data automatically: 
replace_NA <- function(id, item) {NA} 
replace_date_diag <- function(id, item){ 
  data.clean[data.clean[,"id"] == id, item] 
} 
multiply10 <- function(id, item) { 
  data.clean[data.clean[,"id"] == id, item] * 10 
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} 
 
multiply100 <- function(id, item) { 
  data.clean[data.clean[,"id"] == id, item] * 100 
} 
 
divide1000 <- function(id, item) { 
  data.clean[data.clean[,"id"] == id, item] * 0.001 
} 
 
cbt_renal_creatinine_mmolpl <- function(id, item) { 
    data.clean[data.clean[,"id"] == id, "abg_paco2"] * 100 
} 
 
ver.idx <- which(is.na(verification$check) & !is.na( verification$func)) 
for (i in ver.idx){ 
    if (verification[i,"func"]!="replace_value"){ 
        fun <- get(verification[i,"func"], mode = "function") 
        id <- verification[i,"id"] 
        item  <- verification[i, "item"] 
        data.checked[data.checked[,"id"]==id, item] <- fun(id, item) 
    } 
     
    # replace with specific value from the verification spreadsheet: 
     
    if (verification[i,"func"]=="replace_value"){ 
        id <- verification[i,"id"] 
        item  <- verification[i, "item"] 
        value <- verification[i, "value"] 
        data.checked[data.checked[,"id"]==id, item] <- value 
    } 
} 
 
#Create new clinical variables: 
data.checked$DOB <- as.Date(paste(data.checked$birth_day, data.checked$birth_month, 
data.checked$birth_year, sep="/", collapse =NULL), "%d/%m/%Y") 
data.checked$hb_date2 <- as.Date(data.checked$hb_date) 
data.checked$cfh_date_of_diagnosis <- as.Date(data.checked$cfh_date_of_diagnosis) 
data.checked$age_diagnosis <- as.numeric((data.checked$hb_date2 - data.checked$DOB)/365.25) 
data.checked$age_diagnosis <- ifelse(is.na(data.checked$age_diagnosis), 
as.numeric((data.checked$cfh_date_of_diagnosis - data.checked$DOB)/365.25), 
data.checked$age_diagnosis) 
 
data.checked$pcwp_adj <- ifelse(is.na(data.checked$hb_pawp_m) & data.checked$hb_lvedp <=15, 
data.checked$hb_lvedp, ifelse((data.checked$hb_pawp_m > 15 & data.checked$hb_lvedp <=15), 
data.checked$hb_lvedp, ifelse(data.checked$hb_pawp_m <=15, data.checked$hb_pawp_m, NA))) 
 
data.checked$pvr <- (data.checked$hb_pap_m - data.checked$pcwp_adj) / 
data.checked$hb_cardiac_output_value_1 
data.checked$ci <- (data.checked$hb_cardiac_output_value_1 / data.checked$bs_bsa) 
 
data.checked$pp <- data.checked$hb_pap_s - data.checked$hb_pap_d  
data.checked$ca <- (data.checked$hb_cardiac_output_value_1 / data.checked$hb_heart_rate) / 
data.checked$pp 
data.checked$rc <- data.checked$pvr * data.checked$ca * 60 
 
#Create variable vasoresponder if meets strict criteria.   
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#As some data missing vasoresponder 2 removes need for maintaining CO with NO challenge 
data.checked$vasoresponder <- as.factor(ifelse((data.checked$hv_pap_m <40 & 
(data.checked$hb_pap_m - data.checked$hv_pap_m) >10 & 
(data.checked$hb_cardiac_output_value_1 / data.checked$hv_cardiac_output_value_1) >0.8), 
c("vasoresponder"),c("non-responder"))) 
data.checked$vasoresponder2 <- as.factor(ifelse((data.checked$hv_pap_m <40 & 
(data.checked$hb_pap_m - data.checked$hv_pap_m) >10), c("vasoresponder"), c("non-responder"))) 
 
#Only use 6mwt performed on 30m corridor for analysis 
data.checked$smwd <- ifelse(data.checked$ep_1_corridor_length == 30, 
data.checked$ep_1_distance_meters, NA) 
 
#Determine lung function status 
data.checked$fev1_fvc <- data.checked$lf_fev1_liters / data.checked$lf_fvc_liters 
data.checked$obstructive_pfts <- as.factor(ifelse(data.checked$fev1_fvc < 0.7, c("Obstructive"), 
ifelse(data.checked$lf_fvc_pc<80, c("Restrictive"), c("Normal")))) 
 
data.checked$ethnic_category <- ifelse(data.checked$ethnic_category == "A", "British",  
  ifelse(data.checked$ethnic_category == "B", "Irish",  
    ifelse(data.checked$ethnic_category == "C", "Traveller",  
      ifelse(data.checked$ethnic_category == "D", "Other White",  
        ifelse(data.checked$ethnic_category == "E", "White & Black Carribean",  
          ifelse(data.checked$ethnic_category == "F", "White & Black African",  
            ifelse(data.checked$ethnic_category == "G", "White & Asian",  
              ifelse(data.checked$ethnic_category == "H", "Any other mixed ethnicity",  
                ifelse(data.checked$ethnic_category == "I", "Indian",  
                  ifelse(data.checked$ethnic_category == "J", "Pakistani",  
                    ifelse(data.checked$ethnic_category == "K", "Bangladeshi",  
                      ifelse(data.checked$ethnic_category == "L", "Chinese",  
                        ifelse(data.checked$ethnic_category == "M", "Other Asian",  
                          ifelse(data.checked$ethnic_category == "N", "African",  
                            ifelse(data.checked$ethnic_category == "O", "Carribbean",  
                              ifelse(data.checked$ethnic_category == "P", "Other Black",  
                                ifelse(data.checked$ethnic_category == "Q", "Arab",  
                                  ifelse(data.checked$ethnic_category == "R", "Other",  
                                    ifelse(data.checked$ethnic_category == "Z", "Not stated", "ERROR"))))))))))))))))))) 
 
 
# identify legacy subjects: 
data.checked <- merge(data.checked, legacy, by.x = "pah_subject_id_bridge_validated", by.y = 
"legacy_id", all.x = T) 
data.checked$legacy2 <- ifelse(is.na(data.checked$legacy), "prosp", "legacy") 
 
# Diagnosis verified: 
##PVOD_PCH <- unique(indInfo[which(grepl("PVOD", indInfo$pah_subject_diagnosis) |  
##                                   grepl("PCH", indInfo$pah_subject_diagnosis)),"id"]) 
##data.checked$diagnosis_verified <- ifelse(data.checked$id %in% PVOD_PCH, "PVOD/PCH", "PAH") 
##data.checked$diagnosis_verified <- ifelse(data.checked$id %in% Diagnosis_original$ID, 
"PVOD/PCH", data.checked$diagnosis_verified) 
data.checked$diagnosis_verified <- data.checked$diagnosis 
idx <- which(!is.na(data.checked$sub_cause_diagnosis_verified)) 
data.checked$diagnosis_verified[idx] <- data.checked$sub_cause_diagnosis_verified[idx] 
idx <- which(data.checked$sub_cause_diagnosis_verified == "APAH") 
data.checked$diagnosis_verified[idx] <- paste(data.checked$sub_cause_diagnosis_verified[idx], 
data.checked$sub_cause_apah[idx], sep=":") 
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# Family history (yes or no): 
relatives_ocid <- unique(indInfo[which(indInfo$pah_subject_id_group_check=="relative"),"id"]) 
 
#Take only patients in whom a family history of PAH is certain (ie ignore UNK and no responses in 
family_pah) 
Confirmed_Fhx <- family_history[which(family_history$family_pah=="yes"),] 
Confirmed_Fhx <- Confirmed_Fhx[which(!Confirmed_Fhx$id %in% relatives_ocid),] 
 
#Paris FHx: 
Paris_fhx_ids <- c(as.character(Paris_Fhx1[which(Paris_Fhx1$Diagnosis=="Familial PAH"), 
"BRIDGE.ID"]), 
                   as.character(Paris_Fhx2[which(Paris_Fhx2$PAH=="familial"), "BRIDGE"])) 
 
Paris_fhx_ids <- data.checked[which(data.checked$pah_subject_id_bridge_validated %in% 
Paris_fhx_ids),  
                              c("pah_subject_id_bridge_validated", "id")] 
 
FPAH_list <- c(Confirmed_Fhx$id, Confirmed_Fhx$family_ocid, Paris_fhx_ids$id) 
FPAH_list <- FPAH_list[which(!is.na(FPAH_list))] 
FPAH_list <- FPAH_list[!duplicated(FPAH_list)] 
FPAH_list <- FPAH_list[!FPAH_list %in% relatives_ocid] 
data.checked$FHx <- ifelse(data.checked$id %in% FPAH_list, "Yes", "No") 
 
#### Determine drug exposures: 
data.checked$drug_exposure <- ifelse(data.checked$id %in% drug_induced_confirmed$id, "Yes", 
"No") 
data.checked$amphetamines <- ifelse(data.checked$id %in% 
drug_induced_confirmed[which(!is.na(drug_induced_confirmed$Rec_drug)),"id"],  
                                    "Amphetamines", NA) 
data.checked$dasatinib <- ifelse(data.checked$id %in% 
drug_induced_confirmed[which(!is.na(drug_induced_confirmed$Chemo_drug)),"id"],  
                                "Dasatinib", NA) 
data.checked$anorexigen <- ifelse(data.checked$id %in% 
drug_induced_confirmed[which(!is.na(drug_induced_confirmed$Anorexigen_drug)),"id"],  
                                  "Anorexigen", NA) 
 
#Reorder columns and clean data.checked for ease of use in analysis stages: 
basic_variables <- c("id","pah_subject_id_bridge_validated", "pah_subject_id_cohort_validated",  
                     "centre", "diagnosis", "diagnosis_verified", "FHx", "drug_exposure", "amphetamines",  
                     "dasatinib", "anorexigen", "sex", "ethnic_category", "age_diagnosis") 
 
remove_variables <- c(grep("ad_", names(data.checked), value = T), grep("rf_", names(data.checked), 
value = T)) 
other <- names(data.checked)[!names(data.checked) %in% c(basic_variables, remove_variables)] 
 
data.checked <- data.checked[, c(basic_variables, other)] 
 
print(paste0("Saving to ", output_dir, "/data_checked.RData")) 
save(data.checked, file = paste0(output_dir, "/data_checked.RData")) 
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Appendix 8 
 
Tests applied to check the phenotype data 
Type eCRF Check Comment 
Errors All 
 
SaO2 >100%  
Systolic BP > diastolic 
BP 
 
Zero values entered Sometimes entered 
where data missing 
Haemodynamics Date of right heart 
catheter more than 6 
weeks from date of 
diagnosis 
 
Systolic PAP > mean 
PAP > diastolic PAP > 
PCWP 
 
PCWP > 15 mmHg and 
no LVEDP available or 
LVEDP also > 15 mmHg 
 
mPAP < 25 mmHg  
Exercise performance Corridor length (10, 15, 
25 or 30 m in length) 
Corridor length and 
walk test distance 
mixed up 
Imaging investigations End systolic volumes > 
end diastolic volumes 
 
Clinical blood test Hb < 50 g/l May indicate 
incorrect units used 
Demographics Self-declared gender 
same as WGS inferred 
gender 
 
Relationships Haemodynamics mPAP – sPAP  
mPAP – dPAP  
sPAP – dPAP  
FEV1 – FEV1 % predicted  
FVC – FVC % predicted  
TLC – TLC % predicted  
KCO – KCO % predicted  
VA – VA % predicted  
Exercise performance 6mwt distance to 
functional class 
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Appendix 9 
 
Customised proforma used to record radiographic features from computed tomography 
imaging studies from the time of diagnosis 
Parameter Response 
ID  
Date of birth  
Unenhanced CT Y / N 
CTPA Y / N 
HRCT Y / N 
Expiratory CT Y / N 
Pulmonary artery diameter (cm)  
Aorta diameter (cm)  
Ground glass opacification centrilobular pattern 
DENSITY None / Subtle / Present 
Ground glass centrilobular pattern EXTENT 0 %, < 5 %, 5 % – 25 %,  25 % – 50 %, > 50 % 
Ground glass DISTRIBUTION central (C)/peripheral (P)/zonal (Z) or diffuse (D) 
Non-specific mosaic pattern / groundglass 
opacification  
Neovascularity vessels Y / N 
Arterio-venous malformations Y / N 
Bronchial arteries Y / N 
Largest bronchial artery size  
Interlobular septal thickening None, Subtle, Present 
Mediastinal lymphadenopathy Y / N 
Emphysema Y / N and % of parenchyma involved 
Fibrosis Y / N and % of parenchyma involved 
Pleural effusion Y / N 
Air trapping Y / N 
Comments  
Likely diagnosis Any suspicion of PVOD or PCH / PAH 
CT – computer tomography, CTPA – computer tomography pulmonary angiogram, HRCT – 
high resolution CT 
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Appendix 10 
 
The R scripts I wrote to analyse the data and create the tables that are presented in the Thesis 
are provided below: 
 
To create the summary tables presented in the Thesis: 
 
1. Specify the raw data being used (DF) and specify the clinical variable being assessed (VARIABLE; e.g. 
gender): 
 
DF <- clean.data 
VARIABLE <- "sex" 
 
2. Specify the number of levels in the clinical variable being assessed (GROUP; e.g. male/female): 
 
n_levels <- length(levels((as.factor(DF[,VARIABLE])))) 
numeric_summary <- data.frame(matrix(ncol =  2+3*n_levels, nrow = 0), stringsAsFactors = 
F) 
 
3. In each GROUP calculate the median (med), 1st and 3rd quartiles (iqr1 and iqr2) for all numeric 
variables (test_var; e.g. age at diagnosis) in the dataframe (DF_NUMS) sequentially and add to 
summary table (numeric_summary_temp). Rounded each result to one decimal place. 
 
numeric_summary <- data.frame(matrix(ncol =  2+3*n_levels, nrow = 0), stringsAsFactors = 
F) 
 
for (i in test_var) { 
  numeric_summary_temp <- data.frame(matrix(nrow = 1, ncol = 0), stringsAsFactors = F) 
  for (t in GROUP){ 
    temp <- data.frame(variable=i,  
      mean = sprintf("%.1f", round(median(DF_NUMS[which(DF_NUMS[,VARIABLE]==t), i], 
na.rm = T), digits = 2)), 
      iqr1 = sprintf("%.1f", round(quantile(DF_NUMS[which(DF_NUMS[,VARIABLE]==t), i], 
na.rm = T)[2], digits = 2)), 
      iqr2 = sprintf("%.1f", round(quantile(DF_NUMS[which(DF_NUMS[,VARIABLE]==t), i], 
na.rm = T)[4], digits = 2)), stringsAsFactors = F) 
     
    temp[,t] <- paste0(temp$mean, " [", temp$iqr1, " - ", temp$iqr2, "]")    
    temp <- temp[5] 
    numeric_summary_temp <- cbind(numeric_summary_temp, temp) 
  } 
   
3. Hypothesis testing based on number (n_levels) of groups being compared (2 groups – unpaired 
Wilcoxon rank sum test, 3 of more groups – Kruskal-Wallis test): 
 
  if (n_levels == 2){ 
    numeric_summary_temp$p_val <- wilcox.test(DF_NUMS[,i] ~ 
as.factor(DF_NUMS[,VARIABLE]), na.action = na.exclude)$p.value 
  } 
   
  if (n_levels>2) { 
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    numeric_summary_temp$p_val <- kruskal.test(DF_NUMS[,i] ~ 
as.factor(DF_NUMS[,VARIABLE]), na.action = na.exclude)$p.value 
  } 
   
  numeric_summary_temp$variable <- i 
  numeric_summary_temp <- numeric_summary_temp[,c(ncol(numeric_summary_temp), 
1:(ncol(numeric_summary_temp)-1))] 
  numeric_summary <- rbind(numeric_summary, numeric_summary_temp) 
} 
 
4. For all categorical variables (cat_var) calculate the number and percentage of the total in each group 
being assessed (GROUP): 
 
categorical_summary <- data.frame(matrix(nrow = 1, ncol = 0), stringsAsFactors = F) 
 
for(var in cat_var){ 
  table <- table(DF_CAT[,VARIABLE], DF_CAT[,var]) 
  temp2 <- data.frame(matrix(nrow = 1, ncol = 0), stringsAsFactors = F) 
  temp2[,"variable"] = var 
  temp2[,"level_reported"] <- character() 
   
  if (ncol(table) <=2){ 
    temp2[,"level_reported"] = colnames(table)[1] 
  } 
  if (ncol(table) >2){ 
    for (n in 1:length(colnames(table))) 
      temp2$level_reported = paste0(temp2$level_reported, " / ", colnames(table)[n]) 
      temp2$level_reported <- gsub("NA / ", "", temp2[,"level_reported"]) 
  } 
  
 for (g in GROUP){ 
    temp <- data.frame(matrix(nrow = 1, ncol = 0), stringsAsFactors = F) 
    if (ncol(table) <=2){ 
      temp[,g] = paste0(table[rownames(table)==g, 1], " [", sprintf("%.1f", 
round((prop.table(table,1)[rownames(table)==g, 1]) *100 , digits = 1)), "%]") 
      temp2 <- cbind(temp2, temp) 
    }     
    if (ncol(table) > 2){ 
      temp[,g] <- NA 
      for (n in 1:ncol(table)){ 
        temp[,g] = paste0((temp[,g]), " / ", table[rownames(table)==g, n], " [", sprintf("%.1f", 
round((prop.table(table,1)[rownames(table)==g, n]) *100 , digits = 1)), "%]") 
        temp[,g] <- gsub("NA / ", "", temp[,g]) 
      } 
      temp2 <- cbind(temp2, temp) 
      } 
    } 
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5. Hypothesis testing using Fisher’s exact test for non-ordinal variables and the chi square test for 
ordinal variables: 
 
  if (ncol(table) >1 & VARIABLE_ORDINAL=="yes"){ 
    temp2$p_val <- sprintf("%.3f", round(pvalue(chisq_test(table(DF_CAT[,VARIABLE], 
DF_CAT[,var], dnn=c("gt", var)), scores = list("gt" = seq(1:n_levels)))), digits = 3)) 
  }  
  if (ncol(table) >1 & VARIABLE_ORDINAL=="no"){ 
    temp2$p_val <- sprintf("%.3f", round(fisher.test(table(DF_CAT[,VARIABLE], DF_CAT[,var]), 
workspace = 2e9)$p.value, digits = 3)) 
  }  
  if (ncol(table) <=1){ 
      temp2$p_val <- NA 
  }  
  categorical_summary <- rbind(categorical_summary, temp2) 
} 
 
Assessing associations with haemodynamic variables with rank regression models: 
 
1. Select haemodynamic variables and assess their distribution using the Shapiro-Wilk test. 
 
test_var <- c("hb_pap_m", "pcwp_adj", "pvr", "ci", "hb_sv_o2", "hb_rap_m") 
for (i in test_var){ 
  print("*******") 
  print(i) 
  print(shapiro.test((clean.data[,i]))) 
  print("*******") 
} 
 
2. Create univariate rank regression models: 
 
library(Rfit) 
for (i in test_var){ 
  print("*******") 
  print(i) 
  print(summary(rfit(get(i) ~ age_diagnosis, clean.data))) 
  print("*******") 
} 
 
for (i in test_var){ 
  print("*******") 
  print(i) 
  print(summary(rfit(get(i) ~ sex, clean.data))) 
  print("*******") 
} 
 
for (i in test_var){ 
  print("*******") 
  print(i) 
  print(summary(rfit(get(i) ~ centre, clean.data))) 
  print("*******") 
 260 
} 
 
3. Create multivariate rank regression models using age, gender and centre as covariates: 
 
MV_RHC_model <- data.frame(var=character(), var2 = character(), b=character(), 
se=character(), p=character()) 
 
for (i in test_var){ 
  model <- summary(rfit(get(i) ~ (sex + age_diagnosis + centre), clean.data)) 
  temp <- data.frame(var=character(), var2 = character(), b=character(), se=character(), 
p=character()) 
 
  for (t in c("sexmale", "age_diagnosis")){ 
    temp2 <- data.frame(var = i, 
      var2 = t, 
      b = round(model$coefficients[t,"Estimate"], digits = 3), 
      se = round(model$coefficients[t,"Std. Error"], digits = 3), 
      p = round(model$coefficients[t,"p.value"], digits = 3)) 
    temp <- rbind(temp2, temp) 
  } 
   
  MV_RHC_model <- rbind(MV_RHC_model, temp) 
  MV_RHC_model <- MV_RHC_model[which(MV_RHC_model$p <0.05), ] 
} 
 
Perform a non-truncated univariate survival analysis: 
 
1. Sequentially assess all variables (test_var) in a dataset containing survival data (survival.data). The 
analysis censors patients who are not dead (right censoring). Extract hazard ratio and confidence 
value for each variable: 
 
survival_univariate_no_trunc <- data.frame(variable=character(), 
group=character(),HR=character(), CI=character(), p=character(), n=character(), 
n_events=character(), stringsAsFactors = F) 
 
for (var in test_var){ 
  temp <- coxph(Surv(time = survival.data$sur_time2, survival.data$CAUSE, type = "right") ~ 
(survival.data[,var])) 
   
  temp_df <- data.frame(variable=var, 
    HR = round(summary(temp)$conf.int[1,"exp(coef)"], digits = 3), 
    group = "", 
    CI = paste0(round(summary(temp)$conf.int[1,"lower .95"],digits = 3), " - ", 
round(summary(temp)$conf.int[1,"upper .95"], digits = 3)), 
    p = round(summary(temp)$coefficients[1,"Pr(>|z|)"], digits = 5), 
    n = summary(temp)$n, 
    n_events = summary(temp)$nevent, stringsAsFactors = F)   
  survival_univariate_no_trunc <- rbind(survival_univariate_no_trunc, temp_df) 
} 
 
#more than 2 levels categorical variables: 
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survival_univariate2_no_trunc <- data.frame(variable=character(), group=character(), 
HR=character(), CI=character(), p=character(), n=character(), n_events=character(), 
stringsAsFactors = F) 
for (var in three_level_cat){ 
  temp <- coxph(Surv(time = survival.data$sur_time2, survival.data$CAUSE, type = "right") ~ 
(survival.data[,var])) 
   
    for( n in 1:(nrow(summary(temp)$coefficients))){ 
      temp_df <- data.frame(variable=var, 
        group= row.names(summary(temp)$coefficients)[n], 
        HR = round(summary(temp)$conf.int[n,"exp(coef)"], digits = 3), 
        CI = paste0(round(summary(temp)$conf.int[n,"lower .95"],digits = 3), " - ", 
round(summary(temp)$conf.int[n,"upper .95"], digits = 3)), 
        p = round(summary(temp)$coefficients[n,"Pr(>|z|)"], digits = 5), 
        n = summary(temp)$n, 
        n_events = summary(temp)$nevent, stringsAsFactors = F) 
       
      survival_univariate2_no_trunc <- rbind(survival_univariate2_no_trunc, temp_df) 
  } 
} 
 
survival_univariate_all_no_trunc <- rbind(survival_univariate_no_trunc, 
survival_univariate2_no_trunc) 
 
Left truncated survival analyses: 
 
1. The same R code as the non-truncated analysis above was used except replacing the survival 
function with the line below: 
 
temp <- coxph(Surv(time = survival.data$L_TRUNC, time2 = survival.data $sur_time2, 
survival.data $CAUSE, type = "counting") ~ (survival.data [,var])) 
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Appendix 11 
 
Data completion rates for diagnostic data captured in OpenClinica 
Item name Number 
complete 
% 
complete 
Day of birth 1065 99.5 
Month of birth 1065 99.5 
Year of birth 1065 99.5 
Centre 1065 99.5 
Diagnosis group 1065 99.5 
OpenClinica ID 1065 99.5 
Gender 1065 99.5 
Diagnosis 1064 99.4 
BRIDGE ID 1061 99.2 
Date of diagnosis 1040 97.2 
mPAP (mmHg) 1003 93.7 
CO (L/min) 957 89.4 
Functional class 940 87.9 
Day of visit 938 87.7 
Month of visit 938 87.7 
Year of visit 938 87.7 
Ethnic category 937 87.6 
Haemoptysis at onset 923 86.3 
Raynaud’s syndrome 923 86.3 
Infection at onset 922 86.2 
Syncope at onset 922 86.2 
Symptom onset known 917 85.7 
PVR (dynes) 898 83.9 
Date of RHC 895 83.6 
RAP (mmHg) 876 81.9 
CO method 1 857 80.1 
RHC supplemental oxygen used 845 79.0 
6mwt distance (m) 834 77.9 
PCWP (mmHg) 816 76.3 
Date of walk test 799 74.7 
sPAP (mmHg) 779 72.8 
dPAP (mmHg) 776 72.5 
Ankle swelling 775 72.4 
Ascites 775 72.4 
Clubbing 774 72.3 
Spider naevi 774 72.3 
Type of walk test 773 72.2 
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Date of examination 764 71.4 
Weight (kg) 755 70.6 
Walk test supplemental O2 used 742 69.3 
Height (cm) 736 68.8 
Hb unit 734 68.6 
Hb (g/l) 726 67.9 
Serum electrophoresis 727 67.9 
Sodium (mmol/l) 726 67.9 
WBC (x109/l) 722 67.5 
Creatinine unit 722 67.5 
Platelets (x109/l) 720 67.3 
Potassium (mmol/l) 720 67.3 
eGFR unit 719 67.2 
Urea (mmol/l) 716 66.9 
HCT unit 715 66.8 
Creatinine (µmol/l) 715 66.8 
Systemic diastolic BP (mmHg) 711 66.4 
Systemic systolic BP (mmHg) 711 66.4 
ALP (iu) 703 65.7 
Examination supplemental O2 use 703 65.7 
Bilirubin (µmol/l) 699 65.3 
Date of echocardiogram 697 65.1 
RV on echocardiogram 693 64.8 
ALT (iu/l) 692 64.7 
Albumin (g/l) 689 64.4 
Resting SaO2 (%) 664 62.1 
RHC SaO2 (%) 662 61.9 
BSA 660 61.7 
Pre-walk SaO2 (%) 660 61.7 
SvO2 (%) 657 61.4 
FEV1 (l) 651 60.8 
Date of lung function tests 648 60.6 
FVC (l) 647 60.5 
FEV1 (% predicted) 641 59.9 
BMI 637 59.5 
Date of height and weight 637 59.5 
Dominant R wave 626 58.5 
RBBB 626 58.5 
FVC (% predicted) 626 58.5 
Pericardial effusion 623 58.2 
Date of full blood count 607 56.7 
Date of renal function 606 56.6 
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Date of ECG 604 56.4 
ECG done 603 56.4 
Heart rhythm 604 56.4 
HR (bpm) 598 55.9 
Date of liver function tests 593 55.4 
Post walk SaO2 (%) 591 55.2 
Anti-Centromere Ab 574 53.6 
Anti-Rho Ab 573 53.6 
KCO (mmol/min/kPa/l) 573 53.6 
Anti-ENA Ab 572 53.5 
Anti-Scl70 Ab 572 53.5 
ANA 571 53.4 
ANCA 568 53.1 
Total protein (g/l) 567 53.0 
HCT 559 52.2 
Anti dsDNA Ab 553 51.7 
RHC mean BP (mmHg) 551 51.5 
RHC systolic BP (mmHg) 549 51.3 
Anti-cardiolipin Ab 548 51.2 
RHC diastolic BP (mmHg) 548 51.2 
KCO (% predicted) 544 50.8 
TSH (mu/l) 537 50.2 
CRP (mg/l) 527 49.3 
CT CTEPH 528 49.3 
CT fibrosis 519 48.5 
CT emphysema 517 48.3 
Urate unit 496 46.4 
Date of symptoms onset 496 46.4 
VA 496 46.4 
RHC HR (bpm) 495 46.3 
BNP unit 494 46.2 
NT-ProBNP unit 492 46.0 
Troponin unit 488 45.6 
CTPA report 483 45.1 
Date of autoantibody screen 474 44.3 
Corridor length (m) 471 44.0 
TLC 469 43.8 
TLC (% predicted) 456 42.6 
V/Q scan report 454 42.4 
Date of thyroid function tests 449 42.0 
QRS axis 442 41.3 
PE on V/Q scan 440 41.1 
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CI (L/min/m2) 436 40.7 
Date of inflammatory markers 430 40.2 
Date of cardiac blood tests 404 37.8 
VA (% predicted) 393 36.7 
AST (iu/l) 390 36.4 
Date of CTPA 390 36.4 
Date of vasodilator study 370 34.6 
Ferritin unit 366 34.2 
FT4 (pmol/l) 366 34.2 
Transferrin unit 364 34.0 
eGFR (ml/min) 358 33.5 
Vasodilator response 353 33.0 
Hepatitis B serology 352 32.9 
HIV serology 352 32.9 
ABG acidity measurement 349 32.6 
PaCO2 (kPa) 349 32.6 
PaO2 (kPa) 349 32.6 
pH 348 32.5 
Vasodilator used 345 32.2 
Iron (µmol/l) 338 31.6 
Date of V/Q scan 338 31.6 
COHORT ID 332 31.0 
TAPSE (cm) 321 30.0 
ABG supplemental O2 use 319 29.8 
RDW 303 28.3 
Ferritin (µg/l) 300 28.0 
JVP (cm) 288 26.9 
Vasodilator study supplemental oxygen used 285 26.6 
MRI report 266 24.9 
Date of serological assessment 263 24.6 
Vasodilator study mPAP (mmHg) 260 24.3 
Date of iron studies 251 23.5 
ABG date 248 23.2 
Ultrasound report 247 23.1 
Vasodilator study sPAP (mmHg) 241 22.5 
Vasodilator study dPAP (mmHg) 240 22.4 
US portal venous flow 239 22.3 
HRCT report 237 22.1 
Urate (mmol/l) 230 21.5 
Vasodilator study cardiac output method 1 227 21.2 
NT-ProBNP (ng/l) 221 20.7 
Date of MRI 221 20.7 
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Total cholesterol (mmol/l) 217 20.3 
LVEDP (mmHg) 208 19.4 
RA area (cm2) 204 19.1 
Vasodilator study CO (L/min) 204 19.1 
Date of HRCT 200 18.7 
LDH (iu/l) 187 17.5 
Iron binding capacity (µmol/l) 186 17.4 
Lung function supplemental oxygen used 179 16.7 
Vasodilator study systolic BP (mmHg) 178 16.6 
Vasodilator study diastolic BP (mmHg) 176 16.4 
MRI RVEF (%) 175 16.4 
Vasodilator study mean BP (mmHg) 173 16.2 
Vasodilator study SaO2 (%) 172 16.1 
MRI LVEF (%) 170 15.9 
MRI RV diastolic volume (ml) 166 15.5 
MRI RV systolic volume (ml) 165 15.4 
Troponin (µg/l) 164 15.3 
MRI LV diastolic volume (ml) 163 15.2 
MRI LV systolic volume (ml) 163 15.2 
Triglycerides (mmol/l) 162 15.1 
LA size (cm) 162 15.1 
Transferrin (g/l) 161 15.0 
OSS SaO2 (%) 154 14.4 
CO method 2 147 13.7 
CO value 2 (L/min) 147 13.7 
BNP (ng/l) 146 13.6 
Time of walk test 145 13.6 
Date of abdominal ultrasound 141 13.2 
HDL cholesterol (mmol/l) 140 13.1 
Vasodilator study PCWP (mmHg) 136 12.7 
MRI HR (bpm) 134 12.5 
Date of lipids 130 12.1 
Systemic mean BP (mmHg) 128 12.0 
Vasodilator study PVR (WU) 127 11.9 
Vasodilator study SvO2 (%) 120 11.2 
LDL cholesterol (mmol/l) 112 10.5 
Vasodilator study RAP (mmHg) 98 9.2 
Sleep study 94 8.8 
FEV1 (z score) 90 8.4 
CPET date 84 7.9 
CPET supplemental O2 use 84 7.9 
FVC (z score) 82 7.7 
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KCO (z score) 81 7.6 
TLC (z score) 80 7.5 
CPET resting SaO2 (%) 78 7.3 
CPET peak O2 pulse 77 7.2 
CPET peak RER 73 6.8 
CPET peak work (W) 73 6.8 
CPET height (m) 71 6.6 
CPET weight (kg) 71 6.6 
CPET peak Ventilation 70 6.5 
Examination amount of supplemental O2 use 64 6.0 
CPET resting systolic BP (mmHg) 62 5.8 
CPET resting diastolic BP (mmHg) 61 5.7 
Vasodilator study CI (L/min/m2) 61 5.7 
CPET FEV1 (% predicted) 60 5.6 
CPET VC (% predicted) 60 5.6 
CPET resting O2 pulse 58 5.4 
VA (z score) 58 5.4 
Vasodilator study amount of supplemental oxygen 
used 57 5.3 
CI value 2 (L/min/m2) 53 5.0 
RHC amount of supplemental oxygen used 51 4.8 
CPET PET CO2 peak 50 4.7 
CPET peak PETCO2 49 4.6 
CPET VE - VCO2 slope 45 4.2 
Vasodilator study cardiac output method 2 38 3.6 
Vasodilator study CO value 2 (L/min) 39 3.6 
CPET AT VO2 35 3.3 
CPET VCO2 at AT units 35 3.3 
CPET VO2 - WR slope 35 3.3 
ODI 35 3.3 
CPET OUES 31 2.9 
Walk test amount of supplemental O2 used 27 2.5 
ABG amount of supplemental O2 24 2.2 
hsCRP (mg/l) 22 2.1 
Vasodilator study LVEDP (mmHg) 22 2.1 
Lung function amount of supplemental oxygen used 23 2.1 
CPET EqCO2 at AT 20 1.9 
Time of CPET 11 1.0 
Vasodilator study CI value 2 (L/min/m2) 11 1.0 
CPET mean BP at rest 10 0.9 
Vasodilator used 2 3 0.3 
CPET VCO2 at nadir 2 0.2 
CPET supplemental O2 amount 2 0.2 
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6mwt – six minute walk test, Ab – antibody, ABG – arterial blood gas, ALP – alkaline 
phosphatase, ALT – alanine transferase, ANA – anti-nuclear antibody, ANCA - anti-
neutrophil cytoplasmic antibody, anti-ENA – anti-extractable nuclear antigen antibody, 
AST – aspartate transaminase, AT – anaerobic threshold, BMI – body mass index, BNP – 
bone natriuretic peptide, BP – blood pressure, BSA – body surface area, CI – cardiac 
index, CO – cardiac output, CO2 – carbon dioxide, CPET – cardiopulmonary exercise test, 
CRP – C-reactive protein, CT – computer tomography, CTEPH – chronic thromboembolic 
pulmonary hypertension, CTPA – computer tomography pulmonary angiography, dsDNA 
– double stranded DNA, ECG – electrocardiogram, EqCO2 – ventilatory equivalent for 
carbon dioxide, FEV1 – forced expiratory volume in 1 second, FT4 – free thyroxine, FVC 
– forced vital capacity, Hb – haemoglobin, HCT – haematocrit, HDL – high density 
lipoprotein, HR – heart rate, HRCT – high resolution computer tomography, hsCRP – high 
sensitivity C-reactive protein, dPAP – diastolic pulmonary artery pressure, eGFR – 
estimated glomerular filtration rate, JVP – jugular venous pressure, KCO – transfer 
coefficient for carbon monoxide, LA – left atrium, LV – left ventricle, LVEF – left 
ventricular ejection fraction, MRI – magnetic resonance imaging, NT-ProBNP – N 
terminal Pro brain natriuretic peptide, O2 – oxygen, ODI – oxygen desaturation index, 
OSS – overnight sleep study, OUES – oxygen utilisation efficiency slope, PCWP – 
pulmonary capillary wedge pressure, PE – pulmonary embolus, PET – end tidal partial 
pressure, PVR – pulmonary vascular resistance, RA – right atrium, RAP – right atrial 
pressure, RBBB – right bundle branch block, RDW – red blood cell distribution width, RER 
– respiratory exchange ratio, RHC – right heart catheterisation, RV – right ventricle, RVEF 
– right ventricular ejection fraction, SaO2 – peripheral arterial oxygen saturation, sPAP – 
systolic pulmonary artery pressure, SvO2 – mixed venous oxygen saturation, TAPSE – 
tricuspid annular plane systolic excursion, TLC – total lung capacity, TSH – thyroid 
stimulating hormone, US – ultrasound, VC – vital capacity, VCO2 – carbon dioxide output, 
VE/VCO2 – ventilatory equivalents for carbon dioxide, VO2 – oxygen uptake, WBC – white 
blood cells, WR – work rate 
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Appendix 12 
 
Phenotypic differences between patients recruited from different centres 
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n [%] 79 [10.5%] 8 [1.1%] 
233 
[30.9%] 54 [7.2%] 
114 
[15.1%] 53 [7.0%] 29 [3.9%] 
23 
[3.1%] 
116 
[15.4%] 
44 
[5.8%]  
WGS 
population: 
African / East-
Asian / 
European / 
South-Asian  
(n [%]) 
0 [0.0%] / 
0 [0.0%] / 
79 
[100.0%] 
/ 0 [0.0%] 
0 [0.0%] / 
0 [0.0%] / 
6 [75.0%] 
/ 2 
[25.0%] 
11 
[4.7%] / 
7 [3.0%] 
/ 188 
[80.7%] 
/ 27 
[11.6%] 
0 [0.0%] / 
0 [0.0%] / 
53 
[98.1%] / 
1 [1.9%] 
1 [0.9%] 
/ 0 
[0.0%] / 
107 
[93.9%] 
/ 6 
[5.3%] 
0 [0.0%] / 
1 [1.9%] / 
44 
[83.0%] / 
8 [15.1%] 
2 [6.9%] / 
0 [0.0%] / 
22 
[75.9%] / 
5 [17.2%] 
0 [0.0%] 
/ 1 
[4.3%] / 
22 
[95.7%] 
/ 0 
[0.0%] 
1 [0.9%] 
/ 0 
[0.0%] / 
109 
[94.0%] 
/ 6 
[5.2%] 
2 [4.5%] 
/ 3 
[6.8%] / 
38 
[86.4%] 
/ 1 
[2.3%] 
<0.001 
Age at diagnosis 
(years) 
52.3 
[41.1 - 
65.8] 
7.8 [5.3 - 
9.9] 
47.5 
[35.4 - 
65.2] 
59.1 
[41.1 - 
68.7] 
47.8 
[36.3 - 
62.2] 
42.9 
[33.1 - 
53.7] 
46.7 
[34.2 - 
56.9] 
62.0 
[47.9 - 
72.1] 
51.3 
[34.5 - 
64.6] 
45.3 
[29.0 - 
51.3] 
<0.001 
mPAP (mmHg) 
52.0 
[44.5 - 
59.0] 
29.5 
[27.5 - 
33.0] 
54.0 
[45.5 - 
62.0] 
48.0 
[39.0 - 
56.0] 
53.0 
[46.0 - 
60.0] 
53.0 
[42.5 - 
63.5] 
54.0 
[45.0 - 
64.0] 
57.0 
[49.5 - 
63.5] 
55.0 
[49.0 - 
64.0] 
50.0 
[43.0 - 
59.0] 
<0.001 
PCWP (mmHg) 8.0 [5.0 - 10.0] 
7.5 [7.0 - 
8.8] 
10.0 
[8.0 - 
13.0] 
8.0 [5.8 - 
10.2] 
10.0 
[8.0 - 
11.0] 
7.5 [6.0 - 
11.0] 
11.0 [9.0 
- 12.0] 
14.0 
[10.5 - 
15.0] 
10.0 
[8.0 - 
13.0] 
8.0 [7.0 
- 10.0] <0.001 
CO (L/min) 3.8 [3.0 - 4.7] 
3.1 [1.6 - 
3.4] 
3.7 [2.9 
- 4.8] 
4.0 [3.3 - 
4.7] 
3.5 [2.8 
- 4.5] 
3.9 [2.9 - 
5.1] 
4.2 [3.3 - 
5.7] 
3.9 [3.3 
- 4.5] 
4.0 [3.3 
- 5.1] 
4.6 [3.8 
- 6.0] 0.002 
CI (L/min/m2) 2.1 [1.8 - 2.5] 
3.0 [2.3 - 
3.7] 
2.0 [1.6 
- 2.6] 
2.1 [1.8 - 
2.6] 
2.0 [1.6 
- 2.4] 
2.0 [1.6 - 
2.8] 
2.4 [1.9 - 
2.8] 
2.0 [1.7 
- 2.4] 
2.2 [1.8 
- 2.8] 
2.4 [2.0 
- 3.2] 0.005 
Vasoresponder: 
(n [%]) 7 [25.9%] 0 [0.0%] 2 [3.6%] 2 [11.8%] 
7 
[38.9%] 0 [0.0%] 1 [5.9%] 0 [0.0%] 
11 
[21.6%] 2 [8.3%] 0.004 
Weight (kg) 
78.4 
[64.5 - 
94.4] 
21.6 
[18.5 - 
32.3] 
73.0 
[62.1 - 
86.8] 
75.0 
[62.5 - 
89.2] 
74.1 
[64.4 - 
84.0] 
77.5 
[61.2 - 
88.2] 
73.0 
[63.0 - 
84.0] 
87.0 
[77.7 - 
95.5] 
78.5 
[65.9 - 
90.6] 
72.0 
[63.0 - 
82.8] 
<0.001 
BMI 
28.7 
[23.6 - 
34.7] 
16.2 
[14.9 - 
17.8] 
27.6 
[23.9 - 
32.0] 
28.3 
[24.0 - 
32.6] 
27.1 
[23.7 - 
31.3] 
26.8 
[22.8 - 
33.1] 
27.1 
[22.1 - 
30.0] 
31.6 
[27.5 - 
34.6] 
27.9 
[25.2 - 
32.3] 
24.3 
[22.3 - 
28.7] 
<0.001 
ALP (iu) 
103.0 
[78.0 - 
178.0] 
162.5 
[159.0 - 
203.5] 
82.0 
[65.0 - 
107.0] 
88.5 
[77.2 - 
105.0] 
97.5 
[74.0 - 
127.5] 
69.5 
[57.5 - 
98.0] 
73.0 
[59.8 - 
90.0] 
83.0 
[69.0 - 
96.5] 
84.0 
[66.0 - 
104.0] 
81.0 
[62.5 - 
105.0] 
<0.001 
Albumin (g/l) 
43.0 
[39.0 - 
45.0] 
36.5 
[34.5 - 
37.0] 
39.0 
[36.0 - 
42.0] 
43.5 
[40.8 - 
45.0] 
40.0 
[37.8 - 
42.0] 
41.0 
[38.0 - 
44.0] 
44.0 
[42.0 - 
46.0] 
44.0 
[40.0 - 
45.5] 
43.0 
[40.0 - 
45.0] 
38.5 
[36.0 - 
41.8] 
<0.001 
Sodium 
(mmol/l) 
140.0 
[139.0 - 
142.0] 
141.0 
[139.5 - 
142.5] 
139.0 
[137.0 - 
141.0] 
140.0 
[138.0 - 
141.0] 
139.0 
[137.0 - 
141.0] 
138.0 
[136.0 - 
139.0] 
141.5 
[140.0 - 
143.0] 
138.0 
[137.5 - 
140.0] 
139.0 
[138.0 - 
141.0] 
140.0 
[138.0 - 
141.0] 
<0.001 
Creatinine 
(µmol/l) 
88.5 
[78.0 - 
106.0] 
36.0 
[35.5 - 
52.0] 
88.0 
[74.5 - 
104.5] 
95.0 
[79.0 - 
106.0] 
92.0 
[82.5 - 
106.5] 
80.0 
[70.0 - 
89.0] 
79.5 
[69.5 - 
107.0] 
91.0 
[69.5 - 
102.0] 
84.0 
[71.0 - 
98.2] 
87.0 
[72.0 - 
94.0] 
<0.001 
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Free T4 (pmol/l) 
17.5 
[14.0 - 
20.0] 
19.6 
[17.4 - 
21.0] 
15.1 
[13.3 - 
17.2] 
14.4 
[13.4 - 
17.2] 
16.3 
[15.8 - 
18.9] 
13.2 
[12.0 - 
14.3] 
15.8 
[14.2 - 
17.1] 
15.6 
[15.2 - 
16.0] 
16.7 
[14.7 - 
17.9] 
16.6 
[14.4 - 
18.7] 
<0.001 
Corridor length 
(m) 
30.0 
[30.0 - 
30.0] 
0.0 [0.0 - 
0.0] 
30.0 
[30.0 - 
30.0] 
30.0 
[30.0 - 
30.0] 
10.0 
[10.0 - 
10.0] 
15.0 
[10.0 - 
15.0] 
30.0 
[30.0 - 
30.0] 
20.0 
[20.0 - 
20.0] 
15.0 
[15.0 - 
15.0] 
50.0 
[30.0 - 
50.0] 
<0.001 
6mwt distance 
(m) 
320.0 
[181.0 - 
395.5] 
240.0 
[240.0 - 
240.0] 
280.0 
[120.0 - 
405.0] 
313.0 
[210.0 - 
372.8] 
343.0 
[242.5 - 
381.0] 
315.0 
[250.0 - 
400.0] 
352.0 
[299.0 - 
395.0] 
209.0 
[153.5 - 
377.0] 
320.0 
[180.0 - 
412.5] 
475.0 
[387.0 - 
553.0] 
<0.001 
Post walk SaO2 
(%) 
87.0 
[81.2 - 
94.0] 
97.0 
[97.0 - 
97.0] 
93.0 
[86.0 - 
97.0] 
89.0 
[85.0 - 
95.0] 
91.0 
[85.0 - 
95.0] 
92.0 
[86.8 - 
97.0] 
94.5 
[92.2 - 
96.8] 
92.0 
[84.2 - 
94.0] 
86.0 
[80.5 - 
90.0] 
93.0 
[88.5 - 
95.0] 
<0.001 
dPAP (mmHg) 
32.0 
[26.0 - 
36.0] 
16.5 
[13.5 - 
22.5] 
33.0 
[26.0 - 
40.0] 
28.0 
[22.0 - 
34.0] 
35.0 
[29.2 - 
40.0] 
35.0 
[28.0 - 
42.5] 
35.0 
[28.5 - 
46.0] 
38.0 
[34.0 - 
42.0] 
36.0 
[30.0 - 
41.0] 
33.0 
[27.5 - 
39.5] 
<0.001 
RAP (mmHg) 8.0 [5.0 - 10.0] 
5.0 [5.0 - 
6.0] 
10.0 
[6.0 - 
13.0] 
8.0 [4.8 - 
10.0] 
8.0 [6.0 
- 12.0] 
6.0 [4.0 - 
9.0] 
9.0 [7.0 - 
14.0] 
11.0 
[7.5 - 
13.5] 
10.0 
[7.0 - 
14.0] 
7.5 [5.0 
- 10.0] <0.001 
FVC (% 
predicted) 
97.0 
[83.0 - 
107.0] 
56.0 
[56.0 - 
56.0] 
89.0 
[81.0 - 
101.0] 
92.0 
[77.8 - 
104.0] 
100.0 
[86.0 - 
109.0] 
93.2 
[74.5 - 
102.6] 
98.3 
[85.0 - 
114.2] 
101.0 
[92.5 - 
109.0] 
98.3 
[86.5 - 
110.8] 
102.0 
[97.0 - 
114.0] 
<0.001 
Syncope at 
onset: yes (n 
[%]) 
28 
[38.4%] 7 [87.5%] 
65 
[38.2%] 6 [11.3%] 
27 
[25.2%] 
15 
[30.6%] 7 [25.0%] 
5 
[21.7%] 
24 
[21.6%] 
5 
[27.8%] <0.001 
RBBB: yes (n 
[%]) 
15 
[24.6%] 0 [0.0%] 
53 
[81.5%] 7 [18.9%] 
10 
[25.6%] 9 [32.1%] 4 [22.2%] 2 [8.7%] 
11 
[22.9%] 2 [5.7%] <0.001 
Ethnicity: Other 
(n [%]) 0 [0.0%] 1 [12.5%] 
67 
[28.9%] 1 [1.9%] 9 [7.9%] 
12 
[22.6%] 9 [31.0%] 1 [4.3%] 7 [6.1%] 
23 
[53.5%] <0.001 
Height (cm) 
163.0 
[156.6 - 
171.8] 
121.2 
[107.8 - 
135.8] 
165.0 
[159.0 - 
171.0] 
162.5 
[155.8 - 
168.0] 
163.0 
[158.0 - 
170.8] 
164.0 
[162.0 - 
171.0] 
165.0 
[158.0 - 
172.0] 
163.0 
[156.5 - 
173.0] 
165.0 
[160.0 - 
172.0] 
169.0 
[164.0 - 
174.5] 
0.001 
Vasodilator 
study CO 
3.8 [2.9 - 
4.7] 
3.1 [2.4 - 
3.7] 
4.6 [3.2 
- 5.3] 
4.6 [4.2 - 
4.8] 
4.7 [3.5 
- 5.5] 
4.6 [3.0 - 
5.3] 
5.5 [5.0 - 
6.4] 
7.3 [7.0 
- 7.9] 
4.9 [4.1 
- 5.5] 
5.2 [3.9 
- 6.5] 0.001 
FVC (L) 3.0 [2.5 - 3.6] 
1.9 [1.9 - 
1.9] 
2.9 [2.3 
- 3.6] 
2.8 [2.3 - 
3.6] 
3.0 [2.6 
- 4.1] 
3.1 [2.7 - 
4.0] 
3.1 [2.7 - 
3.9] 
3.0 [2.2 
- 3.7] 
3.2 [2.7 
- 4.0] 
3.9 [3.4 
- 4.5] 0.001 
Systemic SBP 
(mmHg) 
121.0 
[110.0 - 
130.0] 
93.5 
[90.8 - 
111.2] 
126.0 
[115.0 - 
140.0] 
118.0 
[110.0 - 
125.0] 
120.0 
[110.0 - 
132.5] 
117.0 
[110.0 - 
130.0] 
118.0 
[110.0 - 
131.0] 
125.0 
[110.5 - 
147.0] 
124.5 
[112.0 - 
135.0] 
114.0 
[110.0 - 
120.0] 
0.002 
MRI RV diastolic 
volume (ml) 
191.0 
[191.0 - 
191.0] 
98.5 
[82.8 - 
114.2] 
203.5 
[159.8 - 
243.5] 
223.0 
[210.5 - 
235.5] 
201.0 
[190.0 - 
243.0] 
190.0 
[161.0 - 
214.0] 
197.0 
[121.0 - 
262.0] 
119.5 
[102.2 - 
152.2] 
146.7 
[122.8 - 
197.9] 
142.0 
[120.0 - 
160.0] 
0.002 
sPAP (mmHg) 
87.0 
[72.0 - 
102.0] 
46.5 
[43.2 - 
52.8] 
85.0 
[71.0 - 
99.0] 
81.0 
[68.0 - 
92.0] 
88.0 
[74.0 - 
97.8] 
79.0 
[64.5 - 
101.0] 
91.0 
[72.0 - 
103.5] 
91.0 
[71.5 - 
100.5] 
87.0 
[76.5 - 
105.0] 
78.0 
[69.0 - 
95.0] 
0.003 
Vasodilator 
study SaO2 
98.0 
[97.0 - 
99.0] 
99.2 
[99.1 - 
99.6] 
98.0 
[93.8 - 
99.0] 
99.0 
[97.8 - 
100.0] 
96.0 
[94.0 - 
98.0] 
94.0 
[89.0 - 
98.0] 
94.5 
[92.2 - 
95.8] 
95.0 
[92.5 - 
96.8] 
97.0 
[94.5 - 
99.0] 
97.5 
[95.5 - 
99.0] 
0.003 
Dominant R 
wave: yes (n 
[%]) 
30 
[48.4%] 1 [33.3%] 
86 
[72.3%] 
15 
[40.5%] 
11 
[40.7%] 7 [33.3%] 
10 
[45.5%] 
13 
[56.5%] 
15 
[39.5%] 
20 
[57.1%] 0.004 
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WBC (x109/l) 8.0 [6.8 - 9.5] 
8.5 [6.9 - 
9.8] 
8.1 [6.6 
- 9.6] 
8.9 [6.6 - 
9.6] 
7.9 [6.6 
- 9.3] 
9.5 [8.1 - 
11.2] 
8.8 [7.4 - 
11.1] 
9.2 [8.2 
- 11.0] 
8.0 [6.9 
- 9.8] 
7.9 [6.0 
- 9.6] 0.005 
Bilirubin 
(µmol/l) 
14.0 [9.2 
- 22.8] 
13.0 
[11.0 - 
18.0] 
17.0 
[11.0 - 
26.0] 
11.0 [8.0 
- 17.0] 
17.0 
[11.0 - 
24.2] 
16.0 
[10.5 - 
20.0] 
15.0 [9.0 
- 26.2] 
12.0 
[8.0 - 
19.0] 
16.0 
[10.0 - 
22.0] 
12.0 
[9.0 - 
16.5] 
0.005 
RHC SaO2 (%) 
96.0 
[93.0 - 
97.0] 
99.0 
[99.0 - 
99.0] 
94.0 
[91.0 - 
97.0] 
95.0 
[92.0 - 
96.0] 
95.0 
[92.0 - 
97.0] 
94.5 
[90.8 - 
96.0] 
96.0 
[93.0 - 
97.0] 
92.0 
[90.2 - 
95.5] 
95.0 
[93.0 - 
97.0] 
96.0 
[94.0 - 
97.0] 
0.005 
FEV1 (L) 2.2 [1.9 - 2.8] 
1.6 [1.6 - 
1.6] 
2.2 [1.8 
- 2.7] 
2.1 [1.5 - 
2.6] 
2.4 [1.8 
- 3.1] 
2.5 [1.7 - 
3.2] 
2.4 [1.9 - 
2.8] 
2.1 [1.8 
- 2.8] 
2.6 [1.9 
- 3.0] 
2.9 [2.4 
- 3.5] 0.005 
US portal 
venous flow: 
abnormal (n [%]) 
2 [40.0%] 0 [0.0%] 9 [5.5%] 1 [100.0%] 0 [0.0%] 1 [4.3%] 1 [8.3%] 0 [0.0%] 0 [0.0%] 0 [0.0%] 0.006 
RHC DBP 
(mmHg) 
76.0 
[71.0 - 
85.8] 
58.5 
[53.5 - 
61.2] 
74.0 
[66.2 - 
83.8] 
74.5 
[66.0 - 
81.5] 
80.0 
[71.0 - 
88.0] 
75.0 
[69.5 - 
81.5] 
83.0 
[71.0 - 
88.0] 
79.0 
[73.5 - 
84.0] 
78.0 
[71.0 - 
86.0] 
82.0 
[69.0 - 
89.0] 
0.009 
ALT (iu/l) 
21.0 
[16.0 - 
29.0] 
31.0 
[23.0 - 
38.0] 
23.0 
[17.0 - 
35.0] 
23.5 
[17.0 - 
31.2] 
28.0 
[22.0 - 
38.0] 
23.0 
[16.5 - 
33.0] 
28.0 
[21.8 - 
36.2] 
25.0 
[20.5 - 
38.0] 
22.0 
[18.5 - 
30.5] 
26.0 
[20.0 - 
40.0] 
0.010 
MRI RVEF (%) 
39.0 
[34.5 - 
44.4] 
58.0 
[58.0 - 
58.0] 
35.0 
[25.0 - 
43.0] 
34.5 
[28.8 - 
40.2] 
36.0 
[20.0 - 
36.8] 
45.0 
[40.0 - 
51.0] 
33.0 
[27.9 - 
38.5] 
46.0 
[44.5 - 
47.0] 
37.0 
[24.5 - 
42.0] 
40.0 
[33.0 - 
50.0] 
0.012 
BSA 1.9 [1.7 - 2.0] 
0.8 [0.7 - 
1.2] 
1.9 [1.7 
- 2.0] 
1.8 [1.6 - 
2.0] 
1.8 [1.7 
- 2.0] 
1.8 [1.7 - 
2.0] 
1.8 [1.7 - 
1.9] 
1.9 [1.8 
- 2.1] 
1.9 [1.7 
- 2.0] 
1.8 [1.7 
- 1.9] 0.014 
RV on 
echocardiogram: 
abnormal (n [%]) 
70 
[95.9%] 
8 
[100.0%] 
218 
[97.3%] 
47 
[97.9%] 
96 
[94.1%] 
46 
[93.9%] 
21 
[77.8%] 
21 
[91.3%] 
74 
[90.2%] 
18 
[94.7%] 0.015 
FEV1 (% 
predicted) 
87.0 
[74.0 - 
96.0] 
52.0 
[52.0 - 
52.0] 
82.1 
[72.0 - 
93.0] 
80.5 
[70.2 - 
97.0] 
88.0 
[77.0 - 
100.0] 
81.2 
[67.8 - 
90.8] 
80.3 
[75.4 - 
98.5] 
90.0 
[80.5 - 
97.5] 
87.5 
[77.8 - 
98.0] 
96.0 
[86.0 - 
104.0] 
0.017 
Heart rhythm: 
sinus / atrial 
fibrillation / 
atrial flutter / 
other (n [%]) 
61 
[95.3%] / 
1 [1.6%] / 
0 [0.0%] / 
2 [3.1%] 
5 
[100.0%] 
/ 0 [0.0%] 
/ 0 [0.0%] 
/ 0 [0.0%] 
211 
[97.7%] 
/ 5 
[2.3%] / 
0 [0.0%] 
/ 0 
[0.0%] 
38 
[100.0%] 
/ 0 [0.0%] 
/ 0 [0.0%] 
/ 0 [0.0%] 
44 
[95.7%] 
/ 2 
[4.3%] / 
0 [0.0%] 
/ 0 
[0.0%] 
39 
[100.0%] 
/ 0 [0.0%] 
/ 0 [0.0%] 
/ 0 [0.0%] 
24 
[100.0%] 
/ 0 [0.0%] 
/ 0 [0.0%] 
/ 0 [0.0%] 
20 
[87.0%] 
/ 1 
[4.3%] / 
2 [8.7%] 
/ 0 
[0.0%] 
75 
[97.4%] 
/ 1 
[1.3%] / 
1 [1.3%] 
/ 0 
[0.0%] 
37 
[97.4%] 
/ 0 
[0.0%] / 
1 [2.6%] 
/ 0 
[0.0%] 
0.017 
Resting SaO2 (%) 
94.5 
[92.0 - 
97.0] 
98.0 
[98.0 - 
99.0] 
95.0 
[91.0 - 
97.0] 
94.0 
[92.0 - 
96.0] 
96.0 
[92.0 - 
97.0] 
95.0 
[93.0 - 
97.0] 
95.0 
[92.2 - 
97.0] 
95.0 
[91.5 - 
97.0] 
96.0 
[93.0 - 
98.0] 
97.0 
[95.0 - 
98.0] 
0.028 
SvO2 (%) 
62.9 
[58.0 - 
68.8] 
69.3 
[64.2 - 
73.2] 
64.0 
[58.0 - 
70.8] 
65.0 
[60.0 - 
71.0] 
66.5 
[58.8 - 
71.8] 
64.7 
[59.0 - 
72.0] 
66.0 
[60.5 - 
70.0] 
61.9 
[56.5 - 
65.5] 
62.4 
[55.8 - 
67.9] 
67.5 
[59.0 - 
72.0] 
0.028 
Clubbing: yes (n 
[%]) 4 [21.1%] 0 [0.0%] 
7 
[11.7%] 1 [2.0%] 8 [7.9%] 0 [0.0%] 2 [7.4%] 0 [0.0%] 1 [1.7%] 0 [0.0%] 0.028 
Ankle swelling: 
yes (n [%]) 
33 
[45.8%] 0 [0.0%] 
66 
[36.9%] 
16 
[32.0%] 
32 
[30.5%] 9 [22.0%] 2 [7.1%] 
9 
[39.1%] 
32 
[29.1%] 
8 
[22.9%] 0.028 
Raynauds: yes (n 
[%]) 
11 
[22.9%] 0 [0.0%] 
12 
[9.1%] 3 [5.9%] 6 [5.6%] 1 [2.3%] 1 [3.6%] 1 [4.3%] 7 [6.1%] 1 [7.1%] 0.028 
Potassium 
(mmol/l) 
4.3 [4.0 - 
4.6] 
3.9 [3.9 - 
4.1] 
4.2 [4.0 
- 4.4] 
4.3 [4.1 - 
4.6] 
4.2 [3.9 
- 4.5] 
4.2 [3.9 - 
4.4] 
4.4 [4.3 - 
4.7] 
4.2 [3.9 
- 4.4] 
4.2 [4.0 
- 4.5] 
4.2 [3.9 
- 4.3] 0.031 
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Systemic DBP 
(mmHg) 
74.0 
[66.5 - 
81.0] 
57.5 
[52.5 - 
62.5] 
78.5 
[68.0 - 
86.0] 
72.0 
[65.0 - 
80.0] 
76.0 
[70.0 - 
83.0] 
74.0 
[66.0 - 
80.0] 
78.0 
[70.0 - 
85.0] 
82.0 
[71.0 - 
87.0] 
78.5 
[68.0 - 
85.0] 
80.0 
[73.5 - 
83.8] 
0.031 
Infection at 
onset: yes (n 
[%]) 
7 [33.3%] 0 [0.0%] 17 [17.5%] 6 [12.0%] 6 [5.6%] 3 [6.7%] 2 [7.1%] 2 [9.1%] 
6 
[12.2%] 1 [6.2%] 0.031 
Pre-walk SaO2 
(%) 
94.5 
[91.0 - 
97.0] 
95.0 
[95.0 - 
95.0] 
96.0 
[93.0 - 
97.0] 
94.0 
[91.0 - 
96.8] 
96.0 
[93.0 - 
98.0] 
97.0 
[94.5 - 
98.0] 
96.5 
[94.0 - 
97.0] 
96.0 
[95.0 - 
97.0] 
95.0 
[92.0 - 
97.0] 
97.0 
[93.2 - 
98.0] 
0.032 
ANA: positive (n 
[%]) 
10 
[18.9%] 0 [0.0%] 
21 
[11.9%] 6 [15.0%] 3 [4.3%] 1 [5.0%] 3 [13.6%] 
4 
[18.2%] 
17 
[22.4%] 
8 
[30.8%] 0.039 
CRP (mg/l) 5.5 [3.0 - 11.0] 
5.0 [5.0 - 
6.0] 
4.0 [2.0 
- 8.0] 
5.0 [5.0 - 
6.5] 
5.0 [2.0 
- 7.2] 
5.0 [2.0 - 
9.0] 
3.0 [1.0 - 
4.0] 
9.0 [3.0 
- 11.0] 
3.9 [1.9 
- 8.6] 
5.3 [3.6 
- 6.7] 0.040 
TAPSE (cm) 1.4 [1.2 - 1.9] 
1.9 [1.6 - 
2.1] 
1.5 [1.2 
- 1.9] 
1.6 [1.4 - 
2.0] 
1.6 [1.3 
- 1.9] 
1.6 [1.3 - 
1.7] 
2.0 [1.8 - 
2.2] 
1.6 [1.3 
- 2.0] 
1.4 [1.2 
- 1.8] 
1.5 [1.2 
- 1.8] 0.041 
mPAP – mean pulmonary artery pressure, PCWP – pulmonary capillary wedge pressure, CO 
– cardiac output, CI – cardiac index, BMI – body mass index, ALP – alkaline phosphatase, 
6mwt – six minute walk test, dPAP – diastolic pulmonary artery pressure, RAP – right atrial 
pressure, FVC – forced vital capacity, RBBB – right bundle branch block, SBP – systolic blood 
pressure, RV – right ventricle, sPAP – systolic pulmonary artery pressure, WBC – white 
blood cells, RHC – right heart catheterisation, FEV1 – forced expiratory volume in 1 second, 
US – ultrasound, DBP – diastolic blood pressure, ALT – alanine transaminase, MRI – 
magnetic resonance imaging, RVEF – right ventricular ejection fraction, BSA – body surface 
area, SvO2 – mixed venous oxygen saturation, ANA – anti-nuclear antibodies, CRP – C 
reactive protein, TAPSE – tricuspid annular plane systolic excursion. Data presented as 
median [IQR] unless stated. Kruskal-Wallis test used to assess continuous variables, Fisher’s 
exact test used to assess categorical variables, Cochran–Armitage test used to assess 
ordinal variables. 
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Appendix 13 
Ethnicity codes adapted from the NHS data dictionary: 
 
White 
A British 
B Irish 
C Any other White background 
  
Mixed 
D White and Black Caribbean 
E White and Black African 
F White and Asian 
G Any other mixed background 
  
Asian or Asian British 
H Indian 
J Pakistani 
K Bangladeshi 
L Any other Asian background 
  
Black or Black British 
M Caribbean 
N African 
P Any other Black background 
  
Other Ethnic Groups 
R Chinese 
S Any other ethnic group 
  
Z Not stated 
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Appendix 14 
 
Variables of prognostic significance in univariate Cox proportional hazards models 
Variable Categorical group 
Number 
of 
patients 
Number 
of 
events 
Hazard 
ratio 
Confidence 
interval 
Corrected 
p 
Left 
truncated 
analysis: 
corrected 
p 
Age at 
diagnosis 
 655 155 1.049 1.038 - 1.060 <0.001 <0.001 
PaO2  231 57 0.811 0.727 - 0.903 0.025  
Red cell 
distribution 
width 
 200 46 1.216 1.102 - 1.341 0.015 0.041 
WBC  487 118 1.137 1.059 - 1.221 0.068  
Albumin  465 117 0.938 0.905 - 0.973 0.079  
Urea  482 118 1.141 1.098 - 1.187 <0.001 0.002 
Estimated 
GFR 
 250 61 0.975 0.962 - 0.988 0.037  
SaO2 at rest  449 110 0.926 0.900 - 0.952 <0.001 <0.001 
SaO2 pre 
walk test 
 437 100 0.914 0.885 - 0.944 <0.001 <0.001 
SaO2 post 
walk test 
 394 93 0.960 0.940 - 0.981 0.036 0.034 
Functional 
class 
 621 149 1.743 1.345 - 2.258 0.005  
RAP  577 135 1.065 1.035 - 1.096 0.003  
SaO2 during 
RHC 
 439 93 0.908 0.880 - 0.937 <0.001 0.002 
SvO2  432 95 0.932 0.912 - 0.953 <0.001  
KCO  377 81 0.075 0.040 - 0.142 <0.001 <0.001 
KCO % 
predicted 
 366 84 0.956 0.946 - 0.967 <0.001 <0.001 
KCO z score  53 13 0.272 0.135 - 0.548 0.043  
6mwt 
distance 
 203 43 0.996 0.994 - 0.998 0.029 0.002 
Gender Male 655 155 1.919 1.398 - 2.634 0.010 0.029 
Ascites Present 368 73 6.465 2.943 - 14.198 <0.001  
RBBB Present 256 55 3.025 1.769 - 5.170 0.008  
Incident / 
Prevalent 
Prevalent 
group 655 155 0.367 0.234 - 0.576 0.001  
Age group Young group 655 155 0.283 0.201 - 0.397 <0.001  
Rhythm AF 408 97 4.793 2.085 - 11.016 0.035  
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AF – atrial fibrillation, GFR – glomerular filtration rate, KCO – transfer coefficient for carbon 
monoxide, PaO2 – Partial pressure of oxygen in arterial blood, RAP – right atrial pressure, RBBB – right 
bundle branch block, SaO2 – peripheral arterial oxygen saturation, WBC – white blood cells. Italic – 
significant in left truncated analysis. 
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Appendix 15 
 
Phenotypic differences between male and female patients with idiopathic PAH 
 Female Male Corrected p 
n [%] 500 [68.6%] 229 [31.4%]  
WGS population:  
African / East-Asian / 
European / South-Asian (n 
[%]) 
17 [3.4%] / 12 [2.4%] / 
439 [87.8%] /  
32 [6.4%] 
5 [2.2%] / 0 [0.0%] 
/ 210 [91.7%] /  
14 [6.1%] 
0.190 
Gender: female (n [%]) 500 [100.0%] 0 [0.0%] <0.001 
Age at diagnosis (years) 48.8 [34.7 - 62.0] 59.5 [42.3 - 68.5] <0.001 
mPAP (mmHg) 53.0 [44.0 - 62.0] 49.0 [41.0 - 56.0] 0.010 
PCWP (mmHg) 9.0 [7.0 - 11.0] 10.0 [7.0 - 12.0] 0.672 
CO (L/min) 3.9 [3.2 - 4.9] 4.4 [3.5 - 5.7] <0.001 
CI (L/min/m2) 2.2 [1.8 - 2.7] 2.1 [1.8 - 2.7] 0.952 
PVR (WU) 11.1 [7.4 - 14.8] 8.5 [6.3 - 12.5] <0.001 
Vasoresponder: (n [%]) 22 [18.8%] 8 [17.8%] 1.000 
Functional class: 1 / 2 / 3 / 4  
(n [%]) 
8 [1.9%] / 91 [21.8%] / 
271 [64.8%] /  
48 [11.5%] 
7 [3.4%] / 46 
[22.5%] / 131 
[64.2%] /  
20 [9.8%] 
0.540 
6mwt distance (m) 305.0 [153.0 - 396.8] 325.0 [212.2 - 426.8] 0.382 
Height (cm) 162.0 [157.0 - 166.0] 174.0 [167.5 - 179.0] <0.001 
Weight (kg) 71.4 [61.0 - 85.2] 84.0 [73.0 - 95.5] <0.001 
BSA 1.8 [1.6 - 1.9] 2.0 [1.9 - 2.1] <0.001 
Platelets (x109/l) 242.0 [198.5 - 294.0] 197.0 [169.0 - 242.0] <0.001 
HCT 0.4 [0.4 - 0.5] 0.5 [0.4 - 0.5] <0.001 
Hb (g/l) 147.5 [134.0 - 159.0] 159.0 [146.0 - 169.0] <0.001 
Ferritin (µg/l) 64.0 [28.0 - 109.0] 121.0 [59.5 - 243.5] <0.001 
Urea (mmol/l) 5.4 [4.2 - 6.9] 6.8 [5.2 - 9.4] <0.001 
Creatinine (µmol/l) 81.0 [70.0 - 95.0] 104.0 [86.0 - 123.0] <0.001 
MRI LV diastolic volume (ml) 80.0 [66.6 - 105.0] 101.0 [91.0 - 143.0] <0.001 
FEV1 (L) 2.0 [1.6 - 2.5] 2.7 [2.2 - 3.2] <0.001 
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FVC (L) 2.8 [2.2 - 3.3] 3.9 [3.2 - 4.5] <0.001 
TLC (L) 4.6 [4.0 - 5.1] 6.2 [5.5 - 6.7] <0.001 
KCO (mmol/min/kPa/l) 1.2 [0.8 - 1.4] 0.9 [0.6 - 1.3] <0.001 
VA (L) 4.0 [3.4 - 4.6] 5.5 [5.0 - 6.3] <0.001 
Coronary artery disease:  
Yes (n [%]) 16 [4.4%] 32 [19.4%] <0.001 
Post walk SaO2 (%) 93.0 [86.0 - 96.0] 88.0 [82.0 - 94.0] 0.004 
MRI LV systolic volume (ml) 28.2 [20.0 - 43.2] 40.5 [30.8 - 68.9] 0.004 
Potassium (mmol/l) 4.2 [3.9 - 4.4] 4.3 [4.1 - 4.6] 0.006 
Resting SaO2 (%) 96.0 [92.0 - 98.0] 94.0 [91.0 - 97.0] 0.008 
Bilirubin (µmol/l) 14.0 [9.0 - 22.0] 15.5 [12.0 - 23.0] 0.011 
Transferrin (g/l) 3.0 [2.6 - 3.4] 2.5 [2.2 - 3.0] 0.014 
Pre walk SaO2 (%) 96.0 [93.0 - 98.0] 95.0 [90.2 - 97.0] 0.014 
CT emphysema: none / 
minimal / mild / moderate / 
severe (n [%]) 
225 [94.5%] / 3 [1.3%] 
/ 7 [2.9%] / 3 [1.3%] / 
0 [0.0%] 
98 [83.1%] / 6 
[5.1%] / 5 [4.2%] / 
8 [6.8%] / 1 [0.8%] 
0.014 
CPET height (m) 164.5 [157.0 - 170.0] 175.5 [167.0 - 178.2] 0.015 
LA size (cm) 3.5 [2.9 - 3.8] 3.9 [3.4 - 4.1] 0.017 
Obesity: Yes (n [%]) 10 [2.8%] 15 [9.1%] 0.017 
sPAP (mmHg) 86.0 [71.0 - 100.0] 79.0 [68.0 - 93.0] 0.018 
RHC SaO2 (%) 95.0 [92.0 - 97.0] 94.0 [91.0 - 96.0] 0.018 
Total cholesterol (mmol/l) 4.7 [3.9 - 5.5] 4.2 [3.5 - 4.8] 0.024 
CPET Peak PET CO2 3.1 [2.6 - 3.6] 2.0 [1.8 - 2.5] 0.025 
PaO2 (kPa) 9.3 [7.5 - 11.1] 7.9 [7.1 - 9.8] 0.030 
TLC (% predicted) 97.0 [86.0 - 104.0] 91.0 [83.0 - 99.0] 0.032 
RHC HR (bpm) 79.0 [70.0 - 90.0] 74.0 [65.0 - 86.0] 0.035 
CT fibrosis: none / minimal / 
mild / moderate / severe (n 
[%]) 
231 [96.2%] / 7 [2.9%] 
/ 2 [0.8%] / 0 [0.0%] / 
0 [0.0%] 
105 [89.0%] / 5 
[4.2%] / 6 [5.1%] / 
1 [0.8%] / 1 [0.8%] 
0.049 
6mwt – six minute walk test, BSA – body surface area, CI – cardiac index, CO – cardiac 
output, CPET – cardiopulmonary exercise test, CT – computer tomography, FEV1 – forced 
expiratory volume in 1 second, FVC – forced vital capacity, Hb – haemoglobin, HCT – 
haematocrit, HR – heart rate, KCO – transfer coefficient for carbon monoxide, LA – left 
atrium, LV – left ventricle, WGS – whole genome sequencing, mPAP – mean pulmonary 
artery pressure, MRI – magnetic resonance imaging, PCWP – pulmonary capillary wedge 
pressure, PET CO2 – partial pressure of end tidal carbon dioxide, PVR – pulmonary vascular 
resistance, RHC – right heart catheterisation, sPAP – systolic pulmonary artery pressure, 
TLC – total lung capacity, VA – alveolar volume. Data presented as median [IQR] unless 
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stated. Wilcoxon rank-sum test used to assess continuous variables, Fisher’s exact test used 
to assess categorical variables, Cochran–Armitage test used to assess ordinal variables. 
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Phenotypic differences between young and old patients with idiopathic PAH 
 Young Old Corrected p 
n [%] 363 [50.0%] 363 [50.0%]  
WGS population: 
African / East-Asian 
/ European / South-
Asian (n [%]) 
10 [2.8%] /  
10 [2.8%] / 310 [85.4%] 
/ 33 [9.1%] 
12 [3.3%] /  
2 [0.6%] / 336 [92.6%] / 
13 [3.6%] 
0.004 
Gender: female  
(n [%]) 276 [76.0%] 221 [60.9%] <0.001 
Age at diagnosis 
(years) 38.1 [28.5 - 44.8] 65.7 [58.6 - 71.7] <0.001 
mPAP (mmHg) 54.0 [46.0 - 63.0] 49.0 [41.0 - 57.5] <0.001 
PCWP (mmHg) 9.0 [6.0 - 11.0] 10.0 [7.8 - 12.0] <0.001 
CI (L/min/m2) 2.3 [1.9 - 2.9] 2.1 [1.7 - 2.6] 0.006 
PVR (WU) 10.7 [7.0 - 15.3] 10.1 [7.0 - 13.4] 0.055 
Vasoresponder: 
(n [%]) 24 [24.2%] 6 [9.5%] 0.059 
Functional class:  
1 / 2 / 3 / 4 (n [%]) 
12 [3.8%] / 95 [30.2%] / 
173 [54.9%] / 35 [11.1%] 
3 [1.0%] / 42 [13.7%] / 
229 [74.8%] / 32 [10.5%] <0.001 
6mwt distance (m) 380.0 [300.0 - 438.0] 217.5 [96.0 - 330.0] <0.001 
PaO2 (kPa) 9.4 [7.9 - 11.6] 8.3 [7.0 - 9.8] <0.001 
BMI 26.4 [22.1 - 31.2] 28.7 [25.2 - 32.8] <0.001 
Urate (mmol/l) 0.4 [0.3 - 0.4] 0.5 [0.4 - 0.6] <0.001 
ALP (iu) 78.0 [65.0 - 104.0] 93.0 [76.0 - 117.5] <0.001 
Urea (mmol/l) 4.8 [3.9 - 5.8] 6.9 [5.4 - 9.3] <0.001 
Creatinine (µmol/l) 79.0 [69.0 - 94.0] 95.0 [80.0 - 113.0] <0.001 
eGFR (ml/min) 79.0 [67.0 - 89.2] 58.2 [45.5 - 70.8] <0.001 
Resting SaO2 (%) 97.0 [95.0 - 98.0] 93.0 [90.2 - 96.8] <0.001 
Systemic SBP 
(mmHg) 118.0 [110.0 - 130.0] 129.5 [115.0 - 142.8] <0.001 
Pre walk SaO2 (%) 97.0 [95.0 - 98.0] 94.0 [90.0 - 96.0] <0.001 
Post walk SaO2 (%) 94.0 [88.0 - 97.0] 88.0 [82.0 - 93.0] <0.001 
dPAP (mmHg) 35.0 [29.0 - 41.2] 30.0 [24.0 - 36.0] <0.001 
SvO2 (%) 67.8 [61.6 - 72.8] 63.5 [58.0 - 69.5] <0.001 
FEV1 (L) 2.6 [2.1 - 3.1] 2.0 [1.6 - 2.5] <0.001 
FVC (L) 3.3 [2.8 - 3.9] 2.8 [2.1 - 3.5] <0.001 
KCO 
(mmol/min/kPa/l) 1.4 [1.2 - 1.6] 0.8 [0.6 - 1.1] <0.001 
 280 
KCO (% predicted) 79.0 [69.0 - 91.0] 55.8 [40.0 - 75.0] <0.001 
Syncope at onset: 
yes (n [%]) 80 [34.9%] 42 [18.3%] <0.001 
Lung function 
pattern:  
Normal / 
Obstructive / 
Restrictive  
(n [%]) 
126 [66.0%] / 24 [12.6%] 
/ 41 [21.5%] 
100 [42.7%] / 102 
[43.6%] / 32 [13.7%] <0.001 
Diabetes mellitus: 
Yes (n [%]) 9 [3.5%] 41 [15.5%] <0.001 
Coronary artery 
disease:  
Yes (n [%]) 
1 [0.4%] 47 [17.8%] <0.001 
Systemic 
hypertension:  
Yes (n [%]) 
5 [1.9%] 31 [11.7%] <0.001 
Hyperlipidaemia: 
Yes (n [%]) 2 [0.8%] 28 [10.6%] <0.001 
Congenital heart 
disease:  
Yes (n [%]) 
26 [10.0%] 6 [2.3%] <0.001 
COPD or ILD:  
Yes (n [%]) 5 [1.9%] 41 [15.5%] <0.001 
Red cell distribution 
width 13.9 [12.9 - 15.5] 14.7 [13.9 - 16.6] 0.002 
Alveolar volume  
(% predicted) 89.5 [82.0 - 100.0] 85.0 [77.0 - 93.2] 0.004 
Ankle swelling:  
Yes (n [%]) 58 [25.2%] 93 [40.4%] 0.004 
CT emphysema:  
none / minimal / 
mild / moderate / 
severe (n [%]) 
157 [96.9%] / 3 [1.9%] / 
0 [0.0%] / 2 [1.2%] / 0 
[0.0%] 
166 [85.6%] / 6 [3.1%] / 
12 [6.2%] / 9 [4.6%] / 1 
[0.5%] 
0.004 
FVC (% predicted) 92.0 [80.0 - 103.0] 98.0 [84.8 - 111.0] 0.005 
NT-ProBNP (ng/l) 567.6 [140.9 - 1463.0] 1564.5 [359.7 - 3181.8] 0.006 
HR (bpm) 80.0 [72.0 - 93.0] 80.0 [70.0 - 86.0] 0.006 
Weight (kg) 73.0 [59.7 - 88.0] 78.8 [67.5 - 90.5] 0.007 
Dominant R wave: 
Yes (n [%]) 80 [61.1%] 59 [41.5%] 0.007 
CT fibrosis:  
none / minimal / 
mild / moderate / 
severe  
(n [%]) 
160 [98.2%] / 2 [1.2%] / 
0 [0.0%] / 1 [0.6%] / 0 
[0.0%] 
176 [90.3%] / 10 [5.1%] 
/ 8 [4.1%] / 0 [0.0%] / 1 
[0.5%] 
0.007 
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RA area (cm2) 20.1 [16.0 - 24.6] 23.4 [19.9 - 30.0] 0.009 
Ascites:  
Yes (n [%]) 1 [0.5%] 10 [5.5%] 0.016 
ANCA:  
Positive (n [%]) 4 [4.2%] 18 [16.2%] 0.019 
CPET Peak PET CO2 3.3 [2.8 - 3.7] 2.4 [2.1 - 3.1] 0.038 
Height (cm) 165.0 [160.0 - 172.0] 164.0 [158.0 - 170.2] 0.044 
Valvular heart 
disease:  
Yes (n [%]) 
0 [0.0%] 7 [2.7%] 0.044 
CPET VO2-WR slope 8.3 [6.3 - 9.3] 6.1 [4.0 - 7.3] 0.045 
Transferrin (g/l) 3.0 [2.7 - 3.4] 2.8 [2.5 - 3.2] 0.046 
6mwt – six minute walk test, ALP – alkaline phosphatase, ANCA – anti-neutrophil 
cytoplasmic antibodies, BMI – body mass index, CI – cardiac index, COPD – chronic 
obstructive pulmonary disease, CPET – cardiopulmonary exercise test, CT – computer 
tomography, dPAP – diastolic pulmonary artery pressure, eGFR – estimated glomerular 
filtration rate, FEV1 – forced expiratory volume in 1 second, FVC – forced vital capacity, HR 
– heart rate, ILD – interstitial lung disease, KCO – transfer coefficient for carbon monoxide, 
mPAP – mean pulmonary artery pressure, NT-ProBNP – N terminal pro bone natriuretic 
peptide, PCWP – pulmonary capillary wedge pressure, PET CO2 – partial pressure of end 
tidal carbon dioxide, PVR – pulmonary vascular resistance, RA – right atrium, SBP – systolic 
blood pressure, WGS – whole genome sequencing, WR – work rate. Data presented as 
median [IQR] unless stated. Wilcoxon rank-sum test used to assess continuous variables, 
Fisher’s exact test used to assess categorical variables, Cochran–Armitage test used to 
assess ordinal variables. 
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Phenotypic differences between idiopathic PAH patients with high and low KCO % 
predicted 
 High Low Corrected p 
n [%] 180 [49.2%] 186 [50.8%]  
WGS population: 
African / East-Asian 
/ European / South-
Asian  
(n [%]) 
4 [2.2%] / 2 [1.1%] / 
160 [88.9%] / 14 
[7.8%] 
4 [2.2%] / 2 [1.1%] / 
169 [90.9%] / 11 
[5.9%] 
0.999 
Gender:  
Female (n [%]) 130 [72.2%] 118 [63.4%] 0.254 
Age at diagnosis 
(years) 45.2 [35.3 - 57.4] 64.7 [51.6 - 71.7] <0.001 
mPAP (mmHg) 55.0 [46.0 - 64.5] 49.0 [42.0 - 56.0] <0.001 
PCWP (mmHg) 10.0 [7.0 - 12.0] 10.0 [8.0 - 12.0] 0.850 
CI (L/min/m2) 2.1 [1.7 - 2.7] 2.2 [1.8 - 2.5] 0.903 
PVR (WU) 11.3 [7.4 - 15.4] 10.1 [7.1 - 13.4] 0.367 
Vasoresponder:  
(n [%]) 14 [25.5%] 8 [14.8%] 0.536 
Functional class:  
1 / 2 / 3 / 4 (n [%]) 
3 [1.7%] / 28 [16.2%] / 
121 [69.9%] / 21 
[12.1%] 
0 [0.0%] / 24 [13.5%] / 
129 [72.5%] / 25 
[14.0%] 
0.457 
6mwt distance (m) 330.0 [260.0 - 408.0] 232.0 [96.0 - 395.0] 0.028 
Urea (mmol/l) 5.4 [4.3 - 6.7] 6.4 [5.1 - 8.3] <0.001 
Resting SaO2 (%) 96.0 [94.0 - 98.0] 93.0 [90.0 - 97.0] <0.001 
Pre walk SaO2 (%) 96.0 [94.0 - 98.0] 94.0 [90.0 - 97.0] <0.001 
Post walk SaO2 (%) 94.0 [89.0 - 96.0] 87.0 [80.8 - 93.0] <0.001 
KCO 
(mmol/min/kPa/l) 1.4 [1.3 - 1.6] 0.7 [0.5 - 0.9] <0.001 
KCO (% predicted) 84.5 [77.9 - 94.2] 48.4 [38.0 - 61.4] <0.001 
CT emphysema: 
none / minimal / 
mild / moderate / 
severe (n [%]) 
126 [98.4%] / 1 [0.8%] 
/ 1 [0.8%] / 0 [0.0%] / 0 
[0.0%] 
110 [82.7%] / 6 [4.5%] 
/ 10 [7.5%] / 6 [4.5%] / 
1 [0.8%] 
<0.001 
Lung function 
pattern:  
Normal / 
Obstructive / 
Restrictive (n [%]) 
107 [60.8%] / 32 
[18.2%] / 37 [21.0%] 
90 [48.9%] / 77 
[41.8%] / 17 [9.2%] <0.001 
COPD or ILD:  
Yes (n [%]) 5 [2.8%] 34 [18.5%] <0.001 
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dPAP (mmHg) 35.0 [28.0 - 40.0] 30.0 [25.0 - 36.0] 0.001 
FVC (% predicted) 91.0 [81.0 - 103.0] 100.0 [86.8 - 111.0] 0.004 
PaO2 (kPa) 9.3 [7.7 - 11.5] 8.2 [6.6 - 9.8] 0.009 
sPAP (mmHg) 90.0 [74.0 - 102.0] 80.0 [69.0 - 94.0] 0.009 
Iron (µmol/l) 16.4 [11.6 - 21.0] 12.9 [8.0 - 17.0] 0.011 
SvO2 (%) 67.7 [60.8 - 72.7] 63.7 [58.0 - 69.2] 0.011 
Coronary artery 
disease:  
Yes (n [%]) 
9 [5.1%] 29 [15.8%] 0.011 
eGFR (ml/min) 72.0 [59.5 - 83.0] 60.0 [50.0 - 73.2] 0.022 
FEV1 (L) 2.4 [1.9 - 3.0] 2.2 [1.6 - 2.7] 0.023 
CPET VE-VCO2 slope 39.8 [32.3 - 56.2] 77.0 [51.4 - 82.5] 0.030 
Hb (g/l) 155.0 [139.5 - 168.5] 150.0 [133.0 - 160.0] 0.032 
CPET Peak O2 pulse 8.1 [6.1 - 9.1] 6.3 [5.0 - 6.9] 0.032 
Congenital heart 
disease:  
Yes (n [%]) 
20 [11.2%] 6 [3.3%] 0.032 
CPET OUES 1113.0 [919.0 - 1274.0] 632.5 [403.0 - 851.8] 0.035 
RDW 14.2 [13.2 - 15.1] 14.5 [13.9 - 16.5] 0.039 
Systemic DBP 
(mmHg) 80.0 [70.0 - 89.0] 76.0 [67.0 - 83.0] 0.043 
CPET Peak PET CO2 3.3 [2.7 - 3.6] 2.3 [2.0 - 2.9] 0.043 
6mwt – six minute walk test, CI – cardiac index, COPD – chronic obstructive pulmonary 
disease, CPET – cardiopulmonary exercise test, CT – computer tomography, DBP – diastolic 
blood pressure, dPAP – diastolic pulmonary artery pressure, eGFR – estimated glomerular 
filtration rate, FEV1 – forced expiratory volume in 1 second, FVC – forced vital capacity, Hb 
– haemoglobin, ILD – interstitial lung disease, KCO – transfer coefficient for carbon 
monoxide, mPAP – mean pulmonary artery pressure, OUES – oxygen uptake efficiency 
slope, PCWP – pulmonary capillary wedge pressure, PET CO2 – partial pressure of end tidal 
carbon dioxide, PVR – pulmonary vascular resistance, RDW – red cell distribution width, 
sPAP – systolic pulmonary artery pressure, VE – expired ventilation, VE-VCO2 - ventilatory 
equivalent for carbon dioxide, WGS – whole genome sequencing. Data presented as 
median [IQR] unless stated. Wilcoxon rank-sum test used to assess continuous variables, 
Fisher’s exact test used to assess categorical variables, Cochran–Armitage test used to 
assess ordinal variables. 
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Appendix 16 
 
Rare and predicted deleterious BMPR2 variants identified in PAH patients 
HGVSc HGVSp CSQ Domain Gender Age FHx Other variant 
c.19delC p.Arg7GlyfsTer40 Frameshift ECD Female 29 No  
c.26_41del
GGCGGGTG
CCCTGGCT 
p.Trp9TyrfsTer33 Frameshift ECD Female 39 No  
c.27G>A p.Trp9Ter Stop gained ECD Female 27 Yes 
 
c.48G>A p.Trp16Ter Stop gained ECD Female 50 Yes 
 
c.76+1G>A  Splice region 
 Female 29 No  
c.76+2T>G  Splice region 
 Male 51 No  
c.93_94insT p.Arg32SerfsTer6 Frameshift ECD Male 48 No  
c.100T>C p.Cys34Arg Missense ECD Female 42 No  
c.100T>C p.Cys34Arg Missense ECD Female 30 Yes  
c.156_157d
elTC p.His53Ter Frameshift ECD Male 20 Yes 
 
c.156_157d
elTC p.His53Ter Frameshift ECD Male 41 Yes 
SMAD1 
(c.400+1
G>A) 
c.156_157d
elTC p.His53Ter Frameshift ECD Female 58 No 
 
c.200A>G p.Tyr67Cys Missense ECD Female 54 Yes  
c.203G>A p.Gly68Asp Missense ECD Female 59 No  
c.218C>G p.Ser73Ter Stop gained ECD Female 73 No 
 
c.244C>T p.Gln82Ter Stop gained ECD Female 40 No 
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c.247+1G>A  Splice region 
 Female 54 No  
c.251G>A p.Cys84Tyr Missense ECD Female 42 Yes  
c.274delC p.Gln92LysfsTer9 Frameshift ECD Female 27 No  
c.280T>C p.Cys94Arg Missense ECD Male 44 No  
c.280T>G p.Cys94Gly Missense ECD Male 37 No  
c.288T>G p.Tyr96Ter Stop gained ECD Female 40 No 
 
c.314delC p.Pro105LeufsTer47 Frameshift ECD Male 64 No  
c.344dupT p.Cys116LeufsTer4 Frameshift ECD Male 30 No  
c.346T>C p.Cys116Arg Missense ECD Female 33 Yes  
c.346T>C p.Cys116Arg Missense ECD Male 35 Yes  
c.349T>G p.Cys117Gly Missense ECD Male 28 No  
c.367T>C p.Cys123Arg Missense ECD Male 38 No SMAD9 (p.Arg294Ter) 
c.367T>C p.Cys123Arg Missense ECD Female 38 No  
c.371dupA p.Asn124LysfsTer6 Frameshift ECD Female 23 Yes  
c.377A>G p.Asn126Ser Missense ECD Male 52 Yes  
c.399delT p.Pro134LeufsTer18 Frameshift ECD Female 34 Yes  
c.408_412d
elAACAC 
p.Pro138GlnfsTer7 Frameshift ECD Female 39 No  
c.417_418+
2delCAGT 
 Splice 
region ECD Female 42 No 
 
c.418+1G>T  Splice region 
 Male 47 Yes  
c.418+1G>T  Splice region 
 Female 13 Yes  
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c.418+5G>A  Splice region 
 Male 44 No  
c.439C>T p.Arg147Ter Stop gained TM Female 65 No 
 
c.439C>T p.Arg147Ter Stop gained TM Female 55 No 
 
c.439C>T p.Arg147Ter Stop gained TM Female 40 No 
 
c.449dupC p.Ile151AsnfsTer30 Frameshift TM Female 37 No  
c.470C>G p.Ser157Ter Stop gained TM Female 58 No 
 
c.529+2dup
T 
 Splice 
region 
 Female 23 Yes  
c.529+2dup
T 
 Splice 
region 
 Female 46 Yes  
c.533_536d
upACCG 
p.Lys180ProfsTer2 Frameshift PK Male 34 No  
c.612delA p.Lys204AsnfsTer5 Frameshift PK Male 45 Yes  
c.619dupG p.Glu207GlyfsTer13 Frameshift PK Female 45 No  
c.621+1G>A  Splice region 
 Female 35 No  
c.621+1G>C  Splice region 
 Female 19 No  
c.621+1G>C  Splice region 
 Female 66 Yes  
c.621+1G>C  Splice region 
 Male 43 No  
c.622-1G>T  Splice region 
 Male 44 No  
c.631C>T p.Arg211Ter Stop gained PK Female 32 No 
 
c.637C>T p.Arg213Ter Stop gained PK Female 28 No 
 
c.657delA p.Gly220AlafsTer10 Frameshift PK Female 64 No  
c.657delA p.Gly220AlafsTer10 Frameshift PK Female 62 No  
c.683delC p.Ala228ValfsTer2 Frameshift PK Female 47 No  
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c.691delG p.Val231CysfsTer21 Frameshift PK Male 79 No  
c.761_762d
elAT 
p.His254ArgfsTer11 Frameshift PK Male 29 No  
c.761_762d
elAT 
p.His254ArgfsTer11 Frameshift PK Female  No  
c.793G>T p.Glu265Ter Stop gained PK Male 51 No 
 
c.796_799d
elAGAG 
p.Arg266SerfsTer12 Frameshift PK Female 51 No  
c.823dupT p.Tyr275LeufsTer23 Frameshift PK Female 34 No  
c.843C>G p.Tyr281Ter Stop gained PK Female 37 No 
 
c.852_852+
1insA 
p.Gly285ArgfsTer13 Frameshift PK Female 28 No  
c.853-1G>A  Splice region 
 Female 47 No  
c.853-2A>G  Splice region 
 Male 44 No  
c.860T>A p.Leu287Ter Stop gained PK Male 34 Yes 
 
c.917A>C p.His306Pro Missense PK Female 62 No  
c.961C>T p.Arg321Ter Stop gained PK Male 45 Yes 
 
c.961C>T p.Arg321Ter Stop gained PK Female 43 No 
 
c.967+4del
A 
 Splice 
region 
 Female 32 No  
c.967+4del
A 
 Splice 
region 
 Female 54 Yes  
c.968-1G>T  Splice region 
 Female 39 No  
c.992A>G p.His331Arg Missense PK Female 34 No  
c.994C>T p.Arg332Ter Stop gained PK Male 59 Yes 
 
c.994C>T p.Arg332Ter Stop gained PK Male 38 No 
 
c.994C>T p.Arg332Ter Stop gained PK Female 66 No 
 
 288 
c.994C>T p.Arg332Ter Stop gained PK Female 49 No 
 
c.994C>T p.Arg332Ter Stop gained PK Female 42 No 
 
c.1019T>C p.Leu340Pro Missense PK Female 55 Yes  
c.1039T>C p.Cys347Arg Missense PK Male 20 Yes  
c.1128+2T>
G 
 Splice 
region 
 Female 36 Yes  
c.1128+2T>
G 
 Splice 
region 
 Female 53 No  
c.1133G>T p.Gly378Val Missense PK Male 34 No  
c.1178A>G p.Asn393Ser Missense PK Female 24 No  
c.1202T>C p.Leu401Ser Missense PK Male 42 No  
c.1202T>C p.Leu401Ser Missense PK Female 31 Yes  
c.1217T>G p.Met406Arg Missense PK Male 52 Yes  
c.1221T>G p.Tyr407Ter Stop gained PK Female 27 Yes 
 
c.1228G>C p.Gly410Arg Missense PK Female 59 No  
c.1242G>A p.Trp414Ter Stop gained PK Male 22 Yes 
 
c.1245_124
6dupGA 
p.Ile416ArgfsTer4 Frameshift PK Male 39 Yes  
c.1255_125
7dupAGA p.Arg419dup 
Inframe 
indel PK Female 32 No 
 
c.1277-
2A>G 
 Splice 
region 
 Male 35 No  
c.1355_135
6dupTC 
p.Val453SerfsTer22 Frameshift PK Female 61 No  
c.1371dupA p.Gln458ThrfsTer13 Frameshift PK Male 60 Yes  
c.1398G>A p.Trp466Ter Stop gained PK Male 67 No 
 
c.1413+1G>
A 
 Splice 
region 
 Female 42 No  
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c.1424C>A p.Ser475Ter Stop gained PK Female 63 Yes 
 
c.1432G>T p.Glu478Ter Stop gained PK Male 31 No 
 
c.1454A>G p.Asp485Gly Missense PK Female 30 No  
c.1471C>T p.Arg491Trp Missense PK Female 27 No  
c.1471C>T p.Arg491Trp Missense PK Female 22 Yes BMPR2 (p.Arg591Gln) 
c.1471C>T p.Arg491Trp Missense PK Female 30 Yes BMPR2 (p.Arg591Gln) 
c.1471C>T p.Arg491Trp Missense PK Female 38 No  
c.1471C>T p.Arg491Trp Missense PK Female 30 Yes  
c.1471C>T p.Arg491Trp Missense PK Male 56 Yes  
c.1472G>A p.Arg491Gln Missense PK Female 49 No  
c.1472G>A p.Arg491Gln Missense PK Male 29 No  
c.1472G>A p.Arg491Gln Missense PK Female 35 Yes  
c.1490_150
7delCTGAG
GAAAGGAT
GGCTG 
p.Ala497_Ala502del 
Inframe 
indel PK Male 36 Yes 
 
c.1606C>T p.Arg536Cys Missense CT Male 71 No  
c.1750C>T p.Arg584Ter Stop gained CT Female 73 No 
 
c.1865C>A p.Pro622Gln Missense CT Female 51 No  
c.1958_195
9delCT 
p.Pro653ArgfsTer21 Frameshift CT Female 59 No  
c.1962_196
3insGA 
p.Cys655AspfsTer5 Frameshift CT Male 39 No  
c.2004delA p.Asp669ThrfsTer31 Frameshift CT Female 74 No  
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c.2014G>T p.Glu672Ter Stop gained CT Male 51 No 
 
c.2027_203
0dupACCT 
p.Lys678ProfsTer6 Frameshift CT Female 51 No SMAD9 (p.Gly367Ser) 
c.2158C>T p.Gln720Ter Stop gained CT Male 38 No 
 
c.2245dupC p.Gln749ProfsTer9 Frameshift CT Female 30 No  
c.2372_237
3delTG 
p.Met791LysfsTer21 Frameshift CT Male 39 Yes  
c.2426dupT p.Ala810GlyfsTer3 Frameshift CT Female 27 No 
 
c.2500C>T p.Gln834Ter Stop gained CT Female 42 No 
 
c.2533delG p.Glu845LysfsTer14 Frameshift CT Female 24 No  
c.2542C>T p.Gln848Ter Stop gained CT Male 45 No 
 
c.2548C>T p.Gln850Ter Stop gained CT Male 45 Yes 
 
c.2558_255
9insA p.Glu854Ter Frameshift CT Female 39 No 
 
c.2608_261
2delTTACT 
p.Leu870GlufsTer9 Frameshift CT Male 37 No  
c.2617C>T p.Arg873Ter Stop gained CT Female 37 No 
 
c.2617C>T p.Arg873Ter Stop gained CT Female 19 No 
 
c.2617C>T p.Arg873Ter Stop gained CT Male 59 No 
 
c.2617C>T p.Arg873Ter Stop gained CT Female 82 Yes 
 
c.2695C>T p.Arg899Ter Stop gained CT Female 32 No 
 
c.2695C>T p.Arg899Ter Stop gained CT Female 48 No 
EIF2AK4 
(p.Arg899Ter) 
c.2866+448_
*10129del 
 Deletion  Female 37 Yes  
c.-
2135886_*1
477184del 
 Deletion  Female 36 No  
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c.418+6917_
968-2529del 
 Deletion  Male 44 No  
c.1413+4060
_1586+1016
del 
 Deletion  Female 32 No ENG (p.Cys652Tyr) 
c.77-
4215_418+1
17del 
 Deletion  Female 30 No  
c.-
469639_*17
93991del 
 Deletion  Female 43 No  
c.-
18799_76+6
577del 
 Deletion  Female 38 No  
c.-
14078_*480
624del 
 Deletion  Female 27 No  
c.-
8079_76+17
3del 
 Deletion  Male 37 No  
c.818_967+3
133del 
 Deletion  Female 56 Yes ENG (p.Thr617Met) 
c.1277-
3948_1414-
2306del 
 Deletion  Female 27 No  
c.247+28_41
8+3004del 
 Deletion  Female 53 No  
c.530-
336_967+42
72del 
 Deletion  Female 27 No  
c.-
1420039_*2
025475del 
 Deletion  Male 29 No  
c.967+1209_
*20667del 
 Deletion  Female 34 No  
c.1277-
573_1414-
2475del 
 Deletion  Female 61 No  
c.77-
2315_248-
646del 
 Deletion  Female 38 Yes  
c.1277-
942_1414-
4738del 
 Deletion  Female 36 Yes  
c.77-
1125_418+9
9del 
 Deletion  Male 46 No  
c.418+9084_
2866+804del 
 Deletion  Female 32 No  
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c.-
243014_*61
340del 
 Deletion  Female 64 No  
CSQ – consequence type, CT – cytoplasmic tail, ECD – extracellular domain, FHx – family 
history of PAH, PK – protein kinase domain, TM – transmembrane domain. 
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Appendix 17 
 
Phenotypic differences between PAH patients with and without BMPR2 variants 
 BMPR2+/- BMPR2+/+ 
Corrected 
p 
n [%] 157 [16.8%] 779 [83.2%]  
WGS population: African / 
East-Asian / European / 
South-Asian (n [%]) 
3 [1.9%] / 2 [1.3%] / 
147 [93.6%] / 5 
[3.2%] 
24 [3.1%] / 14 [1.8%] 
/ 693 [89.0%] /  
48 [6.2%] 
0.741 
Gender: female (n [%]) 105 [66.9%] 544 [69.9%] 0.751 
Age at diagnosis (years) 39.3 [32.0 - 51.1] 51.4 [38.2 - 65.5] <0.001 
Drug exposure: Yes (n [%]) 6 [3.8%] 49 [6.3%] 0.523 
mPAP (mmHg) 58.0 [51.0 - 68.2] 51.0 [43.0 - 60.0] <0.001 
PCWP (mmHg) 10.0 [7.0 - 12.0] 9.0 [7.0 - 11.0] 0.819 
CO (L/min) 3.3 [2.7 - 4.0] 4.1 [3.3 - 5.2] <0.001 
CI (L/min/m2) 1.8 [1.5 - 2.2] 2.2 [1.8 - 2.7] <0.001 
PVR (WU) 14.2 [10.8 - 20.3] 10.2 [7.0 - 14.0] <0.001 
Vasoresponder (n [%]) 0 [0.0%] 31 [18.1%] 0.007 
Functional class:  
1 / 2 / 3 / 4 (n [%]) 
2 [1.4%] / 32 [21.6%] 
/ 89 [60.1%] /  
25 [16.9%] 
15 [2.2%] /  
143 [21.4%] /  
439 [65.7%] /  
71 [10.6%] 
0.388 
6mwt distance (m)  331.0 [286.5 - 426.5] 310.0 [160.0 - 410.0] 0.21 
HCT 0.5 [0.5 - 0.5] 0.4 [0.4 - 0.5] <0.001 
Hb (g/l) 162.0 [152.0 - 173.2] 151.0 [136.0 - 163.0] <0.001 
ALT (iu/l) 30.0 [22.0 - 42.0] 23.0 [17.0 - 33.0] <0.001 
sPAP (mmHg) 92.0 [82.0 - 105.0] 84.0 [70.0 - 97.0] <0.001 
dPAP (mmHg) 40.0 [33.2 - 47.8] 33.0 [26.0 - 39.0] <0.001 
SvO2 (%) 60.1 [56.0 - 65.9] 65.4 [59.6 - 71.3] <0.001 
FEV1 (L) 2.6 [2.2 - 3.3] 2.2 [1.8 - 2.8] <0.001 
FVC (L) 3.5 [2.9 - 4.2] 3.0 [2.3 - 3.8] <0.001 
KCO (mmol/min/kPa/litre) 1.4 [1.2 - 1.6] 1.1 [0.7 - 1.4] <0.001 
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KCO (% predicted) 82.0 [74.0 - 94.0] 70.2 [49.0 - 85.4] <0.001 
Lung function pattern: 
Normal / Obstructive / 
Restrictive (n [%]) 
81 [81.0%] / 12 
[12.0%] / 7 [7.0%] 
244 [53.7%] / 135 
[29.7%] / 75 [16.5%] 
<0.001 
Bilirubin (µmol/l) 19.0 [12.5 - 29.0] 14.0 [10.0 - 22.0] 0.003 
TSH (mu/l) 2.5 [1.7 - 3.7] 2.0 [1.2 - 3.1] 0.013 
HR (bpm) 85.0 [73.0 - 96.0] 78.0 [69.0 - 88.0] 0.013 
WBC (x109) 8.8 [7.3 - 10.8] 8.1 [6.8 - 9.7] 0.014 
Post walk SaO2 (%) 94.0 [89.8 - 97.0] 91.0 [85.0 - 96.0] 0.014 
FEV1 (% predicted) 90.8 [78.0 - 99.4] 85.4 [73.0 - 95.5] 0.033 
Coronary artery disease:  
Yes (n [%]) 
2 [1.7%] 49 [8.8%] 0.034 
6mwt – six minute walk test, ALT – alanine transferase, CI – cardiac index, CO – cardiac 
output, dPAP – diastolic pulmonary artery pressure, FEV1 – forced expiratory volume in 1 
second, FVC – forced vital capacity, Hb – haemoglobin, HCT – haematocrit, HR – heart rate, 
KCO – transfer coefficient for carbon monoxide, mPAP – mean pulmonary artery pressure, 
PCWP – pulmonary capillary wedge pressure, PVR – pulmonary vascular resistance, sPAP – 
systolic pulmonary artery pressure, TSH – thyroid stimulating hormone, WGS – whole 
genome sequencing. Data presented as median [IQR] unless stated. Wilcoxon rank-sum 
test used to assess continuous variables, Fisher’s exact test used to assess categorical 
variables, Cochran–Armitage test used to assess ordinal variables. 
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Appendix 18 
 
Rare and predicted deleterious TBX4 variants identified in PAH patients 
HGVSc HGVSp CSQ SPS Gender Age FHx 
Other 
variant 
c.40_49delTT
CCGGGCCC 
p.Phe14Argfs
Ter28 
Frameshift  Female 30 No  
c.121G>T p.Gly41Ter Stop gained  Male 56 No  
c.884G>C p.Gly295Ala Missense  Male 10 Yes  
c.885dupC 
p.Thr296Hisfs
Ter90 
Frameshift  Female 74 No  
c.972delT 
p.Thr326Profs
Ter12 
Frameshift  Female 79 Yes 
ENG 
(p.Gly645
Ala) 
c.1001_1004d
upATCA 
p.His335Glnfs
Ter52 
Frameshift  Male 5 No  
c.1012A>T p.Lys338Ter Stop gained  Male 29 No  
c.1070C>T p.Ala357Val Missense  Female 81 No  
c.1102C>T p.Arg368Cys Missense  Female 39 No  
c.1112dupC 
p.Pro372Serfs
Ter14 
Frameshift Yes Male 57 No  
c.1112dupC 
p.Pro372Serfs
Ter14 
Frameshift Yes Male 74 No  
c.1145A>C p.Tyr382Ser Missense  Female 67 No  
c.1160_1167d
elCCCCCAGA 
p.Thr387Argfs
Ter29 
Frameshift  Female 57 No  
c.1183T>C p.Ser395Pro Missense  Female 33 No  
c.1274C>A p.Pro425Gln Missense  Female 49 No  
c.1543G>A p.Glu515Lys Missense  Male 41 No  
CSQ – consequence type, FHx – family history of PAH, SPS – previously associated with Small 
Patella Syndrome. 
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Rare and predicted deleterious KCNK3 variants identified in PAH patients 
HGVSc HGVSp 
Consequence 
type 
Gender 
Age at 
diagnosis 
Family 
history 
c.152G>T p.Arg51Leu Missense Female 73 No 
c.340G>A p.Ala114Thr Missense Male 27 No 
c.544G>C p.Glu182Gln Missense Male 21 No 
c.707G>C p.Gly236Ala Missense Female 27 No 
 
 
 
 
Rare and predicted deleterious SMAD9 variants identified in PAH patients 
HGVSc HGVSp CSQ Gender 
Age at 
diagnosis 
FHx Other variants 
c.295C>G p.Pro99Ala Missense Male 51 No  
c.296C>T p.Pro99Leu Missense Female 61 No  
c.790C>A p.Pro264Thr Missense Female 28 No  
c.880C>T p.Arg294Ter Stop gained Male 38 No 
BMPR2 
(p.C123R) 
c.1099G>A p.Gly367Ser Missense Female 51 No 
BMPR2 
(p.Lys678Profs
Ter6) 
CSQ – consequence type, FHx – family history of PAH. 
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Appendix 20 
 
Rare and predicted deleterious EIF2AK4 variants identified 
HGVSc HGVSp CSQ Genotype Gender Age FHx Diagnosis 
KCO % 
predicted 
Other 
c.1072_1073dupGT p.Val359Ter Frameshift Heterozygote Female 39 No PAH 72  
c.44C>T p.Pro15Leu Missense Heterozygote Female 40 No PAH 109  
c.3722A>G p.Glu1241Gly Missense Heterozygote Female 25 No PAH 41  
c.1660G>T p.Asp554Tyr 
Missense 
& splice 
region 
Heterozygote Male 72 No PAH   
c.3711_3713delGA
G 
p.Arg1238del 
Inframe 
deletion 
Heterozygote Female 59 No PAH 95  
c.3604C>T p.His1202Tyr Missense Heterozygote Female 48 No PAH 61 
BMPR2 
(p.Arg899
Ter) 
c.220G>A p.Asp74Asn Missense Heterozygote Female 70 No PAH   
c.2446C>T ^ p.Gln816Ter 
Stop 
gained 
Heterozygote 
Female 24 No PAH 81  
c.3218G>T ^ p.Arg1073Leu Missense Heterozygote 
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c.3605A>T p.His1202Leu Missense Homozygote Female 36 No PAH 40  
c.1795G>C p.Gly599Arg Missense Homozygote Male 22 No PAH 31  
c.4392dupT p.Lys1465Ter 
Frameshift 
& splice 
region 
Homozygote Male 21 No PVOD / PCH 33  
c.3097C>T p.Gln1033Ter 
Stop 
gained 
Homozygote Male 29 Yes PAH 27  
c.1159_1160delCT p.Leu387CysfsTer27 Frameshift Homozygote Male 18 No PAH 28  
c.1795G>C p.Gly599Arg Missense Homozygote Female 25 No PAH 33  
c.281dupA p.Asn94LysfsTer8 Frameshift Homozygote Male 39 No PVOD / PCH   
c.3055_3064delCT
GACCAACG 
p.Leu1019TrpfsTer9 Frameshift 
Potential 
compound 
heterozygote 
Male 23 No PAH 33  
c.3884T>G p.Leu1295Arg Missense 
c.4400dupT p.Glu1468ArgfsTer14 Frameshift Potential 
compound 
heterozygote 
Male 48 No PAH 45  
c.1739dupA p.Arg581GlufsTer9 Frameshift 
c.1392delT p.Arg465ValfsTer38 Frameshift Potential 
compound 
heterozygote 
Female 70 No PAH 33 
SMAD9 
(p.Pro140
Leu) 
c.257+4A>C  
Splice 
region 
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c.1820T>G p.Val607Gly 
Missense 
& splice 
region 
Potential 
compound 
heterozygote 
Female 27 No PVOD / PCH 28 
SMAD9 
(p.Gly367
Ser) 
c.2727C>G p.Ser909Arg Missense 
c.3325G>A p.Gly1109Arg Missense Potential 
compound 
heterozygote 
Female 33 No PVOD / PCH   
c.2841delG p.Ile948SerfsTer35 Frameshift 
c.145-2A>G  
Splice 
acceptor Potential 
compound 
heterozygote 
Female 38 No PAH   c.4418_4421delCA
GA 
p.Thr1473ArgfsTer17 Frameshift 
c.2827A>G p.Thr943Ala Missense 
c.3097C>T p.Gln1033Ter 
Stop 
gained 
Potential 
compound 
heterozygote 
Female 50 Yes PVOD / PCH 30  
c.4769delT p.Leu1590Ter Frameshift 
c.551_552delAA 
* 
p.Glu184GlyfsTer13 Frameshift Potential 
compound 
heterozygote 
Male 43 No PVOD / PCH 46  
c.2721T>G * p.Tyr907Ter 
Stop 
gained 
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^ – also identified in mother, * – identified using the modified variant filtering strategy, CSQ – consequence type, FHx – family history of PAH 
or PVOD / PCH, KCO – transfer coefficient for carbon monoxide 
 
 
